ISSN 2543–5248
e-ISSN 2543–8077

Tom 8 | Numer 6 | Rok 2023

NOWOTWORY 2023, tom 8, numer 6, 407–505

Biuletyn Polskiego Towarzystwa Onkologicznego

Nowotwory

100 lat czasopisma Nowotwory

VIA MEDICA

6/2023

Nowotwory. Journal of Oncology – indeksacja:
Scopus, EMBASE, Google Scholar, CrossRef, 100 punktów MEiN

Biuletyn Polskiego Towarzystwa Onkologicznego

Nowotwory

Biuletyn Polskiego Towarzystwa Onkologicznego

Nowotwory

dwumiesięcznik

oficjalny organ

POLSKIEGO TOWARZYSTWA
ONKOLOGICZNEGO

Narodowy Instytut Onkologii
im. Marii Skłodowskiej-Curie
Państwowy Instytut Badawczy

czasopismo

POLSKIEGO TOWARZYSTWA
CHIRURGII ONKOLOGICZNEJ

Adres redakcji:
Narodowy Instytut Onkologii im. M. Skłodowskiej-Curie – Państwowy Instytut Badawczy
ul. Roentgena 5
02-781 Warszawa

Adres korespondencyjny:
Krakowska Akademia im. Andrzeja Frycza-Modrzewskiego
ul. Gustawa Herlinga-Grudzińskiego 1
30-705 Kraków
pokój 309
tel. 512 177 774
e-mail: redakcja@nowotwory.edu.pl
www.nowotwory.edu.pl

Adres wydawcy:
VM Media Group sp. z o.o.
ul. Świętokrzyska 73, 80-180 Gdańsk
tel. (48) 58 320 94 94, faks (48) 58 320 94 60
e-mail: viamedica@viamedica.pl, www.viamedica.pl

ISSN: 2543–5248
e-ISSN: 2543–8077

22-6131.005.001

Spis treści

VIA MEDICA

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 407–419

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

Artykuł oryginalny / Original article

Rak płuca / Lung cancer

Lung cancer in the course of chronic obstructive pulmonary disease – the clinical picture in light of current diagnostic recommendations

Robert Uliński[1], Marta Dąbrowska[1], Joanna Domagała-Kulawik[2]

[1]*Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Warsaw, Poland*
[2]*Maria Sklodowska-Curie Medical Academy, Institute of Clinical Sciences, Warsaw, Poland*

Introduction. Lung cancer and chronic obstructive pulmonary disease (COPD) are one of the most significant causes of death. The co-existence of COPD and lung cancer has a strong influence on treatment.

Material and methods. The data were collected retrospectively from patients diagnosed with lung tumors between 2016 and 2022. Of the 982 analyzed cases, 180 patients had co-existing primary lung cancer and COPD.

Results. 46.1% of the study group were women. 99.0% of patients presented a history of smoking. 46.7% patients were diagnosed with COPD during lung tumor diagnosis. 71.1% of patients suffered from non-small-cell lung cancer (NSCLC). The majority of patients had locally advanced or metastatic lung cancer.

Conclusions. The high incidences of COPD as well as lung cancer among women is striking. Almost half of the patients were diagnosed with COPD while diagnosing lung tumors. A long history of smoking is still the main factor as regards developing these diseases.

Key words: lung cancer, chronic obstructive pulmonary disease, spirometry, emphysema, non-small-cell lung cancer

Introduction

Lung cancer was the second most commonly diagnosed cancer in 2020, with 2,2 million new cases diagnosed yearly around the world (11.4% of all cancers), remaining the leading cause of cancer-related death, with an estimated 1.8 million deaths (18%) [1].The prognosis in lung cancer is very poor – only 10 to 20% of patients survive 5 years after diagnosis in most countries [1]. Chronic obstructive pulmonary disease (COPD) is the most commonly diagnosed chronic disease of the respiratory tract. Each year, COPD is diagnosed in 17.98 million patients. COPD is the third leading cause of death worldwide, with around 3.324 million deaths, which accounts for 6% of all deaths in 2019 [2]. There is a 4–6 fold greater risk of developing lung cancer in patients with coexistence of COPD in comparison with smokers with normal lung function. In patients with COPD, the 10-year risk of developing lung cancer is about 8.8%, while in patients with normal respiratory function only 2% [3]. Nevertheless, COPD will develop in only 20%, and lung cancer in 15% of cigarette smokers, though death from other smoking-related causes like stroke, heart disease and emphysema often occur in smokers [2, 3]. In patients with moderate COPD, lung cancer is the cause of death in around 30% of cases and it is the most common cause of death in COPD patients [2]. The co-existence of COPD and lung cancer has very important clinical consequences, and has a strong impact on diagnostic procedures and treatment. The most powerful therapeutic approach for non-small-cell lung carcinoma is surgical resection. This treatment is possible mainly in stage I, II and IIIA [1]. However,

Jak cytować / How to cite:

Uliński R, Dąbrowska M, Domagała-Kulawik J. ***Lung cancer in the course of chronic obstructive pulmonary disease – the clinical picture in light of current diagnostic recommendations.*** *NOWOTWORY J Oncol* 2023; 73: 325–337.

this option is associated with higher morbidity and mortality in patients with low ventilatory reserve, which is a common limiting factor for lung cancer surgery in patients with COPD [4]. Coexistence of lung cancer with COPD was described in many previous studies [5, 8–20]. Thus, we aimed to analyze the clinical characteristics of patients with coexistence of lung cancer and COPD in many aspects, taking into account current rules of diagnosis of both diseases and the possible specificity of the Polish population.

Material and methods

The demographic and clinical data were collected retrospectively from medical histories of patients hospitalized and diagnosed with lung tumors between January 1, 2016 and June 30, 2022 in a single lung disease department. A total of 982 patients with lung tumors were diagnosed in the years 2016–2022. Lung cancer was pathologically confirmed in 524 patients. COPD was confirmed in 180 patients (34.4%) of this group. Patients with co-existence of a primary lung cancer and COPD were included in further analysis (fig. 1). The following specifics were collected from medical records: age, sex, smoking status, lung cancer histological type, tumor size, disease stage, presence of metastases, treatment plan, co-existence of other diseases, results of pulmonary function tests and presence of emphysema in computed tomography (CT) scans. The study was approved by the Committee of Research Ethics of the Medical University of Warsaw.

The diagnosis of lung cancer was confirmed pathologically in each case. The following subtypes of lung cancer were defined: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). NSCLC was further categorized as squamous-cell carcinoma (SCC), adenocarcinoma (ADC), large-cell carcinoma or not otherwise specified (NOS), or other [6]. The cancer stage was recorded using the TNM classification 8th edition [7].



Figure 1. Patients selection to study group and reasons for patients exclusion

COPD was diagnosed based on an irreversible obstruction in spirometry (the FEV1%FVC less than 5 percentile after bronchodilation) in correspondence with clinical data. Spirometry values were recorded using European reference values. FVC and FEV1 were presented in liters and as a percentage of predicted values. GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria were used to assign a grade of clinical severity to COPD based on FEV1 [2]. Grade 1 was defined as having an FEV1 more or equal to 80%; grade 2 as more or equal to 50% FEV1 and less than 80%; grade 3 as more or equal to 30% FEV1 and less than 50%; and grade 4 as FEV1 less than 30%. Patients were classified as having COPD at lung cancer diagnosis if they had a previous diagnosis of COPD in their medical records or if they fulfilled the spirometric criteria during current diagnostic procedures. Patients with bronchial asthma or an obvious explanation for abnormality in spirometry, such as a central tumor or atelectasis were excluded from the study.

Patients were classified into four groups (tab. I): A,B,C, and D based on the level of symptoms, measured by the modified Medical Research Council dyspnea scale (mMRC) or the COPD Assessment Test (CAT), and the frequency of previous exacerbations [2].

Test

The presence of emphysema at lung cancer diagnosis was determined based on information from CT scans in medical records. All CT scans were reviewed at diagnosis by a radiologist experienced in pulmonary diseases. When emphysema was detected visually in the CT scan, the patient was classified as having emphysema.

Apart from the whole group characteristic, we performed a comparison of women with men, patients with emphysema and without emphysema, patients with different types of lung cancer. Unfortunately, not all data were available, thus we present in each table the number of patients with completed results of records or results of investigations.

Statistical analysis

Statistical analysis was performed using the STATISTICA 13.1, StatSoft software package. Descriptive statistics were used to describe the features of all participants. Proportions were expressed as percentages, continuous variables by mean if normally distributed or by median otherwise. For group comparison divided in terms of sex, presence of emphysema, lung cancer histological type, the Mann–Whitney test for continuous variables and the Fisher's exact test for categorical variables were used. A p-value of >0.05 was used as the removal criterion.

Table I. GOLD severity staging

Patients		Symptoms	
		CAT 0–9 mMRC < 2	CAT 10–40 mMRC ≥ 2
exacerbations (in past 12 months)	no hospital admission or ≤1 outpatient treatment	group A	group B
	≥1 hospital admission or ≥2 outpatient treatment	group C	group D

mMRC – modified Medical Research Council dyspnea scale; CAT – COPD assessment

Results

Clinical characteristics

The process of qualification of patients to the study group is presented in figure 1. The general and clinical characteristics of the 180 patients finally enrolled in the study and the comparison between male and female are presented in tables II and III. The mean age of the group was 70.4 years. The largest (45.0%) age group of patients was between 65 and 75 years. There were 97 males (53.9%) and 83 females (46.1%). Ninety-nine percent of all patients presented with a history of smoking, whereas 58.7% were still active smokers, with 40.6% ex-smokers who ceased smoking at least 1 year previously. However 1.0% of non-smokers had been exposed to cigarette smoke as passive smokers; 77.7% of the group had a history of 20–60 pack-years, while 13.5% had more than 60 pack-years in their medical history. Males were exposed to significantly greater amounts of cigarette smoke than females (p = 0.001) in the Fisher exact test.

COPD characteristics

Almost half of all patients (46.7%) were diagnosed with COPD during lung tumor diagnosis. Table II lists characteristics of COPD and comparison between male and female. The distribution of patients with COPD according to the severity of the airway obstruction was as follows: grade 1 (FEV1 ≥ 80%) 12 patients (3.9%); grade 2 (50% ≤ FEV1 < 80%) 74 patients (56.9%); grade 3 (30% ≤ FEV1 < 50%) 41 patients (31.6%); and grade 4 (FEV1 < 30%) 2 patients (2.3%). Emphysema was found in 55.9% of patients by CT. In terms of comorbid diseases, the number of patients with one or more comorbidities was

Table II. Demographic characteristics and features of COPD in investigated group. Comparison of female with male using Mann–Whittney test for continuous variables and the Fisher's exact test for categorical variables. Only significant differences were shown (p < 0.05). Data are given as number and percentages or mean ± standard deviation

Patients	All	Female	Male	p-value
number of patients	180	83 (46.1%)	97 (53.9%)	–
age (years)	70.4 (8.6%)	70.0 (7.7%)	70.7 (9.3%)	–
≤55	7 (3.9%)	2 (2.4%)	5 (5.2%)	–
56 ≥ 65	43 (23.9%)	19 (22.9%)	24 (24.7%)	–
66 ≥ 75	83 (46.1%)	44 (53.0%)	39 (40.2%)	–
76 ≥ 85	37 (20.6%)	17 (20.5%)	20 (20.6%)	–
>85	10 (5.6%)	1 (1.2%)	9 (9.3%)	–
smoking status				
active	91 (58.7%)	42 (57.5%)	49 (59.8%)	–
former	63 (40.7%)	31 (42.5%)	32 (39.0%)	–
never	1 (0.6%)	0 (0.0%)	1 (1.2%)	–
no data*	25 (16.1%)			–
exposure – pack, years				
0 < 20	12 (8.2%)	10 (14.5%)	2 (2.6%)	p = 0.001

→

Table II cont. Demographic characteristics and features of COPD in investigated group. Comparison of female with male using Mann–Whittney test for continuous variables and the Fisher's exact test for categorical variables. Only significant differences were shown ($p < 0.05$). Data are given as number and percentages or mean ± standard deviation

Patients	All	Female	Male	p-value
21 < 40	58 (39.5%)	33 (47.8%)	25 (32.1%)	–
41 < 60	57 (38.8%)	22 (31.8%)	35 (44.9%)	–
61 < 80	6 (4.0%)	3 (4.4%)	3 (3.8%)	–
81 < 100	10 (6.8%)	0 (0.0%)	10 (12.8%)	–
<100	4 (2.7%)	1 (1.5%)	3 (3.8%)	–
no data	33 (18.3%)			–
COPD diagnosed during investigation of lung tumor				
yes	84 (46.7%)	37 (44.6%)	47 (48.5%)	–
no	96 (53.3%)	46 (55.4%)	50 (51.5%)	–
COPD severity (FEV1 range)				
grade 1 (>80%)	13 (10.0%)	8 (12.9%)	5 (7.4%)	–
grade 2 (50–80%)	73 (56.2%)	29 (46.8%)	44 (64.7%)	–
grade 3 (30–50%)	41 (31.5%)	24 (38.7%)	17 (25.0%)	–
grade 4 (<30%)	3 (2.3%)	1 (1.6%)	2 (2.9%)	–
no data	30 (16.67%)			–
emphysema				
yes	61 (44.2%)	35 (52.2%)	26 (36.6%)	p = 0.006
no	77 (55.8%)	32 (47.8%)	45 (63.4%)	–
no data	42 (23.3%)			–
GOLD				
A	20 (33.9%)	9 (32.1%)	11 (35.5%)	–
B	27 (45.7%)	13 (46.4%)	14 (45.2%)	–
C	3 (5.1%)	2 (7.1%)	1 (3.2%)	–
D	9 (15.3%)	4 (14.3%)	5 (16.1%)	–
no data	121 (67.2%)			–
number of comorbidities				
0	24 (13.3%)	11 (13.3%)	13 (13.4%)	–
1	38 (21.1%)	20 (24.1%)	18 (18.6%)	–
2	30 (16.7%)	12(14.5%)	18 (18.6%)	–
3	37 (20.6%)	21 (25.3%)	16 (16.4%)	–
4	22 (12.2%)	8 (9.6%)	14 (14.4%)	–
5	11 (6.1%)	5 (6.0%)	6 (6.2%)	–
6	7 (3.9%)	1 (1.2%)	6 (6.2%)	–
7	6 (3.3%)	4 (4.8%)	2 (2.0%)	–
8	2 (1.1%)	0 (0.0%)	2 (2.1%)	–
9	2 (1.1%)	0 (0.0%)	2 (2.1%)	–
10	1 (0.6%)	1 (1.2%)	0 (0.0%)	–

p-values are given for differences between female and male groups; * no data relate to the whole study group; COPD – chronic obstructive pulmonary disease; GOLD – Global Initiative for Chronic Obstructive Lung Disease

Table III. Lung cancer characteristics in the investigated group. Comparison of female with male using Mann–Whittney test for continuous variables and the Fisher's exact test for categorical variables. Data are given as number and percentages

Lung cancer	All patients	Female	Male	p-value
histological types	n = 180	83 (46.1%)	97 (53.9%)	–
NSCLC	128 (71.1%)	55 (66.3%)	73 (75.3%)	–
SCLC	52 (28.9%)	28 (33.7%)	24 (24.7%)	–
histological subtypes of NSCLC				
adenocarcinoma	47 (36.7%)	22 (40.0%)	25 (34.2%)	–
squamous-cell carcinoma	53 (41.4%)	20 (36.4%)	33 (45.2%)	–
not otherwise specified (NOS) NSCLS	19 (14.9%)	7 (12.7%)	12 (16.5%)	–
other	9 (7.0%)	6 (10.9%)	3 (4.1%)	–
central/peripheral tumor				
central	106 (60.2%)	51 (63.0%)	55 (57.9%)	–
peripheral	70 (39.8%)	30 (37.0%)	40 (42.1%)	–
no data*	4 (2.2%)			–
lung right/left				
right	86 (52.1%)	36 (46.2%)	50 (57.5%)	–
left	75 (45.5%)	40 (51.3%)	35 (40.2%)	–
right and left	4 (2.4%)	2 (2.5%)	2 (2.3%)	–
no data	25 (13.89%)			–
lobe				
superior	40 (48.2%)	18 (48.7%)	22 (47.8%)	–
inferior	35 (42.2%)	16 (43.2%)	19 (41.3%)	–
middle	8 (9.6%)	3 (8.1%)	5 (10.9%)	–
no data	97 (53.9%)			–
pleural effusion				
yes	62 (50.0%)	29 (51.8%)	33 (48.5%)	–
no	62 (50.0%)	27 (48.2%)	35 (51.5%)	–
no data	56 (31.1%)			–

p-values are given for differences between female and male groups; NSCLC – non-small-cell lung cancer; SCLC – small-cell lung cancer; COPD – chronic obstructive pulmonary disease; * no data relate to the whole study group

156 (86.7%), and 88 (48.9%) had three or more comorbid diseases. In particular, hypertension was the most common disease and occurred in 106 patients (58.9%) followed by heart failure – 39 (21.7%), diabetes type II – 34 (18.9%) and coronary heart disease – 31 (17.2%), followed by other diseases. There were no significant differences between males and females in age, sex, smoking status, COPD severity, presence of emphysema and number of comorbidities.

Lung cancer characteristics

In the study group there were 71.1% of patients with NSCLC, while in 28.9% of patients SCLC was diagnosed. Table III lists the characteristics of lung cancer in the whole group and a comparison between females and males. Of NSCLCs, squamous-cell carcinoma was the most dominant histological subtype of lung cancer – 41.4%, followed by adenocarcinoma – 36.7%, NOS –14.9% and large-cell carcinoma – 7.0%. Furthermore, in terms of cancer stage, stage III dominated in the group (52.5%), followed by stage IV (38.4%), stage I (5.7%), and stage II (3.4%). Substage IIIB was the most common in the group (28.8%), followed by IVA (23.7%). Potentially resectable cancers (stage I–IIIA) consisted of only 26.6%. Comparison of cancer stage between men and women is presented in figure 2. Cancer was mainly located centrally (60.2%), in the right lung (52.8%) and in the upper lobe (48.7%). Pleural effusion occurred in a minority of patients (38.8%). Additionally, metastases to



Figure 2. Lung cancer stages in patients with lung cancer in the course of COPD – comparison of men and women

the lung were most frequent (21.7% of all metastases), followed by metastases to the liver (15.3%), adrenal glands (14.4%), bones (14.4%), central nervous system (7.69%) and lymph nodes (7.69%). There were no significant differences between men and women as regards the histological type of cancer, tumor localization, presence of pleural effusion, lung cancer stage, number and localization of metastases.

Treatment and outcome

The records on treatment were available in 67 patients (37.2% of the whole group) and on outcome in 32 patients (17.8%). Of them only 10.9% of patients underwent surgical excision of the cancer even though 26.6% of patients were potentially resectable (stage I–IIIA). The most common treatment was the palliative approach (29.7%) which consisted of palliative care and palliative radiotherapy. Chemoradiotherapy was administered in 21.9% of patients. The overall outcome was positive in only 6.25% of patients, while 93.75% of patients died. There were no significant differences between men and women in treatment and outcome.

Comparison of patients with and without emphysema

When comparing patients with and without emphysema, no significant differences in demographic data, lung cancer characteristics and COPD stage were found. There were slightly more men than women in the emphysema group (tab. IV).

Comparison of patients between NSCLC and SCLC, and SCC and non-SCC

Patients with COPD and SCLC were in significantly more advanced stages of lung cancer than those with NSCLC ($p < 0.05$). The treatment was significantly different with chemotherapy as the most common in the SCLC group (obvious situation) and chemoradiotherapy as the most common in the NSCLC group ($p < 0.05$) (tab. V). There were no significant differences between groups in terms of age, sex, smoking status, COPD severity, number of metastases, treatment and outcome. The median pack-years in both groups was equal (45). There were no significant differences in patients with COPD between the two main NSCLC types – SCC and non-SCC – as regards age, sex, smoking status, COPD severity, lung cancer stage, number of metastases, treatment and outcome.

Discussion

The coexistence of COPD and lung cancer is a known clinical observation. However, previous studies are sometimes incomplete with only selective data available or carried out on a small number of patients (8–21). We present a large group of patients with established COPD and lung cancer with precise

Table IV. Lung cancer in patients with COPD – comparison of patients with emphysema with without emphysema using Mann–Whittney test for continuous variables and the Fisher's exact test for categorical variables. Data are given as number and percentages or mean ± standard deviation

Patients	With emphysema	Without emphysema	p-value
n = 138	77	61	–
age	70.8 (8.2%)	70.3 (7.9%)	–
female	32 (41.6%)	35 (57.4%)	p = 0.06
male	45 (58.4%)	26 (42.6%)	–
smoking status			
active	39 (58.2%)	32 (58.2%)	–
former	27 (40.3%)	23 (41.8%)	–
never	1 (1.5%)	0 (0.0%)	–
no data*	16 (11.6%)		–
COPD severity (FEV1 range)			
grade 1 (>80%)	8 (13.8%)	3 (7.3%)	–
grade 2 (50–80%)	30 (51.7%)	25 (61.0%)	–
grade 3 (30–50%)	19 (32.8%)	13 (31.7%)	–
grade 4 (<30%)	1 (1.7%)	0 (0%)	–
no data	39 (28.3%)		–
histological types of lung cancer			
NSCLC	53 (68.8%)	43 (70.5%)	–
SCLC	24 (31.2%)	18 (29.5%)	–
histological subtypes of NSCLC			
adenocarcinoma	19 (35.8%)	13 (30.2%)	–
squamous-cell carcinoma	18 (34.0%)	22 (51.2%)	–
not otherwise specified (NOS) NSCLS	10 (18.9%)	7 (16.3%)	–
other	6 (11.3%)	1 (2.3%)	–
stage	77 (55.8%)	61 (44.2%)	–
IA	0 (0%)	5 (8.3%)	–
IB	1 (1.3%)	1 (1.7%)	–
IIA	2 (2.7%)	0 (0%)	–
IIB	1 (1.3%)	1 (1.7%)	–
IIIA	18 (23.7%)	6 (10.00%)	–
IIIB	18 (23.7%)	15 (25.00%)	–
IIIC	5 (6.6%)	3 (5.00%)	–
IVA	18 (23.7%)	20 (33.3%)	–
IVB	13 (17.0%)	9 (15.00%)	–
no data	2 (1.5%)		–
I–IIIA	19 (24.7%)	12 (19.7%)	–
IIIB–IVB	58 (75.3%)	49 (80.3%)	–

p-values are given for differences between with emphysema and without emphysema groups; NSCLC – non-small-cell lung cancer; SCLC – smal-cell lung cancer; * no data relate to the whole study group

Table V. COPD in two main types of lung cancer – comparison of SCLC and NSCLC using Mann–Whittney test for continuous variables and the Fisher's exact test for categorical variables. Data are given as number and percentages or mean ± standard deviation

Patients	SCLC	NSCLC	p-value
n = 178	52	126	–
age	70.6 (8.2%)	70.2 (8.9%)	–
female	28 (53.8%)	54 (42.1%)	–
male	24 (46.2%)	73 (57.9%)	–
smoking status	45	108	–
active	28 (62.2%)	63 (57.4%)	–
former	17 (37.8%)	45 (41.7%)	–
never	0 (0.0%)	1 (0.9%)	–
no data*	27 (15.2%)		–
COPD severity (FEV1 range)			
grade 1 (>80%)	2 (5.0%)	10 (11.4%)	–
grade 2 (50–80%)	21 (52.5%)	51 (57.9%)	–
grade 3 (30–50%)	16 (40.0%)	25 (28.4%)	–
grade 4 (<30%)	1 (2.5%)	2 (2.3%)	–
no data	52 (29.2%)		–
stage			
IA	0 (0.0%)	7 (5.7%)	–
IB	1 (2.0%)	1 (0.8%)	–
IIA	0 (0.0%)	3 (2.5%)	–
IIB	0 (0.0%)	3 (2.5%)	–
IIIA	6 (12.0%)	24 (19.7%)	–
IIIB	14 (28.0%)	36 (29.5%)	–
IIIC	5 (10.0%)	6 (4.9%)	–
IVA	13 (26.0%)	30 (24.6%)	–
IVB	11 (22.0%)	12 (9.8%)	–
no data	6 (3.4%)		–
I–IIIA	7 (13.7%)	35 (28.2%)	p = 0.041
IIIB–IVC	44 (86.3%)	89 (71.7%)	–
no data	3 (1.7%)		–
number of metastases			
1	11 (44.0%)	26 (60.5%)	–
2	7 (28.0%)	10 (23.2%)	–
3	6 (24.0%)	3 (7.0%)	–
4	1 (4.0%)	4 (9.3%)	–
no data	112 (62.9%)		–

p-values are given for differences between SCLC and NSCLC groups; n – number; NSCLC – non-small-cell lung cancer; SCLC – small-cell lung cancer; COPD – chronic obstructive pulmonary disease; * no data relate to the whole study group

characteristics of both diseases performed according to current guidelines [2]. The advantage of this study is its focus on the Polish population.

The main characteristics of patients with COPD and lung cancer from other studies was shown in table VI. In our study, we reported a similar mean age of patients as in other studies as well as sex distribution, which was almost equal in men and women. It is confirmed in a few studies [9, 11, 13], but most of them show a higher proportion of men [8, 10, 14–20]. Lung cancer and COPD are the diseases generally considered attributable to men. Our results indicate the tendency of high incidence of COPD as well as lung cancer among women which was confirmed by epidemiological studies [22]. In our study, the number of women and men was similar and the features of both serious diseases unexpectedly did not differ in statistical analysis. However, smoking exposure was significantly higher in men than in women, as in other studies [22]. In women, cigarette smoke has a greater influence on developing lung cancer because of the differences in lung anatomy and lung development, as well as other factors such as different hormonal effects due to estrogen playing an important role [23]. Our observation indicates women need to be perceived on the same level in the context of careful early diagnosis and screening programs in lung cancer as well as COPD. The common opinion among physicians should be verified.

Cigarette smoke is the main risk factor for developing COPD and lung cancer [22, 24]. In our study group, almost all of the patients were exposed to cigarette smoke. Interestingly most of the patients are still current smokers after establishing the diagnosis despite medical advice to quit smoking. COPD often remains undiagnosed for a long time [19, 25]. In our group of patients, almost 50% were diagnosed with COPD during the diagnosis of lung cancer. It is a striking number and underlines the importance of active COPD diagnosing in smokers and the need for multiple pulmonary function tests in every smoking patient over the years. COPD with predominance of emphysema are known to be a poor prognostic indicator in lung cancer patients [21, 26]. In our study, more than half of patients presented COPD phenotype with emphysema. However, groups with and without emphysema did not differ statistically in clinical characteristics. COPD with emphysema-predominant phenotype decreases the 5-year survival rate up to 5.4% [26] in stage III–IV, and to 65.2% in stage I–II [27]. In our study, the survival rate is low due to the high proportion of advanced cancer stages (III and IV) (fig. 2). Stage III and IV are the most common and represent almost 70% of newly diagnosed lung cancer [28], in patients with a coexistence of COPD even more: 68.5–88% [11, 13, 15, 17]. A similar observation was found in our study. Some explanation of more advanced stages in cases with coexistence of COPD than in lung cancer only could be a delayed diagnosis in patients with initially COPD. Patients attribute symptoms like cough and dyspnea to COPD, and vigilance for lung cancer is lower [25].

Thanks to increasing cancer vigilance and modern diagnostic methods, more lung cancers are diagnosed at the stages which are potentially resectable over the years. Surgery is the most effective treatment approach but it can only be used in patients with stages I–IIIA. 20.7% of lung cancer patients undergo surgery in USA [29], while in Poland it is about 20% [30]. In the majority of cases COPD is a serious and important contraindication for surgery, especially with severe and very severe obstruction. Because of that less patients are qualified to this radical treatment [4]. In our study, FEV1% of less than 30% was reported in only 3% of patients, but FEV1% 30–50% was reported in even 30% of patients, what had a serious influence on treatment choice. Finally, only 10% of our patients underwent surgical excision of lung cancer, which is not a satisfactory rate, but common among COPD patients [27].

SCLC represents about 13–15% of lung cancers [27]. Our study reports almost twice the incidence of SCLC in COPD patients. There are a few recent studies which analyze COPD with SCLC and NSCLC patients together [13, 16, 18]. The proportion of SCLC patients in these studies is as follows: 7.4%, 9.0%, 2.2%. The difference depends on the method of the selection of the study group. The credibility of our study is underlined by the examination of the full available database of consecutively admitted to our department patients without selection of patients. The high proportion of SCLC is undoubtedly connected with heavy smoking, also among women.

Similarly to the high proportion of SCLC in our group, we also noted the predominance of SCC in patients with NSCLC, probably as a result of the high burden of smoking history. We also compared patients with SCC versus non-SCC since SCC is much more connected with smoking than ADC. The more immunological dysfunctions and destruction of tissue present in COPD patients, the more that favors the development of SCC; for this group immunotherapy could be a promising treatment option [5]. SCC in our study group was no different from the others.

An important limitation of this study is its retrospective character. Thus, some data were lacking in some patients. It especially concerns lung cancer molecular characteristics, programmed death ligand 1 (PD-L1) expression, qualifications to modern therapies and patients' outcome.

Conclusions

In summary, COPD in patients with lung cancer is an important and growing clinical problem. High incidences of COPD as well as lung cancer among women is striking. The clinical pattern of lung cancer coexists with COPD. Lung cancer was considered a male disease, however the frequency of lung cancer and COPD in women and men is similar. Almost half of cigarette smoking patients were diagnosed with COPD while simultaneously diagnosing lung tumors. A long history of smoking is still the main factor for developing both of these diseases. More epidemiological studies on large groups of patients are

Table VI. Demographic data, lung cancer and COPD characteristics from articles published in years 2017–2023 focused on patients with coexistence of lung cancer and COPD. Data are given as number and percentages or mean ± standard deviation

Name, year	Patients number	M/F	Age (years)	Smoking history N/F/C (pack years)	SCLC/ NSCLC	ADC/ SCC/ other	STAGE I/II/III/IV	GOLD 1/2/3/4	Main finding
Dos Santos 2022 [15]	18	12/6	70.2 ± 9.2	69 (50–106)	ND	ND	ND	4/7/7/0	COPD with lung cancer was associated with elevated DNA damage in peripheral lymphocytes
Sandelin 2018 [16]	594	291/303	68.9 ± 8.5	ND	ND	ND	ND	ND	asthma diagnosis and use of inhaled corticosteroids were independently related to decreased risk of lung cancer in COPD patients, while the use of acetylsalicylic acid was associated with an increased risk
Yi 2018 [17]	170	154/16	70.4 ± 8.9	ND/18/152 ND/10.6%/89.4%	0/100%	60/94	0/0/70/ 100	35/103/24/8	high prevalence of COPD among patients with advanced NSCLC, COPD patients complained about various symptoms had diminished quality of life
Schwan Media 2018 [18]	329	191/138	69.4 ± 9.0	7/121/195 2.2%/37.5%/ 64.0% (40.6 ± 21.1)	0/100%	126/136	11.2%/20.5%/36.0%/32.5%	ND	COPD nor other common comorbidities are significantly associated with higher mortality in NSCLC patients
Sunmi 2018 [19]	57	52/5	67.5 ± 7.4	4/22/31 7.0%/38.6%/54.4% (49.5 ± 24.2)	100%/0	ND	24/33 LD/ED	19/21/16/4	although over half of the SCLC patients receiving chemotherapy had COPD, coexisting COPD had no impact on the survival of patients with SCLC
Lim 2019 [20]	68	30/38	75.2 (48–89)	ND	7.4%/92.6%	ND	15/5/9/39	FEV1% 78.4% ± 20.2	never-smoker NSCLC patients with COPD had shorter OS times, compared to non-COPD never-smoker NSCLC patients
Takegahara 2017 [21]	108	86/22	69.3 (46–84)	ND/63/45 ND/55.6%/44.4%	0/100%	53/38	73/23/12/0	ND	for lung cancer patients with COPD, preoperative management using LABA or LAMA bronchodilators and smoking cessation can reduce the frequency of postoperative pulmonary complications after surgical lung resection
Omote 2017 [22]	43	37/6	67 ± 8	(58.5 ± 37)	0/100%	28/7/8	4/1/9/29	27/16/0/0	mild to moderate COPD did not have a significant deleterious impact on toxicity and prognosis in NSCLC patients
Wang 2018 [23]	724	636/88	62.6 ± 8.5	31.1%/68.9% (N/F and C)	9%/81%	341/263/55	71.9%/21%/ 5.7% (I/II/III+IV)	75%/21%/4% (1/2/ 3 and 4)	COPD, especially emphysema-predominant phenotype, is an independent prognostic risk factor for squamous carcinoma only
Yuan 2022 [24]	20	20/0	66.3 ± 7	1/7/12	0/100%	10/6/4	2/15 (I–II/III–IV)	ND	coexistence of COPD leads to worse clinical manifestations and altered gene mutation profiles in patients with NSCLC

→

Table VI cont. Demographic data, lung cancer and COPD characteristics from articles published in years 2017–2023 focused on patients with coexistence of lung cancer and COPD. Data are given as number and percentages or mean ± standard deviation

Suzuki 2022 [25]	132	125/7	70.5 ± 7	ND/85/47	3/132	69/52/8	98/24/9/1	66/58/8/0	the COPD phenotype with both emphysema and bronchial wall thickness on chest CT was associated with poorer performance status, greater extent of dyspnea, greater impairment of pulmonary function, and worse prognosis in patients after surgical resection of lung cancer
Yo 2022 [26]	221	200/ 21	70.7 ± 8.97	37/184 (N/F and C)	0/100%	77/117/27	0/0/106/115	51/121/44/4	pretreatment spirometry and maximal treatment for COPD may offer a chance of optimal management for patients with advanced NSCLC.
Hu 2018 [27]	643	551/92	64.9 ± 8.5	364/279 (N and F/C)	0/100%	302/206/35	378/117/139/9	ND	COPD is a common comorbidity of early stage lung cancer. Lung cancer patients with coexistence of COPD have obviously different clinicopathological features compared to patients without COPD, which requires special attention and management during the perioperative period of lung cancer

ADC – adenocarcinoma; COPD – chronic obstructive pulmonary disease; CT – computed tomography; C – current; DNA – deoxyribonucleic acid; F – female; F – former; GOLD – Global Initiative for Chronic Obstructive Lung Disease; LABA – long-acting beta agonists; LAMA – long-acting muscarinic antagonist; M – male; N – never; ND – no data; NSCLC – non-small-cell lung cancer; SCC – squamous-cell carcinoma; SCLC – small-cell lung cancer

needed for a full understanding of the correlation between COPD and lung cancer.

Article information and declarations

Data availability statement

All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

Ethics statement

This study protocol was reviewed and approved by the Committee of Research Ethics of the Medical University of Warsaw.

Author contributions

Robert Uliński – responsible for the concept and design of the study; involved in data collection; analyzed the data; was responsible for statistical analysis; wrote the manuscript.
Marta Dąbrowska – responsible for the concept and design of the study.
Joanna Domagała-Kulawik – responsible for the concept and design of the study; analyzed the data; wrote the manuscript.
All authors edited and approved the final version of the manuscript.

Acknowledgments

The authors thank Iwona Kwiecień for her supervision.

Conflict of interest

Non declared

Robert Uliński
Medical University of Warsaw
Pulmonary Diseases and Allergy
Department of Internal Medicine
ul. Żwirki i Wigury 61a
02-091 Warszawa, Poland
e-mail: robert.ulinski@wp.pl

Received: 28 Aug 2023
Accepted: 17 Oct 2023

References

1. Allemani C, Matsuda T, Di Carlo V, et al. CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125): 1023–1075, doi: 10.1016/S0140-6736(17)33326-3, indexed in Pubmed: 29395269.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report; 2020. https://goldcopd.org/ (20.06.2023).
3. Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015; 90(2): 121–127, doi: 10.1016/j.lungcan.2015.08.017, indexed in Pubmed: 26363803.
4. Hashimoto N, Matsuzaki A, Okada Yu, et al. Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients. BMC Pulm Med. 2014; 14: 14, doi: 10.1186/1471-2466-14-14, indexed in Pubmed: 24498965.
5. Uliński R, Kwiecień I, Domagała-Kulawik J. Lung Cancer in the Course of COPD-Emerging Problems Today. Cancers (Basel). 2022; 14(15), doi: 10.3390/cancers14153819, indexed in Pubmed: 35954482.
6. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Thoracic-Tumours-2021 (20.06.2023).
7. Lim W, Ridge CA, Nicholson AG, et al. The 8 lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. Quant Imaging Med Surg. 2018; 8(7): 709–718, doi: 10.21037/qims.2018.08.02, indexed in Pubmed: 30211037.
8. Dos Santos CF, Braz MG, de Arruda NM, et al. DNA damage and antioxidant capacity in COPD patients with and without lung cancer. PLoS One. 2022; 17(11): e0275873, doi: 10.1371/journal.pone.0275873, indexed in Pubmed: 36327269.
9. Sandelin M, Mindus S, Thuresson M, et al. Factors associated with lung cancer in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018; 13: 1833–1839, doi: 10.2147/COPD.S162484, indexed in Pubmed: 29922050.
10. Yi YS, Ban WHo, Sohng KY. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer. BMC Cancer. 2018; 18(1): 1053, doi: 10.1186/s12885-018-4976-3, indexed in Pubmed: 30373585.
11. Media AS, Persson M, Tajhizi N, et al. Chronic obstructive pulmonary disease and comorbidities' influence on mortality in non-small cell lung cancer patients. Acta Oncol. 2019; 58(8): 1102–1106, doi: 10.1080/0284186X.2019.1612942, indexed in Pubmed: 31092081.
12. Ju S, Lee HR, Kim JY, et al. Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy. Thorac Cancer. 2018; 9(10): 1271–1278, doi: 10.1111/1759-7714.12832, indexed in Pubmed: 30109781.
13. Lim JUk, Yeo CD, Rhee CK, et al. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients. Int J Chron Obstruct Pulmon Dis. 2019; 14: 929–938, doi: 10.2147/COPD.S190244, indexed in Pubmed: 31118602.
14. Takegahara K, Usuda J, Inoue T, et al. Preoperative management using inhalation therapy for pulmonary complications in lung cancer patients with chronic obstructive pulmonary disease. Gen Thorac Cardiovasc Surg. 2017; 65(7): 388–391, doi: 10.1007/s11748-017-0761-5, indexed in Pubmed: 28281043.
15. Omote N, Hashimoto N, Morise M, et al. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy. Int J Chron Obstruct Pulmon Dis. 2017; 12: 3541–3547, doi: 10.2147/COPD.S149456, indexed in Pubmed: 29270008.
16. Wang W, Dou S, Dong W, et al. Impact of COPD on prognosis of lung cancer: from a perspective on disease heterogeneity. Int J Chron Obstruct Pulmon Dis. 2018; 13: 3767–3776, doi: 10.2147/COPD.S168048, indexed in Pubmed: 30538439.
17. Yuan L, Guo T, Hu C, et al. Clinical characteristics and gene mutation profiles of chronic obstructive pulmonary disease in non-small cell lung cancer. Front Oncol. 2022; 12: 946881, doi: 10.3389/fonc.2022.946881, indexed in Pubmed: 36267961.
18. Suzuki Y, Kitaguchi Y, Ueno F, et al. Associations Between Morphological Phenotypes of COPD and Clinical Characteristics in Surgically Resected Patients with COPD and Concomitant Lung Cancer. Int J Chron Obstruct Pulmon Dis. 2022; 17: 1443–1452, doi: 10.2147/COPD.S366265, indexed in Pubmed: 35761955.
19. Jo H, Park S, Kim NE, et al. Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer. J Clin Med. 2022; 11(9), doi: 10.3390/jcm11092391, indexed in Pubmed: 35566517.
20. Hu XL, Xu ST, Wang XC, et al. Status of coexisting chronic obstructive pulmonary disease and its clinicopathological features in patients undergoing lung cancer surgery: a cross-sectional study of 3,006 cases. J Thorac Dis. 2018; 10(4): 2403–2411, doi: 10.21037/jtd.2018.03.165, indexed in Pubmed: 29850146.
21. Gao YH, Guan WJ, Liu Qi, et al. Impact of COPD and emphysema on survival of patients with lung cancer: A meta-analysis of observational studies. Respirology. 2016; 21(2): 269–279, doi: 10.1111/resp.12661, indexed in Pubmed: 26567533.
22. O'Keeffe LM, Taylor G, Huxley RR, et al. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open. 2018; 8(10): e021611, doi: 10.1136/bmjopen-2018-021611, indexed in Pubmed: 30287668.
23. Orzołek I, Sobieraj J, Domagała-Kulawik J. Estrogens, Cancer and Immunity. Cancers (Basel). 2022; 14(9), doi: 10.3390/cancers14092265, indexed in Pubmed: 35565393.

24. Malhotra J, Malvezzi M, Negri E, et al. Risk factors for lung cancer worldwide. Eur Respir J. 2016; 48(3): 889–902, doi: 10.1183/13993003.00359-2016, indexed in Pubmed: 27174888.
25. Dai J, He Y, Maneenil K, et al. Timing of chronic obstructive pulmonary disease diagnosis in lung cancer prognosis: a clinical and genomic-based study. Transl Lung Cancer Res. 2021; 10(3): 1209–1220, doi: 10.21037/tlcr-20-1017, indexed in Pubmed: 33889503.
26. Ajimizu H, Ozasa H, Sato S, et al. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer. Sci Rep. 2021; 11(1): 23677, doi: 10.1038/s41598-021-03139-5, indexed in Pubmed: 34880386.
27. Wang Q, Gümüş ZH, Colarossi C, et al. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. J Thorac Oncol. 2023; 18(1): 31–46, doi: 10.1016/j.jtho.2022.10.002, indexed in Pubmed: 36243387.
28. Guibert N, Barlesi F, Descourt R, et al. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. J Thorac Oncol. 2017; 12(6): 963–973, doi: 10.1016/j.jtho.2017.02.001, indexed in Pubmed: 28189832.
29. lung org/media/press-releases/solc. https://www.lung.org/media/press-releases/solc-2021 (2021).
30. Adamek M, Biernat W, Chorostowska-Wynimko J, et al. Lung Cancer in Poland. J Thorac Oncol. 2020; 15(8): 1271–1276, doi: 10.1016/j.jtho.2020.03.035, indexed in Pubmed: 32718535.

VIA MEDICA

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 420–428

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

Artykuł oryginalny / Original article

Rak płuca / Lung cancer

Analysis of the clinical and pathological characteristics of patients with the squamous-cell lung carcinoma including group survival rates and the occurrence of symptoms depending on the extent of the tumor

Weronika Targosz[1], Julia Świerczek[1], Błażej Ochman[1], Paweł Kiczmer[2], Paweł Ziora[2], Mateusz Rydel[3], Damian Czyżewski[3], Maciej Borowiecki[1], Bogna Drozdowska[2]

[1]*Medical University of Silesia, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland*
[2]*Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland*
[3]*Department of Thoracic Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland*

Introduction. Non-small-cell lung carcinoma (NSCLC) constitutes 80% of all lung cancer cases, of which 25–30% are squamous-cell carcinoma (SCC). We investigated the impact of comorbidities and other risk factors on the survival of patients with SCC, including the correlation between symptoms and the maximum tumor size.

Materials and methods. The study cohort included 417 patients. The Kaplan-Meier method, the Log-rank test, Gehan's generalized Wilcoxon test, the Mann-Whitney U test, the t-test and Cox's model of proportionality of hazards were applied.

Results. The maximum tumor size exhibited a significant correlation with the presence of symptoms such as cough, hemoptysis, and weight loss. Patients who presented with a positive family history of cancer, a prior history of cancer, respiratory diseases, or hypertension experienced a notably reduced survival time.

Conclusions. Patient's symptoms and their medical history are important in predicting survival.

Key words: lung, carcinoma, squamous-cell, survival analysis

Introduction

According to the GLOBOCAN data for the year 2020, lung cancer constitutes 11.4% of all malignant tumors in terms of morbidity, and it is responsible for 18% of deaths caused by malignant tumors worldwide. Non-small-cell lung carcinoma (NSCLC) constitutes 80% of all lung carcinoma cases, of which 25–30% are squamous-cell carcinoma. The prognosis for patients diagnosed with lung cancer is unfavorable and is closely associated with the cancer's stage at the time of diagnosis, and the specific subtype of NSCLC. Men demonstrate a higher incidence of lung cancer compared to women, a discrepancy probably linked to lifestyle and genetic factors [1–5].

Among NSCLC, squamous-cell lung carcinoma (SCC) is the cancer most strongly associated with smoking. The role of classic or electronic cigarette fumes in the pathogenesis of SCC may be related to a decreased DNA methylation in regions strictly responsible for the proper functioning of the respiratory epithelium. In addition to active smoking, it is important to consider the role of passive smoking, which significantly influences the occurrence of lung cancer. There is substantial evidence suggesting that passive smoking has

Jak cytować / How to cite:

Targosz W, Świerczek J, Ochman B, Kiczmer P, Ziora P, Rydel M, Czyżewski D, Borowiecki M, Drozdowska B. ***Analysis of the clinical and pathological characteristics of patients with the squamous-cell lung carcinoma including group survival rates and the occurrence of symptoms depending on the extent of the tumor.*** *NOWOTWORY J Oncol* 2023; 73: 338–346.

a greater impact on the development of adenocarcinoma than on the development of SCC. The SCC is also associated with environmental factors, genetic predisposition, i.e. a positive family history of cancer, positive cancer history, and also comorbidities – especially lung diseases [6–9].

Symptoms of centrally located tumors are most often a cough, as well as symptoms resulting from atelectasis or obstructive pneumonia, i.e. shortness of breath. Haemoptysis, which is often associated with lung cancer, may occur in SCC due to the extravasation of blood from the bronchial artery within the tumor or less often, from the pulmonary artery [4, 6].

The aim of the study was to determine the characteristics of patients with SCC and the characteristics of tumors such as size, TNM grade, and histopathological grade. The study also aimed to detect a possible relationship between exposure to risk factors and patient survival, so as to detect a correlation between patients' symptoms and maximum tumor size.

Materials and methods

The study included a cohort of 417 patients diagnosed with SCC who underwent radical anatomical resection of the lung tissue (segmentectomy, lobectomy, bilobectomy or pneumonectomy) due to lung cancer between May 2012 and December 2021. A dedicated database was established to compile the medical records of all patients who underwent surgery for lung cancer. Patients were observed for five years from the day of surgery. Data about patients' survival was collected up to 1st May 2022. All further outcomes were considered incomplete. Inclusion criteria: primary SCC confirmed histologically, lobectomy or pneumonectomy, age over 18. Exclusion criteria: histopathologically confirmed adenocarcinoma, histopathologically confirmed secondary lung cancer, the presence of more than one histologically different tumor in the specimen. Limits of our study: lack of information about patients after the end of the 5-year follow-up, lack of exact information about death, lack of exact data about chemotherapy. The detailed study design is presented in figure 1.

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the Medical University of Silesia (No PCN/0022/KB/27/21).

Statistical analysis

Data is presented as the number of cases with percentage and for quantative variables as mean +/– SD or median with Q1 and Q3. The normality assumption was tested for each quantitative variable based on a graphical interpretation of the Q-Q plots and histograms. Odds ratios with 95% confidence intervals were calculated for categorical variables. Pearson's chi-square test, the t-test and the Wilcoxon test were used to determine the significance of differences between groups with different selected characteristics. The Kaplan–Meier method was used to determine the probabilities of survival among the groups. The comparison of survival was performed using the Mantel-corrected log-rank test during which more than two groups were compared. To assess the impact of variables on patient survival, the Cox proportional hazards model was used. P-values less than 0.05 were considered significant. The analysis was carried out using the Rlanguage in the Rstudio software.



Figure 1. Study design flowchart

Results

The study encompassed 281 male and 136 female participants. Among the study participants, 81.5% were active cigarette smokers, while 73.4% had been exposed to second-hand smoke. Complications during the surgical procedure affected 33.3% of patients. The predominant T classifications for the cancer cases were T2 (36.1%) and T1 (33.6%). The majority of patients showed no neoplastic involvement in their lymph nodes (61.3%). Most patients presented with a histopathological malignancy of grade G2. A total of 1.4% of patients died during hospitalization. The mean age of the participants in the study was approximately 68 years. The median pack-years for smokers was approximately 40 years. The median maximum tumor size was 40.00 mm, and the median survival duration was 1321 days (approximately 3.5 years). Notably, no

statistically significant differences were observed between the groups (p > 0.05) (tab. I).

Symptoms indicative of neoplastic disease were reported by 54.9% of the patients. A cough was the most frequently reported symptom, accounting for 41.0% of the total cases and prevalent among both smokers and non-smokers. The median of weight loss was 8.00 kg in the smoking group and 6.50 kg in the non-smoking group. The median of percentage weight loss was 10.00% in the smoking group and 9.00% in the non-smokers group. There were no significant differences observed between these groups (p > 0.05) (tab. I).

A positive cancer history concerned 15.8% of patients, while a positive family history of cancer was noted in 14.9% of patients. Surgical risk factors were identified in 58.3% of patients, with hypertension (60.2%), non-insulin-dependent diabetes mellitus (24.9%), respiratory system diseases (24.5%), and coronary artery disease (24.2%) being the prevailing factors. Statistically significant differences were ob-

Table I. Characteristics of patients grouped by smoking status (n = 417)

Characteristic	Overall	Smoker		p-value
		No	Yes	
	n (%)	n (%)	n (%)	
smoking cigarettes	340 (81.5%)	–	–	–
second-hand smoking	306 (73.4%)	–	–	–
gender				
male	281 (67.4%)	54 (70.1%)	227 (66.8%)	0.664
female	136 (32.6%)	23 (29.9%)	113 (33.2%)	
surgery complication	139 (33.3%)	25 (32.5%)	114 (33.5%)	0.964
hemothorax requiring re-surgery	15 (3.6%)	4 (5.2%)	11 (3.2%)	0.621
blood tranfusion during or after surgery	36 (8.6%)	5 (6.5%)	31 (9.1%)	0.606
drainage	40 (9.6%)	12 (15.6%)	28 (8.2%)	0.078
disease symptoms	229 (54.9%)	35 (45.5%)	194 (57.1%)	0.085
pain	15 (3.6%)	1 (1.3%)	14 (4.1%)	0.389
hemoptysis	48 (11.5%)	6 (7.8%)	42 (12.4%)	0.350
dyspnoea	17 (4.1%)	3 (3.9%)	14 (4.1%)	1.000
cough	171 (41.0%)	30 (39.0%)	141 (41.5%)	0.783
weight loss	21 (5.0%)	2 (2.6%)	19 (5.6%)	0.427
TNM scale				
T feature				
I	135 (33.6%)	23 (30.7%)	112 (34.3%)	0.860
II	145 (36.1%)	27 (36.0%)	118 (36.1%)	
III	80 (19.9%)	18 (24.0%)	62 (19.0%)	
IV	41 (10.2%)	7 (9.3%)	34 (10.4%)	
x	1 (0.2%)	0 (0.0%)	1 (0.3%)	
N feature				
0	253 (61.3%)	44 (57.1%)	209 (62.2%)	0.719
I	87 (21.1%)	16 (20.8%)	71 (21.1%)	
II	5 (1.2%)	1 (1.3%)	4 (1.2%)	
x	68 (16.5%)	16 (20.8%)	52 (15.5%)	
M feature = x	410 (100.0%)	77 (100.0%)	333 (100.0%)	

→

Table I cont. Characteristics of patients grouped by smoking status (n = 417)

Characteristic	Overall	Smoker		p-value
		No	Yes	
	n (%)	n (%)	n (%)	
grade				0.301
I	27 (6.5%)	3 (3.9%)	24 (7.1%)	
II	222 (53.2%)	48 (62.3%)	174 (51.2%)	
III	141 (33.8%)	24 (31.2%)	117 (34.4%)	
IV	1 (0.2%)	0 (0.0%)	1 (0.3%)	
x	26 (6.2%)	2 (2.6%)	24 (7.1%)	
death during hospitalization	6 (1.4%)	1 (1.3%)	5 (1.5%)	1.000
quantitative characteristics				
pack-years				
median	30.00	–	–	–
q1	20.00	–	–	–
q3	45.00	–	–	–
age during surgery				0.387
mean	67.77	68.44	67.62	
stabilization of the disease (SD)	7.11	7.63	6.99	
weight loss (kg)				
median	8.00	6.50	8.00	0.586
q1	4.00	4.75	4.50	
q3	10.00	8.25	11.00	
weight loss (%)				
median	10.00	9.00	10.00	0.809
q1	5.00	6.00	6.50	
q3	15.00	12.00	16.50	
maximum tumor size (mm)				0.987
median	40.00	40.00	40.00	
q1	25.00	25.00	25.00	
q3	55.00	55.00	60.00	
5-year survival (days)				0.731
median	1321.00	1251.00	1358.00	
q1	623.00	684.00	622.00	
q3	1825.00	1825.00	1825.00	

x – feature cannot be assessed

served between smokers and non-smokers who had experienced a myocardial infarction more than six months prior and those diagnosed with coronary artery disease. A higher percentage of patients who had a myocardial infarction six months earlier ($p = 0.022$) and a greater proportion of patients diagnosed with coronary artery disease ($p = 0.044$) were non-smokers (tab. II).

The median of the maximum tumor size was higher among patients who reported disease symptoms. The Wilcoxon test analysis revealed that these differences were highly significant ($p < 0.001$). The median of the maximum tumor size was significantly larger in the group of patients who reported hemoptysis ($p = 0.023$), a cough ($p = 0.0012$) and weight loss ($p = 0.002$) as disease symptoms (tab. S–I [supplementary files], fig. 2).

Table II. Overall medical history and depending on smoking status (n = 417)

Characteristic	Overall	Smoker		p-value
		No	Yes	
	n (%)	n (%)	n (%)	
positive cancer history	66 (15.8%)	17 (22.1%)	49 (14.4%)	0.136
positive family history of cancer	62 (14.9%)	10 (13.0%)	52 (15.3%)	0.737
surgery risk factors and comorbidities	243 (58.3%)	49 (63.6%)	194 (57.1%)	0.353
insulin-dependent diabetes	2 (0.5%)	1 (1.3%)	1 (0.3%)	0.811
insulin-independent diabetes	104 (24.9%)	26 (33.8%)	78 (22.9%)	0.066
cardiac infarction ≤6 months	2 (0.5%)	1 (1.3%)	1 (0.3%)	0.811
cardiac infarction >6 months	35 (8.4%)	12 (15.6%)	23 (6.8%)	0.022
epilepsy	1 (0.2%)	0 (0.0%)	1 (0.3%)	1.000
circulatory failure	8 (1.9%)	2 (2.6%)	6 (1.8%)	0.983
kidney failure	2 (0.5%)	1 (1.3%)	1 (0.3%)	0.811
COPD	83 (19.9%)	13 (16.9%)	70 (20.6%)	0.564
varicose veins and lower extremity venous insufficiency	10 (2.4%)	0 (0.0%)	10 (2.9%)	0.267
hypertension	251 (60.2%)	50 (64.9%)	201 (59.1%)	0.416
coronary artery disease	101 (24.2%)	26 (33.8%)	75 (22.1%)	0.044
respiratory system diseases	102 (24.5%)	17 (22.1%)	85 (25.0%)	0.695
chronic bronchitis	2 (0.5%)	0 (0.0%)	2 (0.6%)	1.000
bronchial asthma	18 (4.3%)	5 (6.5%)	13 (3.8%)	0.465
post-tuberculosis changes in the lungs	4 (1.0%)	0 (0.0%)	4 (1.2%)	0.757

COPD – chronic obstructive pulmonary disease

The median of the maximum tumor size was higher in the group of patients who reported pain (p = 0.47) and dyspnoea (p = 0.054) as disease symptoms. It is essential to note that these differences were not statistically significant (tab. S–I, fig. S–1 [supplementary files]). There were no statistically significant differences in survival duration observed between women and men (p = 0.060) (tab. III, fig. S–2 [supplementary files]). Patients with a positive cancer history were almost twice as likely to experience mortality compared to those with a negative cancer history (p = 0.008) (tab. III, fig. S–3 [supplementary files]). Likewise, patients with a positive family history of cancer had twice the risk of mortality in comparison to those with a negative family history of cancer (p = 0.002) (tab. III, fig. S–4 [supplementary files]). The group of patients exposed to second-hand smoking exhibited an almost sixfold higher risk of mortality compared to those who were not exposed to second-hand smoking (p < 0.001) (tab. III). Patients with surgical risk factors had a fivefold higher risk of death compared to patients without surgical risk factors (p < 0.001) (tab. III, fig. S–5 [supplementary files]).

Patients with hypertension had an approximately twofold higher risk of death compared to those without hypertension (p = 0.011) (tab. III–IV, fig. 3). The division of the patients by gender revealed a significant impact of hypertension on survival exclusively within the male group. There were no significant differences in survival between women with hypertension compared to the group of women without hypertension (fig. 4, S–6 [supplementary files]). Patients with respiratory system diseases had a mortality risk nearly twice as high as those without this group of comorbidities (p = 0.035) (tab. III, fig. 5).

Compared to patients with T1 cancer, patients with T2 had a twofold higher risk of death (p = 0.006), while T3 patients had an almost threefold higher risk (p < 0.001), and T4 patients had an almost fourfold higher risk of death (p < 0.001). Patients with the N feature at the N2 level had an approximately sevenfold higher risk of death compared to patients with N0 (p < 0.001) (tab. III, fig. S–7, S–8 [supplementary files]).

Patients with a tumor grade at G3 had an approximately threefold higher risk of death than patients with G1 (p = 0.047), while patients with G4 had a more than 100-times higher risk of death than patients with G1 (p < 0.001). Furthermore, patients with a larger maximum tumor size had a higher risk of death (tab. III, fig. S–9 [supplementary files]).

Discussion

Our study focused on patients with SCC. However, given that the majority of previous studies in this field have been predo-



Figure 2. Disease symptoms such as hemoptysis, coughing, and weight loss depending on the maximum tumor size (n = 417), boxplot

minantly based on NSCLC studies in general, and considering the similarities between squamous and non-squamous tumors concerning factors influencing postoperative survival, we have concentrated on discussing studies primarily grounded in NSCLC research.

The article by Iachin et al. [10] from 2014 presented the conclusions that patients with cardiovascular disease presented higher mortality rates. The conclusions also show that patients with lung diseases have a higher mortality rate. In our work, we also highlighted different survival rates in these groups of patients. Another study showed that patients with congestive heart failure (CHD) had a higher mortality rate. Likewise, our research revealed varying survival rates among groups of patients with similar comorbidities. Another study showed that patients with congestive heart failure (CHD) exhibited higher mortality rates. However, it was not possible to

Table III. Survival probability depending on specific features (n = 417)

Variable	Beta	HR (95% CI)	Wald. test	p-value
gender – female	–0.43	0.65 (0.42–1.00)	3.60	0.060
smoking cigarettes	–0.13	0.87 (0.54–1.40)	0.30	0.590
second-hand smoking	1.00	6.20 (2.90–13.00)	22.00	<0.001
positive cancer history	0.64	1.90 (1.20–3.00)	7.20	0.008
surgery risk factors and comorbidities	1.00	5.00 (2.90–8.40)	36.00	<0.001
hypertension	0.55	1.70 (1.10–2.70)	6.50	0.011
respiratory system disease	0.45	1.60 (1.00–2.40)	4.40	0.035
disease symptoms	–0.11	0.89 (0.6–1.30)	0.33	0.560
weight loss	-0.4×10^{-3}	1.00 (0.41–2.40)	0.00	0.990
positive family history of cancer	0.71	2.00 (1.30–3.20)	9.40	0.002
pack-years	–0.01	0.99 (0.99–1.00)	1.10	0.290
maximum tumor size	0.01	1.00 (1.00–1.00)	21.00	<0.001
T feature				
II	0.79	2.19 (1.25–3.84)	20.86	0.006
III	1.16	3.18 (1.76–5.76)		<0.001
IV	1.38	3.98 (2.07–7.65)		<0.001
x	–13.39	1.53×10^{-6} (0–Inf)		0.995
N feature				
I	0.06	1.06 (0.95–0.65)	15.56	0.822
II	1.99	7.34 (0.14–2.65)		<0.001
x	–0.15	0.86 (1.17–0.49)		0.594
grade				
II	0.48	1.61 (0.62–0.58)	23.40	0.360
III	1.04	2.82 (0.35–1.01)		0.047
IV	4.62	101.24 (0.01–10.22)		<0.001
x	0.35	1.42 (0.71–0.38)		0.604

x – feature cannot be assessed



Figure 3. Survival probability depending on hypertension appearance, the Kaplan–Meier curve (n = 417)



Figure 4. Survival probability for men depending on hypertension appearance, the Kaplan–Meier curve (n = 417)

delve into this topic extensively in our work due to the limited number of patients suffering from this condition. However, the assumption that cardiovascular diseases are a significantly negative prognostic factor in patients with lung cancer was



Figure 5. Survival probability depending on respiratory system disease appearance, the Kaplan–Meier curve (n = 417)

clarify. A study by Tammemagi [12] showed that the presence of comorbidities negatively affects the survival of patients with lung cancer both in early and late stages of the disease. This observation presents an intriguing avenue for future investigations into the prevention of lung cancer, particularly regarding the prevention of diseases that frequently coexist with this condition [10–12]. Agarwal's study revealed a significant correlation between gender and survival outcome of patients with SCC. This conclusion could not be drawn from our work [13].

A subsequent study, conducted in 1999, presents valuable information, some of which is reflected in our work. This study examined aspects such as quality of life before the onset of lung cancer, the manifestation of disease symptoms, and their impact on survival. The findings from this study indicated that the onset of >5% weight loss and the presence of dyspnea were unfavorable prognostic factors. Despite the passage of time, this study remains a relevant up-to-date analysis of information on how we can predict the course of patients' disease [14].

A study conducted by Montazeri focused on the quality of life of lung cancer patients in relation to survival time. In the study, deceased patients were more likely to report symptoms such as fatigue, loss of appetite, a cough, shortness of breath and haemoptysis. This is reflected in our study, especially weight loss symptoms, shortness of breath and haemoptysis. Additionally, the author emphasizes that the quality of life before the cancer diagnosis significantly impacts survival after diagnosis. This is a relevant topic for future research [15].

A study conducted by Osowiecka, Rucińska, Każarnowicz et al. [16] focused on the influence of gender, T and N features. According to the presented analysis results, gender and T feature had no significant impact on the survival of patients with non-small-cell lung carcinoma treated with radiation. That said, the N feature turned out to have a significant impact on the survival of these patients. Compared to the results of our study, there was no significant effect of gender on the survival of patients with NSCLC but the N feature was significant. Unlike the presented study, the T feature was significant as well. Nevertheless, the similarity of survival depending on N feature despite treatment method is worth to be pointed out, which creates an interesting area of future research [16].

Conclusions

The maximum tumor size significantly influences specific symptoms of patients suffering from squamous-cell lung carcinoma including hemoptysis, weight loss, and coughing. Moreover, patients with a positive family history of cancer and respiratory diseases exhibit reduced survival time following lobectomy. The 5-year survival rate is comparable between women and men. As regards the prediction of patient survival in cases of squamous-cell lung carcinoma, the relationships should be properly considered.

Article information and declarations

Data availability statement

The data presented in this study are available in this article.

Ethics statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Medical University of Silesia (No PCN/0022/KB/27/21).

Author contributions

Weronika Targosz – data curation, funding acquisition, project administration, supervision.
Julia Świerczek – data curation, funding acquisition, project administration, supervision.
Błażej Ochman – formal analysis, methodology, writing – original draft.
Paweł Kiczmer – data curation, formal analysis, funding acquisition, investigation, methodology, project administration, supervision, writing—review & editing.
Paweł Ziora – data curation, resources, writing – review & editing.
Mateusz Rydel – resources, software.
Damian Czyżewski – resources, writing – original draft, validation.
Maciej Borowiecki – software.
Bogna Drozdowska – investigation, resources, validation, writing – review & editing.
All authors have read and agreed to the published version of the manuscript.

Funding

None declared

Conflict of interest

None declared

Weronika Targosz
Medical University of Silesia
Faculty of Medical Sciences in Zabrze

ul. Poniatowskiego 15
40-055 Katowice, Poland
e-mail: s81421@365.sum.edu.pl

Received: 11 Sep 2023
Accepted: 30 Nov 2023

References

1. 39-All-Cancers-Fact-Sheet.Pdf.
2. Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013; 5 Suppl 4(Suppl 4): S389–S396, doi: 10.3978/j.issn.2072-1439.2013.07.10, indexed in Pubmed: 24102012.
3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249, doi: 10.3322/caac.21660, indexed in Pubmed: 33538338.
4. Jackson SS, Marks MA, Katki HA, et al. Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors. Cancer. 2022; 128(19): 3531–3540, doi: 10.1002/cncr.34390, indexed in Pubmed: 35934938.
5. Green J, Cairns BJ, Casabonne D, et al. Million Women Study collaborators. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011; 12(8): 785–794, doi: 10.1016/S1470-2045(11)70154-1, indexed in Pubmed: 21782509.
6. Drilon A, Rekhtman N, Ladanyi M, et al. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 2012; 13(10): e418–e426, doi: 10.1016/S1470-2045(12)70291-7, indexed in Pubmed: 23026827.
7. Tsai JC, Saad OA, Magesh S, et al. Tobacco Smoke and Electronic Cigarette Vapor Alter Enhancer RNA Expression That Can Regulate the Pathogenesis of Lung Squamous Cell Carcinoma. Cancers (Basel). 2021; 13(16), doi: 10.3390/cancers13164225, indexed in Pubmed: 34439379.
8. Kim AS, Ko HJ, Kwon JH, et al. Exposure to Secondhand Smoke and Risk of Cancer in Never Smokers: A Meta-Analysis of Epidemiologic Studies. Int J Environ Res Public Health. 2018; 15(9), doi: 10.3390/ijerph15091981, indexed in Pubmed: 30208628.
9. Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Health. 2019; 85(1), doi: 10.5334/aogh.2419, indexed in Pubmed: 30741509.
10. Iachina M, Jakobsen E, Møller H, et al. The effect of different comorbidities on survival of non-small cells lung cancer patients. Lung. 2015; 193(2): 291–297, doi: 10.1007/s00408-014-9675-5, indexed in Pubmed: 25516286.
11. Islam KM, Jiang X, Anggondowati T, et al. Comorbidity and Survival in Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2015; 24(7): 1079–1085, doi: 10.1158/1055-9965.EPI-15-0036, indexed in Pubmed: 26065838.
12. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003; 103(6): 792–802, doi: 10.1002/ijc.10882, indexed in Pubmed: 12516101.
13. Agarwal M, Brahmanday G, Chmielewski GW, et al. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer. 2010; 68(3): 398–402, doi: 10.1016/j.lungcan.2009.08.008, indexed in Pubmed: 19762109.
14. Herndon J, Fleishman S, Kornblith A, et al. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer. 1999; 85(2): 333–340, doi: 10.1002/(sici)1097-0142(19990115)85:2<333::aid-cncr10>3.0.co;2-q.
15. Montazeri A, Milroy R, Hole D, et al. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer. 2001; 31(2-3): 233–240, doi: 10.1016/s0169-5002(00)00179-3, indexed in Pubmed: 11165402.
16. Osowiecka K, Rucińska M, Każarnowicz A, et al. Przeżycia chorych na niedrobnokomórkowego raka płuca leczonych napromienianiem w latach 2003–2006 w Samodzielnym Publicznym Zakładzie Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie. Nowotwory. Journal of Oncology. 2015; 65(1): 14–22, doi: 10.5603/njo.2015.0003.

VIA MEDICA

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 429–435

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

Artykuł oryginalny / Original article

Epidemiologia nowotworów / Cancer epidemiology

Geographical disparities in survival rates for urological cancers in Poland from 2000 to 2015

Klaudia Barańska[1, 2], Marta Miklewska[1, 3], Iwona Wnętrzak[4], Urszula Wojciechowska[1], Joanna A. Didkowska[1, 5]

[1]*Polish National Cancer Registry, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland*
[2]*Faculty of Biomedical Engineering, Silesian University of Technology, Zabrze, Poland*
[3]*Department of Dietetics, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences, Warsaw, Poland*
[4]*Department of General and Oncological Urology, Praski Hospital, Warsaw, Poland*
[5]*Department of Epidemiology and Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland*

Introduction. In 2020 in Poland, urological cancers (testis, prostate, kidney, urinary bladder) accounted for 32% of cancer incidence among men and 5% among women. There has been an improvement in the survival rate for urological cancers in recent years. The aim of this study was to determine whether survival rates for urological cancers differ according to the region in Poland.

Material and methods. Data on 5-year relative survival come from the Polish National Cancer Registry and cover the patients diagnosed during period 2000–2014. The analysis was performed for four locations of urological cancers: prostate (C61), testis (C62), kidney (C64) and bladder (C67). Differences in survival rates are presented on maps divided into 16 voivodships.

Results. In the years 2000–2014, an increase in the 5-year survival rate of patients with urological cancer was recorded in Poland. A similar trend has been observed in other European countries, with the average survival rate of patients with prostate, bladder, kidney, and testicular cancer being lower in Poland than in the EU. We characterise the geographical differences between survival and the sex of the patient. In prostate, bladder, and kidney cancers, the highest survival rate was recorded in the Pomeranian Voivodship, regardless of gender and period.

Conclusions. In most of the analysed voivodships, survival rates for urological cancers increased in subsequent periods. This is proof that health care in Poland is continuously improving. The level of public knowledge in Poland about urological cancers is still low. National-scale educational and preventive campaigns are needed to achieve a greater increase in 5-year survival rates in the coming years.

Key words: urologic neoplasms, survival rate, Poland

Introduction

Regional differences in 5-year survival rates for the most common cancers are observed in most European countries. Among urinary tract cancers, an example is the survival rate for prostate cancer estimated in the Concord-3 project for selected European country regions analyzed for patients diagnosed in 2010–2014, for example France: 85.5% Somme region *vs.* 96.8% Herault region; Germany: 88.1% Bremen region *vs.* 93.9% Schleswig-Holstein region or Italy: 78.9% Latina region *vs.* 91.8% Ferrara region [1].

Jak cytować / How to cite:

Barańska K, Miklewska M, Wnętrzak I, Wojciechowska U, Didkowska JA. *Geographical disparities in survival rates for urological cancers in Poland from 2000 to 2015.* *NOWOTWORY J Oncol* 2023; 73: 347–353.

In 2020 in Poland, urological cancers (testis, prostate, kidney, urinary bladder) accounted for 32% of cancer incidence among men and 5% among women. Among men, the most common is prostate cancer. There is a continuing trend in which prostate cancer is the most frequently diagnosed cancer among men (19.6% of all incidences in 2020) [2]. Survival rates for testicular cancer, prostate cancer, kidney cancer, and bladder cancer are growing, as in other countries in Europe. In bladder cancer, the survival rate is higher among women than among men, unlike in Europe [3–6].

Survival studies show that survival rates for urologic cancer have improved in countries with the highest spending on health care [7]. In recent years, there has been an improvement in the survival rate for urological cancers, which may be related to the implementation of new drugs [8], and better health care facilities [9]. The purpose of this study was to determine whether survival rates for urological cancers differ depending on region and sex in Poland.

Material and methods

Data on 5-year relative survival come from the Polish National Cancer Registry [10]. The data cover patients diagnosed during the period 2000–2014 and are presented in three 5-year intervals (2000–2004, 2005–2009, 2010–2014). The Pohar-Perme estimator was used to calculate 5-year survival rates [11]. The analysis was performed for four locations of urological cancers: prostate (C61), testis (C62), kidney (C64) and bladder (C67). Differences in survival rates are presented on maps divided into 16 voivodships (fig. 1). All maps use the same percentage scale that corresponds to the same color. A color gradient was used to represent specific values in particular voivodships. All maps were prepared using Python software with the geopandas library [12]. The predefined Poland map was sourced from Chief Sanitary Inspectorate (Główny Inspektorat Sanitarny – GIS) support [13]. This website shares data from geoportal.gov.pl.

Results

Malignant neoplasm of the prostate (C61)

The 5-year survival rate for Poland was higher in each subsequent follow-up period. In the first observation period (2000–2004), the 5-year survival rate for prostate cancer was 70.6%. In the period (2005–2009) it was 76.6%, and in the last observation period (2010–2014) 81.8%.

During the initial observation period from 2000 to 2004, survival rates ranged between voivodeships from 57.5% to 76.8%. The Pomorskie Voivodeship and the Mazowieckie Voivodeship had the highest 5-year survival rates at 76.8% and 76.4%, respectively. Across all voivodeships, an improvement in the 5-year survival rate was observed at the end of the observation period compared to the initial period. The greatest improvement in the analyzed periods occurred in the Lubuskie Voivodship, with a significant increase of 28 percentage points (pp). Furthermore, this voivodeship was characterized by the highest 5-year survival rates in the final observation period (85.5%).

Malignant neoplasm of the testis (C62)

The 5-year survival rate for testicular cancer for Poland as a country was higher in each subsequent observation period. In subsequent observation periods, it was 85.3%, 86.2%, and 89.5%, respectively.

The 5-year survival rate for testicular cancer by voivodship was characterized by the greatest variability in the observed periods among the cancers analyzed. In the Pomorskie, Lubuskie, Lubelskie, and Opolskie Voivodships, the 5-year survival rate increased in the period 2005–2009 and then decreased in the most recent period. During the entire period, the greatest improvement in 5-year survival was observed in the Kujawsko-Pomorskie Voivodship (changed by 16.9 pp). In the last period, the highest 5-year survival rate was recorded in the Zachodniopomorskie Voivodship (99.4%), the Małopolskie Voivodship (95.2%), and the Podlaskie Voivodship (93.9%). In five voivodships (Łódzkie, Warmińsko-Mazurskie, Mazowieckie, Pomorskie, Lubuskie), the survival rate of the last observation period decreased compared to the initial observation period. The greatest reduction in the 5-year survival rate occurred in the Łódzkie Voivodship (reduction by 12.9 pp).

Malignant neoplasm of the kidney, except for the renal pelvis (C64)

The 5-year survival rate for kidney cancer increased in subsequent observation periods across both sexes. Among women in the first period (2000–2004), it was 59.3%, in the middle period (2005–2009) 65.6%, and in the last period (2010–2014) 70.6%. Among men during the same observation periods, survival rates were 54.3%, 58.8%, and 63.9% in the last period.

Over the years under observation, there was a gradual increase in the 5-year survival rate for kidney cancer among men. The largest increase in the 5-year survival rate occurred in the Pomorskie Voivodship (16.5 pp – 61.2% in the period [2000–2004], 77.7% in the period (2010–2014]). During the 2010–2014 period, the Pomorskie Voivodship also had the highest survival rate for this cancer. In the second period (2005–2009), compared to the first (2000–2004), three voivodships (Dolnośląskie, Opolskie, Lubuskie) showed a slight decline in the survival rate, respectively, 0.7, 1.9 and 2.4 pp. In the Podlaskie Voivodship, in the first two analyzed periods of 5-year survival (2000–2004, 2005–2009), the rates remained at the same level – 58.9%. For the period 2000–2005, the lowest survival rate was in the Zachodniopomorskie Voivodship – 45%. In the last observation period, this rate improved by 10 pp.

For women, a similar phenomenon was observed for this cancer site, and the 5-year survival rate increased with subsequent analyzed periods. The Świętokrzyskie Voivodship showed

the greatest increase (by 22.5 pp), reaching 76.2% in the period 2010–2014. But the voivodeship with the highest survival rate in the last period was the Pomorskie Voivodeship – 81%. In the Dolnośląskie Voivodeship, which had the highest survival rate (64.1%) in the first observation period, no improvement was observed in the second observed period. The lowest survival rate in the period 2000–2004 occurred in the Lubuskie Voivodeship (47.7%), but over the following years it improved (by 21.2 pp), and in the last observed period the lowest value of the survival rate was observed in the Zachodniopomorskie Voivodeship (59.8%). Moreover, in Podlaskie and Zachodniopomorskie voivodeships, there were a decline in the survival rate between the periods 2005–2009 and 2010–2014, while in the rest of the voivodeships there was an improvement in this rate.

Malignant neoplasm of the bladder (C67)

The results regarding 5-year survival rates for the entire country increase regardless of gender in the second observation period compared to the first period (among men in the period [2000–2004] 60.4% and in the period [2005–2009] 63.7%; among women in the period [2000–2004] it was 63.1% and in the period [2005–2009] 66.0%). Among men in the third period, it was slightly higher than in the second period (63.3% for the period [2010–2014] compared to 63.1% for the period [2005–2009]). Among women in the last observation period, the 5-year survival rates were lower than in the second observation period (in the period [2005–2009] 66.0% and in the period [2010–2014] 64.9%).

In the last observation period, the 5-year survival rate for bladder cancer for both sexes in the country was similar (63.3% among men and 64.9% among women), but greater disproportions were observed among women depending on the region of Poland. Among both sexes, the highest 5-year survival in the last year of observation were recorded in the following voivodships: Lubelskie, Pomorskie, and Świętokrzyskie. Among men, the highest 5-year survival rates were also observed in the Kujawsko-Pomorskie Voivodship and among women in the Małopolskie and Podkarpackie Voivodships.

For men, the situation worsened in the following 5 voivodeships: Zachodniopomorskie (–9.3 pp, from 60% to 50.7%), Dolnośląskie (–5.7 pp, from 65.3% to 59.6%), Łódzkie (–2.3 pp, from 65.3% to 63%) Śląskie (–1.9 pp, from 60.6% to 58.7%), and Wielkopolskie (–1.7 pp, from 60.6% to 58.9%). The reduction in the 5-year survival rate among women in the last observation period in relation to the first observation period occurred in the six following voivodships: Mazowieckie (–8.1 pp, from 63.8% to 55.7%), Łódzkie (–7.3 pp, from 67.3% to 60%), Dolnośląskie (–6 pp, from 67.9% to 61.9%), Śląskie (–5.6 pp, from 60.9% to 55.3%), Opolskie (–5.5 pp, from 74.1% to 68.6%) and Podlaskie (–3.4 pp, from 66% to 62.6%).

Regardless of gender, the greatest improvement occurred in the Lubuskie Voivodship, 17.6 pp among men (from 43.2% to 60.8%), and 29.3 pp among women (from 36.5% to 65.8%).

Discussion

Survival serves as the most precise indicator of the future of the disease at a specific moment, deriving from data collected on all diagnosed individuals within a defined period and tracking their vital status until the conclusion of the observation period. Cancer mortality rates are crucial for guiding public health and health care priorities. They have proven valuable in recognizing potential distortions in metrics like cancer incidence and survival, such as the risk of overdiagnosis. When coupled with cancer survival data, cancer mortality rates can assess the long-term effectiveness of treatments [14]. The first work on the differentiation of medical care has dissatisfying results. Mortality rates have been observed since the end of the twentieth century, and regional differences within European countries have been observed for many years.

In the period 2000–2014, an increase in the 5-year survival rate of patients with urological cancer was recorded in Poland. A similar trend has been observed in other European countries, with the average survival rate of patients with prostate, bladder, kidney, and testicular cancer being lower in Poland than in the EU. In the CONCORD-3 study for the years 2000–2014, prostate cancer survival rates were higher than in Poland in 23 European countries [1].

The older EUROCARE-5 study for 2000–2007 noted that for testicular cancer, the age-standardized 5-year relative survival (RS) was 93% for patients from Northern Europe, 92% for those from Ireland/UK and from Central Europe, 89% for patients from Southern Europe, and 80% for patients from Eastern Europe. In Poland, the age-standardized 5-year RS was 78.3% [15]. However, for kidney cancer, the best prognosis was observed in Central Europe (64%), particularly in Austria and Germany showing figures ≥70%, and Southern Europe (64%). In Poland, the, age-standardized 5-year RS was 55.1%. For urinary bladder cancer, the best prognosis was observed in Southern and Northern Europe, particularly in Italy and Finland, where survival was ≥75%. In Poland, age-standardized 5-year RS was 61.5% [16].

The lead time is important to assess the survival rate, especially in the case of prostate cancer. Due to the small number of publications on this topic from Europe, we used data from the United States. In prostate cancer, after the introduction of PSA testing, the diagnostic advance is approximately 4.59 years for white people and 6.78 years for black people [17].

In kidney cancer, early stage diagnosis is strongly correlated with survival rates: 5-year cancer-specific survival rates for patients diagnosed with stage I and IV kidney cancer in Europe are 83% and 6%, respectively [18]. In bladder cancer, early detection by cystoscopy or urinary sediment cytology prolongs survival. The relative 5-year survival rates for whites *vs.* blacks are overall 81% *vs.* 58%; for localized disease, 88% *vs.* 74%; for regional disease, 44% *vs.* 30%; for distant disease, 9% *vs.* 8%; and for unknown stage, 61% *vs.* 35% [19].



Figure 1. Differences in survival rates – divided into 16 voivodships



Figure 1 cont. Differences in survival rates – divided into 16 voivodships

The improved survival rate of prostate cancer in Poland can be explained by new treatments that have transformed prostate cancer into a chronic disease. We observe a constant increase in prostate cancer survival rates, due to progress in the treatment of metastatic castration resistant prostate cancer (docetaxel-based chemotherapy (2004), cabazitaxel registration (2010), the introduction of the latest generation of non-steroidal antiandrogen drugs into treatment (abiraterone acetate in 2011, enzalutamide in 2012) [20], and also due to the progress in surgical treatment of prostate cancer (2010 saw the first robot-assisted radical prostatectomy in Poland), the promotion and greater availability of serum PSA concentration determination, and transrectal ultrasound.

In the last period of observation (2010–2014), the highest survival rate was recorded in the Mazowieckie, Pomorskie, Podlaskie, Zachodniopomorskie, and Lubuskie Voivodships, and the lowest in the Lubelskie Voivodships. The phenomenon of highest survival in the Lubuskie Voivodship recorded a high percentage of consultations per 1,000 inhabitants and the highest number of oncology clinics in the country per 10,000. However, no entity meets the criteria of an urooncology center and the criterion of the minimum number of radical prostatectomy procedures.

The same survival rate in the Zachodniopomorskie and Mazowieckie Voivodship. Zachodniopomorskie is characterized by one of the highest percentages of urological consultations per 1,000 inhabitants, and in the Mazowieckie Voivodship we have the largest number of urological clinics in the country, the largest number of physicians working in the field of urology, the largest number of patients of the special drug B.56 program (treatment of patients with prostate cancer with apalutamide, darolutamide, enzalutamide, cabazitaxel, olaparib, radium [Ra-223] dichloride [21]), 6 centers that meet the criterion of the minimum number of radical prostatectomy procedures and one of two centers in Poland that perform robotic surgeries in urology at an expert level [22].

Survival rates in testicular cancer, lower in Poland than in Europe, may be justified by the low level of public knowledge of testicular cancer [23, 24].

Increased survival and decreased mortality in testicular cancer result from the introduction of cisplatin-based chemotherapy for the treatment of non-seminomas in the 1970s. The increase in survival is also due to the greater availability of scrotal ultrasound, the introduction of tumor markers for testicular cancer in diagnostics, and more frequent occurrence of seminomas (they have a better prognosis) than nonseminomas [25].

The greatest reduction in the 5-year survival rate occurred in the Łódź Voivodship by 12.9 pp. The highest survival rate was recorded in the Zachodniopomorskie and Podlaskie Voivodships, and the lowest in the Pomorskie, Łódźkie and Lubuskie Voivodships. The Zachodniopomorskie and Podlaskie Voivodships conduct large-scale preventive campaigns against testicular cancer (they support the Movember campaign, Męskie Zdrowie, Profilaktyka 40Plus, leaflets, educational films for patients, radio broadcasts, campaigns on social networks, teaching self-examination on dummies, etc.) [26, 27].

Survival rates in bladder cancer are lower than in Europe, probably due to the low level of knowledge about bladder cancer [28–30], 15–25% of patients who present in advanced stages of the disease [31], lack of reference centers [32], comprehensive specialist care [32] and long waiting times for radical cystectomy [33]. In bladder cancer, the increase in survival rates is due to intravesical immunostimulation with BCG instillations [34] and intravesical chemotherapy and immunotherapy in patients with locally advanced or metastatic bladder cancer [35]. Progress in surgical treatment did not improve survival rates [36, 37].

In Poland, survival rates among women with bladder cancer are higher than survival rates among men. This situation differs from the trend in Europe. Many studies have shown lower survival rates for women with bladder cancer than for men [3–6]. Among patients with kidney cancer, women also have higher survival rates, although urinary tract infections and nephrolithiasis among women are associated with a delay in the diagnosis of kidney cancer more often than among men [38]. However, this trend does not differ from the European trend. Among women, kidney cancer is detected at an earlier

stage than among men, which in patients aged <59 years reduces mortality from renal cell carcinoma (RCC) by 19% compared to men [39].

The survival rate of kidney cancer patients is increasing in both sexes due to more frequent preventive examinations [18], including abdominal ultrasound and CT scans; many kidney cancers are detected accidentally during these examinations [40]. The reasons for increased survival also include modern drugs (molecularly targeted therapy [41], immunotherapy) [42] .

For both sexes, the survival rate is the highest in the Pomorskie Voivodship and the lowest in the Zachodniopomorskie Voivodship. In the Pomorskie Voivodship, in the years 2000–2015, the survival rate of kidney cancer in both sexes remained one of the highest in Poland.

Survival rates for urological cancers are lower in Poland than in other European countries due to a lack of coordination and centralization of services, low level of education, and early diagnosis, and because modern treatment is not reimbursed to the same extent as in Europe. To change this state of affairs, from May 2022, patients with advanced kidney cancer are covered by modern treatment under the special drug program B.10 (treatment of patients with kidney cancer with pembrolizumab [21]). Socioeconomic status influences the degree of advancement of urological cancers, as shown in many studies [43, 44].

In all urological cancers, efforts should be made to centralize surgical treatment, especially in rare cancers, as well as decentralize chemotherapy and radiotherapy and comprehensive specialist care for patients, which can contribute to increased 5-year survival rates in these cancers. It is also necessary to increase the spending on prevention, early diagnosis, and patient education.

Conclusions

Survival rates for patients with urinary tract cancer are lower in Poland than in Europe. In most of the analyzed voivodeships, survival rates for urological cancers increased in subsequent periods. This is proof that health care in Poland is continuously improving. The exception is the decrease in 5-year survival rates in the Łódzkie Voivodship. There is a need to conduct more studies on this phenomenon.

The level of public knowledge in Poland about urological cancers is still low compared to other European countries. National research on this topic should be conducted. Educational and preventive campaigns are also needed nationwide to achieve a greater increase in 5-year survival rates in the coming years.

Primary care physicians play an important role in referring patients with urological cancers to urologists [45]. There is an increasing need for the urologist to work closely with the primary care physician to prevent, identify, and manage urological cancer [46] because recognition and timely referral to primary care are crucial for early diagnosis of the cancer [47].

The limitation of this study is the use of historical data. The latest available 5-year survival analysis originating from the Polish National Cancer Registry covers the period 2010–2014 (end of observation 31.12.2019), i.e., there is a 10-year delay. A strength of the work is that it is the first voivodship analysis for urological cancers, with data coming from the most reliable source of information on cancer in Poland.

Article information and declarations

Data availability statement

Data available on onkologia.org.pl.

Ethics statement

No ethical issues or concerns were applicable to this research.

Author contributions

Klaudia Barańska – performed the analysis; wrote the manuscript with input from all authors.
Marta Miklewska – performed the analysis; wrote the manuscript with input from all authors.
Iwona Wnętrzak – wrote the manuscript with input from all authors.
Urszula Wojciechowska – devised the project, the main conceptual ideas and proof outline.
Joanna A. Didkowska – devised the project, the main conceptual ideas and proof outline.

Conflict of interest

None declared

Klaudia Barańska
Maria Sklodowska-Curie National Research Institute of Oncology
Polish Cancer Registry
ul. Wawelska 15 B
02-093 Warszawa, Poland
e-mail: klaudia.baranska@nio.gov.pl

Received: 23 Oct. 2023
Accepted: 25 Oct. 2023

References

1. Allemani C, Matsuda T, Di Carlo V, et al. CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125): 1023–1075, doi: 10.1016/S0140-6736(17)33326-3, indexed in Pubmed: 29395269.
2. Wojciechowska U, Barańska K, Miklewska M, et al. Cancer incidence and mortality in Poland in 2020. Nowotwory. Journal of Oncology. 2023; 73(3): 129–145, doi: 10.5603/njo.2023.0026.
3. Andreassen BK, Grimsrud TK, Haug ES. Bladder cancer survival: Women better off in the long run. Eur J Cancer. 2018; 95: 52–58, doi: 10.1016/j.ejca.2018.03.001, indexed in Pubmed: 29635144.
4. Ristau BT, Davies BJ. Disparity in bladder cancer outcomes: what's sex got to do with it? Cancer. 2014; 120(4): 461–463, doi: 10.1002/cncr.28420, indexed in Pubmed: 24496864.
5. Zaitsu M, Toyokawa S, Tonooka A, et al. Sex differences in bladder cancer pathology and survival: analysis of a population-based cancer

registry. Cancer Med. 2015; 4(3): 363–370, doi: 10.1002/cam4.379, indexed in Pubmed: 25533611.
6. Patel MI, Bang A, Gillett D, et al. Poor survival of females with bladder cancer is limited to those aged 70 years or over: a population-wide linkage study, New South Wales, Australia. Cancer Med. 2015; 4(8): 1145–1152, doi: 10.1002/cam4.452, indexed in Pubmed: 25914165.
7. Hemminki K, Försti A, Hemminki A, et al. Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years. PLoS One. 2022; 17(1): e0261124, doi: 10.1371/journal.pone.0261124, indexed in Pubmed: 34982793.
8. Vaishampayan U, Vankayala H, Vigneau FD, et al. The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database. Clin Genitourin Cancer. 2014; 12(2): 124–129, doi: 10.1016/j.clgc.2013.09.007, indexed in Pubmed: 24225251.
9. Richters A, Aben KKH, Kiemeney LA. The global burden of urinary bladder cancer: an update. World J Urol. 2020; 38(8): 1895–1904, doi: 10.1007/s00345-019-02984-4, indexed in Pubmed: 31676912.
10. Krajowy Rejestr Nowotworów. http://onkologia.org.pl/en/report (12.10.2023).
11. Perme M, Stare J, Estève J. On Estimation in Relative Survival. Biometrics. 2011; 68(1): 113–120, doi: 10.1111/j.1541-0420.2011.01640.x.
12. GeoPandas 0.14.0. https://geopandas.org/en/stable/index.html (12.10.2023).
13. GIS Support. https://gis-support.pl/ (12.10.2023).
14. Ellis L, Woods LM, Estève J, et al. Cancer incidence, survival and mortality: explaining the concepts. Int J Cancer. 2014; 135(8): 1774–1782, doi: 10.1002/ijc.28990, indexed in Pubmed: 24945976.
15. Trama A, Foschi R, Larrañaga N, et al. EUROCARE-5 Working Group:. Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study. Eur J Cancer. 2015; 51(15): 2206–2216, doi: 10.1016/j.ejca.2015.07.027, indexed in Pubmed: 26421823.
16. Marcos-Gragera R, Mallone S, Kiemeney LA, et al. EUROCARE-5 Working Group:. Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5. Eur J Cancer. 2015; 51(15): 2217–2230, doi: 10.1016/j.ejca.2015.07.028, indexed in Pubmed: 26421824.
17. Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2008; 64(1): 10–19, doi: 10.1111/j.1541-0420.2007.00825.x, indexed in Pubmed: 17501937.
18. Harrison H, Thompson RE, Lin Z, et al. Risk Prediction Models for Kidney Cancer: A Systematic Review. Eur Urol Focus. 2021; 7(6): 1380–1390, doi: 10.1016/j.euf.2020.06.024, indexed in Pubmed: 32680829.
19. Smart CR. Bladder cancer survival statistics. J Occup Med. 1990; 32(9): 926–928, doi: 10.1097/00043764-199009000-00035, indexed in Pubmed: 2074521.
20. Wardecki D, Dołowy M. Prostate cancer - current treatment options. Farmacja Polska. 2022; 78(5): 268–276, doi: 10.32383/farmpol/152041.
21. Obwieszczenie Ministra Zdrowia z dnia 30 sierpnia 2023 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych.
22. Gryglewicz JJ. Organizacja i finansowanie świadczeń opieki zdrowotnej dla pacjentów diagnozowanych i leczonych z powodu nowotworu gruczołu krokowego ze szczególnym uwzględnieniem programu lekowego 2020.
23. Cieślikowski WA, Kasperczak M, Milecki T, et al. Reasons behind the Delayed Diagnosis of Testicular Cancer: A Retrospective Analysis. Int J Environ Res Public Health. 2023; 20(6), doi: 10.3390/ijerph20064752, indexed in Pubmed: 36981661.
24. Ryszawy J, Kowalik M, Wojnarowicz J, et al. Awareness of testicular cancer among adult Polish men and their tendency for prophylactic self-examination: conclusions from Movember 2020 event. BMC Urol. 2022; 22(1): 149, doi: 10.1186/s12894-022-01098-1, indexed in Pubmed: 36096827.
25. Ondrus D, Ondrusova M, Suchansky M. Recent Trends in Survival of Testicular Cancer Patients - Nation-wide Population Based Study. Klin Onkol. 2018; 31(2): 137–142, doi: 10.14735/amko2018137, indexed in Pubmed: 29708357.
26. Movember w Zachodniopomorskiem. Polskie Regiony 2021. https://polskieregiony.pl/movember-w-zachodniopomorskiem/ (12.10.2023).
27. Białostockie Centrum Onkologii dołącza do obchodów ŚWIĘTA ULICY WARSZAWSKIEJ. https://www.onkologia.bialystok.pl/news/1366-bialostockie-centrum-onkologii-dolacza-do-obchodow-swieta-ulicy-warszawskiej (12.10.2023).
28. van Hoogstraten LMC, Vrieling A, van der Heijden AG, et al. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023; 20(5): 287–304, doi: 10.1038/s41571-023-00744-3, indexed in Pubmed: 36914746.
29. Westhoff E, Maria de Oliveira-Neumayer J, Aben KK, et al. Low awareness of risk factors among bladder cancer survivors: New evidence and a literature overview. Eur J Cancer. 2016; 60: 136–145, doi: 10.1016/j.ejca.2016.03.071, indexed in Pubmed: 27125965.
30. Sell V, Ettala O, Perez IM, et al. Awareness of Smoking as a Risk Factor in Bladder Cancer: Results from the Prospective FinnBladder 9 Trial. Eur Urol Focus. 2022; 8(5): 1246–1252, doi: 10.1016/j.euf.2022.01.012, indexed in Pubmed: 35094962.
31. Sytuacja pacjenta z rakiem pęcherza moczowego – aktualne wyzwania 2022.
32. Chłosta P, Drewa T, Kołodziej A, et al. Nowotwór pęcherza moczowego. Nowotwór pęcherza moczowego. Rekomendacje w zakresie kompleksowej opieki nad pacjentem. 2018; 8-9: 96.
33. Poletajew S, Lisiński J, Moskal K, et al. The time from diagnosis of bladder cancer to radical cystectomy in Polish urological centres - results of CysTiming Poland study. Cent European J Urol. 2014; 67(4): 329–332, doi: 10.5173/ceju.2014.04.art2, indexed in Pubmed: 25667748.
34. Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur Urol. 2000; 37 Suppl 1: 9–15, doi: 10.1159/000052376, indexed in Pubmed: 10575266.
35. Rhea LP, Mendez-Marti S, Kim D, et al. Role of immunotherapy in bladder cancer. Cancer Treat Res Commun. 2021; 26: 100296, doi: 10.1016/j.ctarc.2020.100296, indexed in Pubmed: 33421822.
36. Dobruch J, Oszczudłowski M. Bladder Cancer: Current Challenges and Future Directions. Medicina (Kaunas). 2021; 57(8), doi: 10.3390/medicina57080749, indexed in Pubmed: 34440955.
37. Huang H, Yan B, Hao H, et al. Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis. Int J Urol. 2021; 28(6): 673–680, doi: 10.1111/iju.14537, indexed in Pubmed: 33714227.
38. Peired AJ, Campi R, Angelotti ML, et al. Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence. Cancers (Basel). 2021; 13(18), doi: 10.3390/cancers13184588, indexed in Pubmed: 34572815.
39. Rampersaud EN, Klatte T, Bass G, et al. The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. Urol Oncol. 2014; 32(1): 30.e9–30.13, doi: 10.1016/j.urolonc.2012.10.012, indexed in Pubmed: 23422777.
40. Long J-A, Descotes J-L, Rambeaud J-J. [Kidney cancer diagnosis].
41. Tomita Y. Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment. Int J Urol. 2016; 23(1): 13–21, doi: 10.1111/iju.12899, indexed in Pubmed: 26347163.
42. Gedye C, van der Westhuizen A, John T. Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. Intern Med J. 2015; 45(7): 696–701, doi: 10.1111/imj.12653, indexed in Pubmed: 25444021.
43. Nazemi A, Ghodoussipour S, Pearce S, et al. Socioeconomic and insurance status are independent prognostic indicators of higher disease stage and worse prognosis in bladder cancer. Urol Oncol. 2019; 37(10): 784–790, doi: 10.1016/j.urolonc.2019.04.021, indexed in Pubmed: 31076355.
44. Richardson LC, Neri AJ, Tai E, et al. Testicular cancer: a narrative review of the role of socioeconomic position from risk to survivorship. Urol Oncol. 2012; 30(1): 95–101, doi: 10.1016/j.urolonc.2011.09.010, indexed in Pubmed: 22127018.
45. Ridgway A, Aning J. Role of primary care in the management of prostate cancer. Prescriber. 2021; 32(2): 11–17, doi: 10.1002/psb.1892.
46. Mak V, Barkin J. The primary care physician's role in the monitoring and management of the potential sequelae of the medical treatment of prostate cancer: early and late. Can J Urol. 2016; 23(Suppl 1): 31–36, indexed in Pubmed: 26924593.
47. Sheringham J, King A, Plackett R, et al. Physician associate/assistant contributions to cancer diagnosis in primary care: a rapid systematic review. BMC Health Serv Res. 2021; 21(1): 644, doi: 10.1186/s12913-021-06667-y, indexed in Pubmed: 34217265.

VIA MEDICA

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 436–443

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

Artykuł przeglądowy / Review article

Biologia nowotworów / Tumor biology

Interactions between Notch and matrix metalloproteinases: the role in cancer

Jeeja Hernole, Rajeswari Narayanappa

Department of Biotechnology, Dayananda Sagar College of Engineering in Bangalore, Visvesvaraya Technological University, Karnataka, India

Notch has its importance in the development and maintenance of cells and tissues. Either gain or loss of Notch signalling causes a wide range of abnormalities including cancer. To activate Notch signalling, the notch ligand must be processed by the family of proteases, ADAMs. Until recently, exclusively in a cancer context, a class of proteases, matrix metalloproteinases (MMPs) were known to cleave notch and trigger downstream signalling. Notch was found to regulate the expression of matrix metalloproteinases (through crosstalk. Studies have revealed that interactions between Notch and MMPs are associated with aggressive cancer traits such as invasion, metastasis, angiogenesis, and endothelial mesenchymal transition. In this review, we resummarise the studies which reveal the Notch-MMP interactions that have provided new perceptions into the mechanisms behind Notch-mediated aggressiveness in cancers.

Key words: angiogenesis, epithelial mesenchymal transition, invasion, matrix metalloproteinase, non-canonical Notch signalling

Introduction

The notch signalling pathway is a conserved signalling pathway that regulates normal development and maintains homeostasis by regulating cell fate decisions and cellular processes. It has an oncogenic role and tumour suppressor role depending in a cellular context [1]. Notch is activated *via* canonical and noncanonical ways that lead to the expression of the Notch target genes [2]. Inappropriate activation of Notch causes over-accumulation of the Notch intracellular domain (NICD) thereby activating abnormal cellular transformation and resultant morbid cellular traits. Knockdown of Notch or use of γ-secretase inhibitors reverses such caused morbid traits *in vitro* [3–5]. Matrix metalloproteinases (MMPs) can cleave the notch receptor and activate signalling leading to pathologic outcomes [6].

Matrix metalloproteinases (MMPs) are zinc-dependent proteases which have a role in normal tissue development and maintenance through remodelling an extracellular matrix (ECM) [7]. There are about 23 MMPs known in humans and their expression is stimulated *via* PI3/AKT, MAPK, and ERK signalling pathways, with turnover being regulated by endogenous MMP inhibitors, TIMPs [8]. Dysregulation in MMP turnover has a potential effect on tissue homeostasis and cell signalling dynamics [9–12]. Immunohistochemical (IHC) studies on tumour biopsies show that MMPs are critical role players in the breakage of tumour boundaries leading to tumour cell migration [13].

Role of matrix metalloproteinases in cancer

In general, matrix metalloproteinases contribute to cancer processes *via* migration, EMT, metastasis and angiogenesis. During the migration process, the cell-to-cell and cell-to-matrix adhesion has to be disrupted. MMPs can degrade ECM, and shed the adhesion molecules (cadherins and integrins), making them well-suited for the role during invasion

Jak cytować / How to cite:
Hernole J, Narayanappa R. ***Interactions between Notch and matrix metalloproteinases: the role in cancer.*** *NOWOTWORY J Oncol* 2023; 73: 354–361.

and metastasis [14, 15]. MMP3 directly cleave the E-cadherin, an adhesion molecule of the epithelial cell. Loss of E-cadherin mediates the epithelial cell to acquire the mesenchymal phenotype [16]. MMP2, MMP9 and MT1-MMP degrade the basal membrane and interstitium and promote angiogenesis. The MMP knockout mice did not exhibit such a phenotype [17]. Clinical trials involving broad-spectrum MMP inhibitors have been unsuccessful so far. Not least, the MMP-specifically targeted therapeutics have their challenges such as MMP sub-type selectivity, metabolic risks and toxicity [18–20].

The canonical Notch cascade

Notch signalling occurs between the two juxtaposed cells or within the same cell caused by the interaction of the Notch receptor to its ligand. There are four Notch receptors Notch1, Notch2, Notch3, and Notch4 and five canonical ligands containing DSL-motif – DLL1, DLL3, DLL4, Jagged1, Jagged2, and many non-canonical ligands that lack the DSL-motif [21]. On the ligand binding to the Notch receptor, the NRR region of the receptor undergoes a conformational change to expose the S2 site for cleavage recognised by ADAM proteases. The NRR region protects the extracellular Notch S2 site from proteases until the NRR site is physically destabilised by the ligand binding and ligand endocytosis [22, 23]. The S2 cleavage typically requires ADAM10 and ADAM17, a disintegrin and metalloproteinase for Notch signalling, whereas Notch1 ligand-independent signalling requires ADAM17 [24]. The S2 cleavage is an important event for the succeeding S3 cleavage by γ-secretase [25]. The S3 cleavage liberates the NICD, translocates to the nucleus, interacts with the DNA binding proteins CSL/RBPJ and MAML to form a ternary complex [26, 27]. The ternary complex binds to DNA at the super-enhancer region and causes the transcription of target genes [28, 29]. Common targets of Notch signalling are transcription factors of the HES family – Hes1, Hes5, and Hes7 and HEY family – Hey1, Hey2, and HeyL that modulate fundamental cellular processes such as proliferation, stem cell maintenance, and differentiation during embryonic and adult development [2, 30].

Non-canonical processing of Notch by specific MMPs

Typically, Notch1 requires consecutive two cleavage steps post Notch ligand-receptor binding: first at the S2 site by ADAM protease ADAM10 or 17, and second at S3 by γ-secretase, which resultantly releases the Notch intracellular domain (NICD). ADAM 10 and ADAM17 have been regarded as canonical S2 proteases for cleavage at the S2 site on the Notch receptor which is regularly implied in normal development and tissue homeostasis *via* regulation of cell fate decisions and cellular processes occurring in drosophila, mice, and humans [25–31]. Many canonical and non-canonical Notch pathway components have been identified; the non-canonical ligands include DLK1, VE-cadherin, stanniocalcin-1 and the non-canonical proteases MMP7, MMP9, and MT1-MMP are mostly involved in pathogenesis [31–35]. Sawey and colleagues in 2008 found that MMP7 (matrilysin, an MMP) processes Notch1 independent of ADAMs which causes N1-NICD to be released and translocated to the nucleus [6]. On topical addition of recombinant MMP7 to COS-7 cells that are expressing Notch1 with C-terminal V5 tag underwent Notch activation including γ-secretase cleavage, NICD nuclear translocation, and resultant expression of Notch target genes. Moreover, the immunoblots of the Notch-V5 tag showed that cleavage of the Notch extracellular domain particularly occurred at the S2 site [36]. MMP7 is prevalently overexpressed in advanced cancers, with poor overall survival of patients, and is regarded as a prognostic biomarker in invasive and recurrent cancers [37–39]. MMP7 expression is controlled by PI3-K/AKT and/or ERK signalling *via* NF-κB transcription factor, and its loss of control is indicated in pathogenicity [40]. Similarly, like MMP7, the membrane-bound MT1-MMP (MMP14) can activate Notch by processing it independently of ADAMs (fig. 1). Changes in MT1-MMP expression affect the Notch signalling in melanoma cells. In the experiments, MT1-MMP processes the Notch1 actively in a Jagged1 ligand-dependent or independent manner. Moreover, when the full-length MT1-MMP was expressed in WM266-4 melanoma cells, it cleaved the Notch1. In the same experiment, the Notch processing intensity correlated to the expression of MT1-MMP. The resultant stimulation of the Notch target gene, HES, was confirmed by HES-reporter assay and gene expression analysis [41]. Non-canonical Notch processing by MT1-MMP not only affects cancer in the individuals but immunity too. It acts as a switch in normal B cell development in the bone marrow. Ectopic MT1-MMP cleaves the Notch ligand Delta-like 1 (DLL1) in bone marrow stem cells and thereby diminishes the Notch signalling by switching the B cell development [42].

Notch-MMP interactions: implications

Generally, MMPs are expressed at low levels in tissues, and their expression is induced by stimuli when required for ECM remodelling [11]. Matrix metalloproteinase expression demands multilevel regulation of various stimulating factors such as cell-ECM interactions, cell-cell interactions, ECM stimulation and other cellular environmental factors such as pH, ROS, cellular endopeptidases, lipid peroxidation, hyperglycemic, hypoxia, etc. [9]. MMP expression regulation may involve transcriptional regulatory elements, epigenetic regulation, post-transcriptional regulation, or different regulation occurring due to disease conditions involving gene mutations and promoter polymorphisms in MMP [43]. These external stimuli lead to downstream cell signalling; MMP turnovers are majorly regulated by protein kinases PKA, PKB/AKT, and PKC/MAPKs (JNKs, ERKs, and P38) signalling pathways [44]. Downstream of these signalling pathways, there are cell-type specific transcription factors-NF-κB, AP-1 subunits C-jun/C-fos, PEA3, ETS, and STAT that have binding sites on the promoters of specific MMPs. Moreover,



Figure 1. A diagram of the non-canonical Notch signalling pathway. This schematic shows a simplified overview of the main components of MMP-activated Notch signalling. Upon Notch ligand binding, a two-step proteolysis cleavage process i.e. S2 (small scissors within the juxtamembrane region, and the transmembrane domain of the Notch receptor is catalysed by members of the metalloproteases (MMP) family and the γ-secretase containing complex i.e. S3, respectively, then the Notch intracellular domain (NICD) is released from the membrane and translocates to the nucleus, where it forms a transcriptional activation complex with CSL and coactivators (CoA), thereby inducing the transcription of target genes causing proliferation, invasion, angiogenesis, and EMT in cancer

these transcription factors either upregulate or downregulate the expression of MMPs. Functional collaboration of more than one transcription factor may be required to regulate the gene--specific MMP expression. For example, regulatory interactions between AP-1 and cis-acting ETS elements on the MMP1 promoter are required to induce its expression [45].

Notch-NF-κB-MMP axis: invasion and migration

The notch signalling pathway critically participates in cell proliferation, apoptosis, cell invasion, and metastasis; studies show that notch pathway members are overexpressed [46–48]. Notch inhibition by downregulating Notch1 decreased invasion in prostate cancer [49]. The proliferation and invasion of cancer cells require remodelling of the extracellular matrix surrounding it through the action of MMPs. Studies show Notch controls the expression of ECM component-specific matrix metalloproteinases to bring about the rearrangements in the tumour environment through cross-talks with the NF-κB pathway [50–52]. NF-κB expression is driven by Notch. Also, the ectopic feeding of NICD, usually the nuclear-translocated part of Notch to the breast cancer cells, causes the cells to lose cell to cell adhesion and promotes migration and invasion [51, 53]. Notch1 is an upstream regulator of the NF-κB pathway where Notch1 and Notch3 induce transcription of NF-κB and its various subunits [54], moreover, NICD1 and NF-κB interaction leads to its NF-κB retention in the nucleus and enhances binding to the promoter of its target MMP genes [55, 56] (fig. 2). However, it is not clear whether in addition to retention of NF-κB, NICD1 and NF-κB complexed together is required for its transcriptional activity. That said, Notch1 downregulation leads to inhibition of NF-κB binding activity thereby inhibiting the expression of MMPs [53, 57]. NF-κB has a binding site on promoters of MMP1, MMP2, MMP7, and MMP9 to drive their expression [43, 52, 58]. Apart from MMPs, NF-κB drives the activity of cell adhesion molecules of ICAM, VCAM-1, and ECAM-1 which are essential for the cell migration process [59, 60].

Notch-VEGF and MMP axis: angiogenesis

Studies at the molecular level enable us to understand that Notch plays a pivotal role in sprouting angiogenesis; it maintains the functional integrity of leading apical endothelial cells and growing basal cells. Particularly, the VEGF-Notch axis allows the extravasation of MMPs that degrade the basal membrane and facilitate angiogenic sprouting. In the process, the apical endothelial cell (EC) maintains low-notch signalling and high VEGFR2 expression to preserve the sprouting phenotype. VEGFR2 helps the apical cell to migrate towards the VEGF-transmitting angiogenic centre. It promotes



Figure 2. Schematic illustration of Notch signalling pathway to regulate MMP gene expression. This model summarises, through a literature survey, that Notch activation promotes malignant features such as proliferation and invasion in cancer *via* cross-talking the NF-κB signal pathway

the expression of MT1-MMP, MMP2 and MMP9 which are prime members that bring about the ECM remodelling for apical cell sprouting and migration. On the other hand, the basal EC maintains high Notch signalling, low VEGFR2, high VEGFR1, and low MMP expression to preserve the non-sprouting phenotype in the basal EC [61–63]. Thus, the positive and negative crosstalks between VEGF-Notch in the apical and basal endothelial cells regulate the expression of MMPs to preserve their functional integrity and promote sprouting angiogenesis (fig. 3).

Notch-HEY-MMP axis: epithelial to mesenchymal transition

Epithelial mesenchymal transition is the most aggressive trait in cancers. Epithelial cells acquire mesenchymal phenotype by undergoing remarkable changes. In the transition process, it loses various epithelial markers and gains mesenchymal markers. The loss of epithelial markers such as E-cadherin, γ-catenin, actin cytoskeleton organisation and the gain of vimentin, fibronectin, fibrillar collagen, N-cadherin, and the increased activity of MMPs (MMP2, MMP2, MMP9). The EMT is a complex process triggered by signalling molecules, proteases, and growth factors (fibroblast growth factor [FGF], platelet-derived growth factor [PDGF], transforming growth factor-β [TGF-β]) that trigger the downstream signalling such as TGF-β, Hedgehog, NF-κB and Notch signalling which involves crosstalks that lead to dynamic changes in the phenotype of the epithelial cell [64]



Figure 3. Schematic model of VEGF-Notch and MMP axis in vascular endothelial cell (EC) differentiation. In endothelial tip cells, Low-notch signalling *via* Notch1-DLL4 induces high levels of VEGFR2 and MMPs to promote migration towards the angiogenic centre. In endothelial basal cells, high levels of Notch signalling *via* Notch1-DLL4 suppresses differentiation toward an apical cell phenotype by inducing low expression of VEGFR2 and MMPs



Figure 4. Notch-mediated epithelial-mesenchymal transition (EMT) cross-talk during carcinogenesis: **A.** The above diagram summarises the probable cross-talks between three ways that could drive EMT during carcinogenesis; viz., the canonical Notch signalling, the MMP-Notch-HEY/HES axis and the Growth Factor stimulation that induces notch signalling and translocation of NICD to the nucleus, where it forms a transcriptional activation complex with CSL and coactivators (CoA), thereby inducing the transcription of target genes HES/HEY. HES/HEY expression causes loss of epithelial markers and gain of mesenchymal markers in the epithelial cells leading to EMT. **B.** The EMT process primarily involves progressive loss of epithelial markers and gain of mesenchymal markers. Once the cells acquire a mesenchymal phenotype, they first intravasate and later extravasate from the blood vessel to establish a distant metastasis

(fig. 4). Reports verify that down-regulating Notch signalling inhibits EMT by downregulating MMPs [65, 66]. The Notch target gene, HEY1, controls the expression of MMPs in salivary adenoid cystic carcinoma, on knockdown of HEY1 it suppressed the expression of MMP1, MMP2, MMP3, MMP9, MMP11, and MMP13 which may be involved in driving EMT [30, 67]. Similarly, numerous reports mention MMPs (MMP7, MMP9) having a role in triggering Notch signalling that leads to the induction of the EMT trait [36, 68] (fig. 4).

Conclusions and future perspective

MMP-mediated non-canonical Notch signalling and the involvement of Notch in the regulation of MMPs is associated with aggressive outcome in cancer (tab. I). Though, the MMP expression is majorly driven by NF-κB, MAPK, AKT signalling pathways and TIMPs are regulators of MMPs, it cannot be disregarded that under high Notch signalling, the NICD plays a primary role in retaining NF-κB subunits in the nucleus,

Table I. Summary of Notch and matrix metalloproteinase interactions in human and mouse cancer models and associated functional phenotypes of those interactions

Matrix metalloproteinase	Axis	Phenotype	Type of cancer	Study model	Reference
MMP2, MMP9	Notch- PI3K/AKT/mTOR-MMP	invasion	bladder cancer	UMUC3 cell line	[71]
MMP2, MMP9	Notch-EMMPRIN-NF-κB/MMP	migration, invasion	human breast adenocarcinoma	MDA-MB-231 cell line	[72]
MMP2, MMP9	Notch-PI3/AKT-NF-κB-MMP	invasion, metastasis, angiogenesis	human breast adenocarcinoma	MDA-MB-231 cell line	[51, 53]
MMP9	Notch-NF-κB/uPA-MMP	invasion, metastasis	non-small-cell lung cancer	A549 and H1299 cell lines	[52]
MMP9	Notch-NF-κB/MMP	invasion	pancreatic cancer	BxPC-3 cell line	[64]
MMP9	Notch-NF-κB/MMP	cell growth, migration, invasion and induction of apoptosis	prostate cancer	PC-3, DU145, LNCaP, and C4-2B cell lines	[65]
MT1-MMP (MMP14)	MMP-Notch	cell growth and proliferation	melanoma cancer	WM115 and WM266-4 primary and metastatic cell lines	[41]
MT1-MMP	Notch-MMP	invasion, EMT	Kaposi sarcoma	lymphatic endothelial cell line	[68]
MMP9	Notch-NF-κB/MMP	invasion, angiogenesis	breast cancer	MDA-MB-231, MCF-7, SKBR-3 and T47D cell lines	[57]
MMP9	Notch-AKT-MMP	migration, metastasis, EMT	gastric cancer	SGC7901 and AGS cell lines; BALB/c mice	[66]
MMP7	Hey1-Notch1	self renewal, EMT, metastasis	salivary adenoid cystic carcinoma	SACC-LM cell line	[67]
MMP7	MMP-Notch1	EMT	pancreatic ductal adenocarcinoma	human primary acinar cell line and C57BL/6J mice	[36]

MMP – matrix metalloproteinase; EMT – epithelial-mesenchymal transition

which leads to uncontrolled expression of target MMPs. Notch inhibition alone may not be enough; the negative outcomes of Notch inhibition have been reported in clinical studies which cannot be disregarded, firstly, Notch is a conserved pathway required for normal cell development and homeostasis of tissues by maintaining proliferation and apoptosis balance; due to, low notch activity under Notch inhibitors, the cells may acquire sprouting phenotype leading to angiogenesis. Moreover, several Notch inhibitors under clinical trials have exhibited adverse effects including gastrointestinal issues, infections, skin cancer-related problems, and tumour recurrence [69, 70].

The Notch-MMP axes play important roles in tumour processes like proliferation, migration, EMT, metastasis, and angiogenesis. It has come to our notice that these interactions are lethal impart aggressiveness and have added poorer prognoses to various cancers including those of the brain, breast, and pancreas. Understanding and targeting Notch-MMP interactions may be required to tailor target-specific drugs and combinational therapeutic approaches.

Article information and declarations

Author contributions

Jeeja Hernole – study conception and design, data collection, analysis and interpretation of results, draft manuscript preparation, review and approval of the final version of the manuscript.

Rajeswari Narayanappa – study conception and design, analysis and interpretation of results, draft manuscript preparation, review and approval of the final version of the manuscript.

Funding

None declared

Acknowledgments

We are grateful to many colleagues for their thorough, helpful, and usually prompt response to requests regarding their opinions and advice. We are thankful to the entire Department of Biotechnology, Dayananda Sagar College of Engineering, Bangalore, and Visvesvaraya Technological University, Belagavi, for creating the research opportunities for us.

Conflict of interest

None declared

Rajeswari Narayanappa
Dayananda Sagar College of Engineering
Department of Biotechnology
Shavige Malleshvara Hills
Kumaraswamy Layout
Bangalore 560111, India
e-mail: rajeswari-bt@dayanandasagar.edu

Received: 24 Apr 2023
Accepted: 26 Sep 2023

References

1. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med. 2011; 208(10): 1931–1935, doi: 10.1084/jem.20111855, indexed in Pubmed: 21948802.
2. Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci. 2009; 66(10): 1631–1646, doi: 10.1007/s00018-009-8668-7, indexed in Pubmed: 19165418.
3. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006; 66(3): 1517–1525, doi: 10.1158/0008-5472.CAN-05-3054, indexed in Pubmed: 16452208.
4. Yu JB, Jiang H, Zhan RY. Aberrant Notch signaling in glioblastoma stem cells contributes to tumor recurrence and invasion. Mol Med Rep. 2016; 14(2): 1263–1268, doi: 10.3892/mmr.2016.5391, indexed in Pubmed: 27315154.
5. Li Li, Tang P, Li S, et al. Notch signaling pathway networks in cancer metastasis: a new target for cancer therapy. Med Oncol. 2017; 34(10): 180, doi: 10.1007/s12032-017-1039-6, indexed in Pubmed: 28918490.
6. Sawey ET, Crawford HC. Metalloproteinases and cell fate: Notch just ADAMs anymore. Cell Cycle. 2008; 7(5): 566–569, doi: 10.4161/cc.7.5.5531, indexed in Pubmed: 18239463.
7. Nagase H, Woessner J. Matrix Metalloproteinases. Journal of Biological Chemistry. 1999; 274(31): 21491–21494, doi: 10.1074/jbc.274.31.21491.
8. Quintero-Fabián S, Arreola R, Becerril-Villanueva E, et al. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front Oncol. 2019; 9: 1370, doi: 10.3389/fonc.2019.01370, indexed in Pubmed: 31921634.
9. Gaffney J, Solomonov I, Zehorai E, et al. Multilevel regulation of matrix metalloproteinases in tissue homeostasis indicates their molecular specificity in vivo. Matrix Biol. 2015; 44-46: 191–199, doi: 10.1016/j.matbio.2015.01.012, indexed in Pubmed: 25622911.
10. Obermajer N, Jevnikar Z, Doljak B, et al. Role of cysteine cathepsins in matrix degradation and cell signalling. Connect Tissue Res. 2008; 49(3): 193–196, doi: 10.1080/03008200802143158, indexed in Pubmed: 18661341.
11. Löffek S, Schilling O, Franzke CW. Series "matrix metalloproteinases in lung health and disease": Biological role of matrix metalloproteinases: a critical balance. Eur Respir J. 2011; 38(1): 191–208, doi: 10.1183/09031936.00146510, indexed in Pubmed: 21177845.
12. Blicharz-Dorniak J, Kos-Kudła B, Foltyn W, et al. Is determination of matrix metalloproteinases and their tissue inhibitors serum concentrations useful in patients with gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasms? Endokrynol Pol. 2012; 63(6): 470–476, indexed in Pubmed: 23339005.
13. Alaseem A, Alhazzani K, Dondapati P, et al. Matrix Metalloproteinases: A challenging paradigm of cancer management. Semin Cancer Biol. 2019; 56: 100–115, doi: 10.1016/j.semcancer.2017.11.008, indexed in Pubmed: 29155240.
14. Webb AH, Gao BT, Goldsmith ZK, et al. Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 2017; 17(1): 434, doi: 10.1186/s12885-017-3418-y, indexed in Pubmed: 28633655.
15. Itoh Y. MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life. 2006; 58(10): 589–596, doi: 10.1080/15216540600962818, indexed in Pubmed: 17050376.
16. Zheng G, Lyons JG, Tan TK, et al. Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol. 2009; 175(2): 580–591, doi: 10.2353/ajpath.2009.080983, indexed in Pubmed: 19590041.
17. Jackson C. Matrix metalloproteinases and angiogenesis. Curr Opin Nephrol Hypertens. 2002; 11(3): 295–299, doi: 10.1097/00041552-200205000-00005, indexed in Pubmed: 11981259.
18. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev. 2006; 25(1): 115–136, doi: 10.1007/s10555-006-7894-9, indexed in Pubmed: 16680577.
19. Lenci E, Cosottini L, Trabocchi A. Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020). Expert Opin Ther Pat. 2021; 31(6): 509–523, doi: 10.1080/13543776.2021.1881481, indexed in Pubmed: 33487088.
20. Wróbel-Roztropiński A, Zielińska-Kaźmierska B, Roztropiński H, et al. Expression of matrix metalloproteinases (MMPs) and their inhibitor (TIMP) genes on mRNA and protein levels in oral squamous cell carcinoma. Nowotwory. Journal of Oncology. 2021; 71(1): 1–8, doi: 10.5603/njo.2021.0003.
21. D'Souza B, Meloty-Kapella L, Weinmaster G. Canonical and non-canonical Notch ligands. Curr Top Dev Biol. 2010; 92: 73–129, doi: 10.1016/S0070-2153(10)92003-6, indexed in Pubmed: 20816393.
22. LANNING D, NICHOLAS T. Constant-life diagram modified for notch plasticity. International Journal of Fatigue. 2007; 29(12): 2163–2169, doi: 10.1016/j.ijfatigue.2006.12.014.
23. Gordon WR, Vardar-Ulu D, L'Heureux S, et al. Effects of S1 cleavage on the structure, surface export, and signaling activity of human Notch1 and Notch2. PLoS One. 2009; 4(8): e6613, doi: 10.1371/journal.pone.0006613, indexed in Pubmed: 19701457.
24. Bozkulak EC. Characterization of roles for the disintegrin and metalloproteases, kuzbanian and tumour necrosis factor-alpha converting enzymes, in mammalian Notch signalling. University of California, Los Angeles 2009.
25. Lieber T, Kidd S, Young MW. kuzbanian-mediated cleavage of Drosophila Notch. Genes Dev. 2002; 16(2): 209–221, doi: 10.1101/gad.942302, indexed in Pubmed: 11799064.
26. De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999; 398(6727): 518–522, doi: 10.1038/19083, indexed in Pubmed: 10206645.
27. Nam Y, Weng AP, Aster JC, et al. Structural requirements for assembly of the CSL.intracellular Notch1.Mastermind-like 1 transcriptional activation complex. J Biol Chem. 2003; 278(23): 21232–21239, doi: 10.1074/jbc.M301567200, indexed in Pubmed: 12644465.
28. Wilson JJ, Kovall RA. Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. Cell. 2006; 124(5): 985–996, doi: 10.1016/j.cell.2006.01.035, indexed in Pubmed: 16530045.
29. Wang W, Struhl G, Wang W, et al. Drosophila Epsin mediates a select endocytic pathway that DSL ligands must enter to activate Notch. Development. 2004; 131(21): 5367–5380, doi: 10.1242/dev.01413, indexed in Pubmed: 15469974.
30. Fischer A, Steidl C, Wagner TU, et al. Combined loss of Hey1 and HeyL causes congenital heart defects because of impaired epithelial to mesenchymal transition. Circ Res. 2007; 100(6): 856–863, doi: 10.1161/01.RES.0000260913.95642.3b, indexed in Pubmed: 17303760.
31. Christian J. A tale of two receptors: Bmp heterodimers recruit two type I receptors but use the kinase activity of only one. Proc Natl Acad Sci U S A. 2021; 118(19), doi: 10.1073/pnas.2104745118, indexed in Pubmed: 33893177.
32. Garg P, Jeppsson S, Yang V, et al. MMP-9 mediates colitis associated cancer in mice through Notch-1 via p53 activation. Inflammatory Bowel Diseases. 2011; 17: S9, doi: 10.1097/00054725-201112002-00023.
33. Rodríguez P, Higueras MA, González-Rajal A, et al. The non-canonical NOTCH ligand DLK1 exhibits a novel vascular role as a strong inhibitor of angiogenesis. Cardiovasc Res. 2012; 93(2): 232–241, doi: 10.1093/cvr/cvr296, indexed in Pubmed: 22068159.
34. Fischer A, Braga VMM. Vascular Permeability: Flow-Mediated, Non-canonical Notch Signalling Promotes Barrier Integrity. Curr Biol. 2018; 28(3): R119–R121, doi: 10.1016/j.cub.2017.11.065, indexed in Pubmed: 29408259.
35. Li Y, He ZC, Zhang XN, et al. Stanniocalcin-1 augments stem-like traits of glioblastoma cells through binding and activating NOTCH1. Cancer Lett. 2018; 416: 66–74, doi: 10.1016/j.canlet.2017.11.033, indexed in Pubmed: 29196129.
36. Sawey ET, Johnson JA, Crawford HC. Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proc Natl Acad Sci U S A. 2007; 104(49): 19327–19332, doi: 10.1073/pnas.0705953104, indexed in Pubmed: 18042722.

37. Polistena A, Cucina A, Dinicola S, et al. MMP7 expression in colorectal tumours of different stages. In Vivo. 2014; 28(1): 105–110, indexed in Pubmed: 24425843.
38. Klupp F, Neumann L, Kahlert C, et al. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer. 2016; 16: 494, doi: 10.1186/s12885-016-2515-7, indexed in Pubmed: 27431388.
39. Chen Li, Ke X. MMP7 as a potential biomarker of colon cancer and its prognostic value by bioinformatics analysis. Medicine (Baltimore). 2021; 100(9): e24953, doi: 10.1097/MD.0000000000024953, indexed in Pubmed: 33655961.
40. Guan PP, Yu X, Guo JJ, et al. By activating matrix metalloproteinase-7, shear stress promotes chondrosarcoma cell motility, invasion and lung colonization. Oncotarget. 2015; 6(11): 9140–9159, doi: 10.18632/oncotarget.3274, indexed in Pubmed: 25823818.
41. Ma J, Tang X, Wong P, et al. Noncanonical activation of Notch1 protein by membrane type 1 matrix metalloproteinase (MT1-MMP) controls melanoma cell proliferation. J Biol Chem. 2014; 289(12): 8442–8449, doi: 10.1074/jbc.M113.516039, indexed in Pubmed: 24492617.
42. Jin G, Zhang F, Chan KM, et al. MT1-MMP cleaves Dll1 to negatively regulate Notch signalling to maintain normal B-cell development. EMBO J. 2011; 30(11): 2281–2293, doi: 10.1038/emboj.2011.136, indexed in Pubmed: 21572390.
43. Fanjul-Fernández M, Folgueras AR, Cabrera S, et al. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 2010; 1803(1): 3–19, doi: 10.1016/j.bbamcr.2009.07.004, indexed in Pubmed: 19631700.
44. Reuben PM, Cheung HS. Regulation of matrix metalloproteinase (MMP) gene expression by protein kinases. Front Biosci. 2006; 11: 1199–1215, doi: 10.2741/1873, indexed in Pubmed: 16368506.
45. White LA, Brinckerhoff CE. Two activator protein-1 elements in the matrix metalloproteinase-1 promoter have different effects on transcription and bind Jun D, c-Fos, and Fra-2. Matrix Biol. 1995; 14(9): 715–725, doi: 10.1016/s0945-053x(05)80014-9, indexed in Pubmed: 8785586.
46. Sahlgren C, Gustafsson M, Jin S, et al. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proceedings of the National Academy of Sciences. 2008; 105(17): 6392–6397, doi: 10.1073/pnas.0802047105.
47. O JPD, Murtaugh L. Notch Signaling: Where Pancreatic Cancer and Differentiation Meet? Gastroenterology. 2009; 136(5): 1499–1502, doi: 10.1053/j.gastro.2009.03.022.
48. Fukusumi T, Guo TW, Sakai A, et al. The - Pathway Induces Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2018; 24(3): 619–633, doi: 10.1158/1078-0432.CCR-17-1366, indexed in Pubmed: 29146722.
49. Wang Z, Li Y, Banerjee S, et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem. 2010; 109(4): 726–736, doi: 10.1002/jcb.22451, indexed in Pubmed: 20052673.
50. Venkatesan B, Valente AJ, Prabhu SD, et al. EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling. J Mol Cell Cardiol. 2010; 49(4): 655–663, doi: 10.1016/j.yjmcc.2010.05.007, indexed in Pubmed: 20538003.
51. Li Li, Zhao F, Lu J, et al. Notch-1 signaling promotes the malignant features of human breast cancer through NF-κB activation. PLoS One. 2014; 9(4): e95912, doi: 10.1371/journal.pone.0095912, indexed in Pubmed: 24760075.
52. Rajasinghe LD, Pindiprolu RH, Gupta SV. Delta-tocotrienol inhibits non-small-cell lung cancer cell invasion via the inhibition of NF-κB, uPA activator, and MMP-9. Onco Targets Ther. 2018; 11: 4301–4314, doi: 10.2147/OTT.S160163, indexed in Pubmed: 30100736.
53. Li Li, Zhang J, Xiong N, et al. Notch-1 signaling activates NF-κB in human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT pathway. Med Oncol. 2016; 33(4): 33, doi: 10.1007/s12032-016-0747-7, indexed in Pubmed: 26945854.
54. Jang MS, Miao H, Carlesso N, et al. Notch-1 regulates cell death independently of differentiation in murine erythroleukemia cells through multiple apoptosis and cell cycle pathways. J Cell Physiol. 2004; 199(3): 418–433, doi: 10.1002/jcp.10467, indexed in Pubmed: 15095289.
55. Shin HMu, Minter LM, Cho OkH, et al. Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J. 2006; 25(1): 129–138, doi: 10.1038/sj.emboj.7600902, indexed in Pubmed: 16319921.
56. López-López S, Monsalve EM, Romero de Ávila MJ, et al. NOTCH3 signaling is essential for NF-κB activation in TLR-activated macrophages. Sci Rep. 2020; 10(1): 14839, doi: 10.1038/s41598-020-71810-4, indexed in Pubmed: 32908186.
57. Liu Y, Su C, Shan Y, et al. Targeting Notch1 inhibits invasion and angiogenesis of human breast cancer cells via inhibition Nuclear Factor-κB signaling. Am J Transl Res. 2016; 8(6): 2681–2692, indexed in Pubmed: 27398151.
58. Lee YH, Seo EK, Lee ST. Skullcapflavone II Inhibits Degradation of Type I Collagen by Suppressing MMP-1 Transcription in Human Skin Fibroblasts. Int J Mol Sci. 2019; 20(11), doi: 10.3390/ijms20112734, indexed in Pubmed: 31167359.
59. Aggarwal BB, Van Kuiken ME, Iyer LH, et al. Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp Biol Med (Maywood). 2009; 234(8): 825–849, doi: 10.3181/0902-MR-78, indexed in Pubmed: 19491364.
60. Huang WC, Chan ST, Yang TL, et al. Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives. Carcinogenesis. 2004; 25(10): 1925–1934, doi: 10.1093/carcin/bgh211, indexed in Pubmed: 15217903.
61. Hellström M, Phng LK, Gerhardt H. VEGF and Notch Signaling. Cell Adhesion & Migration. 2014; 1(3): 133–136, doi: 10.4161/cam.1.3.4978.
62. Funahashi Y, Hernandez SL, Das I, et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008; 68(12): 4727–4735, doi: 10.1158/0008-5472.CAN-07-6499, indexed in Pubmed: 18559519.
63. Teodorczyk M, Stanković ND, Bicker F, et al. VEGF and Notch Signaling in Angiogenesis. Endothelial Signaling in Development and Disease. 2015: 3–46, doi: 10.1007/978-1-4939-2907-8_1.
64. Wang Z, Li Y, Kong D, et al. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets. 2010; 11(6): 745–751, doi: 10.2174/138945010791170860, indexed in Pubmed: 20041844.
65. Chen Y, Zheng S, Qi D, et al. Inhibition of Notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS One. 2012; 7(10): e46512, doi: 10.1371/journal.pone.0046512, indexed in Pubmed: 23056328.
66. Peng X, Zhou J, Li B, et al. Notch1 and PI3K/Akt signaling blockers DAPT and LY294002 coordinately inhibit metastasis of gastric cancer through mutual enhancement. Cancer Chemother Pharmacol. 2020; 85(2): 309–320, doi: 10.1007/s00280-019-03990-4, indexed in Pubmed: 31732769.
67. Xie J, Lin LS, Huang XY, et al. The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells. Int J Biol Sci. 2020; 16(4): 598–610, doi: 10.7150/ijbs.36407, indexed in Pubmed: 32025208.
68. Cheng F, Pekkonen P, Laurinavicius S, et al. KSHV-initiated notch activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. Cell Host Microbe. 2011; 10(6): 577–590, doi: 10.1016/j.chom.2011.10.011, indexed in Pubmed: 22177562.
69. López-Nieva P, González-Sánchez L, Cobos-Fernández MÁ, et al. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment. Oncologist. 2021; 26(2): e298–e305, doi: 10.1002/onco.13595, indexed in Pubmed: 33191568.
70. Peereboom DM, Ye X, Mikkelsen T, et al. A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma. Neurosurgery. 2021; 88(2): 246–251, doi: 10.1093/neuros/nyaa412, indexed in Pubmed: 33027815.
71. Chen YT, Huang CR, Chang CL, et al. Jagged2 progressively increased expression from Stage I to III of Bladder Cancer and Melatonin-mediated downregulation of Notch/Jagged2 suppresses the Bladder Tumorigenesis inhibiting PI3K/AKT/mTOR/MMPs signaling. Int J Biol Sci. 2020; 16(14): 2648–2662, doi: 10.7150/ijbs.48358, indexed in Pubmed: 32792862.
72. Wang J, Fu Li, Gu F, et al. Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep. 2011; 26(5): 1295–1303, doi: 10.3892/or.2011.1399, indexed in Pubmed: 21785827.
73. Wang Z, Banerjee S, Li Y, et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006; 66(5): 2778–2784, doi: 10.1158/0008-5472.CAN-05-4281, indexed in Pubmed: 16510599.

VIA MEDICA

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 444–451

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

Artykuł przeglądowy / Review article

Radioterapia / Radiotherapy

Once upon a time in oncology: will we ever win the war against cancer? Critical review of the progresses in cancer therapies

Bogusław Maciejewski[1], Daniel Bula[2], Justyna Rembak-Szynkiewicz[3]

[1]*Div. Research Programmes, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland*
[2]*Dept. Oncologic and Reconstructive Surgery Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland*
[3]*Dept. of Radiology and Diagnostic Imaging, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland*

The aim of the present review of various classic and novel therapeutic strategies in oncology is critical discussion of its efficacy to answer the question: is it realistic and even possible to win the war against cancer. Although technological progress in radiotherapy (RT) has led to the development of many sophisticated 3D, 4D techniques, the use of RT as a sole modality has become more and more limited to the tumors in the early stage of disease, in favor of combined surgery-RT-chemotherapy (CHT) therapies. Nevertheless, patients' curability has never reached a level higher than 95% (stereotactic hypofractionated RT – limited to small tumors only). The CHT for solid malignant tumors is not effective enough, and therefore it is mainly combined with surgery and RT as a method of the boost. Common use of partial or complete regression (PR, CR) as end-points of its efficacy is irrelevant, since it is quasi-quantified tumor cell clearance but not cell kill effects, and the regrowth delay (the time the tumor takes to regrow to the size [volume] at the beginning of therapy) is the only proper end-point. The efficacy of various genetic, molecular, immuno, and antiangiogenic modalities tested in many clinical studies is critically discussed, and it has generally showed some therapeutic benefits, but somewhat unspectacular. It has been well documented that genotypes and phenotypes of the tumors (even within the same location, stage, and histology) are individually highly heterogeneous. Therefore, the term "average probability" referred to individual patients becomes meaningless, and moreover, this term has never been replaced by "certainty" yet. Statistics of many studies and trials consist of various pitfalls and biases. Thus, although we and our patients are more often winners on the individual battlefields, the winning, of the whole war against cancer seems to be possible (hope), but not for sure (real).

Key words: malignant solid tumors, efficacy of various therapeutic modalities, probability *vs.* certainty, statistical pitfalls and biases

The first thought which crosses one's mind as one tries to answer the title question might be "never say never", but "once upon a time" would sound more promising. A plethora of studies in many fields of oncology, genetics, molecular biology and tumor immunology have gathered large swathes of results and comments, which although looking promising, do not necessarily encourage. Therefore, to work out the dilemma whether one can win or not, one needs to consider and discuss

Jak cytować / How to cite:

Maciejewski B, Bula D, Rembak-Szynkiewicz J. ***Once upon a time in oncology: will we ever win the war against cancer? Critical review of the progresses in cancer therapies.*** *NOWOTWORY J Oncol* 2023; 73: 362–369.

the results and achievements of various classic, recent and novel therapeutic modalities used or tested in the realm of oncology.

Innovations in radiotherapy – physics but not only

Technological progress in radiotherapy has brought to the market a wide sort of high-tech accelerators emitting high energy photons, electrons, protons and particle beams, which have been used to develop a precise 3, 4D conformal IMRT, IGRT, IART techniques. Sophisticated algorithms optimizing dose distribution to maximize therapeutic differences between tumor and normal tissue responses have arrived to daily practice, based on an interplay of physics, biology, and clinical oncology [1–11]. It may look like the promise of a new era in radiotherapy. However, sometimes it remains as a promise only, although the RT offers a wide range of treatment time and dose intensity. Expectations of the outcome improvement are immutably based on the simple assumption (or even belief) that the tumor appearing on the CT/MRI images is limited to its bounds, which is often not true at all.

The RT seems to be an attractive offer, because it often claims a success, but it remains unclear what that "success" actually refers to: permanent curability or to local tumor control only. Withers [10], Le [11] and Glatstein [17] have warned that 3D conformal RT techniques result in a heterogeneous dose distribution, which hides discrepancy between physical and biological doses, and the risk of "overconformality". Some tumors with an indolent proliferation activity, such as prostate cancer, chordomas, meningiomas, acoustic neuromas, and some normal tissues as well, are highly sensitive to change in the dose per fraction, expressed by a low α/β ratio. For a long time, we have been convinced fans of the α/β concept. However, with the passing of time, some uncertainty has been steadily growing, suggesting that tumor and surrounding normal tissues consist of various cellular structures, as blood vessels and its epithelium, hypoxic cellular microlesions, muscles, nerves, etc., which respective α/β values differ, and therefore, an average α/β may also differ as well. Therefore, it is unknown, whether alpha, beta or perhaps even gamma value is correct [18], which can result in misleading conclusions and results. In fact, the α/β formalism is rather incidentally used in the daily RT planning.

The great leap forward in RT equipment and techniques is not supported by long-term local cure benefits, which turns out to be lower than expected. In the past, the results of a large number of the trials on altered fractionation was rather disappointing lesson, with an average 6% tumor control benefit [12–15]. Patients with generally poor prognosis are candidates to studies on new RT strategies. The question is whether objective evaluation of 3D IMRT, IGRT, IART efficacy has ever been done or not [18, 19]. There are obviously no convincing results regarding lung cancer [16–19], and some other advanced cancers, irrespective of any theoretical rationale for potential benefits.

Patients expected to live long (e.g., breast or pediatric cancers, etc.) may manifest some unforeseen morbidities that have not yet been precisely reported. Before the start of therapy, prediction of the events, (tumor control, late side effect) has in the past been based on the gathered incidences of such events, but it has never been judged whether a specific event will occur for sure, or not. There is true inconsistency between tumor control probability (TCP), expected before the treatment, and local tumor control (LTC), which is achieved as the result of therapy. The TCP or the risk of complication (NTCP) is the frequency of the event which may occur, and it is considered as a numerical mapping of the degree to which we believe the event will occur. Therefore, "Is this a game of chance?" – "No, it is the way we play it" (W.C. Fields in 36).

Radio-biological principles are rather rarely accounted for in RT planning. Assumption TCP, of let's say 99% ($TCP = e^{-0.01}$), suggests that 10 of 1000 patients, or 100 of 10,000 patients will fail, that means RT local curability is not universal. In the case of the SHRT, an LTC of 85–95% can be achieved using single dose or a few high fractions, but for small tumors only. On the other hand, using the 3D IMRT, IGRT, IART techniques, even a small "cold spot" within the PTV (overconformality), often missed during evaluation of the DVHs, can lead to a significant decrease in the TCP, and therefore, in the LTC as well. Heraclitus' sentence "you can't step in the same river twice" – means for RT, that the same tumor should not be irradiated twice, and re-irradiation is seldom used and rarely effectively. The simple reason is that the planned reirradiation dose is inexplicably but commonly lower (40–50 Gy) than the curative one, although regrowing tumor cells proliferate much faster than native cancer cells, and therefore a recurrent tumor logically needs a higher radical dose than primarily delivered.

RT and surgery as local therapeutic modalities are directed to where the tumor exists, and the theoretical aim is complete elimination of clonogenic cancer cells, proliferating unlimitedly, which can theoretically lead to a cure for the patient. However, it remains unknown whether and how many microcolonies of cancer cells are beyond surgical or irradiated margins, and where they really are. Clinical situations, where RT or surgery is used alone, have been significantly reduced, replaced by pre- or post-operative radiotherapy, and/or chemotherapy. Such combinations of two or three modalities have been found to be successful for head and neck cancer, but not necessarily for lung or rectal cancers [20–23].

Till the mid 80s, various treatment modalities offered for locally advanced cancers were mainly palliative options. Then, reconstructive surgery initiated in the US in the 1980s, later in western European countries, and around 2000 in Poland, made a breakthrough in the treatment of these tumors, mainly H&N, sarcomas and childhood solid malignancies. But that method is limited to individually selected patients. Although the overall therapeutic benefit increased somewhat, it was not significant.

The major failure of many tumors is almost the same – distant metastases, which can subclinically be present even at the time of treatment or likely for some time before [21, 24]. It remains unknown how effective numerical eradication of clonogenic cancer cells is, being below the level of its clinical detection. If a few cancer cells survive, they will be the source of local recurrence for sure, and in the case of cell mutations, also the source of metastatic lesions. In the case of ovarian cancer, distant metastases are a major cause of failure, since the cancer cells spread over the whole abdominal cavity, and they grow intensively and reveal clinically as advanced disease. Thus, surgery is usually limited to palliative cytoreduction, followed by chemotherapy. There is no room for RT, although in the 60s some attempts were made, using the "moving strips" technique. However, that method was abandoned, because the strips overlapped and resulted in serious acute intestinal and bone marrow complications.

Among a long list of malignancies, glioblastoma multiforme is unique. Although surgery and/or RT, with or without temodal, are used with radical intent, neither long-term LTC nor DFS have ever been achieved and reported, and the OS is also very short. The enigma of this malignancy is that even if the gross tumor mass disappears as a result of local therapy, malignant glioma cells already circulate in the brain blood vessels network, controlled by the feedback regulatory system of the hypoxic and angiogenetic processes, which mutually activate each other.

Distant metastases are not the only attribute of advanced tumors. Even in the case of early stages of the cancer (e.g. breast cancer), distant metastases (DM) may occur early within the first 18 months of follow-up, with the rate of 8–23%, as was reported by Kryj et al. [26], suggesting that distant metastases can already be present at the time of surgery. Thomlinson [25] rightly pointed out, that breast cancer should be considered a systemic disease, and cytotoxic chemotherapy should be the modality used at the beginning of therapy. Therefore, it should not surprise, that in contrast to high-tech innovations, the use of RT as a sole treatment has been more and more limited in favor of combined therapies whose sequences are individually tailored, and defined as theragnostic oncology.

The power of chemotherapy – sequential or concurrent

Chemotherapy (CHT) acts within and out of the tumor bounds. In general, the candidates for that form of therapy are advanced tumors with a pronounced risk of dissemination. When cytotoxic agents are injected intravenously, there is however, no further control and a lack of knowledge about their destination. Therefore, the principal cause of CHT failure is inadequate delivery of the drug to some parts of the tumor because of poor local blood flow, which in clinical situations can sometimes only be deduced, but not measured. However, this is not the only reason.

Thomlinson [24, 25] designed and carried out a milestone study, which included 62,000 measurements of tumor volumes made in 239 breast cancer patients, treated with RT or CHT, producing 748 tumor regression curves. The Achilles' heel of the CHT is that multiagent cycles are spaced out by 1–3 weeks, to overcome epithelial and lymphopenia side effects, and to limit its severity to the level of patient tolerance. Making frequent measurements of tumor size (volume) of the breast cancers, Thomlinson [24] noted that tumors partly regress directly after each cycle of the CHT, and regrow later in a cyclic manner during sparing breaks between cycles (fig. 1C). This universal pattern was termed as "Jeffs phenomenon". It clearly shows that, although the intensity of the acute side effects decreases during breaks between the CHT cycles, clonogenic tumor cells do not sleep and wait, but repopulate pretty fast, resulting in tumor regrowth. Therefore, the resultant average tumor regression curve is much shallover than that noted directly after each single cycle. After surgery or RT, tumor deceleration is much deeper (fig. 1A and B), than after CHT, but the final number of surviving tumor cells also remains unknown. When the average number of surviving tumor cells would be equal to 0.001, then the LTC will raise to 99.9% (unrealistic). It means that 10 of 10,000 patients may fail after treatment, and, in fact, 100% cancer curability can never be predicted and achieved, since the cell survival rate is the result of random cell killing, and decreases asymptotically with no chance to reach zero.



Figure 1. Theoretical tumor cell survival curves after: A – surgery; B – radiotherapy; C – chemotherapy. MR – minimal response; PR – partial regression; CR – complete regression; x – average number of survived cells. CHT curves-reprinted from Thomlinson [24]



Figure 2. Spectrum of regression rate of breast cancers after delivery of a same and constant dose of the RT or CHT, estimated by Thomlinson [24, 25]



Figure 3. Scheme illustrating how to measure "regrowth delay" as the only quantitative end-point of CHT efficacy. Extrapolation of the tumor regrowth curves (dotted blue lines) back to the cell survival coordinate allows for an estimation of the approximate decrease in the cell kill effect of a given CHT

Tumor gets smaller (regression) during and after therapy, only when dead clonogenic cells are removed out of the tumor. Thomlinson [24, 25] clearly documented that the regression rate of the same tumor type varies individually, and its spectrum is about 50-fold wide after an identical and constant dose of RT or CHT (fig. 2). There are three formal, clinical end-points to quantify the CHT efficacy in the clinic, i.e. Minimal response (who knows what it quantitively means?), partial regression and complete regression (fig. 1C). This is astounding, that for more than 5 decades, the PR and CR have been persistently used in practice, despite the fact that they are clinically irrelevant and it makes no adds, since they mark the removal of already dead cells by various heterolytic processes only, resulting in the decrease of tumor doublings from about 35–36 (e.g. 3.5–4 cm tumor diameter) to 29–30 (0.5 cm^3 tumor), which is still not enough to achieve the local tumor control. Therefore, the PR and CR with no doubts, do not quantify the CHT cell kill effect. A long time ago, it was clearly pointed out that the only proper quantitative end-point for the CHT effect is the regrowth delay (RD), which measures the time period during which recurrent tumors regrow to the size (volume) at the start of the CHT (fig. 3). In the case of long-term LTC, the RD achieved infinity.

The CHT used as a sole modality to treat solid malignant tumors is not radical, curative therapy, except leukemias and some lymphomas. Therefore, it has often been used as neo- or adjuvant tools. However, metaanalysis of the CHT combined with RT [27] revealed only an average 2% therapeutic benefit after neo- or adjuvant CHT (the result seems to be within the range of statistical error). Concurrent chemo-radiation produces a bit higher LTC gain of about 6% [28]. Such, an average benefit looks suspectedly too low. Therefore, to check that results, we reviewed 15 well documented studies on concurrent RT-CHT (cisplatin, 5-Fu or paclitaxel) carried-out in world-leading cancer centers (3300 H&N cancers). The 3-year LTC has been higher by about 20% [11–26%] than the RT alone. So, previous metaanalysis results recommended as an "evidence" guide seem at least doubtful. A large number of studies suggest that surgery (fig. 1A) and radiotherapy (fig. 1B) have possible but not certain curative power (100% LTC has never been achieved), but not the CHT (fig. 1C). So, we can win some individual battles with cancer, but are not yet in a position to win the whole war.

Genetic and molecular tumor biology and therapeutic perspectives – belief on, or not

During the last 3–4 decades, enormous amount of data has been gathered regarding genomics, proteomics, radiomics and tumor biology [29–31]. Growing recognition of the heterogeneity of genotypes and phenotypes of tumor cells, tumor suppressor genes and intra-cellular multisignaling pathways has led to the initiation of many attempts to develop and test in practice various specific antibodies, which could modify and enhance the therapeutic power of classic treatment modalities. One of the most interesting approaches is targeting the signaling axes of cancer stem cells (CSC) alone or in combination with CHT and/or RT. It has been proven that the survival of even one CSC leads to recurrence for sure. Actually, the combination of CHT with CSC inhibitor GDC-0449 has been tested for the advanced, primary or recurrent small-cell lung cancer. In the case of melanoma, the use of immune check-point inhibitors targeting cytotoxic T-lymphocyte-associated protein CTL4 has clinically promising. Preclinical studies on TGF-β1-neutralizing antibodies have offered an interesting strategy to prevent radiation induced fibrosis. Some experimental studies have shown that the VEGFR2 blocking antibody may decrease the dose of fractionated radiotherapy. By contrast to

the fear of destruction of tumor vasculature by antiangiogenic therapy, some studies have shown the normalization of tumor vasculature in various pilot clinical studies on HER2-negative breast cancer, NSCLC, rectal, hepatocellular, ovary cancers and glioblastoma multiforme. Regarding the last malignancy, a concept has developed that a block of more than one cellular receptors could be more efficient, and pilot the US study on anti-VEGFR2 together with anti-EGFR were combined with the RT. The results were highly disappointing, with no therapeutic benefit, but with a high rate, over 50% of brain lethal necrosis. It may likely suggest that the use of more than one antibody is too much to be tolerated by patients.

Many studies focused on antiangiogenic therapy (fig. 4), have finally shown a surprisingly short and disappointing extension of progression-free survival, by only 1.2–6 months, in addition to very low improvements in overall survival (by 1.4–4.7 months), achieved only for the selected patients [29], although many pilot and randomized studies documented the feasibility and reliability of molecular modifiers combined with CHT-RT for different malignant tumors [30–34]. Similarly, quests of validity molecular predictors [34] have shown that some of them correlate with higher LTC or even DFS. However, it has to be pointed out that an interpretation of the correlation's power may differ, and the correlation coefficient of r = 1.0 only, defines a strong and absolute "predictor-effect" relationship, whereas in many relevant studies, the factor r, even if it is higher than 0.5, has never reached 1.0. So far, the clinical power of the family of tested genetic and molecular predictors can only be interpreted in the category of "likelihood", but not as an absolute and undoubtful guideline. Numerous clinical studies, which extensively explore growing knowledge on genomics and the proteomics of human malignant tumors to test novel concepts of combined therapeutic strategies, are very important and should not be ignored, but the progress in the patients' curability can only be achieved by small steps forward, and for complete victory of the war against cancer we still have to wait.

An interesting aim of some experimental and clinical studies is to intensify processes of the host immune response against primary and metastatic cancer cells by immunotherapy combined with the RT and/or CHT. It has been found out that immunogenicity is mediated by the DNA exonuclease Trex1, which could be used as a potential biomodulator to optimize the RT combined with the CHT. The complimentary pathway is TGF-β, which promotes the RT to induce antitumor immunity. Actual results convince the stereotactic hypofractionated RT (SHRT) should be considered a potentially highly effective treatment, since the use of a large single dose or a few large fractions effectively boosts the tumor immune-response (fig. 5), triggering *in situ* vaccination, T-cell promising infiltration, and immunogenetic killing [30, 32]. Large doses of RT induce Fas-receptors which activate the T-cells. Pre- and clinical studies have shown a complexity of the processes optimizing radiation-immunotherapy interactions. The SHRT frequently used in the setting of limited extra- and intracranial metastases combined with immunotherapy could provide not only LTC improvement, but also distant control as well. Immune agents approved for cancer therapy include cytokines, oncolytic viruses, dendritic-cell vaccine and check-point inhibitors. There is well-grounded excitement regarding design studies exploring RT combined with available immunotherapeutic strategies.

Another fast-growing field in oncologic therapies is a combination of diagnostic and therapeutic modalities with nanoparticles [30]. The use of a nano-radiation dose enhancer (Nano-RDE) to improve RT efficacy has been one of the explored fields by experimental and pilot clinical studies, and has been termed as a "SMART combined modality therapy" [30]. Gold nano-particles (Au NP) have been tested to intensify



Figure 4. PFS and OS improvement after antiangiogenic therapy (taken from Jain et al. review [29])



Figure 5. Scheme of immunostimulation of the indirect cancer cell death induced by high doses of the SHRT [32]. DAMPs – set of molecular factors which induce indirect immunological lethal effect

both the CHT and the RT efficacy. The TNFα – colloidal gold nanoparticle (CYT-6091) selectively delivered to the cancer cells intensifies the apoptotic effect of the RT dose. However, till now, such compounds are not used in routine daily RT practice yet. Nevertheless, an interesting approach concerns the use of direct conjugation of antibody labeled with radionuclide, compatible with SPECT or PET imaging, to localize antibodies in the tumor, inducing a cytoreductive and potentially curative effect (targeted drugs). Major obstacle is, however, insufficient dose delivery to solid tumors because of poor penetration. With no doubts, all these new approaches are very interesting and encouraging, but they are still at the beginning of "a long, long way to Tipperary". As it happened before, some of them will likely be abandoned, and others will be extensively explored. But, they still remain within probabilityland, and not in an absolute certaintyland of the victory.

The miracle of statistics – pitfalls and biases?

One may raise a query about statistical interpretations of clinical data [18, 19]. The roots of statistics' "cause-effect" relationships are in 19th-century laws of physics and mathematics, which are immutable. If something occurs, then that must follow. However, this does not happen in oncology at all. There is a lot of individual genetic, phenotypic, biological variables and pathways, which make a large number of more or less powerful variables of "cause-effect" relationships very difficult to be explicitly establish. Discussing the results of various brilliant concepts and attempts made to win the war against cancer, major question arises as to why the results of major therapeutic achievements are much lower than expected. It seems that one important reason is that the randomization and stratification routinely explored in the trials, produce only ostensibly homogenous groups of patients, whereas in fact, they are genetically, phenotypically and biologically highly individual tumors, and therefore highly heterogeneous, even if its localization, type, and stage are the same. Since the result of such widespread heterogeneities are usually quantified as "averages" or "median", one can generally be disappointed with the rather low therapeutic gain reported. The averages are usually recognized as significant when the "p" value is below 0.05. But according to Glatstein [18, 19], significance does not necessarily mean clinical importance. If, for example, the p-value is 0.06, the results are counted as insignificant. However, are the results really less clinically important when 94 instead of 95 out of 100 patients with cancer will be permanently cured? Somebody could say – "not at all statistically", since they differ by one patient only. But clinically – cure of the one is as important as a cure of the other 100 patients, and the p-value is just a statistical toy to play with the analyzed results of treatment.

Interpretations of the "averages" usually lead to uncertainties and doubts. It is a routine procedure to comment survival (LTC, DFS, OS) curves counting actuarial *vs.* crude survival. The first one often leads to underestimations, since the cases lost during the 3-, 5-, and 10-year follow-up are censored in about 50% as relapses, whereas they might be controlled during the assumed follow-up. Another point of criticism is that the interpretation of the survival curves simplifies their courses to the one number, which is a median value. It seems that the major problem is that the interpretation is focused on one point on the survival curve and its trail is usually ignored. Meanwhile, such a curve is surrounded by the "noise" of many points, representing individual patients. If, for example in some trial, the 5-year actuarial LTC of the H&N cancer was about 85% in the tested arm and 70% in the conventional one, then such a difference would be quantified for sure as statistically significant, in favor of a novel therapy. However, what is often ignored is that, for example, in the control arm a 15% rate of local recurrence has occurred during the first 18 months of follow-up [26]. It becomes clearly evident, based on biology, and the kinetics of tumor growth, that such small subclinical tumor cell lesions beyond the irradiated or excised mass likely already existed at the time of the start the therapy. Therefore, it should not be accounted for the efficacy of the conventional therapy. When such part of the LTC curve would be excluded, then both curve become close each other and significance disappears, and the advantage of the tested therapy as well. This is a simple example of the statistical bias, which often happens.

Important trouble with interpretation of the trials and metaanalyses results is that the actuarial statistics reflect wide biological and genetic heterogeneities of patients and maldistribution of various prognostic factors, although, at first glance, they look homogenous within each study group. For head and neck cancers, about 600 genetic and proteomic predictors were analyzed a couple of years ago, and none of them turned out to be absolute and the sole prognostic predictor. However, when Buffa et al. [34], analyzed that sets of data once again using sophisticated taxonomic cluster statistics, they clearly found overexpression of the four factors as a significant prognostic predictors of the LTC gain by 20%. Similarly, Suwiński et al. [35] designed the trial, to test efficacy of the 7 fractions per week *vs.* conventional 5 fractions per week, used in the postoperative radiotherapy for H&N cancer patients with the increased risk of local recurrences. Classic, actuarial statistics have shown no difference in the effectiveness of both schedules. But, when the authors designed molecular scoring for the overexpression of the four selected genetic predictors, then the score >2 of them predicted an enormous increase in the DFS after 7 fractions/week schedule, much higher (>40%) than after 5 fractions/week. In case of the score ≤2 there is in favor of any these two schedules. These examples, as well as many others, suggest that classic statistics may provide deceptive results. Therefore, a rhetorical question may arise: what can really be considered "evidence". It seems that in many studies the importance of "evidence" remains uncertain. Thus, clinicians should likely prefer clinical importance, experience, and common sense as guidelines,

more than the results predominately based on the p-value. Glatstein [18, 19] strongly suggests that "evidence" should be weighed more carefully, and it seems that in the case of individual patients, the logic and own experience are often more important, but this does not mean that trials should be dismissed either.

Conclusions

Many years ago, the famous oncologist Vincent de Vita pointed out that "if we expect pronounced success in oncology, we have to be patient, because the progress will be realized in many small steps". For the last few decades, our knowledge on genetics, proteomics molecular predictors and modifiers has enormously increased, and we have unexpectedly learned that there are as many genetically and phenotypically different malignant diseases as there are patients suffering from them. It means, that effective combined therapy should be personally individualized, and that we are not able to win whole war against cancer just yet. However, that suggest, we should not lose hope and belief that it could happen in the future. There is a large number of winners on various, single oncologic battlefields, mainly those, which tumors are in very early stage of disease. Undoubtedly, we will likely achieve an important step forward when we will be able to replace "probabilityland" by "certaintyland", but not yet. We should also keep reasonable and limited belief on the statistics, and remember that the "averages" never represent individual heterogeneous characteristics. So far, real progress in cancer curability can likely be expected due to the increased activity and efficacy of prophylaxis and early detection of malignant tumors.

Article information and declarations

Author contributions

Bogusław Maciejewski – was responsible for the main idea, writing and editing of the article.
Daniel Bula – was responsible for supportive writing and editing of the article.
Justyna Rembak-Szynkiewicz – was responsible for supportive writing and editing of the article.

Acknowledgments

M. Czolka and B. Radwan-Jakubina for technical preparing the manuscript and figures.

Funding

None declared

Conflict of interest

None declared

Bogusław Maciejewski
Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch
Div. Research Programmes
Wybrzeże Armii Krajowej 15
44-102 Gliwice, Poland
e-mail: boguslaw.maciejewski@gliwice.nio.gov.pl

Received: 10 Aug 2023
Accepted: 17 Oct 2023

References

1. Ang KK, Garden AS. Radiotherapy for head and neck cancers. Innovations and techniques. II ed. Lippincolt Williams & Wilkins, Philadelphia 2002: 3–41.
2. Wang TJC, Wuu CS, Chao KSC. Intensity-Modulated radiation treatment techniques and clinical applications. In: Perez and Brady's: Principles and Practice of Radiation Oncology. VII ed. Wolters Kluwer, Philadelphia 2019: 260–287.
3. Beitler JJ. Mirror, mirror on the wall--which is the greatest predictive assay of them all? Int J Radiat Oncol Biol Phys. 2004; 59(5): 1272–1273, doi: 10.1016/j.ijrobp.2004.04.024, indexed in Pubmed: 15275709.
4. Goitein M, Niemierko A. Intensity modulated therapy and inhomogeneous dose to the tumor: a note of caution. Int J Radiat Oncol Biol Phys. 1996; 36(2): 519–522, doi: 10.1016/s0360-3016(96)00348-3, indexed in Pubmed: 8892479.
5. Cox JD, Ang KK. Radiation Oncology. VIII ed. Elsevier Sci 2003: 178–281.
6. Simpson DR, Mell LK, Mundt AJ. Image-guided radiation therapy. In: Simpson DR, Mell LK, Mundt AJ. ed. Perez and Brady's: Principle and Practice of Radiation Oncology. VII ed. Wolters Kluwer, Philadelphia 2019: 288–307.
7. Kuchter GJ, Mohan R. Innovations in treatment delivery. Semin Radiat Oncol. 1995; 5: 3–98.
8. Green AA. technical advances in irradiation techniques. Procc & Soc Med. 1959; 52: 344–346.
9. Ho FK, Fowler JF, Syles AJ, et al. IIMRT dose fractionation for head and neck cancer: variation in current approach will make standardization difficult. Acta Oncol. 2009; 48(3): 431–439.
10. Withers HR. Biological aspects of conformal therapy. Acta Oncol. 2000; 39(5): 569–577, doi: 10.1080/028418600750013258, indexed in Pubmed: 11093365.
11. Le QT, Raben D. Integrating biologically targeted therapy in head and neck squamous cell carcinomas. Semin Radiat Oncol. 2009; 19(1): 53–62, doi: 10.1016/j.semradonc.2008.09.010, indexed in Pubmed: 19028346.
12. BOURHIS J, AUDRY H, OVERGAARD J, et al. Meta-analysis of conventional versus altered fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC): Final analysis. Int J Radiat Oncol Biol Phys. 2004; 60: S190–S191, doi: 10.1016/s0360-3016(04)01183-6.
13. Dubben HH, Beck-Bornholdt HP, Fu KK, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000; 48(1): 7–16, doi: 10.1016/s0360-3016(00)00663-5, indexed in Pubmed: 10924966.
14. Rosenthal DI, Ang KK. Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. Semin Radiat Oncol. 2004; 14(2): 153–166, doi: 10.1053/j.semradonc.2004.01.001, indexed in Pubmed: 15095261.
15. Overgaad J, Hausen H, Sapon W, et al. Conventional radiotherapy as the primary treatment of squamous cell carcinoma of the head and neck. A randomized multicenter study of 5 versus 6 fractions per week – preliminary report from the DAHANCA 6 and 7 trial. Radiother Oncol. 1996; 40: 531.
16. Grégoire V, Maingon P. Intensity-modulated radiation therapy in head and neck squamous cell carcinoma: an adaptation of 2-dimensional concepts or a reconsideration of current clinical practice. Semin Radiat Oncol. 2004; 14(2): 110–120, doi: 10.1053/j.semradonc.2003.12.006, indexed in Pubmed: 15095257.
17. Glatstein E. Intensity-modulated radiation therapy: the inverse, the converse, and the perverse. Semin Radiat Oncol. 2002; 12(3): 272–281, doi: 10.1053/srao.2002.32433, indexed in Pubmed: 12118392.
18. Glatstein E, Makuch RW. Illusion and reality: practical pitfalls in interpreting clinical trials. J Clin Oncol. 1984; 2(5): 488–497, doi: 10.1200/JCO.1984.2.5.488, indexed in Pubmed: 6726301.

19. Glatstein E. Personal thoughts on statistics, or lies, damn lies, and (oncologic) statistics. Int J Radiat Oncol Biol Phys. 2004; 58(5): 1329–1333, doi: 10.1016/j.ijrobp.2003.11.034, indexed in Pubmed: 15050306.
20. Veronesi U, Salvadori B, Luini A, et al. Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg. 1990; 211(3): 250–259, indexed in Pubmed: 2106841.
21. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25(22): 3259–3265, doi: 10.1200/JCO.2007.11.4991, indexed in Pubmed: 17577015.
22. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009; 374(9687): 379–386, doi: 10.1016/S0140-6736(09)60737-6, indexed in Pubmed: 19632716.
23. Diefenhardt M, Fleischmann M, Martin D, et al. German Rectal Cancer Study Group. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials. Radiother Oncol. 2023; 179: 109455, doi: 10.1016/j.radonc.2022.109455, indexed in Pubmed: 36572280.
24. Thomlinson RH. Measurement and management of carcinoma of the breast. Clin Radiol. 1982; 33(5): 481–493, doi: 10.1016/s0009-9260(82)80153-0, indexed in Pubmed: 7116770.
25. Thomlinson RH. Cancer: the failure of treatment. Br J Radiol. 1987; 60(716): 735–751, doi: 10.1259/0007-1285-60-716-735, indexed in Pubmed: 3664174.
26. Kryj M, Maciejewski B, Withers HR, et al. Incidence and kinetics of distant metastases in patients with operable breast cancer. Neoplasma. 1997; 44(1): 3–11, indexed in Pubmed: 9201274.
27. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000; 355(9208): 949–955, doi: 10.1016/s0140-6736(00)90011-4.
28. Ball D, Bishop J, Smith J, et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 1999; 52(2): 129–136, doi: 10.1016/s0167-8140(99)00093-6.
29. Jain RK, Martin JD, Duda DG. Molecular pathophysiology of tumours. In: Perez & Brady's: Principles and Practice of Radiation Oncology. VII ed. Wolters Kluwer 2019: 112–132.
30. Coleman CN, Prasanm PG, Capala J. SMART radiotherapy. In: Coleman CN, Prasanm PG, Capala J. ed. Perez & Brady's: Principles and Practice of Radiation Oncology. VII ed. Wolters Kluwer 2019: 133–152.
31. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473(7347): 298–307, doi: 10.1038/nature10144, indexed in Pubmed: 21593862.
32. Maciejewski B, Suwiński R, Blamek S. Radiobiologia kliniczna w radioonkologii. Med Pract, Kraków 2019: 99–104.
33. Baumann M, Kurth I, Cordes N. Molecular cancer and radiation biology. In: Perez & Brady's Principles and Practice in Radiation Oncology. VII ed. Wolters Kluwer 2019: 71–76.
34. Buffa FM, Bentzen SM, Daley FM, et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res. 2004; 10(11): 3745–3754, doi: 10.1158/1078-0432.CCR-03-0248, indexed in Pubmed: 15173081.
35. Suwinski R, Bankowska-Wozniak M, Majewski W, et al. Postoperative Continuous 7-days-a-week Radiotherapy for High-risk Squamous Cell Cancer of the Head and Neck: Long-term Results of a Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2011; 81(2): S104, doi: 10.1016/j.ijrobp.2011.06.212.
36. Bruce PC. Introductory Statistics abs Analysis: A resampling perspective. I ed. John Wiley & Sons, Inc 2015.

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 452–462

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

VIA MEDICA

Artykuł przeglądowy / Review article

Biologia nowotworów / Tumor biology

Wnt pathways in focus – mapping current clinical trials across the cancer spectrum

Renata Pacholczak-Madej[1], Paulina Frączek[2], Klaudia Skrzypek[3], Mirosława Püsküllüoğlu[4]

[1]*Department of Anatomy, Jagiellonian University Medical College, Krakow, Poland*
[2]*Department of Oncology, University Hospital in Krakow, Poland*
[3]*Department of Transplantation, Institute of Pediatrics, Jagiellonian University Medical College, Faculty of Medicine, Krakow, Poland*
[4]*Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland*

The Wnt pathway has a pivotal function in tissue development and homeostasis, overseeing cell growth or differentiation. Aberrant Wnt signalling pathways have been associated with the pathogenesis of diverse malignancies, influencing cell proliferation, differentiation, cancer stem cell renewal, the tumour microenvironment and thereby significantly impacting tumour development and therapeutic responsiveness. Promisingly, current research underscores the potential therapeutic value of targeting Wnt pathways, particularly canonical Wnt/β-catenin signalling, in the context of numerous cancer types. Key constituents of the Wnt pathway, such as the Wnt/receptor, β-catenin degradation or transcription complexes, have been focal points for interventions in preclinical studies. To comprehend potential therapeutic strategies, we conduct an analysis of ongoing clinical trials that specifically aim to target components of the Wnt pathways across a diverse spectrum of cancer types. By scrutinizing these trials, including their respective phases, targeted patient populations ,and observed outcomes, this review provides a consolidated overview of the current translational landscape of Wnt-targeted therapies, thus offering a roadmap for future research endeavours.

Key words: cancer, clinical trials, Wnt signalling pathways, targeted therapy

Introduction

Cancer is one of the main causes of death worldwide [1]. While chemotherapy remains the backbone of systemic treatment for both the radically and palliatively treated cancer patient population, new options including a growing number of molecularly targeted drugs have entered the market with new and new indications [2]. The journey from the initial discovery of a compound to its approval by regulatory bodies like the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is an extensive process. It initiates with preclinical evaluations and advances through a multi-stage series of clinical trials involving human subjects. A significant proportion of compounds displaying promise in the preclinical phase ultimately do not achieve the specified endpoints during the clinical trial phases [3–6]. Figure 1 succinctly outlines this intricate progression.

There are numerous signaling pathways abrupted in cancer cells that have been already used as targets for different therapeutic strategies including kinase inhibitors (Kis), monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), drugs' nanoforms [2]. Activation of these pathways can induce

Jak cytować / How to cite:
Pacholczak-Madej R, Frączek P, Skrzypek K, Püsküllüoğlu M. ***Wnt pathways in focus – mapping current clinical trials across the cancer spectrum.*** *NOWOTWORY J Oncol* 2023; 73: 370–380.



Figure 1. Sequential stages of drug discovery and registration [3–6]

alterations in cell survival capabilities, metabolic processes, cellular proliferation, differentiation, thereby impacting the tumor microenvironment. Moreover, it plays a role in angiogenesis, epithelial to mesenchymal transition, and the formation of metastases [7–10]. Among the numerous pathways with key components that are established targets for treatment, prominent examples comprise epidermal growth factor receptor/RAS/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase (EGFR/RAS/RAF), human epidermal growth factor receptor 2 (HER2), sonic hedgehog (SHH), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and protein kinase B/mammalian target of rapamycin (AKT/mTOR). It is noteworthy that the elements of these pathways often intersect during signal transduction [7–10]. Wnt represents a fundamental pathway crucial in both embryonic development and the onset of tumorigenesis [11]. Presently, there are no registered drugs specifically targeting the elements of this pathway, despite it presenting an apparent target for innovative anticancer agents. The objective of this review is to delve into the prospects of translating elements of the Wnt pathway from preclinical research to clinical applications. Through meticulous examination of these trials, encompassing their phases, targeted population, and the active drug studied, the review furnishes a comprehensive summary of the present translational panorama concerning therapies directed at the Wnt pathways.

Canonical and non-canonical Wnt signalling

The Wnt pathway plays a pivotal role in numerous developmental and homeostatic processes. Aberrations within this pathway have been implicated in a spectrum of pathological conditions, including cancers. The intricate balance and regulation of the Wnt pathway underscore its paramount importance in cellular homeostasis, presenting a potential target for therapeutic interventions in malignancies and other diseases.

There are in fact several signaling pathways that can be activated with the elements of Wnt. The canonical pathway is the most well-known (fig. 2). At the core of this pathway lies β-catenin, a key protein acting as a linchpin orchestrating downstream signaling events. Two other pathways are planar cell polarity (PCP) and calcium-related pathways [11–16].

Wnt proteins are categorized into canonical and noncanonical types, instigating both respective pathways by engaging Frizzled (FZD) receptors (tab. I). Frizzled receptors require a co-receptor, low-density lipoprotein receptor-related protein 5/6 (LRP5/6) for canonical signaling, and receptor tyrosine kinase-like orphan receptor 1/2 (ROR1/2) for non-canonical signaling, to transmit signals effectively [11–17].

Within the canonical pathway, upon activation, Wnt binding disrupts the β-catenin destruction complex, preventing the phosphorylation of β-catenin by GSK-3β, thereby averting its proteasomal degradation. Key components of the destruction complex include:



Figure 2. Canonical Wnt pathway inactive (on the left-hand side) and active (on the right-hand side) (created with BioRender) [11–16] APC – *adenomatous polyposis coli*; CBP – CREB-binding protein; CK1-α – casein kinase 1-alpha; GSK-3β – glycogen synthase kinase 3-beta; LEF – lymphoid enhancer factor; LRP – low-density lipoprotein receptor-related protein; TCF – T cell factor

Table I. Canonical and non-canonical elements of the Wnt family [11, 16]

Pathway		Proteins
canonical	Wnt / β-catenin	Wnt1, Wnt2, Wnt3, Wnt3a, Wnt8a, Wnt8b, Wnt10a, Wnt10b
non canonical	PCP, Wnt / Ca^{2+}	Wnt3, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt11

PCP – planar-cell polarity

- *adenomatous polyposis coli* (APC),
- glycogen synthase kinase 3-beta (GSK-3β),
- axin, casein kinase 1-alpha (CK1-α).

The accumulation of β-catenin in the cytoplasm enables its translocation into the nucleus, where it forms complexes with various transcription factors, primarily lymphoid enhancer factor/T-cell factor (LEF/TCF), initiating the transcription of vital Wnt/β-catenin target genes such as: cMyc, cyclin D1 (CCND1), and VEGF or programmed death-ligand 1 (PD-L1) [11–16].

Non-canonical Wnt pathways are Wnt / PCP and Wnt-cyclic guanosine monophosphate / calcium ion (Wnt-cGMP/Ca^{2+}) signaling. The targets for these non-canonical pathways can include matrix metalloproteinases (MMPs) or AKT/mTOR. These pathways are believed to exert an influence on processes such as epithelial-mesenchymal transition (EMT), cell migration, cell metabolism, chemo-resistance, or the formation of metastases [11, 16, 17].

Preclinical and clinical cancer studies regarding Wnt elements

Inhibition of the Wnt pathway represents an interesting and promising molecular target for novel anticancer therapies in various malignancies. Many new molecules have been investigated in preclinical studies or in clinical trials – mainly phase 1 (tab. II). Some of them have reached phase 2 clinical trials in the treatment of solid malignancies, as well as hematologic, but recruitment is ongoing or the results of those trials are expected to be soon published. An interesting approach represents the combination of Wnt inhibitors with chemotherapy of targeted therapies – PD-1/PD-L1 inhibitors (nivolumab / pembrolizumab) or EGFR inhibitors (cetuximab).

Katoh and Katoh divided Wnt-targeted agents into pan-Wnt inhibitors (like porcupine inhibitors), canonical (like β-catenin protein-protein inhibitor) and non-canonical (like ROR1 inhibitors) [12]. However, there is a significant group of compounds that modulate the signal indirectly or influence

Table II. Agents inhibiting the Wnt pathway which are under investigation. Complied on the basis of clinicaltrials.gov as of April 2023, unless otherwise specified

Name of agent	Mechanism of action	Development stage	Indications	Reference
PKF115–584, CGP049090, PKF222–815, PKF118–310, PKF118–744, ZTM000990	β-catenin – TCF antagonists	preclinical	colorectal cancer, breast cancer	[18, 19]
iCRT3, iCRT5, iCRT14	β-catenin – TCF antagonists	preclinical	colorectal cancer, triple negative breast cancer	[20, 21]
BC21	β-catenin – TCF antagonists	preclinical	colorectal cancer	[22]
FH535	β-catenin – TCF antagonists	preclinical	triple negative breast cancer, colorectal cancer, lung cancer, hepatocellular carcinoma	[23, 24]
CWP232228	β-catenin – TCF antagonists	preclinical	breast cancer	[25]
ICG-001	β-catenin / CBP inhibitor	preclinical	triple negative breast cancer	[26]
CG0009	glycogen synthase kinase 3α/β inhibitor	preclinical	breast cancer	[27]
niclosamide	inhibition the binding of a WNT ligand to LRP5/6 receptors	preclinical	breast cancer	[28]
salinomycin	inhibition the binding of a WNT ligand to LRP5/6 receptors	preclinical	breast cancer, prostate cancer, chronic lymphocytic leukemia	[29, 30]
LGK974 (WNT974)	inhibitor of the WNT-receptor complex (porcupine inhibitor)	phase 1 clinical trial, recruiting	pancreatic cancer, BRAF-mutant colorectal cancer, melanoma, triple negative breast cancer, head and neck squamous-cell cancer, cervical squamous-cell cancer, esophageal squamous-cell cancer, lung squamous-cell cancer	[31]
		phase 1 and 2 clinical trial + cetuximab, completed	BRAF-mutant metastatic colorectal cancer	[32]
		preclinical	Ewing sarcoma	[33]
		preclinical	clear cell, renal cell carcinoma	[34]
ETC-1922159	inhibitor of the WNT-receptor complex (porcupine inhibitor)	phase I clinical trial +/– pembrolizumab, recruiting	advanced solid tumors	[35]
CGX1321	Inhibitor of the WNT-receptor complex (porcupine inhibitor)	phase I clinical trial +/– pembrolizumab or encorafenib + cetuximab, recruiting	advanced gastrointestinal tumors	[36]
		phase 1 clinical trial, recruiting	advanced gastrointestinal tumors	[37]
RXC004	inhibitor of the WNT-receptor complex (porcupine inhibitor)	phase 1 clinical trial +/– nivolumab, recruiting	advanced solid tumors	[38]
		phase 2 clinical trial, recruiting	advanced solid tumors	[39]
		phase 2 clinical trial +/– nivolumab, recruiting	colorectal cancer	[40]
XNW7201	inhibitor of the WNT-receptor complex (porcupine inhibitor)	phase 1 clinical trial, active, not recruiting	advanced solid tumors	[41]
OMP-18R5 (vantictumab)	inhibitor of the WNT-receptor complex (antibody against WNT family proteins – namely FZD1, FZD2, FZD5, FZD7 and FZD8)	phase 1 clinical trial, completed	advanced solid tumors	[42]
		phase 1 clinical trial +/– nab-paklitaxel and gemcitabine, completed	advanced pancreatic cancer	[43, 44]
		phase 1b clinical trial + docetaxel, completed	non-small cell lung cancer	[45]
		phase 1b clinical trial, completed	metastatic breast cancer	[46]

→

Table II cont. Agents inhibiting the Wnt pathway which are under investigation. Complied on the basis of clinicaltrials.gov as of April 2023, unless otherwise specified

Name of agent	Mechanism of action	Development stage	Indications	Reference
OMP-54F28 (ipafricept)	inhibitor of the WNT-receptor complex (antibody against WNT family proteins – namely FZD 8 receptor)	phase 1 clinical trial, completed	advanced solid tumors	[47, 48]
		phase 1 clinical trial + sorafenib, completed	hepatocellular cancer	[49]
		phase 1 clinical trial + paclitaxel and carboplatin, completed	ovarian cancer	[50, 51]
		phase 1 clinical trial + nab-paclitaxel and gemcitabine, completed	pancreatic cancer	[52]
OTSA101	inhibitor of the WNT-receptor complex (antibody against Wnt family proteins – namely FZD 10 receptor)	phase 1 clinical trial, recruiting	synovial sarcoma	[53]
NVP-TNKS656	β-catenin-destruction complex inhibitors, namely tankyrase inhibitors (PARPs family)	preclinical	colorectal cancer	[54]
XAV939	β-catenin-destruction complex inhibitors, namely tankyrase inhibitors (PARPs family)	preclinical	breast cancer	[55]
PRI-724	inhibition of the CBP and β-catenin interaction	phase 1a/1b clinical trial, terminated	advanced solid tumors	[56, 57]
		phase 1 clinical trial + gemcitabine, completed	pancreatic cancer	[58, 59]
		phase 1 and 2 clinical trial, completed	acute myeloid leukemia, chronic myeloid leukemia	[60]
CWP232291	inhibitor of the Wnt pathway, induction of apoptosis *via* activation of caspases	phase 1 clinical trial, completed	refractory acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, myelofibrosis	[61, 62]
		phase 1 clinical trial +/– lenalidomide, dexamethasone, completed	multiple myeloma	[63, 64]
		phase 1 and 2 clinical trial, active, not recruiting	acute myeloid leukemia	[65]
DKN-01	monoclonal antibody, inhibitor of the DKK1 activity, a modulator of Wnt / β-catenin signaling	phase 1 clinical trial +/– paclitaxel or pembrolizumab, completed	esophageal cancer gastroesophageal junction cancer, gastric adenocarcinoma with Wnt signaling alterations	[66, 67]
		phase 1 clinical trial + gemcitabine/cisplatine, completed	carcinoma primary to the intra- or exta-hepatic biliary system or gallbladder	[68, 69]
		phase 1b/2a clinical trial +/– docetaxel, recruiting	prostate cancer	[70, 71]
		phase 1 and 2 clinical trial +/– sorafenib, recruiting	advanced liver cancer	[72]
		phase 2 clinical trial + nivolumab, recruiting	advanced biliary tract cancer	[73]
		phase 2 clinical trial +/– paclitaxel, completed	endometrial cancer, uterine cancer, ovarian cancer, carcinosarcoma	[74]
		phase 2 clinical trial + tiselizumab +/– chemotherapy, recruiting	gastric cancer, gastroesophageal cancer	[75]
		phase 1 clinical trial, completed	multiple myeloma, solid tumors, non-small-cell lung cancer	[76, 77]
		phase 1 clinical trial + lenalidomide/dexamethasone, completed	relapsed or refractory multiple myeloma	[77]
		phase 1 and 2 clinical trial + atezolizumab, recruiting	metastatic esophageal cancer, metastatic gastric cancer	[78]

→

Table II cont. Agents inhibiting the Wnt pathway which are under investigation. Complied on the basis of clinicaltrials.gov as of April 2023, unless otherwise specified

Name of agent	Mechanism of action	Development stage	Indications	Reference
Foxy-5	WNT5A-mimicking peptide	phase 1 clinical trials, completed	breast cancer, colon cancer, prostate cancer	[79, 80]
		phase 2 clinical trial, recruiting	colon cancer (neoadjuvant setting)	[81]
UC-961 (cirmtuzumab)	monoclonal antibody against ROR1 of the non-canonical Wnt pathway	phase 2 clinical trial + docetaxel, not yet recruiting	metastatic castration resistant prostate cancer	[82]
		phase 1 clinical trial, completed	relapsed or refractory chronic lymphocytic leukemia	[83, 84]
		phase 1 and 2 clinical trial + ibrutinib, active, not recruiting	B-cell lymphoid malignancies	[85, 86]
		phase 2 clinical trial, recruiting	chronic lymphocytic leukemia, consolidation after venetoclaxs	[87]
		phase 1 clinical trial + paclitaxel, active, not recruiting	breast cancer	[88]
PRI-724	CBP / β-catenin antagonist	phase 2 clinical trial + FOLFOX and bevacizumab, withdrawn	metastatic colorectal cancer	[89]
		phase 1 clinical trial + gemcitabine, completed	advanced pancreatic cancer	[90, 91]
		phase 1 and 2 clinical trial, completed	acute myeloid leukemia, chronic myeloid leukemia	[92]
		phase 1 clinical trial, terminated	advanced solid tumors	[93]
PF-06647020 (cofetuzumab pelidotin)	monoclonal antibody against PTK7 – inhibition of non-canonical Wnt pathway	phase 1 clinical trial + gedatolisib, completed	triple negative breast cancer	[94–96]
		phase 1 clinical trial, completed	non-small cell lung cancer	[97, 98]
		phase 1 clinical trial, completed	advanced solid tumors	[99, 100]
GDC-0449 (vismodegib)	inhibitor of the hedgehog pathway	FDA and EMA registered	metastatic/locally advanced basal cell carcinoma	[101, 102]
		numerous clinical trials phase 1–3	advanced solid tumors (also advanced breast cancer) hematologic malignancies	#
LDE225 (sonidegib)	inhibitor of the hedgehog pathway	FDA and EMA registered	metastatic/locally advanced basal cell carcinoma	[103, 104]
		numerous clinical trials phase 1–3	advanced solid tumors (also advanced breast cancer) hematologic malignancies	#
itraconazole	antifungal medication, inhibitor of the hedgehog pathway	numerous clinical trials phase 1–3	prostate cancer, lung cancer, ovarian cancer, esophageal cancer, multiple myeloma, solid malignancies	#
PF-04449913 (glasdegib)	inhibitor of the hedgehog pathway	phase 1 and 2 clinical trials	hematologic malignancies	#
		phase 1 clinical trial, completed	solid tumors	[105, 106]
		phase 1 and 2 clinical trial + temozolomide, active, not recruiting	glioblastoma	[107]
IPI-926 (patidegib)	inhibitor of the hedgehog pathway	phase 1 clinical trial, completed	basal cell carcinoma	[108]
		phase 1 and 2 clinical trial + gemcitabine, completed	pancreatic cancer	[109, 110]
		phase 1 + FOLIFIRINOX, completed	pancreatic cancer	[111, 112]
		phase 1 clinical trial, completed	solid tumor malignancies	[113, 114]
		phase 1 clinical trial + cetuximab, completed	head and neck cancer	[115, 116]
		phase 2 clinical trial, completed	unresectable chondrosarcoma	[117]
LY2940680	inhibitor of the hedgehog pathway	phase 2 clinical trial, completed	solid tumor malignancies	[118]

Table II cont. Agents inhibiting the Wnt pathway which are under investigation. Complied on the basis of clinicaltrials.gov as of April 2023, unless otherwise specified

Name of agent	Mechanism of action	Development stage	Indications	Reference
ENV-101	inhibitor of the hedgehog pathway	phase 2 clinical trial, recruiting	advanced solid tumors harboring PTCH1 loss of function mutations	[119]
		phase 1 clinical trial, completed	breast cancer, colon cancer, cholangiocarcinoma, soft tissue sarcoma	[120]
		phase 1 and 2 clinical trial, completed	esophageal or gastroesophageal junction cancer	[121]
lycopene	naturally synthesized carotenoid (an active component of red fruits and vegetables) – suppression of β-catenin nuclear expression	phase 2 clinical trial, active, not recruiting	skin toxicity in patients with colorectal carcinoma treated with panitumumab	[122]
		preclinical	gastric cancer, breast cancer	[123, 124]
artesunate	antimalarial drug – suppression of Wnt pathway by downregulation of c-Myc and cyclin D1	phase 2 clinical trial, active, not recruiting	stage II/III colorectal cancer (pre-operative treatment)	[125, 126]
		phase 1 clinical trial, completed	advanced solid tumors	[127, 128]
		phase 1 clinical trial, completed	metastatic breast cancer	[129, 130]
resveratol	non-flavonoid polyphenol – suppression of Wnt pathway by decreasing the expression of β-catenin and cyclin D1	phase 1 clinical trial, completed	colon cancer	[131, 132]
		preclinical	breast cancer, gastric cancer	[133, 134]
quercetin	flavonoid (component of onion, red grapes, lettuce, tomato). Inhibition of the Notch1, PI3K/AKT and β-catenin signaling pathways	preclinical	breast cancer, ovarian cancer, B-cell lymphomas	[135–137]

CBP – CREB-binding protein; BRAF – B-Raf proto-oncogene, serine/threonine kinase; DKK1 – dickkopf-1 protein; EMA – European Medical Agency; FDA – Food and Drug Administration; FOLFOX – folinic acid, 5-fluorouracil and oxaliplatin; FOLFIRINOX – folinic acid, 5-fluorouracil, irinotecan and oxaliplatin; FZD – frizzled receptor; LRP5/6 – low-density lipoprotein receptor-related protein 5/6; PARPs – poly (ADP-ribose) polymerases; PI3K/AKT – phosphoinositide 3-kinase/protein kinase B; PTK7 – protein tyrosine kinase 7; TCF – T cell factor; # – for details see clinicaltrials.gov

Wnt signalling by interfering with other pathways (like SHH). β-catenin itself plays an important role as a signal transducer in other pathways including trophoblast cell surface antigen 2 (TROP-2) [138].

Current trials, as shown in table II, involve drugs acting on numerous levels of these signaling pathways:

- Outside the cancer cell / on the cell membrane level: Wnt--mimicking agents [79, 80]; monoclonal antibody against ROR1 (cirmtuzumab) [82–86]; Wnt proteins / receptors inhibitors like: porcupine inhibitors LGK974, ETC-1922159, CGX1321, RXC004, XNW7201 [31–41] or FZD inhibitors (vantictumab, ipafricept, OTSA101) [42–53]. Porcupine serves as a vital enzyme within the Wnt signaling pathway, aiding in the palmitoylation of Wnt proteins. This alteration is pivotal for the appropriate secretion of Wnt proteins and the initiation of the Wnt signaling pathway [139]. Monoclonal antibodies against protein tyrosine kinase 7 (PTK7) can also be included into that group. PTK-7 is a transmembrane receptor protein that has been implicated in the regulation of the Wnt signaling pathway (cofetuzumab pelidotin) [94–102].
- In the cytoplasm: dikkopf-1 (DKK1) modulators (DKN-01) [66–71]. Functioning as an extracellular antagonist, DKK1 binds to LRP5/6 co-receptors, interrupting their engagement with Wnt ligands and obstructing the activation of the canonical Wnt pathway. This impediment leads to a halt in the accumulation and nuclear movement of β-catenin [140].
- Within the nucleus e.g. inhibiting the target canonical pathway genes [125, 126] or CREB-binding protein (CBP) / β-catenin inhibitors (ICG-001, PRI-724, PRI-724 [26, 56–60, 89–96). CBP serves as a coactivator for transcription within the canonical Wnt pathway, collaborating with transcription factors such as β-catenin. It amplifies the transcription of Wnt target genes by modifying chromatin structure through the acetylation of histones [141].
- Within other signaling pathways that interact with Wnt including SHH (vismodegib, sonidegib, itraconazole, glasdegib, patidegib, LY2940680, ENV-101) as the most visible example [101–121].

While compounds acting on β-catenin degradation complex show activity in preclinical studies, their clinical activity has

not been confirmed yet (NVP-TNKS656, XAV939) [54, 55]. Numerous limitations accompany the development of Wnt pathway inhibitors. They include: the non-obvious role of Wnt elements in cancer development and progression, its role in physiological processes, its complexity. Notably, WNT inhibitors have the potential to serve not only in cancer therapy but also in a supportive capacity to mitigate treatment-related toxicity [11–17, 142].

Numerous novel molecules have undergone scrutiny in either preclinical investigations or clinical trials. A portion of these compounds has progressed to phase 2 clinical trials, marking the mid-point in the translational process depicted in figure 1.

Conclusions

The precise equilibrium and meticulous regulation observed in the Wnt pathway underline its paramount importance in maintaining cellular homeostasis, thereby delineating it as a promising focal point for therapeutic interventions directed at malignancies. The Wnt pathway branches into canonical and noncanonical categories, each instigating distinctive signaling cascades through specific receptor engagement. A comprehensive understanding of these pathways and their constituent elements is imperative for discerning their potential therapeutic ramifications. Presently, preclinical and clinical inquiries into Wnt elements are progressing, presenting an enticing trajectory for the development of novel anticancer therapies. However, the intricate nature of Wnt signaling, its dual role in both disease and physiological homeostasis, and the complexities surrounding its inhibitors do pose formidable challenges. The number of trials and the variety of molecular targets related to Wnt pathways, as well as different cancer indications within the patient population (tab. II) provide grounds for optimism regarding the possibility of advancing beyond the early phases of clinical trials in the journey from bench to bedside (fig. 1).

Article information and declarations

Author contributions

Renata Pacholczak-Madej – study conception and design, material collection, analysis and interpretation of results: all authors; manuscript preparation.

Mirosława Püsküllüoğlu – study conception and design, material collection, analysis and interpretation of results: all authors; manuscript preparation.

Paulina Frączek – manuscript critical review.

Klaudia Skrzypek – manuscript critical review.

All authors have approved the final version of the paper.

Funding

None declared

Conflict of interest

None declared

Mirosława Püsküllüoğlu

Maria Sklodowska-Curie National Research Institute of Oncology
Krakow Branch
Department of Clinical Oncology
Ul. Garncarska 11
31-115 Krakow, Poland
e-mail: mira.puskulluoglu@gmail.com

Received: 27 Sep 2023
Accepted: 17 Oct 2023

References

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1): 7–33, doi: 10.3322/caac.21708, indexed in Pubmed: 35020204.
2. Ługowska IE. Handbook of Targeted Therapies and Precision Oncology. ESMO Press, Lugano 2022.
3. Choudhari AS, Mandave PC, Deshpande M, et al. Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice. Front Pharmacol. 2019; 10: 1614, doi: 10.3389/fphar.2019.01614, indexed in Pubmed: 32116665.
4. Hughes JP, Rees S, Kalindjian SB, et al. Principles of early drug discovery. Br J Pharmacol. 2011; 162(6): 1239–1249, doi: 10.1111/j.1476--5381.2010.01127.x, indexed in Pubmed: 21091654.
5. Berdigaliyev N, Aljofan M. An overview of drug discovery and development. Future Med Chem. 2020; 12(10): 939–947, doi: 10.4155/fmc-2019-0307, indexed in Pubmed: 32270704.
6. Kaushik I, Ramachandran S, Prasad S, et al. Drug rechanneling: A novel paradigm for cancer treatment. Semin Cancer Biol. 2021; 68: 279–290, doi: 10.1016/j.semcancer.2020.03.011, indexed in Pubmed: 32437876.
7. You M, Xie Z, Zhang N, et al. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023; 8(1): 196, doi: 10.1038/s41392-023-01442-3, indexed in Pubmed: 37164974.
8. Lang BJ, Prince TL, Okusha Y, et al. Heat shock proteins in cell signaling and cancer. Biochim Biophys Acta Mol Cell Res. 2022; 1869(3): 119187, doi: 10.1016/j.bbamcr.2021.119187, indexed in Pubmed: 34906617.
9. Borlongan MC, Wang H. Profiling and targeting cancer stem cell signaling pathways for cancer therapeutics. Front Cell Dev Biol. 2023; 11: 1125174, doi: 10.3389/fcell.2023.1125174, indexed in Pubmed: 37305676.
10. Yip HY, Papa A. Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells. 2021; 10(3), doi: 10.3390/cells10030659, indexed in Pubmed: 33809714.
11. Wilusz M, Majka M. Role of the Wnt/beta-catenin network in regulating hematopoiesis. Arch Immunol Ther Exp (Warsz). 2008; 56(4): 257–266, doi: 10.1007/s00005-008-0029-y, indexed in Pubmed: 18726147.
12. Katoh M, Katoh M. WNT signaling and cancer stemness. Essays Biochem. 2022; 66(4): 319–331, doi: 10.1042/EBC20220016, indexed in Pubmed: 35837811.
13. Pamarthy S, Kulshrestha A, Katara GK, et al. The curious case of vacuolar ATPase: regulation of signaling pathways. Mol Cancer. 2018; 17(1): 41, doi: 10.1186/s12943-018-0811-3, indexed in Pubmed: 29448933.
14. Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, et al. WNT Signaling in Tumors: The Way to Evade Drugs and Immunity. Front Immunol. 2019; 10: 2854, doi: 10.3389/fimmu.2019.02854, indexed in Pubmed: 31921125.
15. Zhang Ya, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020; 13(1): 165, doi: 10.1186/s13045-020-00990-3, indexed in Pubmed: 33276800.
16. Chen Y, Chen Z, Tang Y, et al. The involvement of noncanonical Wnt signaling in cancers. Biomed Pharmacother. 2021; 133: 110946, doi: 10.1016/j.biopha.2020.110946, indexed in Pubmed: 33212376.
17. Xiao Q, Chen Z, Jin X, et al. The many postures of noncanonical Wnt signaling in development and diseases. Biomed Pharmacother. 2017; 93: 359–369, doi: 10.1016/j.biopha.2017.06.061, indexed in Pubmed: 28651237.
18. Lepourcelet M, Chen YNP, France DS, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004; 5(1): 91–102, doi: 10.1016/s1535-6108(03)00334-9, indexed in Pubmed: 14749129.
19. Hallett RM, Kondratyev MK, Giacomelli AO, et al. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS

One. 2012; 7(3): e33976, doi: 10.1371/journal.pone.0033976, indexed in Pubmed: 22470504.
20. Gonsalves FC, Klein K, Carson BB, et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A. 2011; 108(15): 5954–5963, doi: 10.1073/pnas.1017496108, indexed in Pubmed: 21393571.
21. Bilir B, Kucuk O, Moreno CS. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med. 2013; 11: 280, doi: 10.1186/1479-5876-11-280, indexed in Pubmed: 24188694.
22. Tian W, Han X, Yan M, et al. Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction. Biochemistry. 2012; 51(2): 724–731, doi: 10.1021/bi201428h, indexed in Pubmed: 22224445.
23. Handeli S, Simon JA. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008; 7(3): 521–529, doi: 10.1158/1535-7163.MCT-07-2063, indexed in Pubmed: 18347139.
24. Iida J, Dorchak J, Lehman JR, et al. FH535 inhibited migration and growth of breast cancer cells. PLoS One. 2012; 7(9): e44418, doi: 10.1371/journal.pone.0044418, indexed in Pubmed: 22984505.
25. Jang GB, Hong IS, Kim RJ, et al. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells. Cancer Res. 2015; 75(8): 1691–1702, doi: 10.1158/0008-5472.CAN-14-2041, indexed in Pubmed: 25660951.
26. Sulaiman A, McGarry S, Li Li, et al. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. Mol Oncol. 2018; 12(4): 423–440, doi: 10.1002/1878-0261.12167, indexed in Pubmed: 29316250.
27. Kim HMi, Kim CS, Lee JH, et al. CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells. PLoS One. 2013; 8(4): e60383, doi: 10.1371/journal.pone.0060383, indexed in Pubmed: 23565238.
28. Londoño-Joshi AI, Arend RC, Aristizabal L, et al. Effect of niclosamide on basal-like breast cancers. Mol Cancer Ther. 2014; 13(4): 800–811, doi: 10.1158/1535-7163.MCT-13-0555, indexed in Pubmed: 24552774.
29. Lu W, Li Y. Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem. 2014; 115(10): 1799–1807, doi: 10.1002/jcb.24850, indexed in Pubmed: 24905570.
30. Lu D, Choi MY, Yu J, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011; 108(32): 13253–13257, doi: 10.1073/pnas.1110431108, indexed in Pubmed: 21788521.
31. A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands. https://clinicaltrials.gov/ct2/show/NCT01351103 (12.04.2023).
32. Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations. https://clinicaltrials.gov/ct2/show/NCT02278133 (12.04.2023).
33. Hayashi M, Baker A, Goldstein SD, et al. Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma. Oncotarget. 2017; 8(45): 78265–78276, doi: 10.18632/oncotarget.19432, indexed in Pubmed: 29108227.
34. Li J, Wu G, Xu Y, et al. Porcupine Inhibitor LGK974 Downregulates the Wnt Signaling Pathway and Inhibits Clear Cell Renal Cell Carcinoma. Biomed Res Int. 2020; 2020: 2527643, doi: 10.1155/2020/2527643, indexed in Pubmed: 32104684.
35. A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours. https://clinicaltrials.gov/ct2/show/NCT02521844 (25.11.2022).
36. CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596). https://clinicaltrials.gov/ct2/show/NCT02675946 (25.11.2022).
37. Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors. https://clinicaltrials.gov/ct2/show/NCT03507998 (25.11.2022).
38. Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies. https://clinicaltrials.gov/ct2/show/NCT03447470 (25.11.2022).
39. A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2). https://clinicaltrials.gov/ct2/show/NCT04907851 (25.11.2022).
40. A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC). https://clinicaltrials.gov/ct2/show/NCT04907539 (25.11.2022).
41. Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT03901950 (25.11.2022).
42. Smith D, Rosen L, Chugh R, et al. First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors. Journal of Clinical Oncology. 2013; 31(15_suppl): 2540–2540, doi: 10.1200/jco.2013.31.15_suppl.2540.
43. Davis SL, Cardin DB, Shahda S, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020; 38(3): 821–830, doi: 10.1007/s10637-019-00824-1, indexed in Pubmed: 31338636.
44. A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer. https://clinicaltrials.gov/ct2/show/NCT02005315 (25.11.2022).
45. A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC. https://clinicaltrials.gov/ct2/show/NCT01957007 (25.11.2022).
46. Diamond JR, Becerra C, Richards D, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020; 184(1): 53–62, doi: 10.1007/s10549-020-05817-w, indexed in Pubmed: 32803633.
47. Jimeno A, Gordon M, Chugh R, et al. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017; 23(24): 7490–7497, doi: 10.1158/1078-0432.CCR-17-2157, indexed in Pubmed: 28954784.
48. A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01608867 (25.11.2022).
49. Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer. https://clinicaltrials.gov/ct2/show/NCT02069145 (25.11.2022).
50. Moore KN, Gunderson CC, Sabbatini P, et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019; 154(2): 294–301, doi: 10.1016/j.ygyno.2019.04.001, indexed in Pubmed: 31174889.
51. Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer. https://clinicaltrials.gov/ct2/show/NCT02092363 (25.11.2022).
52. Dotan E, Cardin DB, Lenz HJ, et al. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clin Cancer Res. 2020; 26(20): 5348–5357, doi: 10.1158/1078-0432.CCR-20-0489, indexed in Pubmed: 32694153.
53. Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma. https://clinicaltrials.gov/ct2/show/NCT04176016 (25.11.2022).
54. Arqués O, Chicote I, Puig I, et al. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016; 22(3): 644–656, doi: 10.1158/1078-0432.CCR-14-3081, indexed in Pubmed: 26224873.
55. Bao R, Christova T, Song S, et al. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS One. 2012; 7(11): e48670, doi: 10.1371/journal.pone.0048670, indexed in Pubmed: 23144924.
56. El-Khoueiry A, Ning Y, Yang D, et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol. 2013; 31(15_suppl): 2501–2501, doi: 10.1200/jco.2013.31.15_suppl.2501.
57. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01302405 (25.11.2022).
58. Ko A, Chiorean E, Kwak E, et al. Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. J Clin Oncol. 2016; 34(15_suppl): e15721–e15721, doi: 10.1200/jco.2016.34.15_suppl.e15721.
59. Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma. https://clinicaltrials.gov/ct2/show/NCT01764477 (25.11.2022).
60. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies. https://clinicaltrials.gov/ct2/show/NCT01606579 (25.11.2022).

61. Lee JH, Faderl S, Pagel JM, et al. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2020; 4(9): 2032–2043, doi: 10.1182/bloodadvances.2019000757, indexed in Pubmed: 32396615.
62. Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients. https://clinicaltrials.gov/ct2/show/NCT01398462 (25.11.2022).
63. Yoon SS, Manasanch E, Min C, et al. Novel phase 1a/1b dose-finding study design of CWP232291 (CWP291) in relapsed or refractory myeloma (MM). J Clin Oncol. 2017; 35(15_suppl): TPS8058–TPS8058, doi: 10.1200/jco.2017.35.15_suppl.tps8058.
64. Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients. https://clinicaltrials.gov/ct2/show/NCT02426723 (25.11.2022).
65. Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients. https://clinicaltrials.gov/ct2/show/NCT03055286 (25.11.2022).
66. Klempner SJ, Bendell JC, Villaflor VM, et al. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. Mol Cancer Ther. 2021; 20(11): 2240–2249, doi: 10.1158/1535-7163.MCT-21-0273, indexed in Pubmed: 34482288.
67. A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab. https://clinicaltrials.gov/ct2/show/NCT02013154 (25.11.2022).
68. Goyal L, Sirard C, Schrag M, et al. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clin Cancer Res. 2020; 26(23): 6158–6167, doi: 10.1158/1078-0432.CCR-20-1310, indexed in Pubmed: 32878766.
69. Goyal L, Sirard C, Schrag M, et al. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clin Cancer Res. 2020; 26(23): 6158–6167, doi: 10.1158/1078-0432.CCR-20-1310, indexed in Pubmed: 32878766.
70. Wise DR, Schneider JA, Armenia J, et al. International SU2C/PCF Prostate Cancer Dream Team. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2020; 4, doi: 10.1200/PO.20.00097, indexed in Pubmed: 33015525.
71. A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1. https://clinicaltrials.gov/ct2/show/NCT03837353 (25.11.2022).
72. DKN-01 Inhibition in Advanced Liver Cancer. https://clinicaltrials.gov/ct2/show/NCT03645980 (25.11.2022).
73. Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC). https://clinicaltrials.gov/ct2/show/NCT04057365 (25.11.2022).
74. A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma. https://clinicaltrials.gov/ct2/show/NCT03395080 (25.11.2022).
75. A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer. https://clinicaltrials.gov/ct2/show/NCT04363801 (25.11.2022).
76. Edenfield W, Richards D, Vukelja S, et al. A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer. J Clin Oncol. 2014; 32(15_suppl): 8068–8068, doi: 10.1200/jco.2014.32.15_suppl.8068.
77. A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01457417 (25.11.2022).
78. WaKING: Wnt and checKpoint INhibition in Gastric Cancer. https://clinicaltrials.gov/ct2/show/NCT04166721 (25.11.2022).
79. Soerensen P, Andersson T, Buhl U, et al. Phase I dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of Foxy-5 in patients with metastatic breast, colorectal, or prostate cancer. J Clin Oncol. 2014; 32(15_suppl): TPS1140–TPS1140, doi: 10.1200/jco.2014.32.15_suppl.tps1140.
80. Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT02020291 (25.11.2022).
81. Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer. https://clinicaltrials.gov/ct2/show/NCT03883802 (25.11.2022).
82. Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT05156905 (25.11.2022).
83. Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961. https://clinicaltrials.gov/ct2/show/NCT02860676 (25.11.2022).
84. UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia. https://clinicaltrials.gov/ct2/show/NCT02222688 (25.11.2022).
85. Lee H, Choi M, Siddiqi T, et al. Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). J Clin Oncol. 2021; 39(15_suppl): 7556–7556, doi: 10.1200/jco.2021.39.15_suppl.7556.
86. A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies. https://clinicaltrials.gov/ct2/show/NCT03088878 (25.11.2022).
87. Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax. https://clinicaltrials.gov/ct2/show/NCT04501939 (25.11.2022).
88. Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer. https://clinicaltrials.gov/ct2/show/NCT02776917 (25.11.2022).
89. Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer. https://clinicaltrials.gov/ct2/show/NCT02413853 (25.11.2022).
90. Ko A, Chiorean E, Kwak E, et al. Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second--line therapy after FOLFIRINOX or FOLFOX. J Clin Oncol. 2016; 34(15_suppl): e15721–e15721, doi: 10.1200/jco.2016.34.15_suppl.e15721.
91. Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma. https://clinicaltrials.gov/ct2/show/NCT01764477 (25.11.2022).
92. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies. https://clinicaltrials.gov/ct2/show/NCT01606579 (25.11.2022).
93. El-Khoueiry A, Ning Y, Yang D, et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol. 2013; 31(15_suppl): 2501–2501, doi: 10.1200/jco.2013.31.15_suppl.2501.
94. Damelin M, Bankovich A, Bernstein J, et al. A PTK7-targeted antibody--drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017; 9(372), doi: 10.1126/scitranslmed.aag2611, indexed in Pubmed: 28077676.
95. Katoh M. Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis. Ann Transl Med. 2017; 5(23): 462, doi: 10.21037/atm.2017.09.11, indexed in Pubmed: 29285495.
96. An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer. https://clinicaltrials.gov/ct2/show/NCT03243331 (25.11.2022).
97. Radovich M, Solzak JP, Hancock BA, et al. Abstract OT3-06-02: An initial safety study of gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer. Cancer Research. 2019; 79(4_Supplement): OT3-06-02-OT3-06–02, doi: 10.1158/1538-7445.sabcs18-ot3-06-02.
98. An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer. https://clinicaltrials.gov/ct2/show/NCT04189614?term=Cofetuzumab+pelidotin&draw=2&rank=1 (25.11.2022).
99. Maitland ML, Sachdev JC, Sharma MR, et al. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clin Cancer Res. 2021; 27(16): 4511–4520, doi: 10.1158/1078-0432.CCR-20-3757, indexed in Pubmed: 34083232.
100. A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT02222922 (25.11.2022).
101. Sekulic A, Migden MR, Basset-Seguin N, et al. ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017; 17(1): 332, doi: 10.1186/s12885-017-3286-5, indexed in Pubmed: 28511673.
102. CHMP. VISMODEGIB- ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf.
103. Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020; 182(6): 1369–1378, doi: 10.1111/bjd.18552, indexed in Pubmed: 31545507.
104. CHMP. SONIDEGIB- ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdf.

105. Wagner AJ, Messersmith WA, Shaik MN, et al. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015; 21(5): 1044–1051, doi: 10.1158/1078-0432.CCR-14-1116, indexed in Pubmed: 25388167.
106. A Study Of PF-04449913 Administered Alone In Select Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01286467 (25.05.2022).
107. Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma. https://clinicaltrials.gov/ct2/show/NCT03466450 (25.05.2022).
108. Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas. https://clinicaltrials.gov/ct2/show/NCT02828111 (25.05.2022).
109. Richards D, Stephenson J, Wolpin B, et al. A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 2012; 30(4_suppl): 213–213, doi: 10.1200/jco.2012.30.4_suppl.213.
110. A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer. https://clinicaltrials.gov/ct2/show/NCT01130142 (25.05.2022).
111. Ko AH, LoConte N, Tempero MA, et al. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016; 45(3): 370–375, doi: 10.1097/MPA.0000000000000458, indexed in Pubmed: 26390428.
112. FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma. https://clinicaltrials.gov/ct2/show/NCT01383538 (25.05.2022).
113. Jimeno A, Weiss GJ, Miller WH, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013; 19(10): 2766–2774, doi: 10.1158/1078-0432.CCR-12-3654, indexed in Pubmed: 23575478.
114. A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies. https://clinicaltrials.gov/ct2/show/NCT00761696 (25.11.2022).
115. Bowles DW, Keysar SB, Eagles JR, et al. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016; 53: 74–79, doi: 10.1016/j.oraloncology.2015.11.014, indexed in Pubmed: 26705064.
116. Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer. https://clinicaltrials.gov/ct2/show/NCT01255800 (25.11.2022).
117. A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma. https://clinicaltrials.gov/ct2/show/NCT01310816 (25.11.2022).
118. A Study of LY2940680 in Japanese Participants With Advanced Cancers. https://clinicaltrials.gov/ct2/show/NCT01919398 (25.11.2022).
119. A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations. https://www.clinicaltrials.gov/ct2/show/NCT05199584 (25.11.2022).
120. A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT02784795 (25.11.2022).
121. Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer. https://clinicaltrials.gov/ct2/show/NCT02530437 (25.11.2022).
122. Moroni M, Pirovano M, Brugnatelli S, et al. Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer. J Funct Foods. 2021; 83: 104533, doi: 10.1016/j.jff.2021.104533.
123. Kim M, Kim SH, Lim JW, et al. Lycopene induces apoptosis by inhibiting nuclear translocation of β-catenin in gastric cancer cells. J Physiol Pharmacol. 2019; 70(4), doi: 10.26402/jpp.2019.4.11, indexed in Pubmed: 31741457.
124. Preet R, Mohapatra P, Das D, et al. Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. Carcinogenesis. 2013; 34(2): 277–286, doi: 10.1093/carcin/bgs351, indexed in Pubmed: 23129580.
125. Hamoya T, Fujii G, Iizumi Y, et al. Artesunate inhibits intestinal tumorigenesis through inhibiting wnt signaling. Carcinogenesis. 2021; 42(1): 148–158, doi: 10.1093/carcin/bgaa084, indexed in Pubmed: 32710739.
126. A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer. https://clinicaltrials.gov/ct2/show/NCT02633098 (25.11.2022).
127. Deeken JF, Wang H, Hartley M, et al. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2018; 81(3): 587–596, doi: 10.1007/s00280-018-3533-8, indexed in Pubmed: 29392450.
128. Phase I Study of Intravenous Artesunate for Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT02353026 (25.11.2022).
129. von Hagens C, Walter-Sack I, Goeckenjan M, et al. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). Breast Cancer Res Treat. 2017; 164(2): 359–369, doi: 10.1007/s10549-017-4261-1, indexed in Pubmed: 28439738.
130. Study of Artesunate in Metastatic Breast Cancer. https://clinicaltrials.gov/ct2/show/NCT00764036 (25.11.2022).
131. Holcombe R, Holcombe R. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Management and Research. 2009: 25, doi: 10.2147/cmr.s4544.
132. Resveratrol for Patients With Colon Cancer. https://clinicaltrials.gov/ct2/show/NCT00256334?term=NCT00256334&draw=2&rank=1 (25.11.2022).
133. Fu Y, Chang H, Peng X, et al. Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/β-catenin signaling pathway. PLoS One. 2014; 9(7): e102535, doi: 10.1371/journal.pone.0102535, indexed in Pubmed: 25068516.
134. Dai H, Deng HB, Wang YH, et al. Resveratrol inhibits the growth of gastric cancer via the Wnt/β-catenin pathway. Oncol Lett. 2018; 16(2): 1579–1583, doi: 10.3892/ol.2018.8772, indexed in Pubmed: 30008840.
135. Reyes-Farias M, Carrasco-Pozo C. The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism. Int J Mol Sci. 2019; 20(13), doi: 10.3390/ijms20133177, indexed in Pubmed: 31261749.
136. Khorsandi L, Orazizadeh M, Niazvand F, et al. Quercetin induces apoptosis and necroptosis in MCF-7 breast cancer cells. Bratisl Lek Listy. 2017; 118(2): 123–128, doi: 10.4149/BLL_2017_025, indexed in Pubmed: 28814095.
137. Niazvand F, Orazizadeh M, Khorsandi L, et al. Effects of Quercetin-Loaded Nanoparticles on MCF-7 Human Breast Cancer Cells. Medicina (Kaunas). 2019; 55(4), doi: 10.3390/medicina55040114, indexed in Pubmed: 31013662.
138. Zhao W, Jia L, Kuai X, et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer. Cancer Med. 2019; 8(3): 1135–1147, doi: 10.1002/cam4.1934, indexed in Pubmed: 30632714.
139. Rahimi Kalateh Shah Mohammad G, Ghahremanloo A, Soltani A, et al. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. J Cell Physiol. 2020; 235(7-8): 5449–5460, doi: 10.1002/jcp.29491, indexed in Pubmed: 31970790.
140. Jiang H, Zhang Z, Yu Y, et al. Drug Discovery of DKK1 Inhibitors. Front Pharmacol. 2022; 13: 847387, doi: 10.3389/fphar.2022.847387, indexed in Pubmed: 35355709.
141. Yamada K, Hori Y, Inoue S, et al. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling. Cancer Res. 2021; 81(4): 1052–1062, doi: 10.1158/0008-5472.CAN-20-0782, indexed in Pubmed: 33408116.
142. Moroni M, Pirovano M, Brugnatelli S, et al. Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer. J Funct Foods. 2021; 83: 104533, doi: 10.1016/j.jff.2021.104533.

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 463–471

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

VIA MEDICA

Artykuł przeglądowy / Review article

Nowotwory wątroby / Liver tumors

Liver transplantation in metastatic liver tumors

Marcin M. Kotulski, Piotr Smoter, Tadeusz Wróblewski, Michał Grąt

Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland

As transplant medicine has evolved in recent decades so too have the indications for liver transplantation (LT). Active or suspected malignancy has stopped being considered as a contraindication for organ transplantation, and nowadays LT plays a major role in the treatment strategies of liver malignancy, specially primary, but also metastatic. It offers excellent long-term outcomes for certain patients with neuroendocrine tumors liver metastases (NETLMs) and carefully selected patients with colorectal cancer liver metastases (CRLMs), who undergo neoadjuvant chemotherapy. Optimal patient selection has become the key issue to achieve the best possible outcomes and to deal with the alleviating shortage of organs. The recent tendency to incorporate markers of tumor biology into selection criteria, rather than simply focusing on tumor size and number, has led to further extension of indications for LT in patients with liver malignancy. This review article focuses on the current place of liver transplantation in the treatment strategy for patients with metastatic/secondary liver tumors.

Key words: liver transplantation, liver metastases, neuroendocrine tumor, colon cancer

Introduction

The idea of liver transplantation (LTx) as a method of treatment of unresectable tumor metastases limited only to this organ has been considered for several decades. However, due to significantly worse results, overall survival and high recurrence rates, LTs were initially abandoned [1–4]. At the turn of the century, however, the subject of liver transplantation as an effective "intent to cure" multiple metastases of neuroendocrine tumors to the liver (NELM) returned. The proven effectiveness of this procedure has even been reflected in Polish diagnostic and therapeutic recommendations for neuroendocrine tumors of the digestive system [5]. On the other hand, unresectable colon cancer metastases to the liver in the last 20 years of the 20th century were a contraindication to liver transplantation due to the described 5-year survival rate <20% [6, 7]. In 2006, recruitment for the SECA I study was launched in Norway to assess the effectiveness of orthotopic liver transplantation as a treatment for unresectable metastases of colorectal cancer to this organ in the current era of possible neo- and adjuvant therapies, various immunosuppression regimens and appropriate selection of recipients. Initial results showed overall survival of 60% [8]. Currently, about 20 clinical trials are being conducted worldwide to assess the effectiveness of treatment of unresectable metastases of colorectal cancer to the liver with orthotopic liver transplantation from a deceased donor, a fragment of a liver from a living donor and advanced surgical techniques: RAPID (resection and partial liver segment 2/3 transplantation with delayed total hepatectomy) and RAVAS (heterotopic transplantation of segments 2/3 using the splenic vein and artery after splenectomy and with delayed total hepatectomy), and the initial results are promising [9–11]. Currently, there is no trend to extend the indications for liver transplantation to other types of secondary, unresectable liver malignancies. Currently, research is focused on developing detailed recommendations regarding the selection of patients, organs and supportive therapies in order to obtain the overall survival values of patients after LTx due to unresectable cancer metastases similar

Jak cytować / How to cite:
Kotulski MM, Smoter P, Wróblewski T, Grąt M. ***Liver transplantation in metastatic liver tumors.*** *NOWOTWORY J Oncol* 2023; 73: 381–389.

to that in patients without cancer and the longest possible time without recurrence [12].

Transplant oncology

The transplant community has adopted a general guideline that survival at 5 years after liver transplantation by at least 50% of recipients justifies the use of expanded criteria organs (ECD). This principle applies both to transplants from living donors and from donors after brain death with maintained circulation and after cardiac arrest (DCD). From an oncological point of view, removal of the liver, extrahepatic bile ducts, and regional lymph nodes followed by transplantation would theoretically provide the best oncological eradication of primary and secondary hepatobiliary tumors. However, two main issues limit the possibility of using this method as the first line of treatment and the general acceptance of such a procedure. First, in most regions of the world, organ shortage limits the number of transplants and thus exposes waiting list cancer recipients to the progression of the above-mentioned cancer. Secondly, the benefits and risks of transplantation treatment should always be weighed in terms of patient survival, graft survival, the need for lifelong immunosuppression and the risk of recurrence of the underlying disease in immunocompromised patients.

Generally, there are two oncological indications for LT: primary (HCC and CCC according to the Mayo protocol) and secondary (discussed in this review) liver malignancy. Hepatocellular carcinoma (HCC), the most prevalent primary hepatic malignancy, represents 30% of indications for OLT in the United States since 2008 [13], with 5-year tumor recurrence-free survival rates (65–81%) comparable to those for general indications for end-stage liver disease (71–81%). Currently, only two indications for liver transplantation in the case of metastatic cancer are considered – neuroendocrine tumors (neuroendocrine liver metastases – NELM) and colorectal cancer (colorectal liver metastases – CLRM) [14]. LTx is an accepted definitive treatment for NELM as long as the primary NET has been resected and in the absence of more widespread disease. According to a recent systematic review, patients with NELM undergoing LTx provided 5-year overall survival rates between 49% and 97.2% and 5-year disease-free survival rates between 30% and 86.9% [14]. LTx results for CLRM have been discouraging so far. Moris et al. analyzed the data of 66 CLRM patients treated by LTx from 1972 to 2016 and described in 11 studies. Authors noted 1-, 3-, and 5-year overall survival of 85.2%, 48%, and 34.6%, respectively. Recurrence following LTx was very high as 66.7% (n = 44/66) patients recurred and 1-year DFS was only 38.9% [15]. However, according to a recent systematic review, patients with CLRM undergoing LTx provided 5-year overall survival rates between 50% and 83% and 5-year disease-free survival rates reaches 38% [16].

First time used by Hibi in 2017[17] the term of a new multidisciplinary branch of medicine, which is transplant oncology, should be introduced. It is a new concept including many disciplines of transplantation medicine and oncology, which aims to broaden the scope of treatment and research on cancer of the liver and bile ducts. Liver transplantation (LTx) in the case of primary and secondary malignant tumors of the liver and biliary tract is only part of this concept, and the whole critical elements of oncological transplantation are: the use of transplantation techniques in oncological surgery to extend the boundaries of conventional resection and the bridge connecting cancer and transplantation immunology, thus paving the way for a new anti-cancer strategy and genomic research platform based on new insights into cancer immunogenomics. This concept is intended to illustrate this new field of transplantation oncology and to highlight the importance of convening all relevant experts in the field of transplantation medicine and oncology, including transplant and hepatobiliary surgeons, medical oncologists and radiation therapists, hepatologists and gastroenterologists, immunologists, etc. to maximize care and cure cancer patients. In their concept, the authors emphasize the role of the four pillars of the new concept [18]: "The era of transplant oncology has just begun, and we are witnessing a paradigm shift in the treatment and research into hepatobiliary cancer. The 4 pillars of transplant oncology are:

1. evolution of multidisciplinary cancer care by integrating LT,
2. extending the limit of safe hepatobiliary resections by applying transplantation techniques to cancer surgery,
3. elucidation of self and nonself recognition system by linking tumor and transplant immunology, and
4. exploration of biomechanism of disease through genomic studies."

LTx for NELM – introduction

Neuroendocrine tumors/neoplasms (NETs/NENs) are a very heterogenous group of lesions including carcinoid, glucagonoma, gastrinoma, somatostatinoma, insulinoma, VIP-oma, ACTH-oma, pheochromocytoma and paraganglioma [19]. They originate from endocrine organs, the nervous system (peptidergic neurons) or from neuroendocrine cells of the diffuse endocrine system (DES) diffused throughout the whole body. Currently, The Surveillance, Epidemiology and End Results (SEER) program from US [20] states, that the incidence of NETs/NENs is estimated at 35 cases per 100,000 individuals per year.

Of all neuroendocrine neoplasms, about 70% are gastroenteropancreatic neuroendocrine neoplasms (GEP NENs), constituting only 2% of all gastrointestinal neoplasms, while most of them have blood drainage to the portal system and thus the possibility of metastases to the liver [21]. Among GEP-NENs, nearly half are intestinal and one third pancreatic. Among intestinal NENs only one fifth are hormone secreting. Out of pancreatic NENs only 10–30% are functional [22]. A majority of the NENs are non-functional indicating lack of symptoms of hormonal hypersecretion thus making diagnosis difficult [23]. Although NETs are relatively rare, slow-growing tumors,

once they begin to metastasize, the liver is the most commonly affected organ (40–93%, mean over 50%) after lungs and bones [10, 24]. Especially GEP-NENs metastasize to the liver with up to 77% of patients developing neuroendocrine liver metastases (NELM) in their lifetime [25]. The appearance of NELM is a confirmed negative prognostic factor for long-term survival [26].

The classification of neuroendocrine neoplasms according to the WHO 2019 and AJCC 2017 distinguishes 4 subtypes of NETs/NENs depending on proliferation index Ki-67%: NET G1, NET G2, NET G3 and NEC(-ancer) [27, 28]. Only patients with unresectable NET G1, G2 metastases are considered as potential liver recipients for transplantation [29].

Careful selection of patients with advanced NETs for transplantation involves the use of high-quality imaging strategies to accurately depict disease burden, with an emphasis not only on distribution diseases within the liver, but also possible extrahepatic deposits, such that may prevent the patient from qualifying for a transplant. Morphological and functional imaging methods play an important role in the assessment of NETs and their metastases. Three growth types of NELM were identified radiologically and have relevance to prognosis and treatment options: single metastasis (type I), isolated metastatic bulk accompanied by smaller deposits (type II) and disseminated metastatic spread (type III) [30]. Since most NELMs are hypervascular lesions, computed tomography (CT) must take into account the phases of the hepatic artery [31]. In addition, diffusion-weighted magnetic resonance imaging (DW-MRI) should be systematically performed in any NELM assessment as it has the highest specificity of all MRI phases, even in tumors <1 cm [32]. Functional imaging with positron emission tomography (PET) 68-gallium radiolabeled DOTA peptides in association with CT represent gold standard, because it can detect morphological changes imaging modalities cannot, as well as those that have not been identified by somatostatin receptor scintigraphy [22, 33]. ^{68}Ga-DOTA PET/CT imaging detects NELM with high sensitivity between 82–100% and a specificity of 67–100%. And detects extrahepatic diseases with 85–100% sensitivity and specificity 67–90% [22]. In fact, the main advantage of ^{68}Ga-DOTA PET/CT in the condition for surgical selection is its ability to identify extrahepatic disease and thus change clinical strategies, which is especially important when considering multivisceral transplantation [34, 35]. In addition to detailed radiological imaging of the disease state, the patient's functional status and significant comorbidities should also be assessed general condition of patients qualified for transplantation.

In conclusion, the radiological evaluation of the disease should include computed tomography (hepatic artery phase, best three-phase), MRI (especially DW-MRI), somatostatin receptor scintigraphy (in the presence of receptors) and if available, ^{68}Ga-DOTA PET/CT. The latter is essential in patients under liver transplant consideration because it presents the best opportunity to reveal extrahepatic disease that could preclude transplantation.

Selection criteria for LTx for NELM

Most of the authors from several studies agree with Mazzaferro that meeting the Milan criteria by the liver recipient provides the longest overall and disease-free survival. The Milan group reported 5-year overall and disease-free survival of 97% and 89%, respectively, with their patient selection criteria (tab. I) [19, 36]. However, among 280 patients with NELMs, only 88 patients (31%) were on the waiting list for LTx, while 42 patients (15%) underwent OLT [26, 36]. In another report, a subgroup analysis the ELTR study in patients undergoing LTx (n = 106) showed a 5-year overall survival of 59%. When the criteria of Milan was applied retrospectively, the calculated survival rate increased to 79%, but it referred only to 36% of the recipients. Although this study suggests an extension of the Milan criteria, G3 histology grade is considered a contraindication to LTx [37]. In the US, the current OPTN/UNOS OLT guidelines for NELM (tab. I) are mainly based on the Milan-NET Criteria with a few additional conditions (OPTN/UNOS Liver and Intestinal Organ Transplantation Committee) [38]:

Table I. Summary outcomes reported from selected series on LTx for NELMs

First author	Year of publ.	Incl. period	Country	Patients (n)	1-year OS	3-years OS	5-years OS	1-year DFS	3-years DFS	5-years DFS
Nguyen	2011	1988–2011	US	184	79.5%	61.4%	49.2%	–	–	–
Le Treut	2013	1982–2005	Europe	213	81%	65%	52%	65%	40%	30%
Nobel	2016	2002–2014	US	230	87%	69%	63%	–	–	–
Mazzaferro	2016	1995–onwards	Italy	42	–	–	97.2%	–	–	86.9%
Valvi	2021	1988–2018	US	206	89%	75.3%	65%	74.9%	55.7%	43.9%
Maspero	2022	1984–2019	Italy	48	–	98%	95.5%	–	84%	75%
Eshmuminov	2022	1988–2021	international	225	–	–	73%	–	–	64.2%

OS – overall survival; DFS – disease-free survival

Milan-NET selection criteria (2007, revised in 2016):

- low grade NET (G1-G2) confirmed on histology,
- portal drainage of the primary tumor,
- primary tumor and all deposits radically removed in a separate operation before consideration for transplant,
- metastatic liver involvement <50% of liver volume,
- stable disease or response to treatment for at least 6 months prior to listing,
- age under 60 years (relative criteria).

Summary of UNOS guidelines for LT in NELM:

- common criteria with Milan-NET,
- additional criteria:
  - unresectable liver metastasis,
  - radiographic characteristics of NELM,
  - negative metastatic workup by PET scan,
  - lack of extrahepatic tumor recurrence during the past 3 months,
  - the presence of positive findings for lymph node metastases by PET scan,
  - the finding should become negative for 6 months before re-listing,
  - the presence of extrahepatic solid organ metastases (i.e., lungs or bones),
  - the case will be permanently delisted.

Literature review

To date, several studies have been published on OLT in NELM, including registry reports, multicenter series, and single center prospective and retrospective series (tab. I). The largest series reported in 2013 is the ELTR retrospective analysis by Le Treut et al. [39], which identified 213 patients who received OLT between 1982 and 2009. Before LT, 83% of patients underwent surgical treatment with removal of the primary tumor (n – 158) or liver metastases (n – 58); these included 23 cases of severe liver failure after resection (10.8%). In addition, 161 (76%) patients received non-surgical treatment, including somatostatin analogues in 63 patients, and transarterial chemoembolization (TACE) in 76 patients. 90-day post-operative mortality was 10%; significant risk factors included early retransplantation, exenteration, splenectomy, surgery duration over 10 h, margin of R1/R2 resection, hepatomegaly and additional surgeries after LTx. Regarding survival, the median OS after OLT was 67 months, with 1-, 3- and 5-year overall survival rates of 81%, 65%, and respectively 52%. Disease-free survival rates over the same time intervals were respectively 65%, 40%, and 30%. This ELTR study also demonstrated improved 5-year overall survival over time, with rates of 46% for recipients transplanted before 2000 in comparison to 59% for LTx done after 2000, respectively.

A 2011 analysis of the United Network for Organ Sharing (UNOS) database by Nguyen et al. [40] covered 184 patients with NELM (treated in 1988–2011). Overall survival rates at 1, 3, and 5 years were 79.5%, 61.4%, and 49.2% respectively.

Retrospective registry analysis performed by Nobel and Goldberg was reported in 2016. Authors studied the variable use of MELD exception points in patients with NELM and their impact on treatment outcomes; they showed 1-, 3, and 5-year posttransplant patient survival rates among all transplant recipients with metastatic NETs, regardless of exception points, at 87% (79–92%), 69% (59–77%), and 63% (53–72%), respectively. These rates were significantly (11%!) lower than national posttransplant survival rates for all first-time transplant recipients (80% and 74% 3- and 5-year survival, respectively, for all transplant recipients) [41]. In 2016, Mazzaferro et al. [36] evaluated 280 NELM patients referred for LTx consideration – the only prospective study with clearly defined selection criteria comparing transplanted and non-transplanted groups occurred (Milan NET criteria). In the end, 88 qualified and 42 actually passed the LTx. 5-year and 10-year overall survival rates in the transplant and non-transplant groups were 97.2% and 88.8% *vs.* 50.9% and 22.4%. The frequency of recurrence at 5 years and 10 years were 13.1% and 13.1% in the transplant group compared to 83.5% and 89% in the non-transplant group.

In 2022 Maspero et al. published a retrospective analysis comparing survival and disease recurrence in NELM patients undergoing transplantation (n – 48) or liver resection (n – 56) treated at the same center in 1984–2019. Patients undergoing LTx had better long-term outcomes compared to resected patients: 5-year and 10-year OS rates of 95.5% and 93% *vs.* 90% and 75%, respectively; 5-year and 10-year DFS rates of 75% and 52% *vs*. 33% and 18%, respectively.

In the aforementioned Milan group study, there was also a different pattern of cancer recurrence in the treatment groups. Multi-site recurrence was more frequent in patients after LTx (48% *vs.* 12%), in patients after resections mainly in the liver (88% *vs.* 8%), and recipients after LTx had longer median time-to recurrence (6.5 years *vs.* 2 years) than those undergoing only liver resection [42].

Also in 2022, Eshmuminov et al. analyzed a data pool from 15 large international centers on their NELM patients treated with LTx or liver resection (LR). Study concern 455 patients with NELM who underwent LTx (n – 225) or liver resection (n – 230) between 1988 and 2021. Multivariable analysis revealed negative prognostic factors: G2-NELM and LT outside Milan criteria for transplanted patients, while G3-NELM for resected patients. Comparison results are: 73% 5-year OS after LT *vs*. 52.8% 5-year OS after LR and 64.2% DFS after LT *vs.* 14,2% DFS after LR [43].

A favorable LTx result for NELM can be achieved by appropriate risk stratification in tumor biology, burden of the NELM, R0 resection feasibility, patient performance status, and expected waiting time for LTx. Based on the analysis of prognostic factors, the following was reported:

- LTx should be reserved for G1 and G2 NELM only based on mitotic and proliferative index (e.g. Ki-67). A Ki-67 index over 10% has been considered a marker of poor prognosis,

- the Milan group suggested that only liver metastases from NETs with
- portal venous drainage should be considered for LTx,
- functional involvement of the liver parenchyma at a level of 50% has been suggested as a cut-off point in considering to transplant. However, due to the subjectivity of the assessment this should not be considered as an absolute contraindication,
- resection of the primary tumor prior to LTx is recommended in order to
- monitor NELM biological response,
- LTx with R1 or R2 margins is not recommended,
- evidence of extrahepatic spread is a contraindication to LTx,
- the correct LTx time remains debatable. Some authors have proposed 6 months as the waiting time for observation of biological behavior of the tumor,
- there is no consensus on the importance and reasonable cut-off age for LTx [44].

LTx for CRLM – introduction

According to Global Cancer Statistics 2020, colorectal cancer is the third most common cancer in the world's population (out of 36 malignancies in 185 countries) and the second, after lung cancer, with the highest mortality [45]. Over the last quarter of a century, the incidence of colorectal cancer has been increasing, especially in the group of young adults [46]. The 5-year survival rate of patients with colon cancer according to the CONCORD 2 study (1995–2009) was slightly over 60% in twelve Western European countries. In Poland, this rate was 50% in patients with colon cancer and 47% in patients with rectal cancer [47]. The most common malignancy in the liver is metastasis of colorectal cancer [48], which will occur in more than 40% of patients with a primary tumor in the colon [49]. Technically feasible radical liver resection, presents the best treatment option, offering long-term survival [50–52]. More and more advanced parenchyma-sparing techniques are being used, which increase the percentage of patients in whom radical resection is possible [53, 54]. Despite nearly 50% of patients with colorectal liver metastases have unresectable disease [55–57]. This leads to an extremely unfavorable situation, because the 5-year overall survival of patients with CLRM treated only with systemic therapies is less than 20% [58]. In addition, 40–75% of patients experience a recurrence of the malignancy after surgery [59, 60], with more than half the recurrences involving the liver [61, 62]. Despite repeated resections, the prognosis is poor and depends on hepatic failure due to subsequent progression and recurrence. During the initial qualification for LTx of patients with CRLM, in order to exclude extrahepatic lesions, it is mandatory to perform a 3-phase angioCT, MRI and PET-CT with ^{18}F-fluorodeoxyglucose (^{18}F-FDG). However, due to the possible false-negative results of involvement of the lymph nodes of the hepatic lymph confluence (hepatoduodenal ligament) in imaging studies, it is recommended to take a frozen section sample of the above-mentioned lymph nodes [63]. PET-CT is a valuable tool in evaluating extrahepatic metastases. In addition, from the data, PET-CT can be estimated by the so-called defined metabolic tumor volume (MTV) as an enhancement volume that is equal to or greater than 40% of the normalized maximum uptake volume [64]. This helps to assess the biological aggressiveness of the tumor, and MTV seems to be an effective predictor of poor prognosis after LTx in patients with CLRM. Cumulative MTV of all liver lesions per patient below 70 cm^3 clearly differentiates between better and worse long-term survival [65].

Selection criteria for LTx for CRLM

The prerequisite for qualifying a patient with CLRM to LTx is that the primary lesion was radically removed in accordance with the standards of care. The foregoing selection process basically aims to identify patients with favorable tumor biology which is hard to define term. Tumor biological behaviour associated to an array of clinicopathological and molecular features/properties characterized by high variability among patients and types of cancer. After the analysis of the qualification process and the results of trials: SECA II, RAPID, Compagnons group and preliminary data from LDLT trials in North America centers, the factors associated with poor prognosis after LTx for CRLM were given and divided into 4 groups [66].

Group 1 – characteristics of the primary tumor: primary tumor on right side of large intestine, lymph node positive primary tumor, time interval between primary resection to liver transplantation <2 years, signet ring cell carcinoma, BRAF mutation. Group 2 – characteristics of liver metastases: largest lesion >5 cm in size (Fong score) or 5.5 cm (Oslo score), more than one lesion, synchronous metastases, progression of metastases during chemotherapy, metabolic tumor volume (MTV) >70 cm^3. Group 3 – disease extent: presence of extrahepatic disease. Group 4 – molecular biomarkers: carcinoembryonic antigen.

Most of these factors are reflected in the scales used to qualify patients with CLRM to LTX. Mainly, the five-stage Fong scale (Fong Clinical Risk Score – FCRS), which was created in 1999, originally to assess the risk of recurrence of colorectal cancer after resection, and the four-stage Oslo Score (2020), which is the esult of the experience of the Norwegian group in LTx patients with CLRM (SECA I and SECA II studies). The four-stage Oslo score with each criterion value 1: largest lesion diameter >5.5 cm, pre-transplant CEA level >80 lg/ml, progression on chemotherapy, time from resection of primary tumor to transplant <24 months. The five-stage Fong Clinical Risk Score with each criterion value 1: node positive primary, interval from diagnosis of primary to liver metastasis <12 months, >1 liver metastasis, pre-resection CEA level >200 lg/ml, maximal lesion diameter >5.0 cm. For both scales, selection based on a score of 0 to 2 has been associated with 5- year survival outcomes comparable to other indications for liver transplantation [67].

Table II. Summary outcomes reported from selected series on LTx for CRLMs

First author	Year of publ.	Incl. period	Country/city	Patients (n)	1-year OS	3-years OS	5-years OS	1-year DFS	3-years DFS	5-years DFS
Hoti	2008	? –1994	ELTR data	50	62%	–	18%	–	–	–
Hagness	2013	2006–2011	Norway	21	95%	68%	60%	35%	–	–
Toso	2017	1995–2015	Lisbon, Coimbra, Paris, Geneva	12	83%	62%	50%	56%	38%	38%
Dueland	2020	2012–2016	Norway	15	100%	83%	83%	53%	44%	35%

OS – overall survival; DFS – disease-free survival

Literature review

To date, preliminary and longer-term results of only three major considerate studies of the efficacy of LTx in patients with unresectable CLRM have been reported (tab. II).

- SECA I [68]: in period 2006-2011, included 21 patients, Oslo/Norway, results: OS – 1-year 95%, 3-years 68%, 5-years 60%, DFS – 1-year 35%, 2-years 0%, conclusion: LTx is feasible for patients with unresectable CLRM.
- SECA II [69]: in the period 2012-2016, included 15 patients, Oslo/Norway, results: OS – 1-year 100%, 3-years 83%, 5-years 83%, DFS – 1-year 53%, 2-years 44%, 3-years 35%, conclusion: more restrictive selection criteria improve outcomes.
- Compagnons Hepato-Bilaires [70]: included 12 patients, Lisbon/Coimbra/Paris/Geneva, results: OS – 1-year 83%, 3-years 62%, 5-years 50%, DFS – 1-year 56%, 2-years 38%, 3-years 38%.

As mentioned, several studies of the effectiveness of LT in patients with CRLM are currently in progress and the preliminary results are still 2–3 years away. These are prospective, randomized studies on deceased donor liver transplantation, LDLT and Rapid procedure [71].

Conclusions and recommendations

In conclusion for neuroendocrine neoplasms, unresectable NELM resistant to conventional therapy with no evidence of extrahepatic disease is an accepted indication for LTx. However, the recommendations of the working group from the ILTS Transplant Oncology Consensus Conference should be used [72]:

1. "LT should be considered as a potentially curable treatment option for selected patients with unresectable metastatic NET of midgut/hindgut origin confined to the liver (moderate level of evidence and strong recommendation).
2. Selection criteria should consider ^{68}Ga-DOTATATE, Ki-67, histology, site of origin, and a certain time interval of stable disease or good response to therapies (moderate level of evidence and strong recommendation).
3. LT for selected patients with metastatic NET confined to the liver as part of multimodality therapy should achieve comparable outcomes as LT for other diagnoses (moderate level of evidence and strong recommendation).
4. Everolimus has achieved improvement in progression-free survival in NET and should be considered as part of immunosuppression after LT for NETLM (low level of evidence and strong recommendation).
5. Late recurrences beyond 5 years after LT are not uncommon, necessitating long-term follow-up with annual imaging (moderate level of evidence and strong recommendation)."

In conclusion for CRLM, LTx is an exciting therapeutic option for patients with unresectable metastases to the liver from the large intestine, and ultimately it can also be used for selected resectable patients. Current evidence is limited, but many studies are ongoing, and it is likely this field will grow significantly over the next decade with increasing experience and knowledge about outcomes, selection criteria and prognostic factors becoming available.

For liver transplantation due to CRLM, Transplant Oncology working group's guidelines have also been developed to point the way to an optimal selection of patients for LT and prepare the ground for future basic and clinical research [70,72], so quoting:

1. "LT can be a viable option in highly selected patients with unresectable CRLM with only liver involvement (moderate level of evidence and moderate recommendation).
2. LT for CRLM with low Oslo score ≤2 (maximum tumor diameter ≤5.5cm, pretransplant carcinoembryonic antigen ≤ 80 µg/L, response to chemotherapy, time interval: diagnosis to LT ≥ 2 y) may improve the 5-year overall survival rates over those achieved with the current standard of care (moderate level of evidence and moderate recommendation).
3. Minimization of immunosuppression is recommended (low level of evidence and moderate recommendation).
4. Aggressive treatment of all posttransplant resectable recurrences is recommended (low level of evidence and moderate recommendation).
5. There is a need for an international registry to coordinate data collection and design further studies on LT for CRLM (moderate level of evidence and moderate recommendation)."

Various forms of liver transplantation (orthotopic, partial, living related, auxiliary – RAPID/RAVAS) are a challenge

and controversial (mainly ethical), but also potentially the most effective approach to cure patients with NELM or CRLM. Over time, we observe better patient selection (both in terms of transparency and stringency) and better immunosuppression strategies, which transfers to longer overall survival of patients and cancer recurrence-free survival. For patients with NELM, the role of neoadjuvant/adjuvant therapies in reducing post-transplant recurrence needs to be solved. For patients with CRLM, the completion of several ongoing prospective studies in 2–3 years will help to determine the effect of LTx compared to palliative chemotherapy, hepatic artery infusion (HAI) or other best possible therapy and the validity of the selection criteria.

Article information and declarations

Author contributions

Marcin Kotulski (70%) – concept of the study, review of the literature, writing and editing the manuscript.

Piotr Smoter (20%) – review of the literature, writing and editing the manuscript.

Tadeusz Wróblewski (5%) – review of the literature, writing and editing the manuscript.

Michał Grąt (5%) – review of the literature, writing and editing the manuscript.

Conflict of interest

None declared

Marcin M. Kotulski
Medical University of Warsaw
Department of General, Transplant and Liver Surgery
ul. Żwirki i Wigury 61
02-091 Warszawa, Poland
e-mail: mmkot@tlen.pl

Received: 10 Aug 2023
Accepted: 16 Nov 2023

References

1. Mühlbacher F, Huk I, Steininger R, et al. Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver? Transplant Proc. 1991; 23(1 Pt 2): 1567–1568, indexed in Pubmed: 1989293.
2. Starzl TE. The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). J Am Coll Surg. 2002; 195(5): 587–610, doi: 10.1016/s1072-7515(02)01498-9, indexed in Pubmed: 12437245.
3. Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int. 2008; 21(12): 1107–1117, doi: 10.1111/j.1432--2277.2008.00735.x, indexed in Pubmed: 18713148.
4. Curtiss SI, Mor E, Schwartz ME, et al. A rational approach to the use of hepatic transplantation in the treatment of metastatic neuroendocrine tumors. J Am Coll Surg. 1995; 180: 184–187.
5. Kos-Kudła B, Ćwikła J, Jarząb B, et al. Polish diagnostic and therapeuthical recommendations for neuroendocrine tumors of the digestive system. Nowotwory. Journal of Oncology. 2006; 56(5): 584.
6. Gorgen A, Muaddi H, Zhang W, et al. The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. Can J Gastroenterol Hepatol. 2018; 2018: 9531925, doi: 10.1155/2018/9531925, indexed in Pubmed: 29623268.
7. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery. 1991; 110(726): 734; discussion 734-5.
8. Hagness M, Foss A, Line PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013; 257(5): 800–806, doi: 10.1097/SLA.0b013e3182823957, indexed in Pubmed: 23360920.
9. Maspero M, Sposito C, Virdis M, et al. Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues. Cancers (Basel). 2023; 15(2), doi: 10.3390/cancers15020345, indexed in Pubmed: 36672295.
10. Nadalin S, Settmacher U, Rauchfuß F, et al. RAPID procedure for colorectal cancer liver metastasis. Int J Surg. 2020; 82S: 93–96, doi: 10.1016/j.ijsu.2020.03.078, indexed in Pubmed: 32302748.
11. Ravaioli M, Brandi G, Siniscalchi A, et al. Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation. Am J Transplant. 2021; 21(2): 870–875, doi: 10.1111/ajt.16222, indexed in Pubmed: 32715576.
12. Line PD, Dueland S. Liver transplantation for secondary liver tumours: The difficult balance between survival and recurrence. J Hepatol. 2020; 73(6): 1557–1562, doi: 10.1016/j.jhep.2020.08.015, indexed in Pubmed: 32896581.
13. Puigvehí M, Hashim D, Haber PK, et al. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant. 2020; 20(1): 220–230, doi: 10.1111/ajt.15576, indexed in Pubmed: 31437349.
14. Clift AK, Hagness M, Lehmann K, et al. Transplantation for metastatic liver disease. J Hepatol. 2023; 78(6): 1137–1146, doi: 10.1016/j.jhep.2023.03.029, indexed in Pubmed: 37208101.
15. Moris D, Tsilimigras DI, Chakedis J, et al. Liver transplantation for unresectable colorectal liver metastases: A systematic review. J Surg Oncol. 2017; 116(3): 288–297, doi: 10.1002/jso.24671, indexed in Pubmed: 28513862.
16. Ahmed FA, Kwon YK, Zielsdorf S, et al. Liver Transplantation as a Curative Approach for Patients With Nonresectable Colorectal Liver Metastases. Exp Clin Transplant. 2022; 20(2): 113–121, doi: 10.6002/ect.2021.0421, indexed in Pubmed: 35282808.
17. Hibi T, Itano O, Shinoda M, et al. Liver transplantation for hepatobiliary malignancies: a new era of „Transplant Oncology" has begun. Surg Today. 2017; 47(4): 403–415, doi: 10.1007/s00595-016-1337-1, indexed in Pubmed: 27130463.
18. Hibi T, Sapisochin G. What is transplant oncology? Surgery. 2019; 165(2): 281–285, doi: 10.1016/j.surg.2018.10.024, indexed in Pubmed: 30471780.
19. Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007; 47(4): 460–466, doi: 10.1016/j.jhep.2007.07.004, indexed in Pubmed: 17697723.
20. Yao JC, Hassan M, Phan A, et al. One hundred years after „carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063–3072, doi: 10.1200/JCO.2007.15.4377, indexed in Pubmed: 18565894.
21. Ramage JK, De Herder WW, Delle Fave G, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology. 2016; 103(2): 139–143, doi: 10.1159/000443166, indexed in Pubmed: 26730835.
22. Pavel M, Öberg K, Falconi M, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7): 844–860, doi: 10.1016/j.annonc.2020.03.304, indexed in Pubmed: 32272208.
23. Rindi G, Inzani F. Neuroendocrine neoplasm update: toward universal nomenclature. Endocr Relat Cancer. 2020; 27(6): R211–R218, doi: 10.1530/ERC-20-0036, indexed in Pubmed: 32276263.
24. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995; 169(1): 36–42; discussion 42, doi: 10.1016/s0002-9610(99)80107-x, indexed in Pubmed: 7817996.
25. Pavel M, O'Toole D, Costa F, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016; 103(2): 172–185, doi: 10.1159/000443167, indexed in Pubmed: 26731013.
26. Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017; 3(10): 1335–1342, doi: 10.1001/jamaoncol.2017.0589, indexed in Pubmed: 28448665.
27. Bałdys-Waligórska A, Nowak A. Neuroendocrine neoplasms of the digestive system- current classification and terminology. Nowotwory. Journal of Oncology. 2021; 71(1): 26–37, doi: 10.5603/njo.2021.0005.

28. Asare E, Bergsland EK, Brierley J, et al. Part VI Neuroendocrine tumors. In:Amin MB, et al. ed. AJCC Cancer Staging Manual, 8th edition. American College of Surgeons, Chicago 2018: 351–419.
29. Fernandez CJ, Agarwal M, Pottakkat B, et al. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg. 2021; 13(3): 231–255, doi: 10.4240/wjgs.v13.i3.231, indexed in Pubmed: 33796213.
30. Frilling A, Li J, Malamutmann E, et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009; 96(2): 175–184, doi: 10.1002/bjs.6468, indexed in Pubmed: 19160361.
31. Ronot M, Clift AK, Baum RP, et al. Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases. Neuroendocrinology. 2018; 106(1): 74–88, doi: 10.1159/000479293, indexed in Pubmed: 28728155.
32. Ronot M, Clift AK, Vilgrain V, et al. Functional imaging in liver tumours. J Hepatol. 2016; 65(5): 1017–1030, doi: 10.1016/j.jhep.2016.06.024, indexed in Pubmed: 27395013.
33. Breeman WAP, de Blois E, Sze Chan Ho, et al. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011; 41(4): 314–321, doi: 10.1053/j.semnuclmed.2011.02.001, indexed in Pubmed: 21624565.
34. Frilling A, Sotiropoulos GC, Radtke A, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010; 252(5): 850–856, doi: 10.1097/SLA.0b013e3181fd37e8, indexed in Pubmed: 21037441.
35. Ruf J, Heuck F, Schiefer J, et al. Impact of multiphase 68Ga-DOTATOC--PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010; 91: 101–109.
36. Mazzaferro V, Sposito C, Coppa J, et al. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. Am J Transplant. 2016; 16(10): 2892–2902, doi: 10.1111/ajt.13831, indexed in Pubmed: 27134017.
37. Kim J, Zimmerman MA, Hong JC. Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. J Gastrointest Oncol. 2020; 11(3): 601–608, doi: 10.21037/jgo.2019.11.03, indexed in Pubmed: 32655939.
38. Briefing Paper: Liver Review Board Guidance Documents. 2017. https://optn.transplant.hrsa.gov/media/2175/liver_boardreport_guidance_201706.pdf.
39. Le Treut YP, Grégoire E, Klempnauer J, et al. For ELITA. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013; 257(5): 807–815, doi: 10.1097/SLA.0b013e31828ee17c, indexed in Pubmed: 23532105.
40. Nguyen NT, Harring TR, Goss JA, et al. Neuroendocrine Liver Metastases and Orthotopic Liver Transplantation: The US Experience. Int J Hepatol. 2011; 2011: 742890, doi: 10.4061/2011/742890, indexed in Pubmed: 22254141.
41. Nobel YR, Goldberg DS. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes. Transplantation. 2015; 99(11): 2341–2346, doi: 10.1097/TP.0000000000000723, indexed in Pubmed: 25989503.
42. Maspero M, Rossi RE, Sposito C, et al. Long-term outcomes of resection versus transplantation for neuroendocrine liver metastases meeting the Milan criteria. Am J Transplant. 2022; 22(11): 2598–2607, doi: 10.1111/ajt.17156, indexed in Pubmed: 35869798.
43. Eshmuminov D, Studer DJ, Lopez Lopez V, et al. Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis: Tumor Biology Cuts the Deal. Ann Surg. 2023; 277(5): e1063–e1071, doi: 10.1097/SLA.0000000000005663, indexed in Pubmed: 35975918.
44. D'Amico G, Uso TD, Del Prete L, et al. Neuroendocrine liver metastases: The role of liver transplantation. Transplant Rev (Orlando). 2021; 35(2): 100595, doi: 10.1016/j.trre.2021.100595, indexed in Pubmed: 33548685.
45. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249, doi: 10.3322/caac.21660, indexed in Pubmed: 33538338.
46. Vuik FEr, Nieuwenburg SAv, Bardou M, et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut. 2019; 68(10): 1820–1826, doi: 10.1136/gutjnl-2018-317592, indexed in Pubmed: 31097539.
47. Bielska-Lasota M, Krzyżak M, Kwiatkowska K, et al. Zróżnicowanie wyleczalności chorych na wybrane nowotwory złośliwe w Polsce na tle krajów europejskich w latach 2005–2009 na podstawie badania CONCORD 2. Nowotwory. Journal of Oncology. 2016; 66(3): 202–211, doi: 10.5603/njo.2016.0035.
48. de Ridder J, de Wilt JHW, Simmer F, et al. Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients. Oncotarget. 2016; 7(34): 55368–55376, doi: 10.18632/oncotarget.10552, indexed in Pubmed: 27421135.
49. van der Geest LGM, Lam-Boer J, Koopman M, et al. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015; 32(5): 457–465, doi: 10.1007/s10585-015-9719-0, indexed in Pubmed: 25899064.
50. Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012; 4: 283–301, doi: 10.2147/CLEP.S34285, indexed in Pubmed: 23152705.
51. House MG, Ito H, Gönen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010; 210(5): 744–52, 752, doi: 10.1016/j.jamcollsurg.2009.12.040, indexed in Pubmed: 20421043.
52. de Haas RJ, Wicherts DA, Andreani P, et al. Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection. Ann Surg. 2011; 253(6): 1069–1079, doi: 10.1097/SLA.0b013e318217e898, indexed in Pubmed: 21451388.
53. Gold JS, Are C, Kornprat P, et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg. 2008; 247(1): 109–117, doi: 10.1097/SLA.0b013e3181557e47, indexed in Pubmed: 18156930.
54. Torzilli G, Viganò L, Gatti A, et al. Twelve-year experience of „radical but conservative" liver surgery for colorectal metastases: impact on surgical practice and oncologic efficacy. HPB (Oxford). 2017; 19(9): 775–784, doi: 10.1016/j.hpb.2017.05.006, indexed in Pubmed: 28625391.
55. Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006; 13(10): 1271–1280, doi: 10.1245/s10434-006-9045-5, indexed in Pubmed: 16955381.
56. Milana F, Famularo S, Luberto A, et al. Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients. Cancers (Basel). 2022; 14(16), doi: 10.3390/cancers14163952, indexed in Pubmed: 36010944.
57. Isoniemi H, Uutela A, Nordin A, et al. Centralized repeated resectability assessment of patients with colorectal liver metastases during first--line treatment: prospective study. Br J Surg. 2021; 108(7): 817–825, doi: 10.1093/bjs/znaa145, indexed in Pubmed: 33749772.
58. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008; 26(35): 5721–5727, doi: 10.1200/JCO.2008.17.7147, indexed in Pubmed: 19001325.
59. Viganò L, Capussotti L, Lapointe R, et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol. 2014; 21(4): 1276–1286, doi: 10.1245/s10434-013-3421-8, indexed in Pubmed: 24346766.
60. Bredt LC, Rachid AF. Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis. World J Surg Oncol. 2014; 12: 391, doi: 10.1186/1477-7819-12-391, indexed in Pubmed: 25528650.
61. Devaud N, Kanji ZS, Dhani N, et al. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases. HPB (Oxford). 2014; 16(5): 475–480, doi: 10.1111/hpb.12159, indexed in Pubmed: 23927606.
62. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005; 241(5): 715–22, discussion 722, doi: 10.1097/01.sla.0000160703.75808.7d, indexed in Pubmed: 15849507.
63. Grut H, Revheim ME, Line PD, et al. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation. Nucl Med Commun. 2018; 39(7): 621–627, doi: 10.1097/mnm.0000000000000843.
64. Bai B, Bading J, Conti PS. Tumor quantification in clinical positron emission tomography. Theranostics. 2013; 3(10): 787–801, doi: 10.7150/thno.5629, indexed in Pubmed: 24312151.

65. Grut H, Dueland S, Line PD, et al. The prognostic value of F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2018; 45(2): 218–225, doi: 10.1007/s00259-017-3843-9, indexed in Pubmed: 29026950.
66. Clift AK, Hagness M, Lehmann K, et al. Transplantation for metastatic liver disease. J Hepatol. 2023; 78(6): 1137–1146, doi: 10.1016/j.jhep.2023.03.029, indexed in Pubmed: 37208101.
67. Dueland S, Grut H, Syversveen T, et al. Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis. Am J Transplant. 2020; 20(2): 530–537, doi: 10.1111/ajt.15682, indexed in Pubmed: 31674105.
68. Dueland S, Guren TK, Hagness M, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013; 257(5): 800–806, doi: 10.1097/SLA.0b013e3182823957, indexed in Pubmed: 23360920.
69. Dueland S, Syversveen T, Solheim JM, et al. Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases. Ann Surg. 2020; 271(2): 212–218, doi: 10.1097/SLA.0000000000003404, indexed in Pubmed: 31188200.
70. Toso C, Pinto Marques H, Andres A, et al. Compagnons Hépato-Biliaires Group. Liver transplantation for colorectal liver metastasis: Survival without recurrence can be achieved. Liver Transpl. 2017; 23(8): 1073–1076, doi: 10.1002/lt.24791, indexed in Pubmed: 28544246.
71. Maspero M, Sposito C, Virdis M, et al. Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues. Cancers (Basel). 2023; 15(2), doi: 10.3390/cancers15020345, indexed in Pubmed: 36672295.
72. Hibi T, Rela M, Eason JD, et al. Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020; 104(6): 1131–1135, doi: 10.1097/TP.0000000000003118, indexed in Pubmed: 32217939.

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 472–475

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

VIA MEDICA

Artykuł przeglądowy / Review article

Żywienie kliniczne w onkologii /
Clinical nutrition in oncology

Quality of life as an important goal of therapy for cancer patients on home enteral nutrition

Marcin A. Folwarski[1, 2]

[1]Department of Clinical Nutrition and Dietetics, Medical University of Gdansk, Gdansk, Poland
[2]Home Enteral and Parenteral Nutrition Unit, Department of General Surgery, Nicolaus Copernicus Hospital, Gdansk, Poland

Nutritional support is increasingly recognized as an important component of multimodal cancer treatment. The number of cancer patients requiring home enteral nutrition (HEN) is increasing, particularly for head and neck (HNC) and upper gastrointestinal cancers. The quality of life (QoL) of these patients is emerging as a critical aspect that is influenced by the effective management of cancer-related symptoms, psychological support, and the socio-functional impact of HEN. Routine and standardized monitoring of QoL is highlighted as crucial for evaluating the effectiveness of HEN and for adapting treatment strategies. The interaction between nutritional status and other aspects of health such as physical functioning, psychological well-being, social engagement, and pain management is emphasized. Improving quality of life as a goal in palliative care should guide treatment strategies and the need for advanced nutritional support.

Key words: home enteral nutrition, quality of life, cancer, malnutrition

Introduction

The growing awareness of multimodal support in approaches has led to an increased focus on nutritional support, as underscored in European guidelines [1] and Polish recommendations [2–4]. Most oncology patients benefit from food fortification with the support of a clinical dietitian. However, enteral nutrition (EN) is indicated for malnourished patients or patients at risk of malnutrition who cannot meet their needs with oral nutrition and 'have a functioning digestive tract (tube, gastrostomy, jejunostomy) to a functioning digestive tract. If hospitalization is no longer required, these patients can transition to home enteral nutrition (HEN) [5]. In many countries, including Poland, HEN is reimbursed by health care provides. Home care supervised by specialized nutritional support teams (NST) reduces hospital admissions, the incidence of infectious complications, and treatment costs [8] by providing multidisciplinary care. Technological advances such as peristaltic feeding pumps or closed feeding systems can contribute to greater efficacy, safety, and patient comfort [6, 7] in long-term nutritional treatment. This can be achieved through appropriate training of patients and caregivers by specialized healthcare professionals. Improvement or preservation of nutritional status remain primary objectives of nutritional treatment. However, this review aims to draw attention to quality of life as an equally important issue, particularly in cancer patients.

Home enteral nutrition in cancer

Epidemiological studies indicate a worldwide increase in the number of patients requiring HEN [9, 10]. In the United States, the number of HEN patients increased from 463 in 1995 [11] to 1,385 per million citizens by 2017 (248,846 adult patients in total) [12]. This trend is consistent in Europe as reported by countries with national registries or long-term observations [5, 13]. Recent studies show that cancer patients have become

Jak cytować / How to cite:
Folwarski MA. ***Quality of life as an important goal of therapy for cancer patients on home enteral nutrition.*** *NOWOTWORY J Oncol* 2023; 73: 390–393.

a significant group among HEN recipients together with patients with neurological disorders [14]. HEN can be required due to obstruction in the gastrointestinal tract caused by tumor masses, such as in esophageal or gastric cancer, or due to mucosal damage and dysphagia caused by oncological therapy for head and neck cancer (HNC). In Poland, cancer patients accounted for 14% of all HEN cases in 2013 [15] and up to 33.9% in 2018 [16]. A particularly significant increase was seen in HNC patients (from 4.5% of all HEN patients in 2013 to 20% in 2018) and upper gastrointestinal tumors (from 5.2% to 11.7%). UK data also showed similar trends with the rate of oncological patients receiving HEN increasing from 25% in 2000 to 43% in 2015, and HNC patients clearly predominating this group (80% of oncological patients in 2015) [17, 18].

In those groups of cancer patients, especially during oncological treatment, a significant proportion may be unable to fulfill their nutritional requirements through oral intake alone. EN, especially in HNC patients, substantially contributes to therapeutic benefits by preventing chemotherapy dose reduction, excessive weight loss, and complications [19]. Postoperative body mass index (BMI), lean body mass, appendicular muscle mass and the postoperative pneumonia rates also improved in patients with esophageal cancer, compared to patients receiving only an oral diet [20]. In addition, a recent systematic review and meta-analysis has shown that HEN not only improves the postoperative nutritional status but also the physical, social, and role functions of patients with esophageal cancer [20].

The effectiveness of home EN depends on several factors such as diet tolerance, management of EN complications, appropriate pain management, mental health (depression) support, rehabilitation, and physical exercises. The European Society for Clinical Nutrition and Metabolism (ESPEN) recommends HEN for patients with a survival prognosis of at least one month [1]. For cancer cases where the remission or cure cannot be achieved, prolonged nutritional support aimed solely at improving or maintaining quality of life is considered beneficial [21].

Quality of life

Improving or maintaining quality of life is a major goal for cancer patients treated with HEN, especially in advanced stages of the disease. According to the ESPEN guidelines, QoL should be systematically monitored using validated assessment tools [26]. Due to the different populations of HEN patients, some NSTs use disease-specific assessment methods, for example IBDQ [27], QOL-EF for H&N [28], EuroQol-5D (EQ-5D) [29] or EORTC QLQ-C30 with modules for specific cancer types. NutriQoL is a validated and reliable quality of life assessment questionnaire that can be used to identify specific problems for HEN populations [30, 31].

Other studies have shown that QoL in HEN patients is generally worse than that of the general population, although this is dependent on demographics. Better QoL is observed in younger individuals, non-cancer patients, and those receiving care from multiple caregivers. In a study by Sharma et al., the quality of life of HNC patients was analyzed. Within the first three months of treatment, a significant deterioration in physical, emotional, social, and functional aspects was observed. One year after treatment, none of the subscales returned to baseline values. Surgery in combination with chemo-radiotherapy had the strongest impact on QoL among the treatment modalities [23]. Sensitivity problems, mouth opening, dry mouth, viscous saliva, pain, and weight problems can be observed even long after treatment [24]. The health-related quality of life of patients with locally advanced, non-metastatic gastric cancer deteriorated significantly after surgery and chemotherapy, improving after 6–12 months if no recurrence was diagnosed [25].

HEN significantly interferes with daily activities such as meals, sleep, travelling, and work, and often limits social activities due to long feeding times and concerns about damaging the EN tube [35, 36]. Enteral feeding affects social and family life, intimate relationships, and hobbies [32–34]. Nevertheless, patients observe an improvement in QoL during HEN [35–37], which was confirmed by a systematic review by Ojo and co-authors [38]. On the other hand, some studies indicate possible adverse effects, emphasizing the complexity of nutritional interventions in cancer treatment [36]. Lis showed in a systematic review that malnutrition significantly impairs the quality of life of patients with EN [39]. Weight loss is associated with poorer quality of life in patients with HNC and upper gastrointestinal cancer undergoing HEN [40]. Malnutrition assessed according to the Global Leadership Initiative on Malnutrition (GLIM) criteria correlated with QoL in HEN [41]. However, HEN can prevent further weight loss and thus, improve some aspects of QoL [42–43]. Studies on the effect of HEN on nutritional status and QoL in patients with esophageal cancer after esophagectomy found that HEN can stabilize or slightly improve nutritional status and physical performance as well as reduce fatigue [44, 45]. When nutritional support is initiated in the early stages of precachexia or cachexia, it can also improve performance status and survival [46].

Effective management of symptoms associated with cancer and its treatment, such as nausea, vomiting, pain, and digestive problems, is a critical component of QoL. In addition, the physical and mental health and QoL of cancer patients are related to sleeping problems. Sleep quality can be considered a prognostic factor for survival as it is related to cancer progression [25, 47]. More than half of cancer patients report poor sleep quality, and one third report functional impairment due to lack of sleep [48].

Chronic pain is another important factor contributing to the deterioration of quality of life in cancer patients [49, 50]. Although improvements in pain management have been noted in recent years, more than a third of cancer patients

still do not receive adequate treatment [51, 52]. Inadequate pain management leads to further deterioration of QoL [53]. Pain and malnutrition contribute to depression and anxiety, which are common in cancer patients. In palliative stages, almost half of patients can be affected by these problems [54–56]. Psychological support can promote active coping and constructive strategies to manage difficult life situations during oncological treatment [22].

Nutritional support in palliative care requires experienced professionals as it can lead to poorer outcomes in some cases [57]. In cancer patients receiving palliative care, monitoring of QoL in HEN is particularly important. A significant decline in QoL, despite treatment, should prompt a reassessment of the need for more aggressive nutritional strategies. In end-stage disease, it may be more beneficial to prioritize supportive measures such as hydration and analgesia.

Conclusions

QoL is an important outcome for cancer patients receiving HEN. Regular, systematic assessment using validated instruments should be an integral part of patient monitoring. Strategies to improve QoL are essential components of care. Addressing problems affecting QoL like pain, sleeping disorders or depression is one of the key elements of care. HEN patients should have access to psychological support, especially in advanced stages of cancer. Deterioration of QoL can be a helpful parameter when deciding on the nature of palliative care.

Article information and declarations

Author contributions

Marcin Folwarski was responsible for the main idea, writing and editing of the first and final version of the article.

Funding

None declared

Conflict of interest

None declared

Marcin A. Folwarski
Medical University of Gdansk
Department of Clinical Nutrition and Dietetics
ul. Marii Skłodowskiej-Curie 3a
80-210 Gdańsk, Poland
e-mail: marcinfol@gumed.edu.pl

Rceived: 26 Nov 2023
Accepted: 1 Dec 2023

References

1. Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021; 40(5): 2898–2913, doi: 10.1016/j.clnu.2021.02.005, indexed in Pubmed: 33946039.
2. Jankowski M, Qelaj A, Kłęk S, et al. The role of comprehensive nutritional care in cancer patients. Nowotwory. Journal of Oncology. 2021; 71(3): 158–161, doi: 10.5603/njo.a2021.0016.
3. Jarosz J, Kapała A, Kłęk S, et al. Konferencja uzgodnieniowa: problemy żywieniowe w polskiej onkologii. Nowotwory Journal of Oncology. 2012; 62(3): 221–229.
4. Kłęk S, Jankowski M, Kruszewski W, et al. Standardy leczenia żywieniowego w onkologii. Nowotwory. Journal of Oncology. 2015; 65(4): 320–337, doi: 10.5603/njo.2015.0062.
5. Bischoff SC, Austin P, Bowykens K, et al. ESPEN guideline on home enteral nutrition. Clin Nutr. 2020; 39(1): 5–22, doi: 10.1016/j.clnu.2019.04.022, indexed in Pubmed: 31255350.
6. White H, King L. Enteral feeding pumps: efficacy, safety, and patient acceptability. Med Devices (Auckl). 2014; 7: 291–298, doi: 10.2147/MDER.S50050, indexed in Pubmed: 25170284.
7. Babaie F, Ghasemi Z. Role of Enteral Feeding Pumps in Precision Enteral Nutrition. Precision Medicine and Clinical OMICS. 2023; 2(1), doi: 10.5812/pmco-133591.
8. Klek S, Szybinski P, Sierzega M, et al. Commercial enteral formulas and nutrition support teams improve the outcome of home enteral tube feeding. JPEN J Parenter Enteral Nutr. 2011; 35(3): 380–385, doi: 10.1177/0148607110378860, indexed in Pubmed: 21527600.
9. Paccagnella A, Baruffi C, Pizzolato D, et al. Home enteral nutrition in adults: a five-year (2001-2005) epidemiological analysis. Clin Nutr. 2008; 27(3): 378–385, doi: 10.1016/j.clnu.2008.03.005, indexed in Pubmed: 18486282.
10. Parker E, Faruquie S, Talbot P. Trends in home enteral nutrition at a tertiary teaching hospital: 2005–2013. Nutrition & Dietetics. 2015; 72(3): 267–275, doi: 10.1111/1747-0080.12165.
11. Howard L, Ament M, Fleming CR, et al. Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States. Gastroenterology. 1995; 109(2): 355–365, doi: 10.1016/0016-5085(95)90321-6, indexed in Pubmed: 7615183.
12. Mundi MS, Pattinson A, McMahon MT, et al. Prevalence of Home Parenteral and Enteral Nutrition in the United States. Nutr Clin Pract. 2017; 32(6): 799–805, doi: 10.1177/0884533617718472, indexed in Pubmed: 28715295.
13. Paccagnella A, Marcon ML, Baruffi C, et al. Enteral nutrition at home and in nursing homes: an 11-year (2002-2012) epidemiological analysis. Minerva Gastroenterol Dietol. 2016; 62(1): 1–10, indexed in Pubmed: 26887795.
14. Folwarski M, Kłęk S, Zoubek-Wójcik A, et al. Home Enteral Nutrition in Adults—Nationwide Multicenter Survey. Nutrients. 2020; 12(7): 2087, doi: 10.3390/nu12072087.
15. Klek S, Pawlowska D, Dziwiszek G, et al. THE EVOLUTION OF HOME ENTERAL NUTRITION (HEN) IN POLAND DURING FIVE YEARS AFTER IMPLEMENTATION: A MULTICENTRE STUDY. Nutr Hosp. 2015; 32(1): 196–201, doi: 10.3305/nh.2015.32.1.8819, indexed in Pubmed: 26262717.
16. Folwarski M, Kłęk S, Zoubek-Wójcik A, et al. Home Enteral Nutrition in Adults—Nationwide Multicenter Survey. Nutrients. 2020; 12(7): 2087, doi: 10.3390/nu12072087.
17. Smith T, Chairman B. BANS Report 2018 Home Enteral Tube Feeding 2018 (April).
18. Smith T, Naghibi M. British Artificial Nutrition Survey (BANS) Report 2016. Artificial Nutrition Support in the UK 2005-2015. Adult Home Parenteral Nutrition & Home Intravenous Fluids. 2016: 1–27.
19. Kapała A, Surwiłło-Snarska A, Jodkiewicz M, et al. Nutritional Care in Patients with Head and Neck Cancer during Chemoradiotherapy (CRT) and Bioradiotherapy (BRT) Provides Better Compliance with the Treatment Plan. Cancers (Basel). 2021; 13(11), doi: 10.3390/cancers13112532, indexed in Pubmed: 34064057.
20. Zhang C, Hu LW, Qiang Y, et al. Home enteral nutrition for patients with esophageal cancer undergoing esophagectomy: A systematic review and meta-analysis. Front Nutr. 2022; 9: 895422, doi: 10.3389/fnut.2022.895422, indexed in Pubmed: 35967793.
21. Kłęk S, Piechowicz M, Szybiński P, et al. Home parenteral nutrition (HPN) in incurable cancer patients: patients' qualification criteria and treatment outcome. Nowotwory Journal of Oncology. 2013; 63(1): 16–20.
22. Kulpa M, Ciuba A, Duda T, et al. Mental adaptation to cancer diagnosis and the health locus of control in patients undergoing treatment. Nowotwory. Journal of Oncology. 2022; 72(5): 275–281, doi: 10.5603/njo.a2022.0041.
23. Sharma Y, Mishra G, Parikh V. Quality of Life in Head and Neck Cancer Patients. Indian J Otolaryngol Head Neck Surg. 2019; 71(Suppl 1): 927–932, doi: 10.1007/s12070-019-01620-2, indexed in Pubmed: 31742096.
24. Milecki J, Żmijewska-Tomczak M, Osmola K, et al. The impact of radiotherapy on the quality of life in patients with early-stage clinical head and neck cancer. Otolaryngol Pol. 2021; 75(5): 1–8, doi: 10.5604/01.3001.0014.8759, indexed in Pubmed: 34552020.

25. van Amelsfoort RM, van der Sluis K, Schats W, et al. Health-Related Quality of Life in Locally Advanced Gastric Cancer: A Systematic Review. Cancers (Basel). 2021; 13(23), doi: 10.3390/cancers13235934, indexed in Pubmed: 34885043.
26. Bischoff SC, Austin P, Boeykens K, et al. ESPEN practical guideline: Home enteral nutrition. Clin Nutr. 2022; 41(2): 468–488, doi: 10.1016/j.clnu.2021.10.018, indexed in Pubmed: 35007816.
27. Guo Z, Wu R, Zhu W, et al. Effect of exclusive enteral nutrition on health--related quality of life for adults with active Crohn's disease. Nutr Clin Pract. 2013; 28(4): 499–505, doi: 10.1177/0884533613487218, indexed in Pubmed: 23851180.
28. Stevens CS, Lemon B, Lockwood GA, et al. The development and validation of a quality-of-life questionnaire for head and neck cancer patients with enteral feeding tubes: the QOL-EF. Support Care Cancer. 2011; 19(8): 1175–1182, doi: 10.1007/s00520-010-0934-6, indexed in Pubmed: 20574664.
29. Wanden-Berghe C, Nolasco A, Planas M, et al. Grupo NADYA-SENPE. Health-related quality of life according to the main caregiver in patients with home nutritional support. Med Clin (Barc). 2008; 131(8): 281–284, doi: 10.1016/s0025-7753(08)72258-9, indexed in Pubmed: 18803920.
30. Apezetxea A, Carrillo L, Casanueva F, et al. The NutriQoL ® questionnaire for assessing health-related quality of life (HRQoL) in patients with home enteral nutrition (HEN): validation and fi rst results. Nutr Hosp. 2016; 33(6): 1260, doi: 10.20960/nh.769.
31. Cuerda MC, Apezetxea A, Carrillo L, et al. Development and validation of a specific questionnaire to assess health-related quality of life in patients with home enteral nutrition: NutriQoL development. Patient Prefer Adherence. 2016; 10: 2289–2296, doi: 10.2147/PPA.S110188, indexed in Pubmed: 27853360.
32. Jordan S, Philpin S, Warring J, et al. Percutaneous endoscopic gastrostomies: the burden of treatment from a patient perspective. J Adv Nurs. 2006; 56(3): 270–281, doi: 10.1111/j.1365-2648.2006.04006.x, indexed in Pubmed: 17042806.
33. Rogers SN, Thomson R, O'Toole P, et al. Patients experience with long-term percutaneous endoscopic gastrostomy feeding following primary surgery for oral and oropharyngeal cancer. Oral Oncol. 2007; 43(5): 499–507, doi: 10.1016/j.oraloncology.2006.05.002, indexed in Pubmed: 16997615.
34. Martin L, Blomberg J, Lagergren P. Patients' perspectives of living with a percutaneous endoscopic gastrostomy (PEG). BMC Gastroenterol. 2012; 12: 126, doi: 10.1186/1471-230X-12-126, indexed in Pubmed: 22989321.
35. Schneider SM, Pouget I, Staccini P, et al. Quality of life in long-term home enteral nutrition patients. Clin Nutr. 2000; 19(1): 23–28, doi: 10.1054/clnu.1999.0068, indexed in Pubmed: 10700530.
36. Gliwska E, Guzek D, Przekop Z, et al. Quality of Life of Cancer Patients Receiving Enteral Nutrition: A Systematic Review of Randomized Controlled Trials. Nutrients. 2021; 13(12), doi: 10.3390/nu13124551, indexed in Pubmed: 34960103.
37. Kaźmierczak-Siedlecka K, Folwarski M, Ruszkowski J, et al. Effects of 4 weeks of Lactobacillus plantarum 299v supplementation on nutritional status, enteral nutrition tolerance, and quality of life in cancer patients receiving home enteral nutrition – a double-blind, randomized, and placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2020; 24(18): 9684–9694, doi: 10.26355/eurrev_202009_23059, indexed in Pubmed: 33015813.
38. Ojo O, Keaveney E, Wang XH, et al. The Effect of Enteral Tube Feeding on Patients' Health-Related Quality of Life: A Systematic Review. Nutrients. 2019; 11(5), doi: 10.3390/nu11051046, indexed in Pubmed: 31083338.
39. Lis CG, Gupta D, Lammersfeld CA, et al. Role of nutritional status in predicting quality of life outcomes in cancer--a systematic review of the epidemiological literature. Nutr J. 2012; 11: 27, doi: 10.1186/1475-2891-11-27, indexed in Pubmed: 22531478.
40. Gliwska E, Głąbska D, Zaczek Z, et al. Influence of Enteral Nutrition on Quality of Life in Head and Neck Cancer and Upper Gastrointestinal Tract Cancer Patients within a Pair-Matched Sample. Nutrients. 2023; 15(21), doi: 10.3390/nu15214698, indexed in Pubmed: 37960351.
41. Kaźmierczak-Siedlecka K, Skonieczna-Żydecka K, Folwarski M, et al. Influence of malnutrition stage according to GLIM 2019 criteria and SGA on the quality of life of patients with advanced cancer. Nutr Hosp. 2020; 37(6): 1179–1185, doi: 10.20960/nh.03185, indexed in Pubmed: 33119401.
42. Schönenberger KA, Reber E, Huwiler VV, et al. Quality of Life in the Management of Home Parenteral Nutrition. Ann Nutr Metab. 2023; 79(3): 326–333, doi: 10.1159/000530082, indexed in Pubmed: 36934718.
43. Ojo O, Keaveney E, Wang XH, et al. The Effect of Enteral Tube Feeding on Patients' Health-Related Quality of Life: A Systematic Review. Nutrients. 2019; 11(5), doi: 10.3390/nu11051046, indexed in Pubmed: 31083338.
44. Zeng J, Hu J, Chen Q, et al. Home enteral nutrition's effects on nutritional status and quality of life after esophagectomy. Asia Pac J Clin Nutr. 2017; 26(5): 804–810, doi: 10.6133/apjcn.112016.07, indexed in Pubmed: 28802289.
45. Donohoe CL, Healy LA, Fanning M, et al. Impact of supplemental home enteral feeding postesophagectomy on nutrition, body composition, quality of life, and patient satisfaction. Dis Esophagus. 2017; 30(9): 1–9, doi: 10.1093/dote/dox063, indexed in Pubmed: 28859364.
46. Ruggeri E, Giannantonio M, Agostini F, et al. Home artificial nutrition in palliative care cancer patients: Impact on survival and performance status. Clin Nutr. 2020; 39(11): 3346–3353, doi: 10.1016/j.clnu.2020.02.021, indexed in Pubmed: 32143890.
47. Hofmeister D, Schulte T, Mehnert-Theuerkauf A, et al. The association between sleep problems and general quality of life in cancer patients and in the general population. Front Psychol. 2022; 13: 960029, doi: 10.3389/fpsyg.2022.960029, indexed in Pubmed: 36591026.
48. Pai A, Sivanandh B, Udupa K. Quality of Sleep in Patients with Cancer: A Cross-sectional Observational Study. Indian J Palliat Care. 2020; 26(1): 9–12, doi: 10.4103/IJPC.IJPC_164_19, indexed in Pubmed: 32132776.
49. Cox-Martin E, Anderson-Mellies A, Borges V, et al. Chronic pain, health-related quality of life, and employment in working-age cancer survivors. J Cancer Surviv. 2020; 14(2): 179–187, doi: 10.1007/s11764-019-00843-0, indexed in Pubmed: 31828603.
50. Cramer JD, Johnson JT, Nilsen ML. Pain in Head and Neck Cancer Survivors: Prevalence, Predictors, and Quality-of-Life Impact. Otolaryngol Head Neck Surg. 2018; 159(5): 853–858, doi: 10.1177/0194599818783964, indexed in Pubmed: 29943677.
51. Greco MT, Roberto A, Corli O, et al. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol. 2014; 32(36): 4149–4154, doi: 10.1200/JCO.2014.56.0383, indexed in Pubmed: 25403222.
52. Roberto A, Greco MT, Uggeri S, et al. Living systematic review to assess the analgesic undertreatment in cancer patients. Pain Pract. 2022; 22(4): 487–496, doi: 10.1111/papr.13098, indexed in Pubmed: 35014151.
53. Shen WC, Chen JS, Shao YY, et al. Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan. J Pain Symptom Manage. 2017; 54(1): 55–65.e1, doi: 10.1016/j.jpainsymman.2017.02.018, indexed in Pubmed: 28479410.
54. Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol Lett. 2015; 9(4): 1509–1514, doi: 10.3892/ol.2015.2944, indexed in Pubmed: 25788991.
55. Linden W, Vodermaier A, Mackenzie R, et al. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012; 141(2-3): 343–351, doi: 10.1016/j.jad.2012.03.025, indexed in Pubmed: 22727334.
56. Ciaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology. 2001; 10(2): 156–165, doi: 10.1002/pon.505, indexed in Pubmed: 11268142.
57. Kapała A. Nutrition treatment does not improve the efficacy of oncological treatment. Nowotwory. Journal of Oncology. 2018; 67(5): 308–312, doi: 10.5603/njo.2017.0051.

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 476–483

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

VIA MEDICA

Artykuł przeglądowy / Review article

Profilaktyka nowotworów i zdrowie publiczne /
Cancer prevention and public health

Cancer patients and smoking cessation

Magdalena Cedzyńska, Irena A. Przepiórka

Head of Smoking Cessation Unit, Cancer Epidemiology and Primary Prevention Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Abstinence from smoking is the most important element of cancer prevention. Tobacco smoking is responsible for at least 15 different types of cancer and almost 30% of all cancer deaths. There is evidence that not only does smoking after a cancer diagnosis pose negative effects for cancer treatment efficacy and tolerability, but quitting smoking after a cancer diagnosis has significant benefits. They include: increased survival rates and decrease overall mortality, decreased risk of another primary cancer, decreased risk of recurrence, increased tolerance to oncological treatments and increase of its efficacy, reduced pain. Quitting smoking improves quality of life too. Nicotine dependence is not only a patient's choice and lifestyle element but a chronic and relapsing disease. Failure to undertaken nicotine dependence treatment by the centre's staff may be treated as malpractice. Various evidence-based treatment options are available and they can, or even should, be adapted to the specificity of oncological patients.

Key words: cancer prevention, nicotine dependence, tobacco smoking, smoking cessation, cancer patients

Introduction – tobacco smoking and the health burden

In the European Code Against Cancer the first and most important recommendation for cancer prevention is abstinence from tobacco smoking. Tobacco smoking is responsible for almost 30% of all cancer deaths worldwide and is the single most significant factor of them [1]. Tobacco smoke, containing approximately 7,000 thousand chemical compounds, is classified by IARC as a human carcinogen. The scientific evidence is so extensive that it has been included in the highest of four groups of classifications. It means that there is no doubt that exposure to it is associated with a high risk of developing cancer. Approximately 70 carcinogenic substances found in tobacco smoke act as both initiators and promoters of the carcinogenesis process [2]. There are at least 15 different cancer localization in human body with a proven causal relationship with exposure to tobacco smoke. The highest risk is observed for lung cancer, with the risk attributed to be 90% in men and over 70% in women [3]. On average, a lifetime smoker has a 20-fold higher risk of developing lung cancer, compared with a lifetime non-smoker [4]. In the whole of Europe, lung cancer accounts for 24% of all cancer-related deaths and is the most common cause of death among men. In several European countries, including Poland, it is also the leading cause of cancer death among women [5, 6]. A slightly lower attributable risk, as much as 85%, is observed for head and neck cancers, e.g. mouth, throat, larynx, nasal cavity and apart from alcohol consumption, this is their most important cause. According to the results of many years of research conducted by the International Agency for Research on Cancer, tobacco smoking is also causally associated with other cancers, i.e., pancreas, bladder, stomach, liver, renal pelvis, colon, myeloid leukemia, ovary and cervix [7]. Tobacco smoking and tobacco-attributable cancer mortality remains one of the most significant health burdens in the Polish population. Annually, more than 30 thousand Polish men and women die from cancer caused by smoking [8].

Jak cytować / How to cite:
Cedzyńska M, Przepiórka IA. ***Cancer patients and smoking cessation.*** *NOWOTWORY J Oncol* 2023; 73: 394–401.

Despite many efforts to reduce smoking around the world and many successes in this field, the smoking population was 22.3% in 2020 (36.7% of all men and 7.8% of women) [9]. The prevalence of smoking among patients diagnosed with cancer is high – over 60% of them are smokers, former smokers or recent quitters [10]. Continuing to smoke after a cancer diagnosis is particularly disturbing. It seems that patients treat a cancer diagnosis as a death sentence and a condition in which it is too late to quit smoking.

Risk of smoking continuation after cancer diagnosis

Smoking has been linked not only to the development of disease, but also to prognosis upon diagnosis and risk of death during treatment. The adverse effects are found both in patients with smoking-related cancers and in those with nonsmoking-related cancers.

Overall mortality

Research data have proven that continued smoking by cancer patients is causally associated with all-cause and cancer-specific mortality. Continued smoking is among the strongest adverse predictors of survival in cancer patients [11]. For example, in patients with head and neck cancer who smoked during radiation treatment, the two-year survival rates were 39% compared to 66% in non-smokers. In a multivariate analysis, after taking into account age, disease stage and concomitant chemotherapy, the risk of death was 2.5 times higher in patients who continued smoking than in former smokers or never smokers [12].

Increased risk of second primary cancer

There is some evidence that smoking after cancer diagnosis increases not only the incidence of a first, but also a second primary cancer. The most frequent are tobacco related malignancies such as lung, head and neck, stomach and hematological cancers. A systematic review and meta-analysis of randomized and longitudinal observational studies demonstrated a four times higher risk of developing a second primary tumor for small-cell lung cancer patients who continued smoking, than for those who quit at diagnosis. [13] In the study done by Rice et al., a prospective analysis to investigate the risk of second primary cancer in a group of 569 patients with stage I non-small cell lung cancer who had undergone complete pulmonary resection was conducted. Over a median follow-up period of 5.9 years, 15% of the patients developed second primary tumors. Over half of them (56%) were additional lung cancers. The incidence of second primary lung cancers nearly doubled among current smokers compared to those who were former smokers [14].

If the patient was treated with radiation to the chest area, the risk of lung cancer as a second primary tumor increases 13 fold, if he smokes at the same time – 21 fold, in patients undergoing chemotherapy the risk increases 9–13 fold, and in patients who continue smoking – 19 fold [15]. Smoking by women cured of breast cancer increases the risk of lung cancer six fold, and if the patients were treated, among others, radiation to the chest area, this risk increases 9 fold [16]. Active smokers are at particularly high risk of developing lung cancer. In smokers who have been treated for Hodgkin's lymphoma in the past with, among others, radiotherapy, this risk increases 20 fold, and in the case of a combination of smoking, radiotherapy and chemotherapy with alkylating drugs, the risk increases 50 fold [16].

There is also a known relationship between smoking and the risk of prostate cancer recurrence. Men after radical prostatectomy who continue to smoke have a 30% greater risk of biochemical recurrence, a 2.5 times greater risk of resistance to anti-androgen treatment, a 2.5 times greater risk of distant metastases and a twice the risk of death during the course of cancer [17].

Stopping smoking at any stage of cancer reduces the risk of disease recurrence and secondary cancers.

Decreased effectiveness of therapy

The poorer effects of treatment with radiotherapy was observed in smoking patients compared to patients who stopped smoking or were never smokers. An adverse effect of smoking has been observed for efficacy of treatment with radiation and for systemic chemotherapy. In a study done by Browman et al. in smoking patients with head and neck cancer, the percentage of overall responses to treatment during radiation was 45% compared to 74% in non-smokers [12].

Smoking may interact with some drugs pharmacokinetics and can affect treatment outcomes, including cancer treatments. Smoking alters the drug metabolism due to affecting cytochrome P-450. Additionally, smoking increases the risk of drug resistance and the fluctuation of drug concentrations. Research on specific medications has indicated that the extent of pharmacokinetic disruption caused by smoking is comparable to that of other clinically significant drug interactions. This disruption is significant enough to influence recommended dosages. [18]. Lung cancer patients who persist in smoking demonstrate a more rapid elimination of erlotinib and gefitinib compared to non-smokers, potentially necessitating the administration of higher doses of these compounds to achieve comparable systemic levels. In this patient population, pharmacokinetic and toxicity profiles for smokers receiving erlotinib at a 300 mg daily dose is similar to that in nonsmokers receiving 150 mg daily, which could suggest that the daily dose of erlotinib in current smokers should be increased to 300 mg. Tobacco smoke was also demonstrated to affect the pharmacokinetics and toxicity of irinotecan, a topoisomerase-I inhibitor used in small-cell lung cancer [11].

Increased risk of complications in anticancer treatment

In patients with head and neck cancer, smoking during radiotherapy treatment significantly heightens the likelihood

of experiencing radiotherapy-induced complications. These can include oral mucositis, weight loss, fatigue, xerostomia (dry mouth), altered taste sensation, and vocal difficulties [19]. Prostate cancer patients who were currently smoking, in contrast to those who had never smoked, exhibited a higher likelihood of encountering radiotherapy-related symptoms such as defecation urgency, diarrhea, a sensation of the bowel not being completely emptied after defecation, and abdominal cramps. On the other hand, former smokers did not show an elevated prevalence ratio for these symptoms [20].

An additional important issue is also the increased risk of surgical complications in smoking patients. Postoperative healing complications occur significantly more often in smokers compared with nonsmokers and in former smokers compared with those who never smoked. In a total of 140 cohort studies involving 479,150 patients, smokers and non-smokers were compared revealing the increased risk for following complications: almost a 4-fold risk of necrosis, double the healing delay and dehiscence, wound complications, hernia, and almost two and half times greater risk of lack of fistula or bone healing. The surgical site infection in smokers was almost twice that among non-smokers or ex-smokers [21].

In a population of 140,000 patients undergoing major surgical procedures, including oncological ones, cigarette smoking significantly increased the risk of at least one postoperative complication. The following oncological procedures were included in the analysis: removal of the esophagus, stomach, large intestine, pancreas, removal of the kidney or bladder, removal of the uterus and lung resection. In active smokers, compared to never smokers or smokers in the past, the following complications were significantly more common: cardiovascular, pulmonary, neurological, thromboembolic, septic (including septic shock), renal failure, urinary tract infections, need for blood transfusion, the need for reoperation, the need for rehospitalization, smokers required longer hospitalizations; only differences in peri-procedural mortality did not achieve statistical significance [22].

Quality of life and pain

Compared to never or former smokers, patients with head and neck cancer and lung cancer who continued smoking had poorer physical health, self-perception of their general health, emotional and social functioning, and vitality. Patients who continue smoking after a diagnosis of cancer also experience higher levels of cancer-related symptoms than nonsmokers or former smokers. Compared to never or former smokers, cancer patients who continued smoking have worse physical health, self-perception of their general health, and both social and emotional functioning. They also experience less vitality [23–25].

Smoking cessation and benefits for cancer patients

According to studies, evidence is sufficient to infer that smoking cessation reduces the risk of the following cancers: lung, laryngeal, oral cavity and pharynx, esophageal, pancreas, bladder, stomach, colon, liver, cervix, kidney and acute myeloid leukemia [26]. Apart from disease site and stage, abstinence from smoking is considered the strongest predictor of survival in cancer patients who have ever smoked [11]. Stopping smoking is associated with improved outcomes even among patients diagnosed with the most attributable to smoking cancer, i.e. lung cancer. Quitting smoking prolongs survival and reduces the incidence of cancer recurrence in this population of patients. A review of the literature showed that in patients diagnosed with early-stage non-small cell lung cancer, smoking cessation reduced overall mortality by 66% and the risk of recurrence or secondary lung cancer by 46%, compared to those who continued smoking. Similarly, in patients with small-cell lung cancer, smoking cessation reduced overall mortality by 46% and the risk of recurrence or primary lung cancer by 77% [27].

In a study examining the effectiveness and complications of radiotherapy in patients with advanced head and neck cancer, stopping smoking for at least one month was associated with a significant reduction in the duration of mucositis after radiotherapy [16].

In a study described by Daniel et al., moderate to severe pain was reported by 60% of persistent smokers with lung cancer while only 37% of nonsmoking patients reported it [28].

In summary – smoking cessation after cancer diagnosis is connected with many significant benefits like reduced risk of death by 30-40%, reduced risk of recurrence and second primary cancer, reduced risk of treatment complications, increased response for treatment, better quality of life and less pain. Although the benefits of smoking abstinence are evident regardless of stage and prognosis, they are undervalued by both health professional and patients themselves. In most cases the advice on smoking cessation provided by medical staff contains the information about risk of continuation of smoking rather than the information about benefits of quitting smoking. However, good medical practice requires informing the patient not only about the risk of deterioration of prognosis if they continue smoking, but also about the improved chance for anticancer treatment results.

Treatment of nicotine dependence

Smokers with life-threatening illnesses, which may in part be attributable to their use of tobacco, still have great difficulty in achieving permanent abstinence, with as many as about 50% of lung cancer patients returning to smoking after surgery [29]. It is mainly due to the nature of nicotine – a substance acknowledged to be as addictive as alcohol, heroin or cocaine [30]. Nicotine addiction is a disease included in the 11th revision of International Classification of Diseases (6C4A.2). It is characterized by a strong internal craving and impaired control over nicotine use. The need to take nicotine becomes a priority over other activities and a persistent habit despite

the potential harm or negative consequences. The need to use nicotine results from a biological addiction, often accompanied by a subjective craving for its delivery, especially in certain social situations or emotional states. Addicted people often have physiological features of addiction, including tolerance to the effects of nicotine, withdrawal symptoms after stopping or reducing nicotine use. Withdrawal symptoms are a clinically significant set of symptoms, behaviors and physiological characteristics that occur after cessation or reduction of nicotine use in nicotine-dependent individuals. Nicotine withdrawal symptoms may include dysphoric mood, depression, insomnia, irritability, anger, anxiety, difficulty concentrating, restlessness, bradycardia, increased appetite and so-called nicotine craving. In the process of diagnosing nicotine addiction, in addition to determining its occurrence, it is recommended to determine the strength of nicotine addiction and the readiness to stop smoking. The strength of the biological addiction is assessed by the Fagerstrom Nicotine Dependence Test (FNDT), which the patient can complete independently while waiting for the appointment. The FNTD is widely used in clinical practice and in clinical and scientific research. The second important step is to determine the patient's readiness to stop smoking. Readiness to quit is, according to research, one of the important factors determining therapeutic success in maintaining long-term abstinence [31].

In the treatment of nicotine addiction, there is a selection of pharmacological methods available, the effectiveness and safety of which have been confirmed in clinical trials. Currently, those available are: nicotine replacement therapy (NRT), antidepressants and partial agonists of nicotine receptors.

Nicotine replacement therapy

The aim of nicotine replacement therapy (NRT) is to replace the nicotine that people who smoke usually get from cigarettes, so the urge to smoke is reduced and they can stop smoking completely. The main aims of NRT are three: craving reduction, withdrawal control, and abstinence promotion [32]. Nicotine replacement therapy products are available in transdermal form (patches), oral form (gum, lozenge, tablets, inhaler), and in some countries as a nasal spray. They provide nicotine, stabilizing its level in the blood in order to avoid a withdrawal syndrome after stopping smoking. As per producer suggestion, the treatment lasts for 10–12 weeks, but it can be prolonged to 6 or even 12 months. There are two types of product depending on the way of acting – long acting administrated once a day (patches) and short acting which are administrated multiple times per day (lozenges, pills, spray). Using nicotine patches together with another type of NRT (such as gum or lozenges) made it 17% to 37% more likely that a person would successfully stop smoking than if they used one type of NRT alone. Very few people experienced negative effects of using NRT during the quit attempt and there is no contraindications to the use of NRT in patients with cancer.

However, the use of oral, short-acting nicotine preparations may be considered questionable or contraindicated in people with damage to the larynx, esophagus and mucous membrane of the head and neck organs resulting from cancer or oncological therapy. In these patients, it is better to use another treatment with documented effectiveness. People who decide to use nicotine patches should know that they can only be used on intact skin, so they should not be used on areas undergoing radiotherapy. The patient should be aware of the potential risk of allergies in the area where the patch is applied; cases of local loss of subcutaneous fat tissue at the site of application have also been described, so it should be systematically changed.

When determining the initial dose of nicotine, we can use one of its metabolites – cotinine. It is an alkaloid with a long half-life, so its concentration in the blood or urine reflects exposure to the parent substance – nicotine. However, these determinations are not available or cheap, and we can successfully use the estimation method, according to which the daily dose of nicotine is determined based on the number of cigarettes smoked. The latest recommendation is to start from a maximum dose of nicotine and to combine the long- and short-acting form of NRT [33].

Bupropion

Bupropion is a selective inhibitor of noradrenaline and dopamine reuptake and has a minimal effect on serotonin reuptake. Bupropion is an antidepressant available in pills contains 150 mg of active substance. Bupropion administration begins 1–2 weeks before the patient's scheduled smoking cessation date. The treatment length is 12 weeks, but it can be prolonged if necessary. There is high-certainty evidence that bupropion increases smoking cessation rates when compared to a placebo or no pharmacological treatment in the general population [34]. In the cancer patient population, bupropion increases abstinence rates, lowers withdrawal, and increases the quality of life. However, abstinence rates among patients with depression symptoms were lower than in patients without depression symptoms at the beginning of treatment. Additionally, a systematic review of 7 studies proved that bupropion may be an effective and safe intervention for fatigue in cancer and non-cancer conditions. It is especially important since fatigue is a predominant and distressing symptom in cancer and non-cancer conditions for which there is a paucity of recommendations for pharmacological interventions [35]. Since bupropion is contraindicated for patients with seizure disorder, it should be avoided in patients with seizure risk, including those with brain metastases or primary brain tumors. There is evidence that bupropion combined with NRT increases the chance for successful quitting [36].

Partial agonists of nicotine receptor

There are two partial agonists of the nicotine receptor available for smoking dependence treatment – cytisine (herbal)

and varenicline (synthetic). They help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). There is high-certainty evidence that varenicline helps in quitting smoking when compared to a placebo, but also shows superiority to bupropion and single form of nicotine replacement therapy. It is recommended also as safe and effective in the cancer patient population. However, varenicline has been withdrawn from the market due to Nitrosamine impurities and is no longer available. Cytisine is a herbal drug which works by the same mechanism as varenicline and is available for substantially less cost. It may lead to fewer people reporting SAEs than varenicline. There is moderate-certainty evidence (limited by heterogeneity) that cytisine helps more people quit smoking than a placebo. Based on studies that directly compared cytisine and varenicline, there may be no difference or benefit from either medication as regards quitting smoking [37]. The cytisine treatment regimen proposed by the producer is based on a very short, 25-day drug therapy. In some cases, extending the therapy helps to maintain abstinence and, consequently, increase the lasting effectiveness of the drug. Prolonged treatment could be particularly beneficial in oncological patients, but the daily dose should be limited to 6 tablets.

Although cytisine is not included in global guidelines for nicotine dependence treatment in the oncological population, it should be considered for use in cancer patients especially due safety of its use in the general population and its low price.

Electronic cigarettes and heat-not-burn products (HTP)

The use of e-cigarettes and HTPs is not recommended as a way of quitting smoking. There is currently insufficient evidence regarding the safety and effectiveness of their use as a smoking cessation aid in the general population or among patients diagnosed with cancer. Patients should always be advised to use evidence-based treatments for nicotine dependence [36].

Specificity of nicotine dependence treatment in the cancer patient population

Undoubtedly, cancer is connected with a particular physical and psychological burden for patients. A diagnosis of cancer requires patients and their relatives to face many challenges related to treatment, but also to face the diagnosis of a disease that can be fatal. Moreover, being diagnosed with cancers that are causally related to smoking involves the additional burden of dealing with other people's perceptions and feelings of guilt and shame. Although many diseases are related to lifestyle and daily habits, in public opinion, cancer patients, especially lung cancer patients, are most often blamed for their health problems [38]. The stigmatization of tobacco-related cancers and the self-stigmatization of patients is one of the factors that make it difficult to start treatment for nicotine dependence. They may intensify negative emotions, intensify depression and the mental crises that occur after a cancer diagnosis. Patients who feel blamed for their condition are reluctant to talk about addiction, and questions about their smoking history cause discomfort. Some patients, fearing negative evaluation, do not provide true information about addiction. The stigma associated with tobacco-related diseases may therefore significantly influence therapeutic decisions, including the decision to stop smoking. The non-judgmental attitude of medical staff and communication based on empathy and understanding of the fact that the patient is struggling with nicotine addiction is an essential condition for helping smoking cancer patients. It is important to focus on respecting the patient's subjectivity and using inclusive, non-judgmental language. Focusing solely on the negative consequences of continuing to smoke may make the patient feel judged for the development of the disease and lack understanding of how difficult it is to fight addiction. It is beneficial for the patient to discuss in detail the health benefits of quitting smoking in the context of a cancer diagnosis and the planned oncological treatment. Another key element of anti-smoking intervention is the subjective assessment of the patient's level of motivation to quit smoking. The patient's fears, resulting from, for example, past negative experiences in quitting smoking, or lack of confidence in one's own abilities, may be wrongly interpreted as a lack of motivation. Empathy, avoiding schematic thinking and authentic understanding of the difficulties encountered in quitting cigarettes (smoking, despite the harmful consequences, is defined as one of the symptoms of the disease that is nicotine addiction) are necessary conditions in communication with an addicted patient. Cancer diagnosis and anticancer treatment is considered one of the factors in the development of post-traumatic stress disorder (PTSD) [39]. At the same time, the feeling of a threat to one's life may provide an opportunity to reconsider the choice of one's basic life values and trigger changes in the area of health behavior, which may be referred to as post-traumatic growth. A traumatic event involving confrontation with the prospect of the end of life may lead to the activation of various adaptive behaviors. It is often called a teachable moment in people's life. A beneficial response style for the patient is to perceive the disease as a challenge and be ready to take active actions [40]. One such action may be trying to quit smoking. The condition is that patients understand that stopping smoking is important for the course of the disease and its treatment. The awareness that giving up cigarettes after cancer diagnosis may significantly affect the course and results of oncological treatment may be an important factor determining the motivation and willingness to change in smoking patients. Patients often think that "it is too late." Lack of understanding why quitting smoking is particularly important in the current health situation prevents people from taking the appropriate actions.

Equally important is the fact that a cancer diagnosis is a moment of loss of control and the ensuing sense of chaos. One way to regain control is to prepare for treatment and actively engage in the treatment process. Quitting smoking is an action that has a strong, positive impact on the prognosis, and can help the patient regain a sense of influence over his future. Most cancer patients quit or make an attempt to quit within a short time after diagnosis, so the most important message should be delivered as early as possible. Thus, it is necessary to involve medical staff in the process of identifying smoking cancer patients, providing non-judgmental support that includes information on the risks associated with continuing smoking after diagnosis and, above all, the benefits that the patient will receive. Unfortunately, despite the consensus that smoking cessation treatment should be an integral part of cancer care, most patients of cancer centers are not assessed for smoking-related behavior. A study carried out in Poland in 2023 shows that only 29% of oncology patients received information from medical staff about the negative impact of smoking on health, 15% received information about the negative impact of smoking on the effectiveness of oncological treatment, and 58% indicated that they were not talked to about smoking at all [41].

Obstacles to making anti-smoking interventions by medical staff may include beliefs that a cancer diagnosis is not the right time to discuss quitting smoking and talking about addiction would violate a patient's privacy, or that it is not part of their job duties. Health professionals may also have insufficient knowledge about the risks of continuing to smoke and the benefits of stopping smoking, or they may think that they do not have competence in the field of anti-tobacco interventions. Therefore, it is recommended that all physicians and other medical staff complete training in the evidence-based treatment of nicotine dependence. Increasing the level of anti-smoking counseling skills and updating knowledge on an ongoing basis are necessary to build a sense of competence among medical staff and thus ensure a readiness to discuss the issue of smoking addiction with patients. Participation in training has been shown to increase the involvement of health care professionals in smoking cessation counseling and also increase the percentage of patients quitting smoking [42]. Routine practice for cancer patients should be to identify those with an active smoking dependence, record their smoking status in the medical record, recommend smoking cessation and, ideally, offer treatment or discuss available treatment options.

Such interventions should be undertaken at every visit to the doctor and during hospitalization. Research shows that providing short (3 to 5 minutes) clear advice on quitting smoking by a member of the medical team increases both the patient's motivation to try to quit and their chances of achieving and maintaining abstinence [42, 43]. It has been proven that short counseling, so-called minimal intervention (5A's) is an effective way to initiate and monitor the effects of a quit attempt. An alternative to minimal intervention may be its shortened version called ask advise refer (AAR). The elements of the intervention include: routine assessment of smoking status among all patients and recording the information in medical records; brief, non-judgmental counseling on quitting smoking (focusing on the individual benefits of abstinence and indicating the risks associated with continuing smoking); referral of nicotine-dependent people to the National Quitline or other specialists [44].

Conclusions

The evidence is strong enough to incorporate tobacco dependence treatment into routine cancer care, but not many cancer centers report that they effectively identified tobacco use in their patients. Thus, tobacco cessation remains a challenging issue in the oncology population. Although there are many documented benefits of stopping smoking after a cancer diagnosis and the risks associated with continuing smoking, this topic is not often discussed by medical staff. If it is done, it is only during the first visit, however, due to the fact that the readiness of patients to quit smoking is changing over time and the importance of constantly motivating patients, it should be done at every contact with the patient. The message should be framed around the benefits of quitting smoking, not just the risks of continuing to smoke. Failure to inform the patient about the importance of stopping smoking for the effects of his anticancer treatment and overall survival should be considered as malpractice. Interventions should take into account not only those elements that are important in the treatment of smoking addiction in the general population, such as the depth of addiction or readiness to quit smoking, but also the specificity of patients diagnosed with cancer. These include higher levels of stress and anxiety, symptoms of depression, feelings of guilt, and the belief that it is too late to quit smoking. Anti-tobacco interventions conducted by an oncologist may be very short (1–1.5 minutes). It should contain only information conveyed in an empathetic and friendly way about the importance of stopping smoking for the effectiveness of anti-cancer treatment and advice on making a quit attempt with the help of a specialist. A more comprehensive intervention may be provided by a nurse or other specialist available in the hospital. It is important that healthcare professionals and educators continue to provide support and information to people affected by cancer to help them make and maintain positive changes in their health behaviors.

Recommendations

1. Nicotine addiction is a chronic and relapsing disease, thus every smoking patient should receive evidence-based treatment.
2. Nicotine dependence treatment should always include individualized pharmacotherapy, and behavioral counseling.

This may involve referring the patient for specialist help e.g. National Quitline.

3. Interventions aimed at stopping smoking should be carried out at every stage and throughout the patient's treatment process, by the entire team of the center – doctors, nurses, physiotherapists, radiotherapists, psycho-oncologists, health educators, etc.
4. Nicotine Replacement Therapy and/or cytisine should be available for patients during their stay in hospital.
5. The anti-smoking intervention should be tailored to the specificity of cancer patients, i.e. conducted in a non-judgmental way, not arousing a sense of guilt, taking into account the patient's mental state, i.e. higher levels of anxiety, depression, stress. The information should include information not only about further risks of continuing smoking but also about the benefits of quitting smoking for the effects and tolerability of cancer treatment.
6. The electronic database of patient records should enable not only the recording of the patient's smoking status, but also automatic activities supporting anti-smoking interventions for patients, such as, for example, an automatically generated referral to a specialist smoking cessation clinic, an information "leaflet" for patients about the positive impact of stopping smoking on the effects of anticancer treatment, information for primary care physicians on hospital discharge notes and others.
7. All health care professionals of cancers centers should be trained in smoking cessation intervention.

Article information and declarations

Author contributions

Magdalena Cedzyńska – review of the literature. writing and editing the manuscript.

Irena A. Przepiórka – review of the literature, writing the manuscript.

Conflict of interest

None declared

Magdalena Cedzyńska
Maria Sklodowska-Curie National Research Institute of Oncology
Cancer Epidemiology and Primary Prevention Department
Head of Smoking Cessation Unit
ul. Roentgena 5
02-784 Warszawa, Poland
e-mail: magdalena.cedzynska@nio.gov.pl

Received: 31 Oct. 2023
Accepted: 16 Nov. 2023

References

1. Peto R, Lopez AD, Boreham J, et al. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet. 1992; 339(8804): 1268–1278, doi: 10.1016/0140-6736(92)91600-d, indexed in Pubmed: 1349675.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco Smoke and Involuntary Smoking. International Agency for Research on Cancer, Lyon 2004: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 83.
3. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer. 2004; 45 Suppl 2: S3–S9, doi: 10.1016/j.lungcan.2004.07.998, indexed in Pubmed: 15552776.
4. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003; 123(1 Suppl): 21S–49S, doi: 10.1378/chest.123.1_suppl.21s, indexed in Pubmed: 12527563.
5. https://gco.iarc.fr/.
6. Wojciechowska U, Barańska K, Michałek I, et al. Nowotwory złośliwe w Polsce w 2020 roku. Cancer in Poland in 2020. https://onkologia.org.pl/sites/default/files/publications/2023-01/nowotwory_2020.pdf.
7. http://monographs.iarc.fr/ENG/Monographs/vol83/mono83.pdf.
8. Mańczuk M, Sulkowska U, Łobaszewski J, et al. Time trends in tobacco-attributable cancer mortality in Poland — direct estimation method. Nowotwory. Journal of Oncology. 2017; 67(4): 227–235, doi: 10.5603/njo.2017.0037.
9. https://www.who.int/news-room/fact-sheets/detail/tobacco.
10. Warren GW, Kasza KA, Reid ME, et al. Smoking at diagnosis and survival in cancer patients. Int J Cancer. 2013; 132(2): 401–410, doi: 10.1002/ijc.27617, indexed in Pubmed: 22539012.
11. Jassem J. Tobacco smoking after diagnosis of cancer: clinical aspects. Transl Lung Cancer Res. 2019; 8(Suppl 1): S50–S58, doi: 10.21037/tlcr.2019.04.01, indexed in Pubmed: 31211105.
12. Browman GP, Wong G, Hodson I, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med. 1993; 328(3): 159–163, doi: 10.1056/NEJM199301213280302, indexed in Pubmed: 8417381.
13. Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010; 340: b5569, doi: 10.1136/bmj.b5569, indexed in Pubmed: 20093278.
14. Rice D, Kim HW, Sabichi A, et al. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg. 2003; 76(4): 1001–7; discussion 1007, doi: 10.1016/s0003-4975(03)00821-x, indexed in Pubmed: 14529975.
15. Ford MB, Sigurdson AJ, Petrulis ES, et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer. 2003; 98(7): 1457–1464, doi: 10.1002/cncr.11669, indexed in Pubmed: 14508833.
16. Rugg T, Saunders MI, Dische S. Smoking and mucosal reactions to radiotherapy. Br J Radiol. 1990; 63(751): 554–556, doi: 10.1259/0007-1285-63-751-554, indexed in Pubmed: 2390690.
17. Moreira DM, Aronson WJ, Terris MK, et al. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer. 2014; 120(2): 197–204, doi: 10.1002/cncr.28423, indexed in Pubmed: 24127391.
18. Petros WP, Younis IR, Ford JN, et al. Effects of tobacco smoking and nicotine on cancer treatment. Pharmacotherapy. 2012; 32(10): 920–931, doi: 10.1002/j.1875-9114.2012.01117, indexed in Pubmed: 23033231.
19. Warren GW, Sobus S, Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol. 2014; 15(12): e568–e580, doi: 10.1016/S1470-2045(14)70266-9, indexed in Pubmed: 25439699.
20. Alsadius D, Hedelin M, Johansson KA, et al. Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer. Radiother Oncol. 2011; 101(3): 495–501, doi: 10.1016/j.radonc.2011.06.010, indexed in Pubmed: 21737169.
21. Sørensen LT. Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: a systematic review and meta-analysis. Arch Surg. 2012; 147(4): 373–383, doi: 10.1001/archsurg.2012.5, indexed in Pubmed: 22508785.
22. Schmid M, Sood A, Campbell L, et al. Impact of smoking on perioperative outcomes after major surgery. Am J Surg. 2015; 210(2): 221–229.e6, doi: 10.1016/j.amjsurg.2014.12.045, indexed in Pubmed: 25980408.
23. Garces YI, Yang P, Parkinson J, et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest. 2004; 126(6): 1733–1741, doi: 10.1378/chest.126.6.1733, indexed in Pubmed: 15596667.

24. Duffy SA, Terrell JE, Valenstein M, et al. Effect of smoking, alcohol, and depression on the quality of life of head and neck cancer patients. Gen Hosp Psychiatry. 2002; 24(3): 140–147, doi: 10.1016/s0163-8343(02)00180-9, indexed in Pubmed: 12062138.
25. Gritz ER, Carmack CL, de Moor C, et al. First year after head and neck cancer: quality of life. J Clin Oncol. 1999; 17(1): 352–360, doi: 10.1200/JCO.1999.17.1.352, indexed in Pubmed: 10458254.
26. U.S. Department of Health and Human Services. Smoking Cessation: A Report of the Surgeon General—Executive Summary. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA 2020.
27. Carson K, Usmani Z, Robertson T, et al. Smoking cessation interventions for lung cancer patients. Lung Cancer Management. 2013; 2(1): 61–74, doi: 10.2217/lmt.12.55.
28. Daniel M, Keefe FJ, Lyna P, et al. Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. J Pain. 2009; 10(3): 323–328, doi: 10.1016/j.jpain.2008.10.006, indexed in Pubmed: 19254679.
29. Stapleton J. Cigarette smoking prevalence, cessation and relapse. Stat Methods Med Res. 1998; 7(2): 187–203, doi: 10.1177/096228029800700206, indexed in Pubmed: 9654641.
30. Boyle P. Tobacco: science , policy and public health. Oxford University Press 2004.
31. Kleinjan M, Engels RC, van Leeuwe J, et al. Mechanisms of adolescent smoking cessation: roles of readiness to quit, nicotine dependence, and smoking of parents and peers. Drug Alcohol Depend. 2009; 99(1-3): 204–214, doi: 10.1016/j.drugalcdep.2008.08.002, indexed in Pubmed: 18848408.
32. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008(1): CD000146, doi: 10.1002/14651858.CD000146.pub3, indexed in Pubmed: 18253970.
33. Theodoulou A, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023; 6(6): CD013308, doi: 10.1002/14651858.CD013308.pub2, indexed in Pubmed: 37335995.
34. Hajizadeh A, Howes S, Theodoulou A, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023; 5(5): CD000031, doi: 10.1002/14651858.CD000031.pub6, indexed in Pubmed: 37230961.
35. Correa-Morales JE, Cuellar-Valencia L, Mantilla-Manosalva N, et al. Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. J Pain Symptom Manage. 2023; 65(1): e21–e28, doi: 10.1016/j.jpainsymman.2022.09.011, indexed in Pubmed: 36198335.
36. Shields PG, Bierut L, Arenberg D, et al. Smoking Cessation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023; 21(3): 297–322, doi: 10.6004/jnccn.2023.0013, indexed in Pubmed: 36898367.
37. Livingstone-Banks J, Fanshawe T, Thomas K, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2023; 2023(6), doi: 10.1002/14651858.cd006103.pub9.
38. https://tosieleczy.pl/wp-content/uploads/2022/05/Raport-FWZ--TSL_stygmatyzacja-pacjentow-z-RP_310522.pdf.
39. Cordova M, Giese-Davis J, Golant M, et al. Breast Cancer as Trauma: Posttraumatic Stress and Posttraumatic Growth. Journal of Clinical Psychology in Medical Settings. 2007; 14(4): 308–319, doi: 10.1007/s10880-007-9083-6.
40. Domanowska G, Greszta E, Ćwiklińska-Zaborowicz A. Odkrywanie wartości życia w chorobie nowotworowej. Kwartalnik Naukowy Fides Et Ratio. 2018; 33(1): 202–218.
41. https://tosieleczy.pl/wp-content/uploads/2023/05/Raport-Problem--palenia-wsrod-pacjentow-300523.pdf.
42. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013; 2013(5): CD000165, doi: 10.1002/14651858.CD000165.pub4, indexed in Pubmed: 23728631.
43. Aveyard P, Begh R, Parsons A, et al. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction. 2012; 107(6): 1066–1073, doi: 10.1111/j.1360-0443.2011.03770.x, indexed in Pubmed: 22175545.
44. Vidrine JI, Shete S, Cao Y, et al. Ask-Advise-Connect: a new approach to smoking treatment delivery in health care settings. JAMA Intern Med. 2013; 173(6): 458–464, doi: 10.1001/jamainternmed.2013.3751, indexed in Pubmed: 23440173.

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 484–485

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

VIA MEDICA

Edytorial / Editorial

Rak piersi / Breast cancer

Does an apple a day keep the doctor away? Cardiovascular prevention in breast cancer patients

Michał Jarząb

Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

The aphorism "An apple a day keeps the doctor away", first in print coined as "Eat an apple on going to bed and you'll keep the doctor from earning his bread" as early as in 1866, has been tested by rigorous evidence-based approach [1]. Although the study was published on April Fool's Day in 2015 in JAMA Internal Medicine, it seriously tested the hypothesis that keeping to the rule above reduces the necessity of at least one visit per year. Unfortunately, the proverb did not pass the strict EBM threshold, although the study suggested that each-day-apple-consumers used fewer prescription medicines than the general population.

Dyrbuś et al. in this issue of *Nowotwory. Journal of Oncology* describe the variety of pharmacological preventive methods applied in contemporary cardio-oncology (*Pharmacological prevention methods in patients with cardiovascular disease with breast cancer – when, how, and for whom?*). The authors define when, how and for whom cardioprevention shall be applied; my insight here relates mainly to the question "Why?".

Since the beginning of cancer therapy, cardiotoxicity has been an issue of utmost importance. The first reports were related to post-anthracycline heart failure; the low magnitude of QRS complexes in ECG examination was the first considered, obviously not an early feature of this complication [2]. Polish oncological and cardiological community recognised the necessity of adequate patient monitoring. For example, Malinowski et al. analysed ECG data of patients treated by breast radiation between 1985 and 2002 and described the excess of ischemic features in patients with left-sided disease [3]. More recently, Kufel-Grabowska et al. studied the cardiotoxicity in patients treated with adjuvant trastuzumab after earlier anthracycline therapy [4]. The authors find significant differences in NT-proBNP concentrations at a post-treatment follow-up visit in patients with cardiotoxicity, while no such association for cardiac troponin levels. We have our Polish cardioprevention trials, both completed, e.g. ramipril study of Cracow team [5] or ongoing -- studies financed by Agency of Medical Research (EMPACT in Warsaw, MAINSTREAM in Zabrze, see clinicaltrials.gov).

In 2023 we can identify early signs of cardiotoxicity evoked by anti-cancer therapy and diminish its impact with effective preventive strategies. It was proven by some trials, which I refer to as "first generation". In second-generation studies, the population of patients for the intervention was selected by a marker of cardiotoxicity, with a defined population of high-risk patients eligible (see the review of Dyrbuś et al. for references). There comes a question – is the optimised management bringing benefit to patients' overall health? This issue is of raising importance, as last year European Society of Cardiology published comprehensive guidelines on cardio-oncology, developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). The document shows a complicated landscape of current cardio-oncology, with numerous procedures and classification schemes; many oncological practices and centres have problems fully implementing the algorithms into patient management pathways.

We urgently need the trials of "third generation", where biomarkers/imaging strategies and pharmacological preven-

Jak cytować / How to cite:
Jarząb M. ***Does an apple a day keep the doctor away? Cardiovascular prevention in breast cancer patients.*** *NOWOTWORY J Oncol* 2023; 73: 402–403.

tive approaches are linked to the tailoring of cancer therapy. There are many ways to adjust the intensity of cancer treatment, either adapting it to the response/toxicity or trying to make a perfect fit a priori, before initiating therapy. In breast cancer, we could easily avoid anthracyclines in HER2-positive patients (however, sometimes for a price of excess fatigue or non-cardiac toxicity), we may try to spare from cardiac burden patients with luminal cancers (although avoiding radiation or chemotherapy is not as straightforward, especially in premenopausal patients, where the potential long-term toxicity might be of utmost importance). Finally, in triple-negative individuals, where we usually apply relatively aggressive chemotherapy, we could add anti-PD-L1 immunotherapy or leave the patient without this additional cardiac risk factor. However, we deeply do not understand, what is the survival impact of every one of these decisions on patient survival. When decreasing the intensity of oncological therapy will provide a net benefit due to better cardiac health? Cardiologists sometimes joke that it is easier to fix the heart than cure cancer; however, we all know from epidemiological data that the death toll of late cardiac toxicity among cancer survivors is substantial. It holds true not only for the old cytotoxic chemotherapy but also for many novel targeted treatments [6].

I invite the readers of the article prepared by colleagues from Zabrze to get acquainted with cardiopreventive strategies and to apply them as broadly as possible, with benefit to the cardiac health of our patients. There shall also be a time for reflection, how is cardiology shaping oncology nowadays? Will cardiac specialists fix our failures or instead provide a critical selection gateway to the treatment? It is evident that merging both approaches is potentially the most effective; how to test it in clinical trials? And last but not least, it is critically vital that trials of oncological therapies will be open for wisely selected high-risk cardiac patients; only then we could learn whether in such a setting modifying the oncological treatment in parallel with maximal cardioprotection and effective rescue strategies provide a net health benefit.

And coming back to the role of a healthy lifestyle. There will be a time for fourth-generation trials, comparing pharmacological interventions with proactive exercise, diet, psychotherapy, education approach and testing which patients benefit, as well as providing rational advice on how to mix these strategies and provide patient compliance.

Article information and declarations

Conflict of interest

None declared

Michał Jarząb
Maria Sklodowska-Curie National Research Institute of Oncology
Gliwice Branch
Breast Cancer Center
Wybrzeże Armii Krajowej 15
44-102 Gliwice, Poland
e-mail: michal.jarzab@gliwice.nio.gov.pl

Received: 17 Oct 2023
Accepted: 18 Oct 2023

References

1. Davis MA, Bynum JPW, Sirovich BE. Association between apple consumption and physician visits: appealing the conventional wisdom that an apple a day keeps the doctor away. JAMA Intern Med. 2015; 175(5): 777–783, doi: 10.1001/jamainternmed.2014.5466, indexed in Pubmed: 25822137.
2. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973; 32(2): 302–314, doi: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2, indexed in Pubmed: 4353012.
3. Malinowski Z, Skowrońska-Gardas A, Jodkiewicz Z, et al. Preliminary risk assessment of radiation-induced cardiac sequelae in breast cancer patients receiving adjuvant radiotherapy after breast conserving therapy. Nowotwory. 2004; 54(2): 108–113.
4. Kufel-Grabowska J, Katarzyński S, Szmit S, et al. Cardiotoxicity in patients with early breast cancer treated with adjuvant trastuzumab. Nowotwory. Journal of Oncology. 2022; 72(5): 288–293, doi: 10.5603/njo.a2022.0047.
5. Słowik A, Jagielski P, Potocki P, et al. Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study. Kardiol Pol. 2020; 78(2): 131–137, doi: 10.33963/KP.15163, indexed in Pubmed: 31995035.
6. Jagielska B, Tałasiewicz K, Czachowska A, et al. Are molecular target therapies limited by cardiotoxicity — causes and symptoms of cardiovascular damage. Nowotwory. Journal of Oncology. 2017; 67(1): 34–40, doi: 10.5603/njo.2017.0005.

VIA MEDICA

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 486

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

The diagnostic dilemma of low-grade adrenal cortical carcinoma in a young female patient

Maciej D. Bugajski, Agata Popow-Gierba, Małgorzata Wysocka-Malik

Department of Radiology and Diagnostic Imaging, Maria Sklodowska-Curie Institute of Oncology, Krakow Branch, Krakow, Poland



Figure 1. MRI, T_2-weighted image showing 11cm oval, well-circumscribed mass with high, heterogeneous signal, higher than the adjacent liver



Figure 2. Fluorine-^{18}F-FDG-PET-CT PET-CT scan indicating high FDG uptake (SUV max 9.0), more than 3 times higher than the adjacent liver

A 33-year-old woman with hypertension and oligomenorrhea for last 6 months, with an incidentally diagnosed abdominal mass on ultrasound underwent an MRI and ^{18}F-FDG PET-CT (fig. 1, 2). No abnormalities were seen on lab tests. Initial diagnoses were ganglioneuroma, adrenal cortical carcinoma (ACC) and pheochromocytoma. Ganglioneuroma was supported by age, normal/lower level of adrenal hormones, well-circumscribed margins, progressive enhancement and persistent in delayed phase (in T_1w before and after dynamic administration of gadobutrol) and no evidence of metastasis [1, 2]. ACC was supported by haemorrhage on T_1w, heterogeneous T_2w signal – higher than an adjacent liver, enhanced density of periadrenal fat [1, 2]. Pheochromocytoma was less confident due to the relatively low signal on T_2w. High FDG uptake (SUVmax 9.0) suggested a malignant character. For all diagnosis parameters like lesion size (11 cm), there was no presence of drop of signal during out-of-phase sequence, no evidence of IVC invasion and local compressive symptoms showed imaging overlap [1, 2]. DWI revealed a high signal within the lesion, with a low signal on ADC maps. However, DWI does not help a lot in malignant/benign adrenal lesion differentiation [2]. ACC is a very rare and aggressive malignancy, with annual incidence 0.5–2 cases/ million [2]. Excision is a primary treatment for stage I–III disease with adjuvant therapy due to high risk of recurrence even with complete resection [2]. In this case, PET-CT showed adrenal/liver SUV ratio >1.8, indicating the malignant character of the lesion [2]. On laparotomy low-grade ACC, Weiss score 5, Ki-67: 11% was confirmed.

References

1. Shawa H, Elsayes K, Javadi S, et al. Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clin Endocrinol. 2013; 80(3): 342–347, doi: 10.1111/cen.12320.
2. Ahmed AA, Thomas AJ, Ganeshan DM, et al. Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management. Abdom Radiol (NY). 2020; 45(4): 945–963, doi: 10.1007/s00261-019-02371-y, indexed in Pubmed: 31894378.

Jak cytować / How to cite:

Bugajski MD, Popow-Gierba A, Wysocka-Malik M. *The diagnostic dilemma of low-grade adrenal cortical carcinoma in a young female patient*. *NOWOTWORY J Oncol* 2023; 73: 404.

VIA MEDICA

Obrazy w onkologii / Pictures in oncology

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 487

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

A pregnant woman with invasive cervical carcinoma

Anna Dąbrowska[1], Adrian Perdyan[2], Bartosz K. Sobocki[1], Jacek Rutkowski[3]

[1]*Student Scientific Circle of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland*
[2]*3P-Medicine Laboratory, Medical University of Gdansk, Gdansk, Poland*
[3]*Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland*



Figure 1. MRI before (A, B) and after (C, D) neoadjuvant chemotherapy

A 34-year-old woman in the 24th week of her third pregnancy was admitted to the Department of Gynecology and Obstetrics after a few episodes of short, vaginal bleeding, beginning in the 18th week, which raised a suspicion of cervical cancer. A routine cytology was performed during the 12th week of pregnancy (the first in the past 7 years), which yielded an inconclusive result. Therefore, it was recommended to extend the diagnostics. At admission, a gynecological examination showed uterine cervix shape deformation and immobilization, with visible nodular lesion on the cervical surface, confirmed as invasive squamous-cell carcinoma. The MRI of the pelvis and abdomen showed a circular neoplasm located in the upper part of the cervical canal, with a tumor measuring 37x46x48 mm (fig. 1). On the right side, the tumor infiltrates the parametria. Pelvical and abdominal lymphadenopathy were not observed, as well as distant metastases (stage IIB according to the FIGO Classification [1]). Therefore, the patient was qualified for neoadjuvant chemotherapy. The patient received three cycles of cisplatin and paclitaxel (the first cycle in the 24th week of pregnancy) in standard doses based on body weight, taking into account the weight of the fetus. The pregnancy ended with a planned caesarean section in the 34th week. The patient gave birth to a daughter (Apgar score of 9) with no complications during delivery and confinement. The post-chemotherapy MRI revealed a partial regression of the primary lesion to 25x14x14 mm. During confinement, the patient received teleradiotherapy for the pelvic region (45 Gy/25 fractions) with concomitant weekly cisplatin chemotherapy (40 mg/m^2) and a high dose rate (HDR) brachytherapy (28.5 Gy/4 fractions) (Ir 192, 3D planning). Complete remission in clinical and radiological control was observed 3 months after treatment completion. After 48 months, the patient's condition remains excellent, with no signs of relapse.

References

1. Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018; 143 Suppl 2(Suppl 1): 22–36, doi: 10.1002/ijgo.12611, indexed in Pubmed: 30306584.

Jak cytować / How to cite:
Dąbrowska A, Perdyan A, Sobocki BK, Rutkowski J. ***A pregnant woman with invasive cervical carcinoma.*** *NOWOTWORY J Oncol* 2023; 73: 405.

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 488–490

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

VIA MEDICA

Varia

Historia onkologii / History of oncology

Początki leczenia oszczędzającego w raku piersi w Polsce

Arkadiusz Jeziorski

Oddział Chirurgii Ogólnej z Poddodziałem Chirurgii Onkologicznej, Szpital Wojewódzki w Sieradzu, Sieradz

W chirurgicznym leczeniu kobiet chorych na raka piersi przez wiele lat standardem postępowania były operacje radykalne, technikami zaproponowanymi przez Williama S. Halsteda czy Davida H. Pateya. Zainteresowanie metodami oszczędzającymi pierś zawdzięczamy chirurgom prowadzącym swoje programy badawcze w latach sześćdziesiątych i siedemdziesiątych ubiegłego stulecia. Wśród nich należy wymienić nazwiska sir Hedleya J.B. Atkinsa, Johna L. Haywarda, Umberto Veronesiego czy Bernarda Fishera. A jaka była droga leczenia oszczędzającego w onkologii polskiej?

Początki leczenia oszczędzającego w Polsce związane są z nazwiskiem prof. Jana Bernera, Kierownika Kliniki Chirurgii Onkologicznej Akademii Medycznej w Łodzi. Profesor Berner, chcąc wprowadzić nowe techniki operacyjne u pacjentów onkologicznych, udał się w 1980 roku na staż do Instytutu Onkologii w Mediolanie. W czasie wizyty u profesora Umberto Veronesiego poznał technikę chirurgiczną i sposób napromieniania chorych na raka piersi leczonych metodą oszczędzającą. Zapoznał się z wynikami dopiero co zakończonego programu Milan I. W tamtych czasach w Polsce standardem postępowania chirurgicznego w raku piersi była amputacja z elektywną limfadenektomią pachową. Profesor Berner po powrocie do Polski skontaktował się z prof. Tadeuszem Koszarowskim, opisał metodę leczenia oszczędzającego i zaproponował stosowanie jej w onkologii polskiej. Po dyskusji z prof. Koszarowskim uzyskał akceptację dla tego projektu. Następnie omówił założenia programu z dr. Eugeniuszem Studenckim, radioterapeutą, szefem Zakładu Radioterapii w ośrodku onkologii w Łodzi, oraz z prof. Leszkiem Woźniakiem, patomorfologiem, ówczesnym szefem Katedry Onkologii Akademii Medycznej w Łodzi.

Założenia zaproponowanego programu były podobne jak w programie Milan I, w którym podstawą kwalifikacji był guz piersi nieprzekraczający 2 cm w swym największym wymiarze. W polskiej rzeczywistości początków lat osiemdziesiątych dominowały stany o większym niż T1 miejscowym zaawansowaniu. Toteż pierwsza pacjentka do łódzkiego programu leczenia oszczędzającego została zakwalifikowana dopiero w marcu 1981 roku. W oparciu o pozytywny wynik biopsji cienkoigłowej 21 marca wykonano kwadrantektomię, a po potwierdzeniu raka piersi w badaniu patomorfologicznym, 2 kwietnia wykonano elektywną limfadenektomię pachową.

Kiedy prof. Berner zaprosił mnie do współpracy, byłem jego asystentem. Profesor kwalifikował pacjentki do leczenia oszczędzającego. Natomiast do moich obowiązków należało przygotowanie pacjentek do procedury leczenia oszczędzającego, przede wszystkim staranne poinformowanie ich o metodzie, możliwych powikłaniach i efektach ubocznych oraz uzyskanie zgody na ten sposób leczenia. Wprowadzałem dane osobowe pacjentek do bazy danych, którą prowadziłem, wyznaczałem terminy badań kontrolnych i prowadziłem *follow-up*. Mieliśmy trochę szczęścia, ponieważ początki kwalifikacji chorych do leczenia oszczędzającego przypadały na okres, w którym w szpitalu otwarto nowoczesną pracownię diagnostyczną z pierwszym w Łodzi aparatem do mammografii. Również badania kontrolne można było prowadzić w oparciu o zdjęcia mammograficzne. W 1985 roku szpital kupił pierwszy aparat do ultrasonografii, co sprawiło, że pracownię diagnostyki piersi

Jak cytować / How to cite:
Jeziorski A. ***Początki leczenia oszczędzającego w raku piersi w Polsce.*** *Biuletyn PTO NOWOTWORY J Oncol* 2023; 73: 488–490.

można było uznać za kompletną i przygotowaną do badania pacjentek.

Ścisłe zasady kwalifikacji sprawiły, że liczba naszych chorych kwalifikowanych do leczenia oszczędzającego była niewielka, a odsetek leczonych tą metodą niski. Do 1986 roku w naszej bazie mieliśmy dane 50 leczonych kobiet, co stanowiło około 3% chorych leczonych na oddziale z powodu raka piersi. Nie obserwowaliśmy nawrotów miejscowych, przerzutów odległych i innych powikłań, a dobre efekty kosmetyczne uzyskaliśmy u 70% chorych. Z takim materiałem wystąpiliśmy po raz pierwszy na forum ogólnopolskim, w czasie 16. Zjazdu Naukowego PTO, 15–16 listopada 1986 roku, prezentując pracę zatytułowaną: „Wyniki oszczędzającego leczenia chorych z rakiem sutka T1N0". Wykonałem plakat na tę konferencję, a pracę w czasie sesji plakatowej prezentował prof. Berner. Nowatorska w polskiej onkologii metoda leczenia oraz zaprezentowane wyniki przyjęto bardzo chłodno, a niemrawa dyskusja ocierała się nawet o sugestie popełnienia błędu w sztuce. Profesor Berner w swojej autobiograficznej książce, wspominając ten moment, napisał tak: „(…) Po ogłoszeniu wyników końcowych, mówiących o skuteczności metody oszczędzającej nastąpiła cisza, a nieliczne głosy w dyskusji, zwłaszcza przedstawicieli Instytutu Onkologii w Warszawie, świadczyły o zdaniu odrębnym i powątpiewaniu co do słuszności przyjętych przeze mnie sposobów postępowania" [1].

Po tej pierwszej konferencji rozpoczęliśmy starania, aby metodę leczenia oszczędzającego przedstawić na forum polskiej onkologii. Przyjmowaliśmy zaproszenia na każdą konferencję o tematyce raka piersi i propagowaliśmy ideę leczenia oszczędzającego według ustalonego schematu: ja wygłaszałem referat i prezentowałem najnowsze nasze dane, a profesor Berner brał udział w dyskusji, przyjmując na siebie ciężar wszelkich zdań odrębnych. W roku 1987, po kolejnym spotkaniu naukowym, w czasie którego metoda oszczędzająca nie uzyskała powszechnej akceptacji, prof. Berner zaproponował mi, abym przygotował pracę doktorską na temat tej metody. Wobec powszechnej niechęci do tego sposobu leczenia uznałem, że to zadanie jest wielkim wyzwaniem. Odniosłem wrażenie, że prof. Berner tę moją pracę doktorską potraktował jako priorytetową w dążeniu do uznania metody oszczędzającej w onkologii polskiej. Doktorat napisałem i obroniłem w 1988 roku [2]. Jest wiele anegdot z nią związanych, z których warto przytoczyć jedną. Recenzentów wybierała Rada Wydziału Lekarskiego Akademii Medycznej w Łodzi. W czasie obrad ktoś zaproponował, że z uwagi na pionierski oraz budzący kontrowersje temat na recenzenta należy powołać przedstawiciela Instytutu Onkologii w Warszawie. Wtedy Profesor Berner poprowadził dyskusję w taki sposób, że spośród kilku propozycji Rada Wydziału jako recenzentów wybrała: prof. Annę Płużańską, konsultanta regionalnego w dziedzinie chemioterapii dla województwa łódzkiego, doc. Lucjana Kurylcio, specjalistę chirurga onkologa z Lublina i prof. Stanisława Barcikowskiego, specjalistę chirurgii z Wojskowej Akademii Medycznej w Łodzi.

Gdy obroniłem pracę doktorską, prof. Berner powiedział: „Kolego, na podstawie doktoratu proszę teraz napisać artykuł do *Nowotworów*". *Nowotwory* były w owym czasie jedynym pismem w polskiej onkologii, a opublikowanie w nim artykułu było świadectwem znaczenia poruszanego tematu i wielką nobilitacją dla autora. Artykuł napisałem i w 1989 roku wysłałem do redakcji. Niestety, nie został przyjęty do druku. Recenzent napisał, m.in.: „Artykuł (…) nie kwalifikuje się do druku z powodu niskiej wartości merytorycznej oraz niewielkiego znaczenia praktycznego metodyki w nim opisanej". Wobec tego fragment pracy doktorskiej opublikowałem w lokalnym piśmie łódzkiej Akademii Medycznej [3].

Nadszedł rok 1991. Wraz z profesorem Bernerem przygotowywaliśmy się do Sympozjum PTO *Rak sutka – nowe koncepcje, kontrowersje*, które odbywało się w Krakowie 25–26 kwietnia. Było to sympozjum ogólnopolskie i zdawaliśmy sobie sprawę ze znaczenia naszego w nim udziału. Profesor Berner w swojej książce tak opisuje tamto wydarzenie: „Pojechaliśmy do Krakowa z trzema referatami o leczeniu oszczędzającym. Przewodniczyłem sesji razem z profesorem Andrzejem Kułakowskim, a kolega Jeziorski miał wygłosić referat główny. Byliśmy gotowi stoczyć kolejną batalię o uznanie metody oszczędzającej. Tymczasem w czasie konferencji, tuż przed naszym referatem profesor Kułakowski powiedział: *Nadszedł w Polsce czas, aby zaakceptować metodę oszczędzającą leczenia chorych na raka piersi jako metodę dającą takie same wyniki jak amputacja.* To był przełom w polskiej chirurgii onkologicznej – przełom w polskiej medycynie. Sukces po 10 latach!" [1]. Referat, który wygłosiłem spotkał się już z pełną akceptacją [4]. Pytań nie było, a komentarze, jakie usłyszeliśmy, były wyłącznie życzliwe. Był to ważny referat, ponieważ po raz pierwszy w Polsce podjęliśmy temat kwalifikacji do leczenia oszczędzającego, czyli wskazań i przeciwwskazań, przedstawiając nasze propozycje. Omówiliśmy optymalny zakres resekcji piersi oraz zakres postępowania z węzłami chłonnymi pachowymi. Określiliśmy udział radioterapii w leczeniu oszczędzającym. Podjęliśmy także trudny temat niepowodzeń, zwłaszcza przyczyn niedoskonałości efektu kosmetycznego, po leczeniu oszczędzającym. Zwróciliśmy uwagę na lepszy stan psychiczny kobiet leczonych tą metodą. Referat, który wygłosiłem [5], podobał się tak bardzo, że redakcja *Nowotworów* zaprosiła mnie, abym te obserwacje opublikował w formie artykułu w pełnym brzmieniu [6]. Ale wcześniej w *Nowotworach* ukazała się nasza główna praca, poprawiona i zaktualizowana, do której komentarz napisał prof. Andrzej Kułakowski [7]. Następna większa publikacja naszego materiału w polskim piśmiennictwie recenzowanym dotyczyła obserwacji piętnastoletnich [8], a pozytywne komentarze do niej napisali doc. Janusz Jaśkiewicz i prof. Lucjan Kurylcio. W tym samym roku ukazała się też praca poglądowa [9]. Nasz materiał i wyniki prezentowaliśmy także na konferencjach zagranicznych [10–12], co w latach osiemdziesiątych ubiegłego stulecia nie było takie proste.

Rycina 1. Jan Berner i Arkadiusz Jeziorski w roku 2010
Zdjęcie: archiwum prywatne

Takie oto były niełatwe początki „przedzierania się" leczenia oszczędzającego przez meandry medycyny polskiej. Ale zdarzały się też sytuacje zabawne. Wysłaliśmy pracę do *Polskiego Tygodnika Lekarskiego*, który w trakcie oczekiwania na jej publikację zmienił nazwę i stał się *Polskim Merkuriuszem Lekarskim*. Praca nosiła tytuł: *100 kwadrantektomii – doświadczenia własne*. Rada naukowa pisma uznała jednak, że sto jest liczbą zbyt małą i samowolnie zmieniła tytuł pracy na „1000 kwadrantektomii – doświadczenia własne", w tekście artykułu zamieniła „sto" na „tysiąc", a w streszczeniu angielskim „one hundred" na „one thousand" [13].

Kiedy prof. Jan Berner przeszedł na emeryturę, w klinice, którą po nim objąłem, nadal miał swój gabinet. Często do niego przychodził. Zawsze wtedy wpadał do mnie na herbatkę (ryc. 1). Delektując się jej aromatem często rozmawialiśmy o naszej współpracy w przeszłości, określając ją mianem dobrego okresu w naszej karierze zawodowej. Podziwiam dokonania Profesora Bernera w tej dziedzinie i bez wątpienia uważam, że należy mu się honorowy tytuł pioniera leczenia oszczędzającego w Polsce [14].

Konflikt interesów: nie zgłoszono

Arkadiusz Jeziorski
Szpital Wojewódzki w Sieradzu
Oddział Chirurgii Ogólnej z Poddodziałem Chirurgii Onkologicznej
ul. Armii Krajowej 7
98-200 Sieradz
e-mail: ajeziorski19@gmail.com

Zgłoszono: 15 września 2023
Zaakceptowano: 26 września 2023

Piśmiennictwo

1. Berner J. Chirurgiczna pasja 1955-2015. 60 lat fascynacji chirurgią na przełomie XX i XXI wieku. Forum Bibl Med. 2015; 8(1).
2. Jeziorski A. Leczenie oszczędzające u chorych na raka sutka we wczesnym stopniu zaawansowania. Praca doktorska. AM w Łodzi 1988.
3. Jeziorski A. Conservative treatment in patients with early breast cancer. Annales Academiae Medicae Lodzensis. 1989; XXX: 75–88.
4. Berner J, Jeziorski A. Leczenie oszczędzające we wczesnym raku sutka. Sympozjum PTO „Rak piersi – nowe koncepcje, kontrowersje, Kraków 1991, 30.IV.2.
5. Jeziorski A, Berner J. Psychologiczne aspekty leczenia oszczędzającego chorych na raka sutka. Sympozjum PTO „Rak piersi – nowe koncepcje, kontrowersje, Kraków 1991, 41.A.7.
6. Jeziorski A. Psychologiczne aspekty leczenia oszczędzającego chorych na raka sutka. Nowotwory. 1994; 44(supl II): 74–78.
7. Jeziorski A, Berner J. Wyniki leczenia oszczędzającego u chorych na raka sutka we wczesnym stopniu zaawansowania. Nowotwory. 1993; 43: 11–19.
8. Jeziorski A, Berner J, Wrężel B. Wyniki odległe leczenia oszczędzającego chorych na raka sutka. Pol Przeg Chir. 1997; 69: 469–482.
9. Berner J, Jeziorski A. Leczenie oszczędzające we wczesnym raku sutka. Pol Przeg Chir. 1997; 69(9): 985–988.
10. Berner J, Jeziorski A. Conservative treatment in Early Brest Cancer. 4-th EORTC Breast Cancer Conference. Abstract Book, London 1987: C-21.
11. Berner J, Jeziorski A. Psychological and social advantages of limited surgery in Early Breast Cancer. J Cancer Res and Clin Oncol. 1990: 116, A.138.43.
12. Jeziorski A, Berner J.: The role of Brest conserving therapy in Early Breast cancer: long term results and estimation of cosmetics effect after 16 years of the Trial. 6th Hellenic Congress on Senology 12-16 June 1997 June 1997, P14.
13. Jeziorski A, Berner J. 1000 kwadrantektomii – doświadczenia własne. Pol Merk Lek. 1996; 4: 229–231.
14. Kułakowski A, Jeziorski A. Profesor Jan Berner (1932–2020). Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory. 2020; 5(3): 159–160.

VIA MEDICA

Varia

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 491–492

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

Sprawozdanie z *XIII Krakowskiej Konferencji Onkologicznej* Krakowskiego Komitetu Zwalczania Raka

Kraków, 6–7 października 2023

W dniach 6–7 października 2023 r. odbyła się *XIII Krakowska Konferencja Onkologiczna* zorganizowana przez stowarzyszenie Krakowski Komitet Zwalczania Raka. W spotkaniu w formie hybrydowej wzięło udział blisko trzystu uczestników. Tematyka wykładów wygłoszonych w trakcie ośmiu sesji naukowych obejmowała szeroki wachlarz informacji dotyczących najnowszych osiągnięć w onkologii na świecie – ze szczególnym uwzględnieniem możliwości ich wykorzystania w naszym kraju.

W drugim dniu obrad we współpracy z Krakowskim Oddziałem Polskiego Towarzystwa Badań Radiacyjnych przeprowadzono Konkurs Młodych Naukowców. Spośród zgłoszonych prac Komisja Konkursowa (w składzie: piszący – przewodniczący, prof. Beata Sas-Korczyńska – zastępca przewodniczącego, dr Aleksandra Grela-Wojewoda, prof. Renata Kopeć, dr hab. Justyna Miszczyk, dr hab. Jerzy Mituś) zakwalifikowała do prezentacji ustnej sześć doniesień. Uczestników podzielono na dwie grupy: naukowców przed uzyskaniem stopnia doktora oraz studentów.

Za najlepszą prezentację w grupie pierwszej uznano wystąpienie lek. med. Krzysztofa Wójcickiego z Zakładu Radioterapii NIO-PIB Oddziału w Krakowie – *Wpływ infekcji HPV16 w nowotworach narządów głowy i szyi na ekspresję białka PD-L1 i jego prognostyczne znaczenie*. W grupie drugiej zwyciężył Mateusz Iwański ze Studenckiego Koła Kardioonkologii, Uniwersytetu Rzeszowskiego, który zaprezentował pracę *Analiza częstości występowania hipotonii ortostatycznej u pacjentów z nowotworami*. Ponadto jury wyróżniło pracę *Charakterystyka LET pojedynczych protonów z wykorzystaniem detektora Timepix dla zastosowań w radioterapii protonowej*, którą przedstawiła Paulina Stasica z Centrum Cyklotronowego Bronowice, Instytutu Fizyki Jądrowej im. Henryka Niewodniczańskiego Polskiej Akademii Nauk w Krakowie. W opinii oceniających i słuchaczy poziom konkursu był wysoki. Uczestnicy otrzymali dyplomy i nagrody książkowe, laureatów ponadto uhonorowano nagrodami pieniężnymi ufundowanymi przez KKZR oraz PTBR Oddział w Krakowie. Poniżej prezentujemy streszczenia zwycięskich prac.

prof. Kazimierz Karolewski,
przewodniczący jury Konkursu Młodych Naukowców

Wpływ infekcji HPV16 w nowotworach narządów głowy i szyi na ekspresję białka PD-L1 i jego prognostyczne znaczenie

Krzysztof Wójcicki, Anna Mucha-Malecka, Beata Biesaga

Wstęp. Od kiedy ponad 30 lat temu po raz pierwszy opisano wpływ zakażenia wirusem brodawczaka ludzkiego (*human papilloma virus* – HPV) na powstawanie nowotworów regionu głowy i szyi (*head and neck squamous cell carcinoma* – HNSCC), przeprowadzono liczne badania, w których wykazano, że w przypadku zakażeniaHPV chorzy na nowotwory zlokalizowane w obrębie jamy ustnej i ustnej części gardła mają lepsze rokowanie niż chorzy bez infekcji. Grupa chorych na tego typu nowotwory nie jest jednak jednorodna pod względem rokowania, ponieważ u ok. 40% pacjentów obserwuje się progresję nowotworu. Wskazuje to na pilną potrzebę poszukiwania nowych czynników prognostycznych różnicujących rokowanie w obrębie chorych na HNSCC z infekcją HPV. Celem badania jest ocena wpływu infekcji HPV16 w nowotworach narządów głowy i szyi na ekspresję białka PD-L1 oraz jego prognostyczne znaczenie.

Materiał i metody. Badanie przeprowadzono w grupie 155 chorych na HNSCC, u których we wcześniejszych naszych analizach oceniono aktywną transkrypcyjnie infekcję HPV16 [1]. Ekspresję PD-L1 oceniono w oparciu o utrwalone w formalinie i zatopione w parafinie skrawki parafinowe – metodą immunohistochemiczną.

Wyniki. Nasze wcześniejsze badania wykazały w grupie 155 chorych na HNSCC występowanie aktywnie transkrypcyjnej infekcji HPV 16 w 28 guzach (18,1%). Wyniki analizy statystycznej

Rycina 1. Laureaci i jury Konkursu Młodych Naukowców. Od lewej stoją: Justyna Miszczyk (jury), Kamil Wawrowicz (Uniwersytet Jagielloński), Monika Ruszała (Uniwersytet Medyczny w Lublinie), Marta Mękarska (Uniwersytet Medyczny w Warszawie), Mateusz Iwański (Uniwersytet Rzeszowski), Paulina Stasica (Instytut Fizyki Jądrowej PAN w Krakowie), Krzysztof Wójcicki (Narodowy Instytut Onkologii w Krakowie), Aleksandra Grela-Wojewoda (jury), Renata Kopeć (jury), Beata Sas-Korczyńska (jury), Kazimierz Karolewski (przewodniczący jury), Jerzy Mituś (jury)

dotyczącej wpływu infekcji HPV16 w nowotworach narządów głowy i szyi na ekspresję białka PD-L1 i jego prognostyczne znaczenie zostały zaprezentowane na konferencji.

Wnioski. Uzyskane wyniki dotyczące wpływu infekcji HPV16 w nowotworach narządów głowy i szyi na ekspresję białka PD-L1 i jego prognostyczne znaczenie mogą przyczynić się do usprawnienia molekularnej diagnostyki chorych na HNSCC, poprawy wyników ich leczenia i obniżenia kosztów terapii.

Analiza częstości występowania hipotonii ortostatycznej u pacjentów z nowotworami

Mateusz Iwański, Aldona Sokołowska, Roman Wojdyła, Katarzyna Stryczkiewicz

Wstęp. Hipotonia ortostatyczna (OH) jest następstwem dysfunkcji autonomicznego układu sercowo-naczyniowego. Do tej pory za istotny czynnik ryzyka występowania OH uważano podeszły wiek. U osób starszych OH ma istotne znaczenie kliniczne, zwiększając ryzyko upadków, chorób układu krążenia i powiązaną z nimi śmiertelność. Niewiele wiadomo na temat częstości występowania OH u pacjentów z nowotworami, mimo że często są to osoby starsze i – z uwagi na stosowane leczenie onkologiczne i sam nowotwór – szczególnie podatne na zaburzenia regulacji ciśnienia krwi (*blood pressure* – BP). Celem badania było porównanie częstości występowania OH u pacjentów z aktywną chorobą nowotworową w porównaniu z pacjentami bez nowotworu.

Materiał i metody. Do badania włączono 410 pacjentów (232 kobiety, 178 mężczyzn, wiek60 ± 14 lat). Grupę I (n = 204) stanowili chorzy z aktywnie leczonym nowotworem (chemioterapia, radioterapia), grupę II (n = 206) chorzy bez rozpoznania nowotworu. Analizie poddano dane demograficzne, historię choroby, a także przeprowadzone pomiary BP w pozycji leżącej i stojącej według obowiązujących standardów. OH definiowano jako spadek BP w pozycji stojącej o ≥20 mmHg wprzypadku BP skurczowego lub ≥10 mmHg w przypadku BP rozkurczowego w ciągu 1 lub 3 minuty pionizacji; lub zmniejszenie BP skurczowego krwi <90 mmHg.

Wyniki. Wyjściowo BP skurczowe w pozycji leżącej wynosiło w grupie I – 128 ± 18 mmHg *vs.* w grupie II – 126 ± 16 mmHg (p-NS), a BP rozkurczowe w grupie I – 74 ± 9 mmHg *vs.* 75 ± 10 mmHg w grupie II (p-NS). OH występowała częściej u pacjentów chorych na nowotwór w porównaniu z populacją nienowotworową (48 *vs.* 30 przypadków, p < 0,01). Obserwowano korelację między rodzajem nowotworu a częstością występowania OH (OH występowała najczęściej u chorych na raka płuca), a także zwiększoną częstość OH u pacjentów ≥65. roku życia, chorych na cukrzycę i nadciśnienie tętnicze.

Wnioski. Pacjenci onkologiczni, a zwłaszcza chorzy na raka płuca, charakteryzują się większą częstością występowania OH w porównaniu do populacji bez nowotworu. Wprowadzenie rutynowego skryningu pod kątem występowania OH, oprócz tradycyjnych pomiarów BP, u pacjentów leczonych z powodu choroby nowotworowej mogłoby zwiększyć bezpieczeństwo leczenia oraz poprawić opiekę w tej grupie.

VIA MEDICA

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 493

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

Prof. Sylwia Grodecka-Gazdecka: *Nowotwory otwierały nam oczy na świat onkologii*

Moje pierwsze kontakty z *Nowotworami* są równoległe z początkiem pracy zawodowej. W latach 70. byłam świeżo po studiach i zaczynałam specjalizację z zakresu chirurgii. Pracowałam wówczas w dopiero co organizującym się Ośrodku Onkologii w Poznaniu, z którego potem ewoluowała Klinika Onkologii Uniwersytetu Medycznego. Była to pierwsza akademicka instytucja o profilu onkologicznym w Poznaniu. Wszyscy, którzy tam pracowaliśmy, byliśmy pełni entuzjazmu i bardzo interesowała nas onkologia. Wtedy – nawet w środowisku medycznym – ciążyło nad nią odium pewnej beznadziejności i dramatyzmu, które wiązały się ze złymi wynikami leczenia chorób nowotworowych. Onkologia była dziedziną medycyny, która dopiero torowała sobie drogę w świadomości lekarzy. I w tamtym czasie *Nowotwory* były jednym z najważniejszych, jeśli nie jedynym, źródłem naszej wiedzy. Bardzo nas pasjonowało to, co tam czytaliśmy, z nich uczyliśmy się, jak leczyć bardziej skutecznie. Potem mogliśmy się tą wiedzą dzielić.

Natomiast moje związki z tym czasopismem, jako autorki artykułów, są dość luźne. Dopiero w 1987 roku ukazała się praca, której byłam współautorką [1]. Wartość danego pisma naukowego określają artykuły oryginalne, jednak cieszyły mnie także inne publikacje. Byłam sekretarzem podczas XVII Zjazdu PTO, który odbył się w Poznaniu. Przygotowywaliśmy streszczenia do suplementu na ten zjazd i byliśmy dumni, że z naszego ośrodka było ich aż 9. W *Nowotworach* ukazało się także streszczenie mojej pracy habilitacyjnej [2]. Wspominam też artykuł, który napisałam na 25-lecie naszej Kliniki Onkologii. Jednak najbardziej tkwią mi w pamięci publikacje związane z *Debatami onkologicznymi*, które zainicjował prof. Jacek Jassem. Dziś cieszy mnie to, gdy w *Nowotworach* widzę publikacje moich doktorantów. Bardzo cenię to, że w czasopiśmie ukazują się różne polskie i międzynarodowe rekomendacje oraz zalecenia dotyczące leczenia nowotworów czy nawet żywienia klinicznego. Pozwala to szybko pewne rzeczy zobaczyć i przeanalizować, daje szeroką i bezcenną perspektywę. Doceniam, że redakcja postanowiła dokształcić potencjalnych autorów także w innych dziedzinach – prawa autorskiego czy prostego języka w pracach naukowych.

Z przyjemnością obserwowałam, jak pismo się rozwija. Gdy byłam w zarządzie PTO, prezesem był prof. Jassem i on bardzo dbał o to, by *Nowotwory* były coraz lepsze, bardziej nowoczesne. Zresztą mają też szczęście do charyzmatycznych redaktorów naczelnych – taki był prof. Edward Towpik, taki jest prof. Wojciech Wysocki. Czasopismo wciąż ewoluuje, trzyma wysoki poziom. Mam ambiwalentne odczucia dotyczące pogoni za punktami, wskaźnikiem cytowań. Wydaje mi się, że gdzieś się w tym pogubiliśmy jako środowisko naukowe, że trochę tracimy z oczu istotę naszej pracy. Dlatego życzę *Nowotworom*, aby dalej rozwijały się tak, jak do tej pory. Żeby miały jeszcze więcej artykułów oryginalnych na wysokim poziomie i nie zapominały także o innych treściach, które też są ważne dla onkologów. I tylko czasem żal, że nie mają szerokiego zasięgu międzynarodowego.

References

1. Chwalisz K, Grodecka-Gazdecka S, Baron J. Zmiany stężeń globuliny wiążacej steroidy płciowe (SHBG), estradiolu i testosteronu w surowicy kobiet chorych na raka sutka w przebiegu różnych rodzajów hormonoterapii. Nowotwory. 1987; 37(1): 16–24.
2. Grodecka-Gazdecka S. Wartość rokownicza wybranych czynników patoklinicznych i markerów immunohistochemicznych w raku gruczołu piersiowego bez przerzutów do węzłów chłonnych. Nowotwory. 1998; 48(2): 231–267.

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 494

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

Prof. Stanisław Góźdź: *Nowotwory były dla nas – młodych onkologów – źródłem praktycznej wiedzy*

Kiedy w latach 70. zaczynałem pracę jako onkolog, dostęp do aktualnej wiedzy był znacznie utrudniony. Nie każdy mógł pojechać do biblioteki medycznej, by przeczytać jakieś zagraniczne pismo naukowe, nie wszyscy przecież pracowali też w Instytucie Onkologii, który miał własną bibliotekę. Poza tym to także wysiłek czasowy i finansowy. Dlatego jeśli ktoś chciał przeczytać zagraniczny artykuł, szukał streszczenia w Index Medicus, a potem pisał do autora publikacji prośbę o przesłanie kopii autorskiej. Sam tak robiłem. Do dziś mam w swojej bibliotece egzemplarze z krótkimi notatkami od autorów. Zresztą taki kontakt bezpośredni był bardzo cenny. Zresztą dziś dalej tak jest, mamy ten kontakt – wszyscy piszemy do siebie maile.

Kilkadziesiąt lat temu z pomocą przychodziły nam *Nowotwory* – pamiętam, gdy były jeszcze takimi zgrzebnymi zielonymi zeszytami. Były powszechnie dostępne w klinikach onkologicznych. Artykuły, które tam publikowano, były tak przygotowywane, aby miały jak największą wartość kliniczną. Były dla nas – zwłaszcza młodych onkologów – źródłem praktycznej wiedzy, pomagały nam w rozwoju zawodowym. Kiedy przygotowywałem się do swojej specjalizacji, korzystałem właśnie także z publikacji, które czytałem w *Nowotworach*. Zakreślałem nawet niektóre fragmenty. Z niecierpliwością zawsze czekałem na kolejny zeszyt.

Dziś jest inaczej. Wszystko przeniosło się do internetu. Mówię nawet, że lekarze w moim centrum mają całą bibliotekę dostępną w swoich telefonach – zresztą to mój obowiązek jako dyrektora, żeby tak było. *Nowotwory* także są wydawane w formie elektronicznej. Jest w nich coraz więcej ciekawych artykułów, wychodzą w języku angielskim, dzięki temu mają większy zasięg. I mają się czym chwalić – niewiele jest na świecie pism onkologicznych, które mają 100 lat. W dodatku *Nowotwory* towarzyszą rozwojowi całej polskiej onkologii, w której obecnie coraz więcej nowych technologii. Dlatego także im życzę, by tak prężnie rozwijały się dalej.

Z kalendarium Zarządu PTO

październik–grudzień 2023 r.

Profesor Andrés Cervantes, Prezydent European Society for Medical Oncology (ESMO), wystąpi podczas Ceremonii Otwarcia VI Kongresu Onkologii Polskiej, który odbędzie się w dniach 17–19.10.2024 r.

Więcej informacji: http://www.kongres.pto.med.pl.

Komunikaty PTO

- 10 października 2023 r. odbyło się posiedzenie Zarządu Głównego Polskiego Towarzystwa Onkologicznego, podczas którego omówiono sprawy organizacyjne związane z VI Kongresem Onkologii Polskiej oraz inne sprawy bieżące.
- 9 listopada 2023 r. podczas spotkania Komitetu Naukowego VI Kongresu Onkologii Polskiej omówiono projekt programu naukowego Kongresu.
- 14 listopada 2023 r. odbyło się kolejne spotkanie Sekcji Standaryzacji Nadzoru po Leczeniu Onkologicznym, której przewodniczy dr n. med. Marcin Ziętek.
- PTO rozstrzygnęło konkurs dla onkologów poniżej 35 roku na stypendium zjazdowe na Kongres ESMO, który odbył się w dniach 20–24 października 2023 r. Komisja konkursowa wyłoniła dwóch laureatów, którzy otrzymali stypendia w wysokości 9 tys. zł.
- PTO ogłosiło drugą edycję grantu edukacyjno-naukowego realizowanego we współpracy z firmą Servier Polska pod auspicjami Warsaw Health Innovation Hub. Grant w wysokości 175 tys. zł zostanie przeznaczony na projekty, których celem będzie rozwój i poprawa wyników diagnostyki i leczenia chorych z nowotworami układu pokarmowego. Więcej informacji na www.pto.med.pl.

Wywiady i artykuły prasowe

Prof. Piotr Rutkowski znalazł się w międzynarodowych zestawieniach naukowców z całego świata: rankingu Top Medicine Scientists

Druga edycja rankingu Research.com, obejmującego najlepszych naukowców w dziedzinie medycyny, opiera się na danych pochodzących z szerokiej gamy źródeł, w tym OpenAlex i CrossRef. Dane bibliometryczne do opracowania wskaźników opartych na cytowaniach zebrano 21.12.2022 r. Pozycja w rankingu opiera się na indeksie D badacza (Discipline H-index), który obejmuje wyłącznie publikacje i wartości cytowań dla badanej dyscypliny.

Źródło: www.rynekzdrowia.pl

Palenie papierosów, alkohol i niezdrowia dieta – główni winowajcy raka żołądka, wątroby i trzustki

Nowotwory górnego odcinka układu pokarmowego stanowią nadal duże wyzwanie zarówno w profilaktyce, diagnostyce jak i leczeniu. Co roku odnotowujemy ok. 10 tysięcy zachorowań łącznie na raka żołądka, wątroby i trzustki. Objawy tych nowotworów są często niespecyficzne lub skąpe, nie wprowadzono do tej pory dedykowanych programów przesiewowych, leczenie bywa rozproszone, a rokowania pacjentów są złe, zwłaszcza w przypadku raka trzustki i dróg żółciowych – podkreślali eksperci podczas kolejnej debaty Polskiego Towarzystwa Onkologicznego z cyklu *Onkologia – Wspólna Sprawa*.

Co można zatem zrobić, aby oprawić los pacjentów? – Kluczowe jest przestrzeganie przez specjalistów medycznych wytycznych diagnostyczno-terapeutycznych, stosowanie w praktyce klinicznej nowych terapii, koncentracja leczenia lokoregionalnego w ośrodkach, które mają doświadczenie w leczeniu tych nowotworów (ośrodki referencyjne) oraz udrożnienie ścieżki pacjenta w ramach Krajowej Sieci Onkologicznej – podkreślił prof. Piotr Rutkowski, przewodniczący PTO. – Ogromną rolę odgrywa kompleksowa, wielodyscyplinarna opieka nad pacjentem.

Źródło: www.medicalpress.pl

DCOPiH opracuje innowacyjny program skryningowy w kierunku raka prostaty

W ramach innowacyjnego projektu o nazwie PRAISE-U, 25 organizacji z 12 krajów wspólnoty, w tym DCOPiH, przy współpracy z Państwowym Zakładem Higieny, podjęło się opracowania rekomendacji dotyczących skryningu i wczesnego wykrywania raka prostaty. Wrocławski ośrodek, ma za

zadanie opracować nowy algorytm wczesnego wykrywania raka prostaty w badaniach przesiewowych dla Polski i innych krajów wspólnoty, by zmniejszyć śmiertelność spowodowaną tym nowotworem. Poza Polską, która zajmuje w projekcie kluczowe miejsce, ponieważ wykona największą liczbę badań, jest także Hiszpania, Litwa i Irlandia. Mają one w sumie zrekrutować do programu 10 tys. mężczyzn. Program odbywa się pod patronatem IARC (International Agency for Research on Cancer) – agencją WHO. – Cieszę się, że istotny dla całej Europy program będzie realizowany we Wrocławiu. Program PRAISE-U wpisuje się także w cele Narodowej Strategii Onkologicznej na lata 2020–2030, która zakłada m.in. wprowadzenie nowych metod badań przesiewowych w kierunku raka prostaty. Polska, do tej pory, nie miała zorganizowanego programu badań przesiewowych w zakresie raka prostaty – wyjaśnia Adam Maciejczyk, dyrektor DCOPiH. – Projekt PRAISE-U ma za zadanie stworzenie modelowego systemu, który może być wdrożony nie tylko na poziomie krajowym, ale także w skali Unii Europejskiej. Współpraca z Ministerstwem Zdrowia ma umożliwić wdrożenie programu na szeroką skalę w Polsce. – To jest nowotwór, który pod względem chorobowości występuje najczęściej. Z roku na rok koszty jego leczenia wzrastają niewiarygodnie. Pilotaż oparty na międzynarodowych badaniach jest jak najbardziej słuszną drugą, bo dziś nie ma żadnego dobrego rozwiązania w tym zakresie. Teraz koncepcje, programu PRAJSE-U muszą być sprawdzone w praktyce. Jeśli założenia projektu się potwierdzą, w 2028 roku rozpoczną się rutynowe badania przesiewowe w kierunku tego nowotworu. W raku gruczołu krokowego należy skoncentrować się na grupach ryzyka i właściwym podejściu do istotnych przypadków klinicznych – dodaje prof. Rutkowski.

Źródło: www.dcopih.pl

Immunoterapia to przełom w leczeniu nowotworów

– Sam dostęp do terapii nie wystarcza. Aby chory mógł być zakwalifikowany do leczenia, konieczne jest przeprowadzenie szeregu badań i spełnienie ściśle określonych zapisami programu lekowego kryteriów. Zaniedbanie na początkowym etapie może przekreślić szanse chorego na wdrożenie optymalnej i dostępnej w ramach refundacji terapii, w pierwszej i kolejnych liniach leczenia. Nie każdy pacjent może i powinien otrzymać immunoterapię ze względu na rodzaj nowotworu czy ogólny stan zdrowia. Obserwujemy jednak, że w przypadku nowotworów wysoce immunogennych stosowanie immunoterapii przynosi bardzo dobre i długotrwałe efekty, często na lata. Badania kliniczne dowodzą, że często jeszcze lepsze korzyści osiągnąć można łącząc immunoterapię z lekami o różnym mechanizmie działania lub cząsteczką immunokompetentną o innym punkcie uchwytu – podkreśla prof. Piotr Rutkowski, przewodniczący Zarządu Głównego Polskiego Towarzystwa Onkologicznego.

Źródło: www.cowzdrowiu.pl

Krajowa Sieć Onkologiczna. Prof. Maciejczyk: to nie jest projekt na jedną zmianę władzy

Dr hab. Adam Maciejczyk, dyrektor Dolnośląskiego Centrum Onkologii, Pulmonologii i Hematologii we Wrocławiu, przewodniczący ministerialnego Zespołu ds. wdrożenia Krajowej Sieci Onkologicznej, mówił podczas sesji „Onkologia - organizacja leczenia" na XIX Forum Rynku Zdrowia o pracach Zespołu związanych z przygotowaniem do wprowadzenia Sieci.

– Staramy się przede wszystkim stworzyć nowy system raportowania i monitorowania przebiegu opieki onkologicznej, czyli nową kartę DiLO. Tworzymy też nowy system rozliczania, oczywiście zgodny z ustawą. Jednocześnie analizujemy możliwości i zasadność zbierania danych, które pozwolą nam wypracować wskaźniki jakościowe. Wszystko to jest oparte o analizy AOTMiT – wyjaśniał przewodniczący Zespołu. – Dyskutowaliśmy również o możliwościach wsparcia Sieci już w procesie wstępnym, ponieważ modernizując organizację opieki onkologicznej działamy na systemie, który cały czas funkcjonuje i jest w pełni aktywny. To oznacza, że podejmowane decyzje i rozpoczynane procesy nie będą łatwe. Zebraliśmy również, we współpracy z koderami, informacje dotyczące trudności z rozliczaniem świadczeń onkologicznych. Mamy też w składzie przedstawiciela e-Zdrowia – budujemy elektroniczną kartę DiLO – zaznaczył dr hab. Adam Maciejczyk. – Co rekomendowałbym przyszłemu ministrowi zdrowia? Chciałbym, aby pamiętano, że pewne elementy koordynacji i poprawy opieki onkologicznej zostały już wypracowane przez całe środowisko onkologów i bezwzględnie należy to kontynuować, bo innych rozwiązań na razie nie widzimy. Należy również dbać, aby wdrażane rozwiązania były bezpieczne. Dlatego nasz Zespół koncentruje się na tym, aby Sieć była wdrażana spokojnie, stopniowo, z wykorzystaniem tylko kilku wskaźników, aby była skupiona na najważniejszych celach systemowych, w tym np. na obserwacji efektywności i jakości konsyliów onkologicznych. To jeden z ważniejszych celów do zrealizowania – mówił dr hab. Adam Maciejczyk.

Źródło: www.rynekzdrowia.pl

Światowy Dzień Onkologii: klinicyści, pacjentka, diagnostka o chorobie

4 października obchodzimy Światowy Dzień Onkologii. Lekarze w rozmowie z nami przypominają o regularnych badaniach, ale też szybkim rozwoju medycyny, dzięki któremu część pacjentów udaje się wyleczyć, a innym znacznie wydłużyć życie. Diagnostka laboratoryjna mówi o roli tej grupy zawodowej, ale też innych w kompleksowej opiece, a przedstawicielka pacjentów chwali zmiany w dostępie do leków.

Profesor Rutkowski zwraca uwagę, że najlepiej zacząć leczenie na wstępnym etapie choroby. – Dlatego profilaktyka (…) jest tak ważna – wyjaśnia. Wspomina o badaniach kontrolnych i np. ciekawym billboardzie, który widział na lotnisku w Stanach Zjednoczonych. Informacja na plakacie dotyczyła tego, że na lotnisku spędza się średnio 2 godziny, a żeby zrobić

mammografię czy cytologię, wystarczy 5 do 10 minut. – I to jest dopiero prawda, tyle potrzebujemy i nie jest wielkim problemem zapisanie się na to badanie. Nie trzeba czekać w kolejce, wystarczy się zapisać na badanie, zrobić je i to może nam uratować życie – podkreśla prezes PTO. Onkologia potrzebuje też jego zdaniem spokojnego, stałego działania, niezależnie od polityki. Zwraca uwagę na potrzebę realizacji Narodowej Strategii Onkologicznej, która jego zdaniem jest bardzo dobrym dokumentem. – Przede wszystkim chodzi o to, żeby wszystkie punkty tej strategii były zrealizowane – wyjaśnia. Wspomina również Krajową Sieć Onkologiczną, która ma m.in. poprawić ścieżki pacjenta, umożliwić koordynację na każdym etapie i komunikowania się pomiędzy różnymi poziomami opieki onkologicznej, ale również dostęp do danych.

Dr hab. n. med. Bożena Cybulska-Stopa, prof. PWr. – w onkologii bardzo wiele się zmienia. Myślę, że wszystko idzie w bardzo dobrym kierunku. Mamy coraz więcej nowych leków dla naszych chorych, coraz więcej nowych terapii, możliwości diagnostycznych i z pewnością to jest bardzo dobra informacja. Pacjenci żyją z chorobą nowotworową nawet 100 razy dłużej niż kiedyś – mówi ekspertka. I za przykład podaje czerniaka, którym zajmuje się od wielu lat, gdzie jeszcze 20 lat temu rokowania pacjentów wynosiły 6 miesięcy życia od postawienia diagnozy, a teraz przeżycia są wieloletnie. – Jesteśmy w tej chwili w fazie ogromnych zmian organizacyjnych w naszym kraju, wprowadzana jest Krajowa Sieć Onkologiczna, która ma zmienić to, co jest największą bolączką, czyli organizację leczenia w Polsce – mówi ekspertka. Przypomina, że leczenie onkologiczne to nie jest tylko leczenie systemowe, z wykorzystaniem leków, ale też leczenie chirurgiczne i leczenie radioterapią. – Musi być ono w odpowiednich sekwencjach, musi współgrać – zaznacza. Stąd organizacja pracy jest kluczową kwestią.

Źrodło: www.cowzdrowiu.pl

Konferencje i wydarzenia z udziałem członków Zarządu Głównego PTO

- 2 października 2023 r. w Warszawie odbyła się debata *Wcześniej znaczy lepiej – dlaczego wczesne interwencje w onkologii są tak ważne dla pacjenta i dla systemu ochrony zdrowia* w ramach konferencji *Wizja Zdrowia*, podczas której eksperci omówili raport na ten temat oraz zmiany, które powinny zostać wdrożone. W dyskusji wzięła udział prof. Bożena Cybulska-Stopa.
- 5 października 2023 r. w Warszawie zorganizowano konferencję Polskiego Towarzystwa Onkologicznego pt. *Wytyczne diagnostyczno-terapeutyczne w nowotworach złośliwych*.
- W dniach 6–7 października 2023 r. miała miejsce 13. Krakowska Konferencja Onkologiczna, podczas której prof. Piotr Rutkowski wygłosił wykład o postępach w leczeniu nowotworów skóry.
- W dniach 13-14 października 2023 r. we Wrocławiu odbyła się konferencja *„Autumn Excellence Lung Cancer and Melanoma and Breast School"*.
- 14 października 2023 r. odbyła się konferencja „Toruńskie Spotkania Kardio-Onkologiczne", w których udział wzięła dr hab. Bożena Cybulska-Stopa, prof. PWr.
- W dniach 16–17 października 2023 r. w Warszawie odbyło się XIX Forum Rynku Zdrowia, w którym wziął udział prof. Adam Maciejczyk.
- 20 października 2023 r. w Narodowym Instytucie Onkologii zorganizowano spotkanie pt. *Diagnostyka molekularna pacjenta onkologicznego – rozwiązania systemowe* Odbyło się ono w ramach cyklu *O przyszłości onkologii. Forum Organizacji Pacjentów i Ekspertów*, którego inicjatorem i organizatorem jest Polskie Towarzystwo Onkologiczne. Celem inicjatywy jest wymiana wiedzy i doświadczeń oraz partnerski dialog pomiędzy ekspertami klinicznymi i przedstawicielami organizacji pacjentów.
- W dniach 22–24 października 2023 r. w Madrycie odbył się kongres ESMO (European Society For Medical Oncology), podczas którego prof. Piotr Rutkowski poprowadził sesję *Mini Oral Sarcoma*.
- W dniach 1–4 listopada 2023 r. w Dublinie zorganizowano kongres CTOS (Connective Tissue Oncology Society), podczas którego wystąpił prof. Piotr Rutkowski.
- 7 listopada 2023 r. odbyła się debata ekspercka pt. *Wyzwania w diagnostyce i leczeniu raka jelita grubego* zorganizowana w ramach cyklu debat Polskiego Towarzystwa Onkologicznego *Onkologia – Wspólna Sprawa*.
- 18 listopada 2023 r. miała miejsce konferencja Bulgarian Association of Dermatooncology. Prof. Piotr Rutkowski wygłosił wykład o nowych horyzontach w leczeniu systemowym nowotworów skóry.
- 23 listopada 2023 r. w Warszawie odbyło się spotkanie w ramach inicjatywy HPV Board. Celem było omówienie wyzwań i kolejnych kroków związanych z wyeliminowaniem wirusa HPV.
- W dniach 23–25 listopada 2023 r. w Warszawie zorganizowano XVII Konferencję Polskiej Grupy Raka Płuca, nad którą patronat objęło Polskie Towarzystwo Onkologiczne.
- 24 listopada 2023 r. odbyła się konferencja z cyklu *Warsaw Skin Cancer Conference*, której przewodniczy prof. Piotr Rutkowski.
- 28 listopada 2023 r. miała miejsce debata ekspercka pt. *Wyzwania w diagnostyce i leczeniu górnego odcinka układu pokarmowego* zorganizowana w ramach cyklu debat Polskiego Towarzystwa Onkologicznego *Onkologia – Wspólna Sprawa*.
- 1 grudnia 2023 r. w Szpitalu Specjalistycznym w Brzozowie, Podkarpackim Ośrodku Onkologicznym im. Ks. B. Markiewicza odbyła się kolejna konferencja w ramach cyklu Akademia Czerniaka 2023, której przewodniczy prof. Piotr Rutkowski.

VIA MEDICA

Journal Club

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 498–504

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

NALIRIFOX *versus* nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Wainberg Z., Melisi D., Macarulla T. i wsp.

Lancet, 2023; 402: 1272–1281

Gruczołowy przewodowy rak trzustki (*pancreatic ductal adenocarcinoma* – PDAC) jest nadal jednym z nowotworów o największej śmiertelności, a możliwości jego leczenia są ograniczone. W badaniu NAPOLI 3 porównywano skuteczność i bezpieczeństwo chemioterapii według schematu NALIRIFOX w porównaniu z zastosowaniem nab-paklitakselu z gemcytabiną w pierwszej linii leczenia chorych na rozsianego PDAC (*i wsp. Lancet, 2023; 402: 1272–1281 Gruczołowy przewodowy rak trzustki (pancreatic ductal adenocarcinoma – PDAC) jest nadal jednym z nowotworów o największej śmiertelności, a możliwości jego leczenia są ograniczone. W badaniu NAPOLI 3 porównywano skuteczność i bezpieczeństwo chemioterapii według schematu NALIRIFOX w porównaniu z zastosowaniem nab-paklitakselu z gemcytabiną w pierwszej linii leczenia chorych na rozsianego PDAC (metastatic pancreatic ductal adenocarcinoma* – mPDAC).

Metody. Otwarte badanie kliniczne III fazy NAPOLI 3 przeprowadzono w 187 ośrodkach medycznych i akademickich w 18 krajach na całym świecie (w Europie, Ameryce Północnej, Ameryce Południowej, Azji i Australii). Chorych na mPDAC, w stanie sprawności ocenionym według kryteriów Eastern Cooperative Oncology Group (ECOG) jako 0 lub 1, przydzielono losowo (w stosunku 1:1) do stosowania chemioterapii z użyciem schematu NALIRIFOX (liposomalny irynotekan 50 mg/m^2, oksaliplatyna 60 mg/m^2, leukoworyna 400 mg/m^2 i fluorouracyl 2400 mg/m^2, podawane sekwencyjnie w ciągłej infuzji dożylnej trwającej 46 godzin, w dniach 1. i 15. 28-dniowego cyklu) lub do przyjmowania nab-paklitakselu w dawce 125 mg/m^2 z gemcytabiną w dawce 1000 mg/m^2 (podawanych dożylnie, w dniach 1., 8. i 15. 28-dniowego cyklu). Podczas randomizacji chorych stratyfikowano według regionu geograficznego, stanu sprawności oraz obecności przerzutów w wątrobie. Pierwszorzędowym punktem końcowym było całkowite przeżycie w grupie zgodnej z zamiarem leczenia, ocenione po wystąpieniu co najmniej 543 zdarzeń w obu grupach. Bezpieczeństwo terapii oceniono u wszystkich chorych, którzy otrzymali przynajmniej jedną dawkę leku.

Wyniki. Od 19 lutego 2020 roku do 17 sierpnia 2021 roku 770 chorych przydzielono losowo do leczenia (chemioterapia zgodnie ze schematem NALIRIFOX u 383 chorych; nab-paklitaksel + gemcytabina u 387; mediana obserwacji wyniosła 16,1 miesiąca [IQR 13,4–019,1]). Mediana całkowitego przeżycia wyniosła 11,1 miesiąca (95% przedział ufności [*confidence interval* – CI] 10,0–12,1) w grupie otrzymujących NALIRIFOX w porównaniu z 9,2 miesiąca (8,3–10,6) w przypadku leczonych nab-paklitakselem z gemcytabiną (współczynnik ryzyka [*hazard ratio* – HR] 0,83; 95% CI 0,70–0,99; p = 0,036). Poważne działania niepożądane związane z leczeniem, w stopniu 3. lub wyższym, stwierdzono u 322 spośród 370 chorych (87%) otrzymujących NALIRIFOX oraz u 326 spośród 379 chorych (86%) stosujących nab-paklitaksel z gemcytabiną; w przypadku 14 chorych (2%) stwierdzono zgon związany z leczeniem: 6 w grupie otrzymującej NALIRIFOX i 8 (2%) w grupie otrzymującej nab-paklitaksel z gemcytabiną.

Wnioski. Chemioterapię według schematu NALIRIFOX można stosować w leczeniu pierwszej linii u chorych na mPDAC.

Atezolizumab for advanced alveolar soft part sarcoma

Chen A., Sharon E., O'Sullivan-Coyne G. i wsp.

N. Engl. J. Med., 2023; 389: 911–921

Pęcherzykowy mięsak tkanek miękkich (*alveolar soft part sarcoma alveolar soft part sarcoma* – ASPS) to rzadki nowotwór o złym rokowaniu; nie określono zasad jego leczenia. Ostatnio przedstawiono obiecującą odpowiedź na leczenie z użyciem inhibitorów punktów kontrolnych układu odpornościowego.

Metody. Przeprowadzono wieloośrodkowe jednoramienne badanie kliniczne II fazy, w którym oceniano zastosowanie atezolizumabu – przeciwciała przeciwko ligandowi programowanej śmierci typu 1 (PD-L1) – u dorosłych i dzieci chorych na zaawansowanego ASPS. Atezolizumab podawano dożylnie, w dawce 1200 mg (u chorych ≥18. roku życia) lub 15 mg/kg mc. z ograniczeniem do 1200 mg (u chorych <18. roku życia) co 21 dni. Punkty końcowe badania stanowiły: udział obiektywnych odpowiedzi na zastosowane leczenie, czas trwania odpowiedzi i przeżycie wolne od progresji zgodnie z kryteriami odpowiedzi na leczenie RECIST w wersji 1.1; badano także farmakodynamiczne biomarkery wieloetapowego działania leku.

Wyniki. Łącznie oceniono wyniki leczenia 52 chorych. Obiektywną odpowiedź zaobserwowano u 19 spośród nich (37%), w tym 1 całkowitą i 18 częściowych. Mediana czasu do uzyskania odpowiedzi wyniosła 3,6 miesiąca (zakres 2,1–19,1), mediana czasu trwania odpowiedzi wyniosła 24,7 miesiąca

(zakres 4,1–55,8), a mediana przeżycia wolnego od progresji 20,8 miesiąca. U 7 chorych przerwano leczenie po 2 latach, a ich odpowiedzi utrzymywały się do chwili zamknięcia danych. Nie odnotowano działań niepożądanych związanych z leczeniem 4. lub 5. stopnia. Odpowiedzi wystąpiły pomimo zróżnicowanej wyjściowej ekspresji receptora programowanej śmierci PD-1 i PD-L1.

Wnioski. Atezolizumab okazał się skuteczny w wywoływaniu trwałych odpowiedzi u około jednej trzeciej chorych na zaawansowanego ASPS.

Dabrafenib plus trametinib in pediatric glioma with *BRAF* V600 mutations

Bouffet E., Hansford J.R., Garrè M.L. i wsp.
N. Engl. J. Med., 2023; 389: 1108–1120

Obecność mutacji V600E genu *BRAF* w glejaku wieku dziecięcego o niskim stopniu złośliwości jest związane z gorszą odpowiedzią na standardową chemioterapię. W poprzednich badaniach dabrafenib (zarówno w monoterapii, jak i w połączeniu z trametynibem) był skuteczny w leczeniu dzieci z nawrotem glejaka o niskim stopniu złośliwości charakteryzującego się mutacją *BRAF* V600, co uzasadnia dalszą ocenę tego połączenia w leczeniu pierwszej linii.

Metody. W badaniu klinicznym II fazy dzieci chore na glejaka o niskim stopniu złośliwości z mutacją *BRAF* V600, zakwalifikowane do leczenia pierwszej linii, przydzielano losowo (w stosunku 2:1) do leczenia dabrafenibem z trametynibem lub do standardowej chemioterapii (karboplatyna z winkrystyną). Pierwszorzędowym punktem końcowym była ogólna odpowiedź na leczenie (całkowita lub częściowa) oceniana przez niezależną komisję, na podstawie kryteriów odpowiedzi w neuroonkologii. Oceniano również korzyści kliniczne (całkowita lub częściowa odpowiedź lub stabilna choroba przez ≥24 tygodnie) oraz przeżycie wolne od progresji.

Wyniki. Łącznie poddano randomizacji 110 chorych (73 otrzymało dabrafenib z trametynibem, a 37 poddano standardowej chemioterapii). Po obserwacji o medianie wynoszącej 18,9 miesiąca udział ogólnych odpowiedzi wyniósł 47% wśród leczonych dabrafenibem z trametynibem oraz 11% wśród poddanych chemioterapii (HR 4,31; 95% CI 1,7–11,2; p < 0,001). Korzyść kliniczną uzyskano u 86% chorych leczonych dabrafenibem z trametynibem i u 46% poddanych chemioterapii (HR 1,88; 95% CI 1,3–2,7). Mediana przeżycia wolnego od progresji choroby była znamiennie dłuższa w przypadku leczonych dabrafenibem z trametynibem w porównaniu z poddanymi chemioterapii (20,1 miesiąca *vs* 7,4 miesiąca; HR 0,31; 95% CI 0,17–0,55; p < 0,001). Działania niepożądane 3. lub wyższego stopnia wystąpiły u 47% chorych otrzymujących dabrafenib z trametynibem i u 94% chorych poddanych chemioterapii.

Wnioski. Wśród dzieci chorych na glejaka o niskim stopniu złośliwości z mutacją *BRAF* V600, dabrafenib w połączeniu z trametynibem wiązał się ze znamiennie większym odsetkiem odpowiedzi, dłuższym przeżyciem wolnym od progresji oraz lepszym profilem bezpieczeństwa w porównaniu ze standardową chemioterapą w leczeniu pierwszej linii.

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial

Chang J. H., Lin S., Dong W. i wsp.
Lancet, 2023; 402: 871–881

Stereotaktyczna radioterapia ablacyjna (*stereotactic ablative radiotherapy* – SABR) to standardowa metoda leczenia nieoperacyjnego, wczesnego niedrobnokomórkowego raka płuca (NDRP), aczkolwiek zdarzają się nawroty regionalne i/lub odległe. Immunoterapia zmniejsza częstość nawrotów nowotworu i poprawia przeżywalność u chorych na raka płuca w III stopniu zaawansowania po chemioradioterapii, ale jej przydatność w I i II stopniu jest niejasna. Przeprowadzono badanie kliniczne II fazy z randomizacją porównujące wyłączną SABR i SABR w połączeniu z immunoterapią (I-SABR) u chorych na NDRP we wczesnym stopniu zaawansowania.

Metody. Do otwartego badania klinicznego II fazy porównującego SABR z I-SABR, prowadzonego w trzech różnych szpitalach w Teksasie, w USA, włączono chorych w wieku co najmniej 18 lat z histopatologicznie potwierdzonym rozpoznaniem NDRP w stopniu zaawansowania IA–IB (rozmiar guza ≤4 cm, N0M0), IIA (rozmiar guza ≤5 cm, N0M0) lub IIB (rozmiar guza >5 cm i ≤7 cm, N0M0) według ósmej wersji klasyfikacji TNM American Joint Committee on Cancer, a także chorych z izolowanym nawrotem (rozmiar guza ≤7 cm) NDRP w płucu (jakiekolwiek T, jakiekolwiek N, M0 przed zabiegiem operacyjnym lub chemioradioterapią). Chorych przydzielono losowo (w stosunku 1:1; z wykorzystaniem metody Pococka i Simona) do SABR stosowanej wyłącznie lub w połączeniu z czterema cyklami niwolumabu (480 mg, raz na 4 tygodnie, z pierwszą dawką w tym samym dniu co pierwsza frakcja SABR lub w ciągu 36 godzin po niej). Pierwszorzędowym punktem końcowym był udział 4-letnich przeżyć wolnych od zdarzeń (nawrót miejscowy, regionalny lub odległy; wystąpienie drugiego pierwotnego raka płuca lub zgon). Analizy przeprowadzono zarówno w grupie zgodnej z zamiarem leczenia (ITT), jak i w grupie leczonej zgodnie z protokołem.

Wyniki. Od 30 czerwca 2017 roku do 22 marca 2022 roku 156 chorych przydzielono losowo do leczenia. Ostatecznie u 141 spośród nich zastosowano przypisane leczenie. Po obserwacji o medianie wynoszącej 33 miesiące I-SABR znacząco zwiększyła częstość 4-letnich przeżyć wolnych od zdarzeń: z 53% (95% CI 42–67%) w grupie SABR do 77% (66–91%; w grupie leczonej zgodnie z protokołem współczynnik HR wyniósł 0,38; 95% CI 0,19–0,75; p = 0,0056; w grupie ITT uzyskano HR

0,42; 95% CI 0,22–0,80; p = 0,0080). Nie odnotowano ciężkich działań niepożądanych (stopnia 3. lub wyższego) związanych z SABR. Z kolei w grupie I-SABR u 10 chorych (15%) stwierdzono immunologiczne działania niepożądane stopnia 3. związane z niwolumabem; nie wystąpiło zapalenie płuc stopnia 3. ani toksyczność stopnia 4. lub wyższego.

Wnioski. Terapia łączona I-SABR znacząco zwiększyła częstość 4-letnich przeżyć wolnych od zdarzeń u chorych na wczesnego NDRP lub u chorych z nawrotem NDRP w płucu bez zajęcia węzłów chłonnych w porównaniu z leczeniem opartym wyłącznie na SABR, przy zachowaniu akceptowalnej toksyczności. I-SABR może stanowić opcję leczenia dla tej grupy chorych, ale wymaga to dalszego potwierdzenia w wielu obecnie trwających badaniach III fazy.

Anti-Epstein-Barr virus BNLF2b for mass screening for nasopharyngeal cancer

Li T., Li F., Guo X. i wsp.

N. Engl. J. Med., 2023; 389: 808–819

Populacyjne badania przesiewowe pod kątem obecności DNA lub przeciwciał przeciwko wirusowi Epsteina-Barr (EBV) u osób bez objawów zakażenia tym wirusem poprawiły diagnostykę i przeżywalność chorych na raka nosowej części gardła. Jednak dodatnia wartość predykcyjna obecnych strategii badań przesiewowych jest niezadowalająca, nawet na obszarach, gdzie rak nosowej części gardła ma charakter endemiczny.

Metody. Zaprojektowano bibliotekę peptydów reprezentujących epitopy komórek B sekwencji kodujących EBV w celu określenia nowych surowiczych biomarkerów raka nosowej części gardła. Po retrospektywnym badaniu typu *case-control* zwalidowano skuteczność nowego biomarkera, przeciwciała anty-BNLF2b (P85-Ab), w ramach dużego prospektywnego programu badań przesiewowych, i porównano ze standardową metodą przesiewową opartą na dwóch przeciwciałach (EBV antygen jądrowy 1 [EBNA1] – IgA i swoisty dla EBV wirusowy antygen kapsydowy [VCA] – IgA).

Wyniki. P85-Ab było najbardziej obiecującym biomarkerem do badań przesiewowych raka nosowej części gardła, charakteryzującym się wysoką czułością (94,4%; 95% CI 86,4–97,8) i swoistością (99,6%; 95% CI 97,8–99,9) w badaniu retrospektywnym. Wśród 24 852 uczestników prospektywnej kohorty stwierdzono 47 przypadków raka nosogardła (38 we wczesnym stadium). P85-Ab wykazało większą czułość niż metoda z dwoma przeciwciałami (97,9% *vs* 72,3%; stosunek 1,4 [95% CI 1,1–1,6]), wyższą swoistość (98,3% *vs* 97,0%; stosunek 1,01 [95% CI 1,01–1,02]) i wyższą dodatnią wartość predykcyjną (10,0% *vs* 4,3%; współczynnik 2,3 [95% CI 1,8–2,8]). Połączenie testu P85-Ab i metody z dwoma przeciwciałami znacząco zwiększyło dodatnią wartość predykcyjną do 44,6% (95% CI 33,8–55,9), przy czułości 70,2% (95% CI 56,0–81,4).

Wnioski. Wyniki badania sugerują, że P85-Ab jest obiecującym nowym biomarkerem do badań przesiewowych w kierunku raka nosowej części gardła, charakteryzującym się większą czułością, swoistością i dodatnią wartością predykcyjną niż standardowo stosowane oznaczanie dwóch przeciwciał.

Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma

Richardson P.G., Trudel S., Popat R. i wsp.

N. Engl. J. Med., 2023; 389: 1009–*10*22

Pomimo istotnego postępu odnotowanego w leczeniu szpiczaka mnogiego, nadal pozostaje on chorobą nieuleczalną. Mezygdomid to nowy modulator kompleksu ligazy ubikwitynowej E3 i cereblonu. Wykazał on silne działanie antyproliferacyjne i przeciwnowotworowe w przedklinicznych badaniach na modelach szpiczaka mnogiego, również w opornych na lenalidomid i pomalidomid.

Metody. W badaniu I–II fazy chorym na nawrotowego i opornego na leczenie szpiczaka podawano doustnie mezygdomid w skojarzeniu z deksametazonem. Głównymi celami badania I fazy (grupa ze zwiększaniem dawki) była ocena bezpieczeństwa i farmakokinetyki oraz określenie dawki i schematu dawkowania do zastosowania w badaniu II fazy. W badaniu II fazy (grupa z rozszerzeniem dawki) cele obejmowały ocenę ogólnych odpowiedzi (odpowiedź częściowa lub lepsza), bezpieczeństwo i skuteczność mezygdomidu w połączeniu z deksametazonem w dawce i schemacie określonym w fazie I.

Wyniki. Do badania I fazy włączono ogółem 77 chorych. Najczęstszymi działaniami niepożądanymi wpływającymi na ograniczenie dawki były neutropenia i gorączka neutropeniczna. Na podstawie wyników badań I fazy ustalono zalecaną dawkę mezygdomidu do użycia II fazie – wyniosła ona 1 mg raz na dobę w skojarzeniu z deksametazonem przez 21 dni, po których następowało 7 dni przerwy (28-dniowe cykle). W badaniu II fazy łącznie 101 chorych otrzymało dawkę określoną w I fazie; u wszystkich chorych stwierdzono oporność na 3 grupy leków; 30 spośród nich (30%) otrzymywało wcześniej antygen dojrzewania komórek B (anty-BCMA), a 40 (40%) chorowało na szpiczaka odosobnionego. Najczęstszymi działaniami niepożądanymi (z których prawie wszystkie okazały się odwracalne) były: neutropenia (u 77% chorych) i zakażenie (u 65%; stopień 3. – 29%; stopień 4. – 6%). Nie stwierdzono nieoczekiwanych działań niepożądanych. Udział ogólnych odpowiedzi wyniósł 41% (95% CI 31–51), mediana czasu trwania odpowiedzi wyniosła 7,6 miesiąca (95% CI 5,4–9,5; dane nie są jeszcze dojrzałe), mediana przeżycia wolnego od progresji wniosła 4,4 miesiąca (95% CI 3,0–5,5), a mediana okresu obserwacji 7,5 miesiąca (zakres 0,5–21,9).

Wnioski. Połączenie mezygdomidu i deksametazonu podawanych doustnie wykazało obiecującą skuteczność u chorych na opornego na leczenie szpiczaka mnogiego. Działania niepożądane związane z leczeniem obejmowały głównie mielotoksyczność.

Camrelizumab plus rivoceranib *versus* sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Qin S., Chan S.L., Gu S. i wsp.

Lancet, 2023; 10408: 1133–1146

Wykazano, że immunoterapia inhibitorami punktów kontrolnych układu odpornościowego w połączeniu z antyangiogennym inhibitorem kinazy tyrozynowej (TKI) wydłuża całkowite przeżycie chorych na zaawansowane guzy lite w porównaniu z wyłącznym leczeniem antyangiogennym, ale nie potwierdzono takiej zależności u chorych na raka wątrobowokomórkowego (*hepatocellular carcinoma* – HCC). Przeprowadzono badanie kliniczne porównujące skuteczność i bezpieczeństwo kamrelizumabu (przeciwciała anty-PD-1) w skojarzeniu z rywoceranibem (TKI ukierunkowanym na VEGFR2, znanym również jako apatynib) w porównaniu z sorafenibem w leczeniu pierwszej linii leczenia chorych na nieoperacyjnego HCC.

Metody. Otwarte międzynarodowe badanie III fazy CARES-310 przeprowadzono w 95 ośrodkach badawczych w 13 krajach i regionach na całym świecie. Chorych na nieoperacyjnego lub rozsianego HCC, niepoddanych wcześniej leczeniu ogólnoustrojowemu, przydzielono losowo (w stosunku 1:1) do leczenia kamrelizumabem (200 mg dożylnie co 2 tygodnie) w skojarzeniu z rywoceranibem (250 mg doustnie raz na dobę) lub do grupy otrzymującej sorafenib (400 mg doustnie dwa razy na dobę). Pierwszorzędowymi punktami końcowymi były: przeżycie wolne od progresji ocenione przez zaślepioną niezależną komisję (zgodie z kryteriami RECIST v1.1) oraz przeżycie całkowite w grupie zgodnej z zamiarem leczenia. Bezpieczeństwo oceniano u wszystkich chorych, którzy otrzymali co najmniej jedną dawkę badanych leków. Przedstawiono wyniki przeprowadzonej wcześniej analizy pierwotnej dotyczącej przeżycia wolnego od progresji oraz analizy pośredniej dotyczącej przeżycia całkowitego.

Wyniki. Od 28 czerwca 2019 roku do 24 marca 2021 roku przydzielono losowo 543 chorych – do grupy otrzymującej kamrelizumab z rywoceranibem właczono 272 osoby, a do leczenia sorafenibem 271 osób. W pierwotnej analizie przeżycia wolnego od progresji (10 maja 2021 r.) mediana czasu obserwacji wyniosła 7,8 miesiąca (IQR 4,1–10,6). Mediana czasu wolnego od progresji była znamiennie dłuższa wśród leczonych kamrelizumabem z rywoceranibem w porównaniu z leczonymi sorafenibem (5,6 miesiąca [95% CI 5,5–6,3] w porównaniu z 3,7 miesiąca [2,8–3,7]; współczynnik ryzyka [HR] 0,52 [95% CI 0,41–0,65], jednostronne p < 0,0001). W cząstkowej analizie przeżycia całkowitego (8 lutego 2022) mediana czasu obserwacji wyniosła 14,5 miesiąca (IQR 9,1–18,7). Mediana całkowitego przeżycia była znamiennie dłuższa w grupie leczonych kamrelizumabem z rywoceranibem w porównaniu z otrzymującymi sorafenib (22,1 miesiąca [95% CI 19,1–27,2] *vs* 15,2 miesiąca [13,0–18,5]; HR 0,62 [95% CI 0,49–0,80], jednostronne p < 0,0001). Najczęstszymi zdarzeniami niepożądanymi 3. lub 4. stopnia były nadciśnienie (u 102 spośród 272 chorych [38%] w grupie otrzymującej kamrelizumab w skojarzeniu z rywoceranibem w porównaniu z 40 spośród 269 chorych [15%] w grupie otrzymującej sorafenib), zespół erytrodyzestezji dłoniowo-podeszwowej (33 [12%] *vs* 41 [15%]), podwyższone stężenie aminotransferazy asparaginianowej (45 [17%] *vs* 14 [5%]) i aminotransferazy alaninowej (35 [13%] *vs* 8 [3%]). Poważne zdarzenia niepożądane związane z leczeniem zgłoszono u 66 chorych (24%) w grupie leczonej kamrelizumabem z rywoceranibem i u 16 chorych (6%) w grupie otrzymującej sorafenib. Zgon związany z leczeniem odnotowano w przypadku u 2 chorych: 1 w grupie otrzymującej kamrelizumab i rywoceranib (zespół niewydolności wielonarządowej) i 1 w grupie otrzymującej sorafenib (niewydolność oddechowa i krążeniowa).

Wnioski. Kamrelizumab w skojarzeniu z rywoceranibem znamiennie wydłużył przeżycie wolne od progresji i przeżycie całkowite u chorych na nieoperacyjnego HCC w porównaniu z leczeniem opartym na sorafenibie; to połączenie stanowi nową skuteczną opcję leczenia pierwszej linii w tej grupie chorych.

Improved outcomes with enzalutamide in biochemically recurrent prostate cancer

Freedland S.J., Luz M.A., Giorgi U.D. i wsp.

N. Engl. J. Med., 2023; 389: 1453–1465

W przypadku chorych na raka gruczołu krokowego, u których dochodzi do wznowy biochemicznej wysokiego ryzyka, ryzyko progresji nowotworu jest większe niż u pozostałych. Nie określono dotąd skuteczności i bezpieczeństwa enzalutamidu w skojarzeniu z blokadą androgenów i wyłącznego leczenia enzalutamidem w porównaniu z blokadą androgenów.

Metody. Do badania III fazy włączono chorych na raka gruczołu krokowego, u których wystąpiła wznowa biochemiczna, a czas podwojenia stężenia antygenu swoistego dla stercza (*prostate-specific antigen* – PSA) wyniósł 9 miesięcy lub mniej. Chorych przydzielono losowo (w stosunku 1:1:1) do grupy otrzymującej enzalutamid (160 mg na dobę) i leuprolid co 12 tygodni (grupa leczenia skojarzonego), placebo i leuprolid (grupa otrzymująca sam leuprolid) lub wyłącznie enzalutamid w monoterapii (grupa monoterapii). Pierwszorzędowym punktem końcowym badania było przeżycie wolne od przerzutów, oceniane centralnie w niezależnym, zaślepionym, przeglądzie, w grupie stosującej leczenie skojarzone w porównaniu z grupą otrzymującą wyłącznie leuprolid. Kluczowym drugorzędowym punktem końcowym było przeżycie wolne od przerzutów w grupie leczonej wyłącznie enzalutamidem w porównaniu z grupą otrzymującą wyłącznie leuprolid. Innymi drugorzędowymi punktami końcowymi były wyniki zgłaszane przez chorych i bezpieczeństwo.

Wyniki. Spośród 1068 chorych 355 przydzielono losowo do grupy stosującej leczenie skojarzone, 358 do grupy otrzymującej wyłącznie leuprolid, a 355 do grupy przyjmującej wyłącznie enzalutamid. Mediana czasu obserwacji wyniosła 60,7 miesiąca. Udział 5-letnich przeżyć wolnych od przerzutów wyniósł: 87,3% (95% CI 83,0–90,6) w grupie otrzymującej leczenie skojarzone, 71,4% (95% CI 65,7–76,3) w grupie otrzymującej wyłącznie leuprolid i 80,0% (95% CI 75,0–84,1) w grupie leczonej wyłącznie enzalutamidem. Czas wolny od przerzutów był znamiennie dłuższy dla otrzymujących enzalutamid w skojarzeniu z leuprolidem w porównaniu z leczonymi wyłącznie leuprolidem (HR dla przerzutów lub zgonu 0,42; 95% CI 0,30–0,61; p < 0,001) oraz wśród leczonych wyłącznie enzalutamidem w porównaniu z leczonymi wyłącznie leuprolidem (HR dla przerzutów lub zgonu 0,63; 95% CI 0,46–0,87; p = 0,005). Nie zaobserwowano żadnych nowych sygnałów dotyczących bezpieczeństwa ani znamiennych różnic pomiędzy grupami w zakresie wskaźników jakości życia.

Wnioski. Udział przeżyć wolnych od przerzutów u chorych na raka gruczołu krokowego ze wznową biochemiczną był wyższy wśród leczonych enzalutamidem w skojarzeniu z leuprolidem w porównaniu z leczonymi wyłącznie leuprolidem. Monterapia enzalutamidem była również skuteczniejsza niż wyłączne leczenie leuprolidem. Profil bezpieczeństwa enzalutamidu był zgodny z przedstawionym w poprzednich badaniach klinicznych, nie stwierdzono niekorzystnego wpływu leczenia na jakość życia.

Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet, 2023; 402: 1991–2003

Od lat 80. XX wieku radioterapia stała się znacznie bardziej precyzyjna, co wiązało się ze zwiększeniem zarówno jej bezpieczeństwa, jak i skuteczności. U chorych na raka piersi radioterapia na obszar węzłów chłonnych ma na celu zmniejszenie ryzyka nawrotu i zgonu. Była oceniana w badaniach klinicznych z losowym doborem chorych, zarówno przed latami 80. XX wieku, jak i później. Celem badania była ocena wyników zastosowania radioterapii na obszar węzłów chłonnych w tych dwóch okresach.

Metody. W metaanalizie oceniono dane poszczególnych chorych z wszystkich badań z losowym doborem chorych, porównujących radioterapię na obszar regionalnych węzłów chłonnych z jej brakiem u chorych na wczesnego raka piersi (w tym jedno badanie dotyczące radioterapii na obszar węzłów chłonnych tylko u chorych na raka prawej piersi). Badania odnaleziono w wyniku regularnego systematycznego przeglądu baz danych przeprowadzonego przez EBCTCG, takich jak MEDLINE, Embase, Biblioteka Cochrane i streszczenia konferencyjne. Uwzględniono badania, które rozpoczęły się przed 1 stycznia 2009 roku. Jedyną systematyczną różnicą pomiędzy grupami leczenia było zastosowanie radioterapii na obszar węzłów chłonnych (piersiowych wewnętrznych, dołu nadobojczykowego, pachowych lub dowolnego połączenia tych obszarów). Pierwszorzędowym punktem końcowym był nawrót nowotworu w dowolnej lokalizacji, zgon z powodu raka piersi, zgon z innych przyczyn oraz ogólna umieralność. Dane były dostarczane przez badaczy i standaryzowane do formatu odpowiedniego do analizy. Streszczenie sformatowanych danych przesłano badaczom do weryfikacji. Analizy log-rank dostarczyły wskaźników względnego ryzyka (*realtive risk* – RR) i przedziałów ufności dla pierwszego zdarzenia.

Wyniki. Znaleziono 17 badań, spośród których w 16 dostępne były odpowiednie dane (14 324 chorych); dane z 1 badania (wykluczonego) były niedostępne (165 chorych). W 8 nowszych badaniach (12 167 chorych), które rozpoczęły się w latach 1989–2008, radioterapia obszaru węzłowego znamiennie zmniejszyła częstość nawrotów (HR 0,88, 95% CI 0,81–0,95; p = 0,0008). Główny wynik dotyczył nawrotów odległych, ponieważ zgłoszono niewiele nawrotów w obszarze węzłów chłonnych. Radioterapia znacząco zmniejszyła też umieralność z powodu raka piersi (RR 0,87, 95% CI 0,80–0,94; p = 0,0010), bez znamiennego wpływu na umieralność z innych przyczyn niż rak piersi (0,97, 0,84–1,11; p = 0,63), co skutkowało znamiennie zmniejszoną ogólną umieralnością (0,90, 0,84–0,96; p = 0,0022). Oszacowane bezwzględne zmniejszenie umieralności z powodu raka piersi w ciągu 15 lat wyniosło 1,6% w przypadku chorych bez zajęcia pachowych węzłów chłonnych, 2,7% wśród chorych z 1–3 zajętych węzłów chłonnych pachowych oraz 4,5% u chorych z 4 lub więcej zajętymi węzłami chłonnymi pachy. W ośmiu starszych badaniach (2157 chorych), które rozpoczęły się w latach 1961–78, radioterapia obszaru węzłowego miała niewielki wpływ na umieralność z powodu raka piersi (RR 1,04, 95% CI 0,91–1,20; p = 0,55), ale znamiennie zwiększała umieralność z innych przyczyn (1,42, 1,18–1,71; p = 0,00023), głównie po 20. roku życia, oraz ogólną umieralność (1,17, 1,04–1,31; p = 0,0067).

Wnioski. Radioterapia obszaru węzłowego znamiennie zmniejszyła umieralność z powodu raka piersi i ogólną umieralność w badaniach przeprowadzonych po latach 80., XX wieku, ale nie w starszych badaniach. Te przeciwstawne wyniki mogą odzwierciedlać postęp, jaki nastąpił w radioterapii od lat 80. XX wieku.

First-line selpercatinib or chemotherapy and pembrolizumab in *RET* fusion-positive NSCLC

Zhou C., Solomon B., Loong H. i wsp.
N. Engl. J. Med., 2023; 389: 1839–1850

Selperkatynib, silnie wybiórczy inhibitor RET, zdolny do przenikania do mózgu, wykazał skuteczność u chorych na

zaawansowanego niedrobnokomórkowego raka płuca (NDRP) z fuzją genu *RET* w badaniu I–II fazy bez randomizacji.

Metody. W badaniu klinicznym III fazy z losowym doborem chorych oceniono skuteczność i bezpieczeństwo selperkatynibu w leczeniu pierwszej linii w porównaniu ze standardowym leczeniem – chemioterapią zawierającą pochodną platyny, z pembrolizumabem lub bez – zgodnie z decyzją badacza. Pierwszorzędowym punktem końcowym był czas wolny od progresji, oceniany centralnie przez niezależną komisję, zarówno w grupie zgodnej z zamiarem leczenia pembrolizumabem (tj. chorzy, których planowano leczyć z użyciem pembrolizumabu w grupie kontrolnej), jak i w ogólnej grupie zgodnej z zamiarem leczenia. *Cross-over* z grupy kontrolnej do grupy selperkatynibu był dopuszczalny po stwierdzeniu progresji, ocenionej przez niezależną centralną komisję w trakcie stosowania standardowego leczenia.

Wyniki. Łącznie 212 chorych przydzielono losowo do grupy z zamiarem leczenia pembrolizumabem. W chwili zaplanowanej analizy skuteczności mediana czasu wolnego od progresji wyniosła 24,8 miesiąca (95% CI 16,9–nieokreślony) w grupie leczonej selperkatynibem i 11,2 miesiąca (95% CI 8,8–16,8) w grupie kontrolnej (HR dla progresji lub zgonu 0,46; 95% CI 0,31–0,70; p < 0,001). Udział obiektywnych odpowiedzi wyniósł 84% (95% CI 76–90) w grupie leczonych selperkatynibem i 65% (95% CI 54–75) w grupie kontrolnej. Współczynnik ryzyka zdarzenia związanego z progresją w ośrodkowym układzie nerwowym wyniósł 0,28 (95% CI 0,12–0,68). Wyniki skuteczności w ogólnej grupie zgodnej z zamiarem leczenia (261 chorych) były podobne do tych w grupie z zamiarem leczenia pembrolizumabem. Działania niepożądane, które wystąpiły przy stosowaniu selperkatynibu i standardowego leczenia, były zgodne z wcześniejszymi doniesieniami.

Wnioski. Leczenie selperkatynibem znamiennie wydłużyło czas wolny od progresji w porównaniu z leczeniem opartym na chemioterapii zawierającej pochodne platyny z pembrolizumabem lub bez u chorych na zaawansowanego NDRP z fuzją genu *RET*.

Osimertinib with or without chemotherapy in *EGFR*-mutated advanced NSCLC

Planchard D., Jänne P., Cheng Y. i wsp.

N. Engl. J. Med., 2023; 389: 1935–1848

Ozymertynib to inhibitor kinazy tyrozynowej receptora dla naskórkowego czynnika wzrostu (EGFR-TKI) trzeciej generacji, selektywny dla aktywujących mutacji *EGFR* oraz mutacji oporności T790M. Dane z badań wskazują, że jego połączenie z chemioterapiią może przedłużyć korzyści z leczenia EGFR-TKI.

Metody. W międzynarodowym otwartym badaniu III fazy chorych na zaawansowanego niedrobnokomórkowego raka płuca (NDRP) z mutacjami w genie *EGFR* (delecja w eksonie 19. lub mutacja L858R), wcześniej nieleczonych z powodu zaawansowanego nowotworu, przydzielano losowo (w stosunku 1:1), do przyjmowania ozymertynibu (80 mg raz dziennie) w połączeniu z chemioterapią (pemetreksed [500 mg/m^2] plus cisplatyna [75 mg/m^2] lub karboplatyna [dawka dostosowana farmakologicznie]) albo do leczenia wyłącznie ozymertynibem (80 mg raz dziennie). Pierwszorzędowym punktem końcowym było przeżycie wolne od progresji według oceny badacza. Oceniano także odpowiedź na terapię i jej bezpieczeństwo.

Wyniki. Do leczenia przydzielono losowo łącznie 557 chorych. Przeżycie wolne od progresji według oceny badacza było znamiennie dłuższe wśród otrzymujących ozymertynib w połączeniu z chemioterapią niż w grupie leczonej wyłącznie ozymertynibem (HR progresji lub zgonu 0,62; 95% CI 0,49–0,79; p < 0,001). Po 24 miesiącach żyło i było wolnych od progresji 57% (95% CI 50–63) chorych w grupie otrzymującej ozymertynib z chemioterapią i 41% (95% CI 35–47) w grupie leczonej wyłącznie ozymertynibem. Przeżycie wolne od progresji oceniane centralnie przez niezależną komisją było zgodne z analizą pierwotną (HR 0,62; 95% CI 0,48–0,80). Udział obiektywnych odpowiedzi (całkowitych lub częściowych) wyniósł 83% w grupie otrzymującej ozymertynib z chemioterapią i 76% w grupie leczonej wyłącznie ozymertynibem, mediana czasu trwania odpowiedzi wyniosła odpowiednio 24,0 miesiąca (95% CI 20,9–27,8) i 15,3 miesiąca (95% CI 12,7–19,4). Występowanie działań niepożądanych stopnia 3. lub wyższego z dowolnej przyczyny częściej stwierdzano u leczonych w sposób skojarzony w porównaniu z leczonymi wyłącznie ozymertynibem – wynik ten był skutkiem występowania znanych działań niepożądanych związanych z chemioterapią. Profil bezpieczeństwa ozymertynibu w połączeniu z pemetreksedem i pochodnymi platyny był zgodny z ustalonymi profilami poszczególnych leków.

Wnioski. Leczenie ozymertynibem w połączeniu z chemioterapią znamiennie wydłużyło przeżycie wolne od progresji w leczeniu pierwszej linii u chorych na zaawansowanego NDRP z mutacją w genie *EGFR* w porównaniu z leczeniem wyłącznie ozymertynibem.

Sotorasib plus panitumumab in refractory colorectal cancer with mutated *KRAS*G12C

Fakih M., Salvatore L., Esaki T. i wsp.

N. Engl. J. Med., 2023; 389: 2125–2139

Mutacja *KRAS* G12C występuje u około 3–4% chorych na rozsianego raka jelita grubego. Leczenie wyłącznie inhibitorami KRAS G12C jest umiarkowanie skuteczne. Połączenie inhibitora KRAS G12C sotorasibu z panitumumabem, inhibitorem receptora naskórkowego czynnika wzrostu (EGFR), może być bardziej efektywne

Metody. W wieloośrodkowym otwartym badaniu III fazy chorych na rozsianego raka jelita grubego opornego na chemioterapię, z mutacją *KRAS* G12C, którzy wcześniej nie otrzymali inhibitorów KRAS G12C, przydzielono do stosowania sotorasibu w dawce 960 mg raz dziennie w połączeniu z panitumumabem

(53 chorych), sotorasibu w dawce 240 mg raz dziennie w połączeniu z panitumumabem (53 chorych) lub do standardowego leczenia według wyboru badacza (triflurydyna–typiracyl lub regorafenib; 54 chorych). Pierwszorzędowym punktem końcowym był czas wolny od progresji, oceniany przez niezależną centralną komisję zgodnie z Kryteriami Oceny Odpowiedzi w Nowotworach Litych, wersja 1.1. Głównymi punktami końcowymi były także ogólne przeżycie i obiektywna odpowiedź na leczenie.

Wyniki. Po obserwacji o medianie wynoszącej 7,8 miesiąca (zakres 0,1–13,9), mediana czasu wolnego od progresji wyniosła 5,6 miesiąca (95% CI 4,2–6,3) i 3,9 miesiąca (95% CI 3,7–5,8) w grupach otrzymujących sotorasib w dawkach 960 mg i 240 mg w połączeniu z panitumumabem, w porównaniu z 2,2 miesiąca (95% CI 1,9–3,9) w grupie leczenia standardowego. Współczynnik ryzyka progresji lub zgonu w grupie otrzymującej sotorasib w dawce 960 mg w połączeniu z panitumumabem w porównaniu do standardowego leczenia wyniósł 0,49 (95% CI 0,30–0,80; p = 0,006), a współczynnik ryzyka w grupie otrzymującej sotorasib w dawce 240 mg w połączeniu z panitumumabem – 0,58 (95% CI 0,36–0,93; p = 0,03). Dane dotyczące ogólnego przeżycia nie są kompletne. Udział obiektywnych odpowiedzi wyniósł odpowiednio 26,4% (95% CI 15,3–40,3), 5,7% (95% CI 1,2–15,7) i 0% (95% CI 0,0–6,6) w grupach otrzymujących sotorasib w dawkach 960 mg i 240 mg razem z panitumumabem oraz w grupie standardowego leczenia. Działania niepożądane związane z leczeniem stopnia 3. lub wyższego wystąpiły odpowiednio u 35,8%, 30,2% i 43,1% chorych. Działania niepożądane związane z toksycznością skórną i hipomagnezemia były najczęstszymi działaniami niepożądanymi obserwowanymi wśród leczonych sotorasibem w połączeniu z panitumumabem.

Wnioski. W badaniu klinicznym III fazy inhibitor KRAS G12C w połączeniu z inhibitorem EGFR u chorych na rozsianego raka jelita grubego opornego na chemioterapię obie dawki sotorasibu w połączeniu z panitumumabem wydłużyły czas wolny od progresji w porównaniu do standardowego leczenia. Działania niepożądane były zgodne z oczekiwaniami dla każdego z leków stosowanych osobno i prowadziły do niewielu przerw w leczeniu.

Anna Kowalczyk
Ewa Szutowicz
Magdalena Dróżka
Anna Laskowska
Paweł Szymański

VIA MEDICA

Komunikaty

Biuletyn Polskiego
Towarzystwa Onkologicznego
NOWOTWORY
2023, tom 8, nr 6, 505

ISSN: 2543–5248, e-ISSN: 2543–8077
www.nowotwory.edu.pl

XXX Zjazd Polskiego Towarzystwa Chirurgii Onkologicznej XLI Konferencja Naukowo-Szkoleniowa PTChO

16–18 maja 2024 r.

Kraków

Więcej informacji na stronie: https://ptcho.pl

VI Kongres Onkologii Polskiej 2024

17–19 października 2024 r.

Warszawa

Motywem przewodnim kongresu będzie interdyscyplinarna opieka onkologiczna. W programie zaplanowano ponad 50 sesji edukacyjnych, w tym blisko 150 wykładów, a udział potwierdziło ponad 150 wykładowców – ekspertów w zakresie przedstawianych zagadnień. Wśród gości zagranicznych będzie Prezydent ESMO (European Society for Medical Oncology).

Więcej informacji na stronie: https://www.pto.med.pl